

GenCore version 5.1.4 ps_4578
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 26, 2003, 00:55:20 ; Search time 3253 Seconds
(without alignments)
15871.004 Million cell updates/sec

Title: US-09-854-300-7

Perfect score: 1774

Sequence: 1 agctggagctccaccgcggt.....ataggcaagttctctctcag 1774

Scoring table: IDENTITY NUC %

Gapop 10.0 , Gapext 1.0

Searched: 2054640 seqs, 14551402878 residues

Total number of hits satisfying chosen parameters: 4109280

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

```

1: gb.ba.*
2: gb.htg.*
3: gb.in.*
4: gb.om.*
5: gb.ov.*
6: gb.pat.*
7: gb.ph.*
8: gb.pl.*
9: gb.pr.*
10: gb.ro.*
11: gb.sts.*
12: gb.sy.*
13: gb.un.*
14: gb.vi.*
15: em.ba.*
16: em.fun.*
17: em.hum.*
18: em.in.*
19: em.mu.*
20: em.om.*
21: em.or.*
22: em.ov.*
23: em.pat.*
24: em.ph.*
25: em.pl.*
26: em.ro.*
27: em.sts.*
28: em.un.*
29: em.vi.*
30: em.htg.hum.*
31: em.htg.inv.*
32: em.htg.other.*
33: em.htg.mus.*
34: em.htg.pln.*
35: em.htg.rtd.*
36: em.htg.mam.*
37: em.htg.vrt.*
38: em.sy.*
39: em.htgo.hum.*
40: em.htgo.mus.*
41: em.htgo.other.*

```

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1662.8	93.7	2796	6	AX337968
2	1659.6	93.6	2830	9	AK074264 Homo sapi
3	1280.8	72.2	1297	9	AF394689 Homo sapi
4	1205.2	67.9	1928	10	BC010477 Mus muscu
5	1203.6	67.8	1936	10	AB041548
6	1106.8	62.4	1287	10	AF426411
7	714.4	40.3	1871	9	AK027169
8	674.4	38.0	169812	9	AL391315 Human DNA
9	674.4	38.0	169863	2	AL591467
10	392.2	22.1	404	6	AK071980
11	372.6	21.0	646	6	AX341568
12	310	17.5	435	6	AX396961
13	280.4	15.8	195263	2	AC115936 Mus muscu
14	278.4	15.7	167021	2	AC111461
15	268.8	15.2	1391	9	AB070023 Macaca fa
16	268.8	15.2	1395	9	AB070058 Macaca fa
17	266.8	15.0	1429	9	AK098524
18	266.8	15.0	1430	9	BC022038 Homo sapi
19	266.8	15.0	1446	9	AF447589 Homo sapi
20	266.8	15.0	120984	9	AC006463
21	256.4	14.5	1328	9	BC029264 Homo sapi
22	254.8	14.4	1355	6	AK061659
23	253.2	14.3	1261	9	AK098654
24	220.2	12.4	116739	2	AC14183
25	220.2	12.4	140346	2	AC109686
26	220	12.4	119995	10	AL731648
27	217.4	12.3	116739	2	AC114183
28	209	11.8	1200	6	AX083416
29	209	11.8	1527	6	AX083426
30	209	11.8	2001	9	BC019355
31	207.4	11.7	2013	9	BC032328
32	156.8	8.8	839	9	AK058116
33	148.8	8.4	1452	10	AF171875
34	148.8	8.4	1506	10	BC018199
35	147.6	8.3	1153	9	AF155650
36	147.6	8.3	1253	6	AR030960
37	147.6	8.3	1257	6	AX083320
38	147.6	8.3	1433	6	AX083330
39	147.6	8.3	1445	9	BC017100
40	140	7.9	118766	2	AC128696
41	108.4	6.1	5111	9	AB033040
42	105.6	6.0	382	6	AX261677
43	87.2	4.9	2369	3	DROGOLTHA
44	84.8	4.8	2586	3	AY069169
45	79	4.5	2448	4	OCU132110

ALIGNMENTS

RESULT 1
AX337968
LOCUS AX337968 2796 bp DNA linear PAT 09-JAN-2002
DEFINITION Sequence 9 from Patent WO0194391.
ACCESSION AX337968
VERSION AX337968.1 GI:18128679
KEYWORDS human.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Yue, H., He, A., Nguyen, D.B., Yao, M.G., Bandman, O., Burford, N.,
Tang, Y.T., Xu, Y., Hafalia, A., Azimzai, Y. and Wallia, N.K.
TITLE Intracellular signaling proteins

JOURNAL Patent: WO 0194391-A 9 13-DEC-2001;

Incyte Genomics, Inc. (US)

FEATURES Location/Qualifiers

source 1..2796

/organism="Homo sapiens"

/db xref="taxon.9606"

/note="Incyte ID No: 2791668B1"

BASE COUNT 821 a 548 c 620 g 807 t

ORIGIN

Query Match 93.7%; Score 1662.8; DB 6; Length 2796;
 Best Local Similarity 99.4%; Pred. No. 0;
 Matches 1690; Conservative 0; Mismatches 8; Indels 3; Gaps 2;

Qy 74 CCGAGGAGCTGCATCTGGGCAACCTGTGTGCTGACGCTACGTCCTCTGGCTCCGAGC 133
 Db 28 CCGAGGAGCTGCATCTGGGCAACCTGTGTGCTGACGCTACGTCCTCTGGCTCCGAGC 87

Qy 134 TAGCTCGCAGCTCCCCAGTCTCACTCCATTCCTTCCCACCTGGCGCGCACCTGCTCAAG 193
 Db 88 TAGCTCGCAGCTCCCCAGTCTCACTCCATTCCTTCCCACCTGGCGCGCACCTGCTCAAG 147

Qy 194 ACCAGGTCCTGCCAAGCGCTAGGAGGCGCGTGCAGGGGCGCTAGGGAACTGCGGAGC 253
 Db 148 ACCAGGTCCTGCCAAGCGCTAGGAGGCGCGTGCAGGGGCGCTAGGGAACTGCGGAGC 207

Qy 254 GCGCGCGCATGGGCGCGCCGCTGGGGCCGGGGTCTCTGCGCGCGTGGCTGGCGCTTT 313
 Db 208 GCGCGCGCATGGGCGCGCCGCTGGGGCCGGGGTCTCTGCGCGCGTGGCTGGCGCTTT 267

Qy 314 TCCAGATTGCTGGCATGTGTCTCTGCTGCGCTGAGTCCGCGAGGACCGGTTCCCGG 373
 Db 268 TCCAGATTGCTGGCATGTGTCTCTGCTGCGCTGAGTCCGCGAGGACCGGTTCCCGG 327

Qy 374 GGGCTGAAGCAGTGTGGACCGCTACCTCAACGTGTCTGGCGGGTTCGCGCACGCGGA 433
 Db 328 GGGCTGAAGCAGTGTGGACCGCTACCTCAACGTGTCTGGCGGGTTCGCGCACGCGGA 387

Qy 434 GTGAACCTGAGTGTGGAGCTGAGCGAGGAGGCGGTGTACGGCGAGGACTGCGCGCTG 493
 Db 388 GTGAACCTGAGTGTGGAGCTGAGCGAGGAGGCGGTGTACGGCGAGGACTGCGCGCTG 447

Qy 494 GAGCTGTGGTGGGCTCTGGTACCGCCGACCGCGCCGGCGGCTTAAGCGCTGTAAAC 553
 Db 448 GAGCTGTGGTGGGCTCTGGTACCGCCGACCGCGCCGGCGGCTTAAGCGCTGTAAAC 507

Qy 554 CCGCACAGAAATTTACGGTGCACCGTTTGGGGAAGACACCGTGCAGTCTCTTGGTTG 613
 Db 508 CCGCACAGAAATTTACGGTGCACCGTTTGGGGAAGACACCGTGCAGTCTCTTGGTTG 567

Qy 614 GCGCTCATCCACGCGCGGGGCTGCACCTTCGCGACAGATCCATCTGGCTTATGAG 673
 Db 568 GCGCTCATCCACGCGCGGGGCTGCACCTTCGCGACAGATCCATCTGGCTTATGAG 627

Qy 674 AGATGGGCTGTGAGCGCTCATCTTTAACTTCCCGCGGACCCGCAATGAGGTCAATCCC 733
 Db 628 AGATGGGCTGTGAGCGCTCATCTTTAACTTCCCGCGGACCCGCAATGAGGTCAATCCC 687

Qy 734 ATGTCTACCCGGTGTGAGTGTAGACATTTGTTGCAATCATGATCGGCAATCTGAAAGGACA 793
 Db 688 ATGTCTACCCGGTGTGAGTGTAGACATTTGTTGCAATCATGATCGGCAATCTGAAAGGACA 747

Qy 794 AAAATTTCTGCAATCTATTCAAAGAGGCATACAAGTGACAAATGGTCATAGAGTAGGAAA 853
 Db 748 AAAATTTCTGCAATCTATTCAAAGAGGCATACAAGTGACAAATGGTCATAGAGTAGGAAA 807

Qy 854 AAACATGCGCTTGGTGAATCACTATTCAATTTTTTTTCTGTTCTGTTCTCTTTTATT 913
 Db 808 AAACATGCGCTTGGTGAATCACTATTCAATTTTTTTTCTGTTCTGTTCTCTTTTATT 867

Qy 914 ATTACGGCGGCACTGTGGCTATTTTATCTTTATCTGCTCGAAGGCTACGGAATGCA 973
 Db 868 ATTACGGCGGCACTGTGGCTATTTTATCTTTATCTTTATCTGCTCGAAGGCTACGGAATGCA 927

Qy 974 AGAGCTCAAAGCAGGAGCAGAGGCAATTAAAGGCAGATGCTAAAAAGCTATTGGAGG 1033
 Db 928 AGAGCTCAAAGCAGGAGCAGAGGCAATTAAAGGCAGATGCTAAAAAGCTATTGGAGG 987

Qy 1034 CTTCAACTACGCACACTGAAACAGGAGACAGGAAATTTGGCCCTGATGGAGATAGTTGT 1093
 Db 988 CTTCAACTACGCACACTGAAACAGGAGACAGGAAATTTGGCCCTGATGGAGATAGTTGT 1047

Qy 1094 GCTGTGTCATTGAAATTTGTATATAAACCAATGATTTGGTACGCATCTTAAACGTGCAACCAT 1153
 Db 1048 GCTGTGTCATTGAAATTTGTATATAAACCAATGATTTGGTACGCATCTTAAACGTGCAACCAT 1107

Qy 1154 ATTTTCCATAAGACATGTTGACCCATGGCTTTTAAACACACAGACATTGGCCCATGTGC 1213
 Db 1108 ATTTTCCATAAGACATGTTGACCCATGGCTTTTAAACACACAGACATTGGCCCATGTGC 1167

Qy 1214 AATCTGCATACCTCAAGCTTTGGGAATTTGAGGTGGATTTGAAGATGGATCAGTGCT 1273
 Db 1168 AATCTGCATACCTCAAGCTTTGGGAATTTGAGGTGGATTTGAAGATGGATCAGTGCT 1227

Qy 1274 TTACAAGTCCCTGTATCCAATGAAATATCTAATAGTGCCTCTCCCATGAAGAGATAAT 1333
 Db 1228 TTACAAGTCCCTGTATCCAATGAAATATCTAATAGTGCCTCTCCCATGAAGAGATAAT 1287

Qy 1334 CCGCAGGAGACCGCATCATCTGGATATGCTTCAGTACAGGGAAACAGATGAACCGCTCTG 1393
 Db 1288 CCGCAGGAGACCGCATCATCTGGATATGCTTCAGTACAGGGAAACAGATGAACCGCTCTG 1347

Qy 1394 GAGGAACACGTGCTCAACAAATGAAAGTCTACAGCTGGTAAACCATGAAGCAAAATCT 1453
 Db 1348 GAGGAACACGTGCTCAACAAATGAAAGTCTACAGCTGGTAAACCATGAAGCAAAATCT 1407

Qy 1454 GTGCGAGTGGATTTTCTCATGTNGACAAACCCACTTTTGAAGAGACGAACTCT 1513
 Db 1408 GTGCGAGTGGATTTTCTCATGTNGACAAACCCACTTTTGAAGAGACGAACTCT 1467

Qy 1514 AATCAAGACGCTGCTTGGAGAAATTAATCTTAAATCTGTGTAAATAGAAACTTGA 1573
 Db 1468 AATCAAGACGCTGCTTGGAGAAATTAATCTTAAATCTGTGTAAATAGAAACTTGA 1527

Qy 1574 ACCATTAGTAATAACAGAACTGCCAATCAGGCGCTAGTTTCTATTAAATTTGGATAAA 1633
 Db 1528 ACCATTAGTAATAACAGAACTGCCAATCAGGCGCTAGTTTCTATTAAATTTGGATAAA 1587

Qy 1634 TTTAATAAATAAGAGTGTACTGAAAGTGTCTCAGATGACTAATATTATGCTATAGTTAA 1693
 Db 1588 TTTAATAAATAAGAGTGTACTGAAAGTGTCTCAGATGACTAATATTATGCTATAGTTAA 1647

Qy 1694 AATGCTTAAATAATTTAACTTTTTCACCAAACTCATTATAATATTTT 1753
 Db 1648 A--TGCTTAAATAATTTAACTTTTTCCTTAACTTTTTCCTTAACTTTTTCCTTAACTTTT 1704

Qy 1754 CATAGGCAAGTTTCTCTCTCAG 1774
 Db 1705 CATAGGCAAGTTTCTCTCTCAG 1725

RESULT 2

AK074264

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

AK074264
 Homo sapiens cDNA FLJ23684 fis, clone HEP09821.
 2830 bp mRNA linear PRI 15-FEB-2002

AK074264
 Homo sapiens cDNA FLJ23684 fis, clone HEP09821.
 2830 bp mRNA linear PRI 15-FEB-2002

AK074264
 Homo sapiens cDNA FLJ23684 fis, clone HEP09821.
 2830 bp mRNA linear PRI 15-FEB-2002

AK074264
 Homo sapiens cDNA FLJ23684 fis, clone HEP09821.
 2830 bp mRNA linear PRI 15-FEB-2002

AK074264
 Homo sapiens cDNA FLJ23684 fis, clone HEP09821.
 2830 bp mRNA linear PRI 15-FEB-2002

AK074264
 Homo sapiens cDNA FLJ23684 fis, clone HEP09821.
 2830 bp mRNA linear PRI 15-FEB-2002

AK074264
 Homo sapiens cDNA FLJ23684 fis, clone HEP09821.
 2830 bp mRNA linear PRI 15-FEB-2002

AK074264
 Homo sapiens cDNA FLJ23684 fis, clone HEP09821.
 2830 bp mRNA linear PRI 15-FEB-2002

AK074264
 Homo sapiens cDNA FLJ23684 fis, clone HEP09821.
 2830 bp mRNA linear PRI 15-FEB-2002

AK074264
 Homo sapiens cDNA FLJ23684 fis, clone HEP09821.
 2830 bp mRNA linear PRI 15-FEB-2002

AK074264
 Homo sapiens cDNA FLJ23684 fis, clone HEP09821.
 2830 bp mRNA linear PRI 15-FEB-2002

AK074264
 Homo sapiens cDNA FLJ23684 fis, clone HEP09821.
 2830 bp mRNA linear PRI 15-FEB-2002

AK074264
 Homo sapiens cDNA FLJ23684 fis, clone HEP09821.
 2830 bp mRNA linear PRI 15-FEB-2002

AK074264
 Homo sapiens cDNA FLJ23684 fis, clone HEP09821.
 2830 bp mRNA linear PRI 15-FEB-2002

AK074264
 Homo sapiens cDNA FLJ23684 fis, clone HEP09821.
 2830 bp mRNA linear PRI 15-FEB-2002

AK074264
 Homo sapiens cDNA FLJ23684 fis, clone HEP09821.
 2830 bp mRNA linear PRI 15-FEB-2002

AK074264
 Homo sapiens cDNA FLJ23684 fis, clone HEP09821.
 2830 bp mRNA linear PRI 15-FEB-2002

AK074264
 Homo sapiens cDNA FLJ23684 fis, clone HEP09821.
 2830 bp mRNA linear PRI 15-FEB-2002

TITLE
JOURNAL
REFERENCE
AUTHORS

Shibahara, T., Tanaka, T., Nakamura, Y., Isogai, T. and Sugano, S.
NEDO human cDNA sequencing project
Unpublished
2 (bases 1 to 2830)

Sugano, S., Suzuki, Y., Ota, T., Obayashi, M., Nishi, T., Isogai, T.,
Shibahara, T., Tanaka, T. and Nakamura, Y.
Direct Submission
Submitted (14-PEB-2002) Sumio Sugano, Institute of Medical Science,
University of Tokyo, Laboratory of Genome Structure, Human Genome
Center, Shirokane-dai, 4-6-1, Minato-Ku, Tokyo 108-8639, Japan
(E-mail: cdnal@ims.u-tokyo.ac.jp, Tel: 81-3-5449-5286,
Fax: 81-3-5449-5416)

COMMENT
NEDO human cDNA sequencing project supported by Ministry of
Economy, Trade and Industry of Japan; cDNA full insert sequencing;
Research Association for Biotechnology; cDNA library construction;
5'- & 3'-end one pass sequencing; Department of Virology and Human
Genome Center, Institute of Medical Science, University of Tokyo
(partly supported by Science and Technology Agency).

FEATURES
source

1. 2830
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="HEP09821"
/cell_line="HepG2"
/cell_type="hepatoma"
/clone_lib="HEP"
/notes="Cloning vector: pME18SFL3"
251..1537
/notes="unnamed protein product"
/codon_start=1
/protein_id="BAB85033.1"
/db_xref="GI:18676819"
/translations="MGPPPGAGVSCGCGFSLRLAWCFLLALSLSPQAGSRGAEAVWT
AYLVNWRVPHTVNTWELSEBVGQDSELPVAGVLPDPGALNCPHTNF
TVPTWGSTVQVSWLALIQGGCTPADKHLAYRAGSGAVINFPPTNRNVI PMSH
PGADVIAIMGNLKGKTIQSTQGIQVIMVIEVKGKHPWNYSPFVSVSFII
TAATVGYFIPYSARLRNARQSRKQOLKADAKKAIQRLQRLTKQDKEITGPQDGS
CAVICELYPNDLVRILTNCNHPKTCVDPMLLEHPTCPMKCDILKALGIEVDVDEG
SVSLQVPVNEISNSASSHEEDNRSETASSGVASVQGTDEPFLBEHVQSTNESLQLVN
HEANSVAVDVIPHVDNPTFEDETPNQVAVREIKS"

CDS

BASE COUNT
ORIGIN

Query Match 93.6%; Score 1659.6; DB 9; Length 2830;
Best Local Similarity 99.2%; Pred. No. 0;
Matches 1688; Conservative 0; Mismatches 10; Indels 3; Gaps 2;

Qy	74	CCGAGGAGCTGCTCGGCAACCTGTGTGCTGACGCTACGTGCCTCTCGGCTCCGACG	133
Db	62	CCGAGGAGCTGCTCGGCAACCTGTGTGCTGACGCTACGTGCCTCTCGGCTCCGACG	121
Qy	134	TAGCTCGAGCTCCCGAGCTCACTCCATTCCTTCCACCTGGCGGACCTGCTCAAG	193
Db	122	TAGCTCGAGCTCCCGAGCTCACTCCATTCCTTCCACCTGGCGGACCTGCTCAAG	181
Qy	194	ACGAGGCTCTGCGCAAGCGCTAGGAGGCGCGTGCAGGCGCGCTAGGGAACCTGCGGAGC	253
Db	182	ACGAGGCTCTGCGCAAGCGCTAGGAGGCGCGTGCAGGCGCGCTAGGGAACCTGCGGAGC	241
Qy	254	GCGCGCGCATGGGCGCGCGCTGGGCGCGGGTCTCTCGCGCGGTGCTCGCGCTTT	313
Db	242	GCGCGCGCATGGGCGCGCGCTGGGCGCGGGTCTCTCGCGCGGTGCTCGCGCTTT	301
Qy	314	TCCAGATTGCTGGCATGCTCTCTGCTGCGCTGAGTCCGAGGACCCCGGTTCCCGG	373
Db	302	TCCAGATTGCTGGCATGCTCTCTGCTGCGCTGAGTCCGAGGACCCCGGTTCCCGG	361
Qy	374	GGGCTGAAGCAGTGTGGAACCGGCTACCTCAACGCTGCTCGGCGGGTTCGCGACACGGGA	433
Db	362	GGGCTGAAGCAGTGTGGAACCGGCTACCTCAACGCTGCTCGGCGGGTTCGCGACACGGGA	421
Qy	434	GTGAACCGTACGCTGGGAGCTGAGCGAGGCGGTGTACGCGCAGGACTCGCGCTG	493

Db	422	GTGAACCGTACGCTGGGAGGCTGAGCGAGGAGGCGGTGTACGCGCAGGACTCGCGCGTG	481
Qy	494	GAGCCTGTGGCTGGGCTCTCTGTACCGCCCGACGCGGCCCGGGGCGCTTAAAGCCTGTAAAC	553
Db	482	GAGCCTGTGGCTGGGCTCTCTGTACCGCCCGACGCGGCCCGGGGCGCTTAAAGCCTGTAAAC	541
Qy	554	CGGACACGAAATTTACGGTCCCGACGGTTTGGGGAAGCACCGTGCAGATCTCTTGGTGTG	613
Db	542	CGGACACGAAATTTACGGTCCCGACGGTTTGGGGAAGCACCGTGCAGATCTCTTGGTGTG	601
Qy	614	GCCTCTCATCAACGCGCGGCGGTGACCTTTCGACAGCAAGATCCATCTCGCTTATGAG	673
Db	602	GCCTCTCATCAACGCGCGGCGGTGACCTTTCGACAGCAAGATCCATCTCGCTTATGAG	661
Qy	674	AGATGGGCGTCTGGAGCGCTCATCTTTAACTTTCGCGGACCCGCAATGAGGTATCCCC	733
Db	662	AGAGGGGCGTCTGGAGCGCTCATCTTTAACTTTCGCGGACCCGCAATGAGGTATCCCC	721
Qy	734	ATGCTCTACCGGCGGTGACGATGACATTTGTCATCATGATCGGCAATCTGAAAGGCACA	793
Db	722	ATGCTCTACCGGCGGTGACGATGACATTTGTCATCATGATCGGCAATCTGAAAGGCACA	781
Qy	794	AAAAATCTGCAATCTATTCAAAGGCGCATCAAGTGACAATGGTGCATAGAGTAGGGAAA	853
Db	782	AAAAATCTGCAATCTATTCAAAGGCGCATCAAGTGACAATGGTGCATAGAGTAGGGAAA	841
Qy	854	AAACATGGCCCTTGGGTGAATCACTATTCAATTTTTTCTGTTCTGTCTCTTTTATT	913
Db	842	AAACATGGCCCTTGGGTGAATCACTATTCAATTTTTTCTGTTCTGTCTCTTTTATT	901
Qy	914	ATTACGGCGGCAACTGTGGGCTATTTTATCTTTCTGCTCGAGGCTACGGAATGCA	973
Db	902	ATTACGGCGGCAACTGTGGGCTATTTTATCTTTCTGCTCGAGGCTACGGAATGCA	961
Qy	974	AGAGCTCAAAGCAGGAGCAGAGGCAATTAAGGCGAGATGCTAAAAAGCTATTGGAAAG	1033
Db	962	AGAGCTCAAAGCAGGAGCAGAGGCAATTAAGGCGAGATGCTAAAAAGCTATTGGAAAG	1021
Qy	1034	CTTCAACTACGACACACTGAAACAAGGAGACAAGGAAATTTGGCCCTGTATGGAGATGTTGT	1093
Db	1022	CTTCAACTACGACACACTGAAACAAGGAGACAAGGAAATTTGGCCCTGTATGGAGATGTTGT	1081
Qy	1094	GCTGTGTCATTTGAATGCTATAAACCAATGATTTGGTACGATCTTAAACGTCGACCAT	1153
Db	1082	GCTGTGTCATTTGAATGCTATAAACCAATGATTTGGTACGATCTTAAACGTCGACCAT	1141
Qy	1154	ATTTTCCATAAGACATGTGTGACCCATGCTTTAAAAACAAGACTTGGCCCATGTGC	1213
Db	1142	ATTTTCCATAAGACATGTGTGACCCATGCTTTAAAAACAAGACTTGGCCCATGTGC	1201
Qy	1214	AAATGTGACATCTCAAGCTTTGGGAATTTGAGGTGAGATTTGAAGATGAGTGTCT	1273
Db	1202	AAATGTGACATCTCAAGCTTTGGGAATTTGAGGTGAGATTTGAAGATGAGTGTCT	1261
Qy	1274	TTCAAGTCCCTGTATCAATGAAATATCTAATAGTGCCTCTCCCTGAGAGGATAT	1333
Db	1262	TTCAAGTCCCTGTATCAATGAAATATCTAATAGTGCCTCTCCCTGAGAGGATAT	1321
Qy	1334	GCGAGGAGCCGATCATCTGGATATGCTTCAGTACAGGGAACAGATGAACCGCCTCTG	1393
Db	1322	GCGAGGAGCCGATCATCTGGATATGCTTCAGTACAGGGAACAGATGAACCGCCTCTG	1381
Qy	1394	GAGGAGCAGTGCAGTCAACAAATGAAAGTCTACAGCTGGTAAACCATGAAGGAAATCT	1453
Db	1382	GAGGAGCAGTGCAGTCAACAAATGAAAGTCTACAGCTGGTAAACCATGAAGGAAATCT	1441
Qy	1454	GTGGCAGTGGATGTTATTCCTCATGTGACAAACCACTTTTGAAGAGAGAGAACTCT	1513
Db	1442	GTGGCAGTGGATGTTATTCCTCATGTGACAAACCACTTTTGAAGAGAGAGAACTCT	1501
Qy	1514	AATCAAGAGACTGCTGTTCGAGAAATTAATCTTTAAATCTGTGTAAATAGAAACTTGA	1573
Db	1502	AATCAAGAGACTGCTGTTCGAGAAATTAATCTTTAAATCTGTGTAAATAGAAACTTGA	1561

```

QY 1574 ACCATTAGTAATAACAGAACTGCCAATCAGGGCCTAGTTCTTATTATAAATTTGGATAAA 1633
Db 1562 ACCATTAGTAATAACAGAACTGCCAATCAGGGCCTAGTTCTTATTATAAATTTGGATAAA 1621
QY 1634 TTTAATAAATAAGAGTGATACTGAAAGTGCTCAGATGACTAATAATATTATCTATAGTTAA 1693
Db 1622 TTTAATAAATAAGAGTGATACTGAAAGTGCTCAGATGACTAATAATATTATCTATAGTTAA 1681
QY 1694 AATGCGTTAAATAATATTAACTCTGTAACCTTTTTCACCAAACTCAATTATAATATTTT 1753
Db 1682 A--TGGCTTAAATAATATTAACTCTGTAACCTTTTTCACCAAACTCAATTATAATATTTT 1738
QY 1754 CATAGGCAAGTTTCTCTCTCAG*W74
Db 1739 CATAGGCAAGTTTCTCTCTCAG 1759

RESULT 3
AF394689 1297 bp mRNA linear PRI 25-JUL-2001
LOCUS Homo sapiens GRAIL (GRAIL) mRNA, complete cds.
DEFINITION AF394689
ACCESSION AF394689
VERSION AF394689.1 GI:15011451
KEYWORDS
SOURCE
ORGANISM Homo sapiens.
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 1297)
Soares,L.R. and Fathman,G.
REFERENCE
AUTHORS Soares,L.R. and Fathman,G.
TITLE Grail: a novel ring finger protein upregulated in anergic T cells
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 1297)
AUTHORS Soares,L.R. and Fathman,G.
DIRECT SUBMISSION
TITLE Direct Submission
JOURNAL Submitted (22-JUN-2001) Pathology, Stanford University, 800 Welch
Rd, Palo Alto, CA 94304, USA
FEATURES
Location/Qualifiers
1..1297
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="X"
gene 1..1297
/feature="GRAIL"
CDS 11..1297
/feature="GRAIL"
note="E3, ring finger ubiquitin ligase; regulated in
anergy-induced lymphocytes"
/codon_start=1
/product="GRAIL"
/protein_id="AAK77554.1"
/db_xref="GI:15011452"
/translation="MGPLPGVSGRGGSGFRLWCFLLALSPOAGSRGAEAVMT
AYLVNVRVPHGTGNRTVWELSEBVGVDQSPLEPVAGVLVPPDGLNACNPHNPF
TVPTVMSTQVSNLALIQGGGCTFADKHLAVERGASGAVLFPNPTNVEVPMWH
PGADVLAIMTGNLKTGKLIQSIQGIQVTVWIEVKGKHPWNHYSIFPVSPFPII
TYATGGIFIFYSRLRLNARXSKQRLKADAKAIGRLQLRLKQDKIEIGPDGS
CAVIEYKPNDLVRLITCNHIFKTCVDPWLEHRTCPMKCDILKALGIEVDGDS
SVSLQVPSVNSISNSASHEEDNRSETSASSYASVQGTDEPPLPEEHVQSTNESLQLVN
HEANSVAVDVIPHYNDPTFEDETPNQTAVREIKS"
BASE COUNT 324 a 311 c 355 g 303 t 4 others
ORIGIN
Query Match 72.2%; Score 1280.8; DB 9; Length 1297;
Best Local Similarity 99.1%; Pred. No. 5.8e-283;
Matches 1285; Conservative 0; Mismatches 12; Indels 0; Gaps 0;
QY 253 CGCGCGCGCATGGGGCGCGCGCTGGGGCGGGGCTCTCTGCCCGGTGGCTGGCGTT 312
Db 1 CGCGCGCGCATGGGGCGCGCTGCCCTGGGGCGGGGCTCTCTGCCCGGTGGCTGGCGTT 60
QY 313 TTCCAGATTGCTGCATGTTGCTTCTCTGCTGCCCTGAGTCCGCGAGGCCGCCGTTCCCG 372

```

```

Db 61 TTCCAGATTGCTGCATGTTGCTTCTCTGCTGGCCCTCAGTCCGCGAGCACCCGCTTCCCG 120
QY 373 GGGGGCTGAAGCAGCTGGACCGGGTACCTCAAGTGTCTCTGGCGGGTTCGACACAGGG 432
Db 121 GGGGGCTGAAGCAGCTGGACCGGGTACCTCAAGTGTCTCTGGCGGGTTCGACACAGGG 180
QY 433 AGTGAACCGTACGGTGTGGGAGCTGAGCGAGGAGGGGCTGTACGCCAGGACTCGCGCT 492
Db 181 AGTGAACCGTACGGTGTGGGAGCTGAGCGAGGAGGGGCTGTACGCCAGGACTCGCGCT 240
QY 493 GGAGCTGTGCTGGGCTCTGGTACCGCCGACGGGGCGGGGGCTTAACGGCTGTAA 552
Db 241 GGAGCTGTGCTGGGCTCTGGTACCGCCCGGAGGGGCGGGCTTAACGGCTGTAA 300
QY 553 CCGGCACACGAATTTACGGTGCCCAACGGTTTGGGGAAGACACCGTGAAGTCTCTTGGTT 612
Db 301 CCGGCACACGAATTTACGGTGCCCAACGGTTTGGGGAAGACACCGTGAAGTCTCTTGGTT 360
QY 613 GGGCCTCATCAACCGCGCGGGGCTGCACCTTCGACAGCAAGATCCATCTGGCTTATGA 672
Db 361 GGGCCTCATCAACCGCGCGGGGCTGCACCTTCGACAGCAAGATCCATCTGGCTTATGA 420
QY 673 GAGATGGGGCTCTGGAGCGGCTCATCTTTAACTTCCCGGGACCGCAATGAGTCAATCCC 732
Db 421 GAGATGGGGCTCTGGAGCGGCTCATCTTTAACTTCCCGGGACCGCAATGAGTCAATCCC 480
QY 733 CATGCTCACCCGGGTGCAGTAGACATTTGTTGCAATCATATGATCGGCAATCTGAAGGCAC 792
Db 481 CATGCTCACCCGGGTGCAGTAGACATTTGTTGCAATCATATGATCGGCAATCTGAAGGCAC 540
QY 793 AAAAATTCGCAATCTATTCAAAGAGGCATACAGTGAACAATGTCATAGAGTAGGAA 852
Db 541 AAAAATTCGCAATCTATTCAAAGAGGCATACAGTGAACAATGTCATAGAGTAGGAA 600
QY 853 AAAACATGGCCCTCTGGGTGAATCACTATTCAATTTTTTCTGTGCTCTTTTAT 912
Db 601 AAAACATGGCCCTCTGGGTGAATCACTATTCAATTTTTTCTGTGCTCTTTTAT 660
QY 913 TATTACGGCGCAACTGTGGGCTATTTTATCTTTTATCTGCTCGAAGGTACGGAATGC 972
Db 661 TATTACGGCGCAACTGTGGGCTATTTTATCTTTTATCTGCTCGAAGGTACGGAATGC 720
QY 973 AAGAGCTCAAGCAGGAGGAGGCAATTAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1032
Db 721 AAGAGCTCAAGCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 780
QY 1033 GCTTCAACTACGCACACTGAAACAGGAGAGCAAGGAAATTTGGCCCTGATGGAGATAGTTG 1092
Db 781 GCTTCAACTACGCACACTGAAACAGGAGAGCAAGGAAATTTGGCCCTGATGGAGATAGTTG 840
QY 1093 TGTGTGTGCATGAAATTTGATAAAACCAATGATTTGGTGAACGATCTTTAAAGTGAACCA 1152
Db 841 TGTGTGTGCATGAAATTTGATAAAACCAATGATTTGGTGAACGATCTTTAAAGTGAACCA 900
QY 1153 TATTTTCCATAAGACATGTTTGACCCCATGGCTGTATAAAACCAAGACTTTGCCCATGTG 1212
Db 901 TATTTTCCATAAGACATGTTTGACCCCATGGCTGTATAAAACCAAGACTTTGCCCATGTG 960
QY 1213 CAAATGTGACATCTCAAAAGCTTTGGGAATTTGAGGTGGATTTGAGATGGATCAAGTGTCT 1272
Db 961 CAAATGTGACATCTCAAAAGCTTTGGGAATTTGAGGTGGATTTGAGATGGATCAAGTGTCT 1020
QY 1273 TTTTCAAGTCCCTGTATCCAATGAATATCTAATAGTGCCTCTCCCATGAAGAGATAA 1332
Db 1021 TTTTCAAGTCCCTGTATCCAATGAATATCTAATAGTGCCTCTCCCATGAAGAGATAA 1080
QY 1333 TCGACGAGAGACCGCATCATCTGGGATATGCTTTCAGTACAGGAAACAGATGAACCGCTCT 1392
Db 1081 TCGACGAGAGACCGCATCATCTGGGATACGCTTCAGTACAGGAAACAGATGAACCGCTCT 1140
QY 1393 GAGGAAACAGTGCAGTCAACAAATGAAGAGTCTACAGTGGTAAACCATGAAGAGAAATTC 1452

```


Db 1141 GGAGAACACGTCAGTCAACAAATGAAAGTCTACAGCTGGTAAACCATGAACGAATTC 1200

Qy 1453 TGTGGCAGTGAATTTATTCCTCATGNGACACCCACCTTTGAAGAACGCAACTCC 1512

Db 1201 TGTGGCAGTGAATTTATTCCTCATGNGACACCCACCTTTGAAGAACGCAACTCC 1260

Qy 1513 TAATCAAGAGACTGCTGTGTCAGAGAAATTAATCTTAA 1549

Db 1261 TAATCAAGAGACTGCTGTGTCAGAGAAATTAATCTTAA 1297

RESULT 4

BC010477

LOCUS

DEFINITION Mus musculus, RIKEN cDNA 1300002C13 gene, clone MGC:19395

ACCESSION BC010477

VERSION

KEYWORDS

SOURCE MGC.

ORGANISM

Mus musculus

house mouse.

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

1 (bases 1 to 1928)

Strausberg,R.

Direct Submission

Submitted (10-JUL-2001) National Institutes of Health, Mammalian Gene Collection (MGC), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590, USA

NIH-MGC Project URL: <http://mgc.nci.nih.gov>

Contact: MGC help desk

Email: cgapb-re@mail.nih.gov

Tissue Procurement: Lohar Hennighausen Ph.D., Chu-Xia Deng Ph.D.

cDNA Library Preparation: Life Technologies, Inc.

cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)

DNA Sequencing by: Baylor College of Medicine Human Genome Sequencing Center

Center code: BCM-HGSC

Web site: <http://www.hgsc.bcm.tmc.edu/cdna/>

Contact: amg@bcm.tmc.edu

Gunaratne, P.H., Garcia, A.M., Lu, X., Hulyk, S.W., Hale, S.M., Yoon, V.S., Kowis, C.R., Lawrence, S., Martin, R.G., Muzny, D.M., Richards, S., Gibbs, R.A.

Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>

Series: IRAK Plate: 23 Row: b Column: 12

This clone was selected for full length sequencing because it passed the following selection criteria: matched mRNA gi: 12963610.

FEATURES

Location/Qualifiers

1..1928

/organism="Mus musculus"

/db_xref="taxon:10090"

/map="129,C57BL/6J,FVB/N"

/clone="MGC:19395 IMAGE:3154433"

/translations="MGPPPGIGYVCRGGGAARLLAWCFLLALSPHAPSGRAEAVVT AYLNWNRVPTGVNRTVWELSEGVYGDSPLEPVSVGLVPDGPALNACNPTNF TPTVWGSTVQVSNLALIQRGSGCTFADKHLASERGASGAVIFNPGRNRVIFPMH PGAGDVIFMIGNLKGTILQSGIQGVMTVIEVKGKHPWNHYISIFFVSVSFIIT TAATVAFIFYSARLNRAPQSRKQRLKADAKAIGKLQRLTKQKQKPGDGS CAVCIELYKPNDLVILTCNHIHFHTKVDVPLLEHRTCPMKCKDILKALGIEVDVEDG

CDS

176..1462

/note="Vector: pCMV-SPORT6"

/codon_start=1

/product="RIKEN cDNA 1300002C13 gene"

/protein_id="AAH10477.1"

/db_xref="GI:14714673"

/db_xref="LocusID:66889"

/translations="MGPPPGIGYVCRGGGAARLLAWCFLLALSPHAPSGRAEAVVT AYLNWNRVPTGVNRTVWELSEGVYGDSPLEPVSVGLVPDGPALNACNPTNF TPTVWGSTVQVSNLALIQRGSGCTFADKHLASERGASGAVIFNPGRNRVIFPMH PGAGDVIFMIGNLKGTILQSGIQGVMTVIEVKGKHPWNHYISIFFVSVSFIIT TAATVAFIFYSARLNRAPQSRKQRLKADAKAIGKLQRLTKQKQKPGDGS CAVCIELYKPNDLVILTCNHIHFHTKVDVPLLEHRTCPMKCKDILKALGIEVDVEDG

SVSLQVPVNEASNTASPHEDSRSETASSGYASVQGADEPPLLEHAQSANENLQLVN
HEANSVADVPHVDNPTFEDDETPQEAARVBIKS"

BASE COUNT 482 a 466 c 498 g 482 t

ORIGIN

Query Match 67.9%; Score 1205.2; DB 10; Length 1928;
Best Local Similarity 89.6%; Pred. No. 1.4e-265;
Matches 1364; Conservative 0; Mismatches 149; Indels 10; Gaps 6;

Qy 252 GCGCGCGCCATGGGCGCGCGCTGGGGCGGGGCTCTCTGCGCGCGCTGGCTGCGGCT 311

Db 165 GAGTGGCGCCATGGGCGCGCGCTGGGGCGGGGCTCTCTGCGCGCGCTGGCTGCGGAG 224

Qy 312 TTTCCAGATTTGCTGGCATGGTCTTCTGCTGGCCCTGAGTCCGAGGACACCCGGTTCCC 371

Db 225 CTGCCCGGCTACTGGCTTTGGTCTTCTCTGCTCTGAGTCCGACGCGCGCGGTTCCC 284

Qy 372 GGGGGGCTGAAGCAGTGTGGACCGGTACTCAAGCTGCTCTGGCGGGTCCGACACGG 431

Db 285 GGGGAGCGAAGCGGTGTGGACCGGTACTCAAGCTGCTCTGGCGGGTCCGACACCG 344

Qy 432 GAGTGAACCGTACCGTGTGGAGCTGAGCGAGGAGGGGCTGTACGGCAGGACTCGCGCG 491

Db 345 GAGTGAACCGCACCGTGTGGAGCTGAGCGAGGAGGGGCTGTACGGCAGGACTCGCGCG 404

Qy 492 TGGAGCTGTGGCTGGGGTCTCTGTTACCGCCGAGCGGCGCGGGCGCTTAAACGCTGTA 551

Db 405 TGGAGCGGCTCTCGGGGCTCTGTTACCGCCGAGCGGCGCGGGCGCTTAAACGCTGTA 464

Qy 552 ACCCGCACACCAATTTTCCAGCTGCGCCAGGTTTGGGGAAGCACCGTCAAGTCTCTTGGT 611

Db 465 ACCCGCACACCAATTTTCCAGCTGCGCCAGGTTTGGGGAAGCACCGTCAAGTCTCTTGGT 524

Qy 612 TGGCCCTCATCAACCGCGCGGGGCTGCACCTTCGACAGACAAGATCCATCTGGCTTATG 671

Db 525 TGGCCCTCATCAACCGCGGTGGAGGCTGCACCTTCGCGGACAGATCCATCTGGCTTCA 584

Qy 672 AGAGATGGCGCTCTGGAGCGCTCATCTTTAACTTCCCGGAGACCGGCAATGAGTCACTCC 731

Db 585 AGAGAGGGGCTTCTGGAGCGGCTCATCTTTAACTTCCCGGAGACCGGCAATGAGTCACTCC 644

Qy 732 CCATCTCTCACCCGGGTCAGTAGACATTTGTGCAATCATGATGGCAATCTGAAAGGCA 791

Db 645 CCATCTCTCACCCGGGTCAGTAGACATTTGTGCAATCATGATGGCAATCTGAAAGGAA 704

Qy 792 CAAAATTTCTGCAATTTTCAAGAGGATCAAGTGAACAATGTCATAGAAGTAGGGA 851

Db 705 CAAAATTTCTGCAATTTTCAAGAGGATCAAGTGAACAATGTCATAGAAGTAGGGA 764

Qy 852 AAAAAATGCGGCTGGGCTGGAATCACTATTCAATTTTCTGTTCTGCTCTCTTTTCA 911

Db 765 AAAAAATGCGGCTGGGCTGGAATCACTATTCAATTTTCTGTTCTGCTCTCTTTTCA 824

Qy 912 TTATTACGCGCGCAACTCTGGGCTATTTTATCTTTTATCTGCTCGAAGGCTACGGAATG 971

Db 825 TAAATACGCGCGCAACTCTGGGCTATTTTATCTTTTATCTGCTCGAAGATACGAATG 884

Qy 972 CAAAGCTCAAGAGGAGGAGGCAATTTAAAGGCGAGATGCTAAAAAGCTATTGAA 1031

Db 885 CAAAGCTCAAGAGGAGGAGGCAATTTAAAGGCGAGATGCTAAAAAGCTATTGAA 944

Qy 1032 GGCCTCAACTAGCACACTGAACAAGGAGACAGGAATTTGGCCCTGATGGAGTAGTT 1091

Db 945 AGCTTCAGCTGGCACCTTTGAAACAAGGAGACAGGAATTTGGCCCTGATGGAGTAGCT 1004

Qy 1092 GTGCTGTGTCATTTGAAATTTGTAACCAAAATGATTTGGTACGCAATCTTAAACGTGCAACC 1151

Db 1005 GTGCTGTGTCATTTGAGCTCTTAAAGCCAAATGATTTGGTGGCATCTCACTACCTGCAATC 1064

Qy 1152 ATATTTTCCATAAGACATGTTGTGACCCATGGCTGTTAAAAACAAGAATTTGCCCATGT 1211

Db 1065 ATATTTTCCATAAGACATGTTGTGACCCATGGCTGTTAAAAACAAGAATTTGCCCATGT 1124

QY 1212 GCAATGTGACATCTCAAGCTTTGGCAATTGAGTGGATGTTGAAGATGGATCAGTGT 1271
 Db 1125 GCAAGTGTGACATCTCAAGCTTTGGCAATTGAGTGGATGTTGAAGATGGATCAGTGT 1184
 QY 1272 CTTTCAAGTCCCTGTATCCCAATGAATATCTAATAGTGCCTCTCCCATGAAGAGGATA 1331
 Db 1185 CTTTCAAGTCCCTGTATCCCAATGAATATCTAATAGTGCCTCTCCCATGAAGAGGATA 1244
 QY 1332 ATCGCAGGAGACCGCATCTCTGATATGTTTCAGTACAGGGAACAGATGAACCGCTC 1391
 Db 1245 GTGCGAGTGCAGTGCATCATCTGATATGTTTCAGTACAGGGAACAGATGAACCGCTC 1304
 QY 1392 TGGAGGAACAGTGCAGTGCACAAATGAAGTCTACAGTGGTAAACCATGAACCAATT 1451
 Db 1305 TGGAGGAACAGTGCAGTGCACAAATGAAGTCTACAGTGGTAAACCATGAACCAATT 1364
 QY 1452 CTGTGGCAGTGGATGTTATCTCTCATGTNGACAACCCCACTTTGAAGAACCAAACTC 1511
 Db 1365 CTGTGGCAGTGGATGTTATCTCTCATGTNGACAACCCCACTTTGAAGAACCAAACTC 1424
 QY 1512 CTAATCAAGAGACTCTGTTGAGAAATTAATCTT-AAATCTGTGTAAATAGAAACT 1570
 Db 1425 CTGATCAAGAGAGACTCTGTTGAGAAATTAATCTT-AAATCTGTGTAAATAGAAACT 1484
 QY 1571 TGAACCATTAG-TAATAACAGAACTGCCAATCAGGCTCTAGTCTT-CTATTAAATTAATGG 1628
 Db 1485 TGAACCATTAG-TAATAACAGAACTGCCAATCAGGCTCTAGTCTT-CTATTAAATTAATGG 1544
 QY 1629 ATAAATTTAATAAATAGAGTGTACTGAAAGTGTCTCAGATGACTAATATTATGCTATA 1688
 Db 1545 GTAAA---CGTAAACAAAGATGATCTGAAAGTGTCTCAGATGACTAATATTATGCTATA 1601
 QY 1689 GTAAATGGCTTAAATAATTAATCTGTTAACTTTTCCACCAAACTCATTAATA 1748
 Db 1602 GTAAA---TGGCTTAAATATTTACCCAGTACCGTTT---CCACAAACTCACCATAACG 1657
 QY 1749 TTTTTCATAGGCAAGTTTCTCT 1771
 Db 1658 TTTTTCATAGGCAAGTTTCTCT 1680

RESULT 5
 AB041548 1936 bp mRNA linear ROD 30-JUN-2000
 LOCUS Mus musculus brain cDNA, clone MNCB-3816, similar to AF171875
 DEFINITION gl-related zinc finger protein (Mus musculus).
 ACCESSION AB041548
 VERSION AB041548.1 GI:7670361
 KEYWORDS fis (full insert sequence).
 SOURCE Mus musculus (strain: C57BL) cDNA to mRNA, clone_lib: Sugano mouse brain mncb clone: MNCB-3816.

ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (sites)
 Osada, N., Kusuda, J., Tanuma, R., Ito, A., Hirata, M., Sugano, S. and Hashimoto, K.
 Isolation of full-length cDNA clones from mouse brain cDNA library made by oligo-capping method

REFERENCE
 AUTHORS Hashimoto, K., Osada, N., Kusuda, J. and Sugano, S.
 TITLE Direct Submission
 JOURNAL Submitted (10-APR-2000) Katsuyuki Hashimoto, National Institute of Infectious Diseases, Division of Genetic Resources; 23-1, Toyama 1-chome, Shinjuku-ku, Tokyo 162-8640, Japan
 (E-mail: khashi@nih.go.jp, URL: http://www.nih.go.jp/yoken/genebank/, Tel: 81-3-5285-1111 (ex. 2120), Fax: 81-3-5285-1181)
 URL: http://www.nih.go.jp/yoken/genebank/
 LIB NAME: Sugano mouse brain mncb
 LAB HOST: TOP10
 VECTOR: pME18S-FL3
 1st strand cDNA was primed with an oligo (dT) primer

[ATGTGGCCTTTT] ; double-stranded cDNA was synthesized using specific 5' and 3' primers and amplified by PCR. The PCR product was digested with SfiI and size selection was performed to exclude fragments <1.5kb. The SfiI-digested PCR product was cloned into distinct DraIII sites of pME18S-FL3. XhoI sites just outside the DraIII sites can be used to isolate the cDNA insert. Library was constructed by Sugano et al. (University of Tokyo, Institute of Medical Science). Custom primer used for sequencing (5' end primer [CTTCTGCTCTAAAGCTGG]; 3' end primer [CGACTGCAGTCTGAGCA]).

A part of this sequence is reported in AU079081.

FEATURES
 source Location/Qualifiers
 1..1936
 /organism="Mus musculus"
 /strain="C57BL"
 /db_xref="taxon:10090"
 /clone="MNCB-3816"
 /clone_lib="Sugano mouse brain mncb"
 187..1473
 /note="unnamed protein product"
 /codon_start=1
 /protein_id="BAA95033.1"
 /db_xref="GI:7670362"
 /translation="MGPPRGIVYRCGCGAARLLAMCFLLALSPHAPGSRGAFAVVT
 AYLVNWRVPHGTGNTVWELSEGVYQDSPLFVSGVLVPPGPGALNACNPHNTP
 TVPTVMSGTVOVSWLALIQGGCTFADKVLHSLERGASGAVIFNFGTRNEVPMH
 PGAGDIVALIMTGNLKGILQSIQGIQVTMVEVKKHGWVNHYSIFFVSVFFII
 TAATVGYFIFYSARRLNARQSRQKADAKKAIKQLRLTKGDKIEIGPDGDS
 CAVCIELYKPNDLVRLITCNHIFHKTCTVDPMLHRTCPMKCKDILKALGTEVDVG
 SVSLQVPVNSASNTASPHSDRSSTASSGYASVQGADEPPELHAQSANENLQLVN
 HEANSVADVVPVVDNPTFDEDETQDEAAVREIKS"
 BASE COUNT 477 a 466 c 506 g 487 t
 ORIGIN
 Query Match 67.8%; Score 1203.6; DB 10; Length 1936;
 Best Local Similarity 89.5%; Pred. No. 3.2e-265;
 Matches 1363; Conservative 0; Mismatches 150; Indels 10; Gaps 6;
 QY 252 GCGCGCGCCCATGGGCGCGCGCTTGGGCGCGGGGTCTCTTGGCGGGTGGCTCGGCT 311
 Db 176 GAGTGGCGCCCATGGGCGCGCGCTTGGGCGCGGGGTCTCTTGGCGGGTGGCTCGGAG 235
 QY 312 TTTCCAGATTGCTGGCATGCTCTCTGCTGGCCCTGAGTCCGAGCACCCCGTTCCT 371
 Db 236 CTGCGCGGCTACTGGCTTGGTCTCTCTCTCTGAGTCCGCGCGCGGCTTCCT 295
 QY 372 GGGGGGCTGAAGCAGTGTGGACCGGCTACCTCAACGTGTCTCTGGCGGGTTCGCGACACG 431
 Db 296 GGGGAGCCGAGCGGTGTGGACCGGCTACCTCAACGTGTCTCTGGCGGGTTCGCGACACG 355
 QY 432 GAGTGACCGTACGTTGGAGCTGAGGAGGAGGGGTGTACGGCCAGGACTCGCGCC 491
 Db 356 GAGTGAACCGACCGTGTGGAGCTGAGCGAGAGGGGTGTGTACGGCCAGGACTCGCGCC 415
 QY 492 TGGAGCTCTGTGGGGTCTGTGTACCGCGCGCGCGCGGGCTTAAACGCTGTA 551
 Db 416 TGGAGCGCTCTCGGGGTCTGTGTACCGCGCGCGCGCGGGGTCTCAACGCTGTA 475
 QY 552 ACCCGCACAGAAATTCACGTTGCCCA CGGTTTGGGGAGCACCGTGTCAAGTCTCTTGGT 611
 Db 476 ACCCGCACAGCAATTCACGTTGCCCA CGGTTTGGGGAGCACCGTGTCAAGTCTCTTGGT 535
 QY 612 TGGCCCTCATCCACGCGCGGGGGTGCACCTTTCGCGAGACAGATCATCTGGCTTATG 671
 Db 536 TGGCCCTCATCCACGCGCGGGGTGCACCTTTCGCGAGACAGATCATCTGGCTTATG 595
 QY 672 AGAGATGGCGGTCTGGAGCGGTCTCTTTAACTTCCCGGGGACCCGCAATGAGTCTATCC 731
 Db 596 AGAGAGGGGCTTCTGGAGCGGTCTCTTTAACTTCCCGGGGACCCGCAATGAGTCTATCC 655
 QY 732 CCATGTCTCACCCGGGTGAGTAGACATTTGTTGCAATCATGATCGGCAATCTTGAAGGCA 791
 Db 656 CCATGTCTCACCCGGGTGAGTAGACATTTGTTGCAATCATGATCGGCAATCTTGAAGGAA 715


```

QY 623 CAACGCGCGGGGCTGCACCTTCGACAGACAAGATCCATCTGGCTTATGAGATGGCG 682
Db 361 CAACGCGGTGGAGGCTGCACCTTCGCGGACAAGATCCATCTGGCTTCAGAGAGAGGGCT 420
QY 683 TCTGAGCGGTCATCTTTAACTTCCCGGACCGCGAATGAGTCATCCCATGCTCTCAC 742
Db 421 TCTGAGCGGTCATCTTTAACTTCCCGGACCGCGAATGAGTCATCCCATGCTCTCAC 480
QY 743 CCGGGTGCAGTACATCTTTGCAATCATGATCGCAATCTGAAAGGACACAAAATTCG 802
Db 481 CCGGGTGCAGTACATCTTTGCAATCATGATCGCAATCTGAAAGGACACAAAATTCG 540
QY 803 CAATCTATTCAAGAGGATCAAGTACAAATGCTGATAGAGTAGGAGAAAACATGGC 862
Db 541 CAGTCTATTCAAGAGGATCAAGTACAAATGCTGATAGAGTAGGAGAAAACATGGC 600
QY 863 CTTGGGTGAATCACTATTCAATTTTTCGTTCTGTCGCTTTTATTATTATGCGGG 922
Db 601 CTTGGGTGAATCACTATTCAATTTTTCGTTCTGTCGCTTTTATTATTATGCGGA 660
QY 923 GCAACTGTGGCTATTTTATCTTTTATCTGCTGAAGGCTACGGAATGCAAGAGCTCAA 982
Db 661 GCAACCGTGGCTATTTTATCTTTTATCTGCTGAAGATTCGAAATGCAAGAGCTCAA 720
QY 983 AGCAGGAGCAGAGCAATTAAAGGAGATGCTTAAAGAGCTATTGGAAGGCTTCACTA 1042
Db 721 AGCAGGAGCAGAGCAATTAAAGGAGATGCTTAAAGAGCTATTGGAAGGCTTCACTG 780
QY 1043 CGCACACTGAAACAAGGAGACAAGAAATTTGGCCCTCATGAGATAGTGTGCTGTGC 1102
Db 781 CGCACCTTGAACAAGGAGACAAGAAATTTGGCCCTCATGAGATAGTGTGCTGTGC 840
QY 1103 ATTGAATGTATAAACAATGATTTGGTACGATCTTAAACGTCGCAACCATATTTCCAT 1162
Db 841 ATTGAGCTCTATAAGACCAATGATTTGGTGGCATCTTAACCTGCAATCATATTTCCAT 900
QY 1163 AAGACATGTGTGACCCATGCTGTTTAAACAACAAGACTTGGCCCATGTCGCAATGTGAC 1222
Db 901 AAGACATGTGTGACCCGCTGCTTTTAAACAACAAGACTTGGCCCATGTCGCAATGTGAC 960
QY 1223 ATACTCAAGGCTTTGGGAATTTGAGTGGATGTTGAAGATGGATCAGTGTCTTTTACAAGTC 1282
Db 961 ATTCTCAAGGCTCTGGGAATTTGAGTGGATGTTGAAGATGGATCAGTGTCTTTACAAGTT 1020
QY 1283 CCTGTATCCAATGAATATCTAATAGTGCCTCTCCCATGAAGAGGATAATCGCAGGAG 1342
Db 1021 CCTGTATCCAATGAATATCTAATAGTGCCTCTCCCATGAAGAGGACAGTCGCAATGAG 1080
QY 1343 ACCGATCATCTGATATGCTTCAGTACAGGAGACAGATGAACCGCTCTGGAGGACAC 1402
Db 1081 ACTGCATCATCTGATATGCTTCAGTACAGGAGCAGATGAGCCCTCTGGAGGAAACAT 1140
QY 1403 GTGAGTCAACAATGAAGTCTACAGTGGTAAACCATGAAGCAAAATTCGTGGCAGTG 1462
Db 1141 GCGCAGTCAGCAATGAATCTACAGTGGTAAACCATGAAGCAAAATTCGTGGCAGTG 1200
QY 1463 GATGTTATCTCATGNGACACCCACCTTTGAAGAGACGAAATCTCTAATCAAGAG 1522
Db 1201 GATGTTATCTCATGNGACACCCACCTTTGAAGAGACGAAATCTCTAATCAAGAG 1260
QY 1523 ACTGCTGTTCCAGAAATTAATCTTAA 1549
Db 1261 GCAGCTGTTCCGGAGATTAATCTTAA 1287

RESULT 7
AK027169 1871 bp mRNA linear PRI 29-SEP-2000
LOCUS Homo sapiens cDNA: FLJ23516 fis, clone LNG04848.
DEFINITION AK027169
ACCESSION AK027169
VERSION AK027169.1 GI:10440232
KEYWORDS oligo capping; fis (full insert sequence).
SOURCE Homo sapiens human lung cDNA to mRNA, clone lib:LNG clone:LNG04848.

```

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (sites)
AUTHORS Kawakami,T., Noguchi,S., Itoh,T., Shigeta,K., Senba,T., Matsumura,K., Nakajima,Y., Mizuno,T., Morinaga,M., Tanigami,A., Fujiwara,T., Ono,T., Yamada,K., Fujii,Y., Ozaki,K., Hirao,M., Ohmori,Y., Ota,T., Suzuki,Y., Obayashi,M., Nishi,T., Shibahara,T., Tanaka,T., Nakamura,Y., Isegai,T. and Sugano,S.
NEDO human cDNA sequencing project
Unpublished
2 (bases 1 to 1871)
AUTHORS Sugano,S., Suzuki,Y., Ota,T., Obayashi,M., Nishi,T., Isegai,T., Shibahara,T., Tanaka,T. and Nakamura,Y.
Direct Submission
Submitted (29-AUG-2000) Sumio Sugano, Institute of Medical Science, University of Tokyo, Laboratory of Genome Structure Analysis, Human Genome Center, Shirokane-dai, 4-6-1, Minato-Ku, Tokyo 108-8639, Japan (E-mail:cdna@ims.u-tokyo.ac.jp, Tel:81-3-5449-5286, Fax:81-3-5449-5416)
NEDO human cDNA sequencing project supported by Ministry of International Trade and Industry of Japan; cDNA full insert sequencing; Research Association for Biotechnology; cDNA library construction, 5'- & 3'-end one pass sequencing; Department of Virology and Human Genome Center, Institute of Medical Science, University of Tokyo (partly supported by Science and Technology Agency).

FEATURES
source
1..1871
/organism="Homo sapiens"
/db xref="taxon:9606"
/clone="LNG04848"
/tissue type="human lung"
/clone lib="LNG"
/notes="cloning vector pME18SFL3"
76..546
/note="unnamed protein product"
/codon start=1
/protein id="BAB15682.1"
/db xref="GI:10440233"
/translation="MEIVLCALNCINQIMIVSILTCNHIFHKTCTVDPWLEHRTCPMCKDILKALGIEVDVDSASLQVPSNEISNASSHEEDNRSEASSGVASVQGTDEPPIEEHVQSTNESLQVNEANSVAVDVIPIHVDNPTFEDETPNQETAVREIKS"

BASE COUNT 670 a 277 c 321 g 603 t
ORIGIN

Query Match 40.3%; Score 714.4; DB 9; Length 1871;
Best Local Similarity 97.9%; Pred. No. 5e-153;
Matches 755; Conservative 0; Mismatches 12; Indels 4; Gaps 3;

QY 1005 AGGCAGATGCTAAAAAGCTATTGGAAGGCTTCAACTACGCACACTGAAACAAGGAGACA 1064
Db 1 AGGCAGATGCTAAAAAGCGTTAGGAAGCTTCAACTACACTGAAACAAGGAGACA 60
QY 1065 AGGAATTTGGCCCTGATGAGATAGTGTGCTGTGCTGATGATTAATGATTAACAATG 1124
Db 61 AGGAATTTGGCCCTGATGAGATAGTGTGCTGTGCTGATGATTAATGATTAACAATG 120
QY 1125 ATTTGGGTAC-GCATCTTAACTGCAACCATATTTTTCATAGACATGTTGTGACCCCATGG 1183
Db 121 ATTTGGGTACGACATCTTAACCTGCAACCATATTTTTCATAGACATGTTGTGACCCCATGG 180
QY 1184 CTGTTAAACAACAAGCTTGGCCCATGTCGCAATGTGCAATCTCAAGCTTTTGGGAATT 1243
Db 181 CTGTTAAACAACAAGCTTGGCCCATGTCGCAATGTGCAATCTCAAGCTTTTGGGAATT 240
QY 1244 GAGTGGGATGTTGAGATGATGATGCTCTTTTACAAGTCCCTGTATCCAATGAATATCT 1303
Db 241 GAGTGGGATGTTGAGATGATGATGATGCTCTTTTACAAGTCCCTGTATCCAATGAATATCT 300
QY 1304 AATAGTGCCTCTCCCATGAAGAGATAATCGCAGCGAGACCGCATCATCTGGGATATGCT 1363
Db 301 AATAGTGCCTCTCCCATGAAGAGATAATCGCAGCGAGACCGCATCATCTGGGATATGCT 360

QY 1364 TCAGTACAGGACAGATGAACCGCCTCTGGAGGACACGTCAGTCAGTCAACAAATGAAAGT 1423
 |||||
 Db 361 TCAGTACAGGACAGATGAACCGCCTCTGGAGGACACGTCAGTCAGTCAACAAATGAAAGT 420
 |||||
 QY 1424 CTACAGCTGGTAAACCATCAAGCAATCTCTGGAGGACACGTCAGTCAGTCAACAAATGAAAGT 1483
 |||||
 Db 421 CTACAGCTGGTAAACCATCAAGCAATCTCTGGAGGACACGTCAGTCAGTCAACAAATGAAAGT 480
 |||||
 QY 1484 AACCCAACTTTGAAGACAGCAAACTCTCAATCAAGAGACTGCTGTTTCGAGAAATTAATA 1543
 |||||
 Db 481 AACCCAACTTTGAAGACAGCAAACTCTCAATCAAGAGACTGCTGTTTCGAGAAATTAATA 540
 |||||
 QY 1544 TCTTAAATCTGTGTAATAGAAACTTGAACCATTAGTAATAACAGAACTGCCAATCAG 1603
 |||||
 Db 541 TCTTAAATCTGTGTAATAGAAACTTGAACCATTAGTAATAACAGAACTGCCAATCAG 600
 |||||
 QY 1604 GGCCTAGTTCTTATTAATAATTTGATTAATTTAATAAATTAAGAGTGTATCTGAAAGTG 1663
 |||||
 Db 601 GGCCTAGTTCTTATTAATAATTTGATTAATTTAATAAATTAAGAGTGTATCTGAAAGTG 660
 |||||
 QY 1664 CTCAGATGACTAATATTATGCTATAGTTAAATGGCTTAAATATTTAACTGTTAACT 1723
 |||||
 Db 661 CTCAGATGACTAATATTATGCTATAGTTAAATGGCTTAAATATTTAACTGTTAACT 718
 |||||
 QY 1724 TTTTCCCAAACTCATTAATATTTTTCATAGCAAGTTTCTCTCAG 1774
 |||||
 Db 719 TTTTCCCA-AAAACTCATTAATATTTTTCATAGCAAGTTTCTCTCAG 768
 |||||

RESULT 8

AL391315 169812 bp DNA linear PRI 27-JUN-2001
 LOCUS Human DNA sequence from clone RP11-150F24 on chromosome X, complete
 DEFINITION sequence.
 ACCESSION AL391315
 VERSION AL391315.22 GI:14575271
 KEYWORDS HTG.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 1 (bases 1 to 169812)
 Brown, A.
 Direct Submission
 Submitted (27-JUN-2001) Sanger Centre, Hinxton, Cambridgeshire,
 CB10 1SA, UK. E-mail enquiries: humquery@sanger.ac.uk
 requests: clonerequest@sanger.ac.uk

On Jun 28, 2001 this sequence version replaced gi:14455902.
 During sequence assembly data is compared from overlapping clones.
 Where differences are found these are annotated as variations
 together with a note of the overlapping clone name. Note that the
 variation annotation may not be found in the sequence submission
 corresponding to the overlapping clone, as we submit sequences with
 only a small overlap as described above.
 This sequence was finished as follows unless otherwise noted: all
 regions were either double-stranded or sequenced with an alternate
 chemistry or covered by high quality data (i.e., phred quality >= 30);
 an attempt was made to resolve all sequencing problems, such
 as compressions and repeats; all regions were covered by at least
 one plasmid subclone or more than one M13 subclone; and the
 assembly was confirmed by restriction digest. The following
 abbreviations are used to associate primary accession numbers given
 in the feature table with their source databases: Em, EMBL; SW.,
 SWISSPROT; Tr, TREMBL; Wp, WORMPEP; Information on the WORMPEP
 database can be found at
 http://www.sanger.ac.uk/Projects/C_elegans/wormpep This sequence
 was generated from part of bacterial clone contigs of human
 chromosome X, constructed by the Sanger Centre Chromosome X Mapping
 Group. Further information can be found at
 http://www.sanger.ac.uk/HGP/ChrX
 RP11-150F24 is from the library RPI1-11.1 constructed by the group
 of Pieter de Jong. For further details see

http://www.chori.org/bacpac/home.htm

VECTOR: pBACes.6
 This sequence is the entire insert of clone RP11-150F24 The true
 left end of clone RP11-321G1 is at 6861 in this sequence. The true
 right end of clone RP11-697G3 is at 161410 in this sequence.

FEATURES

source

Location/Qualifiers

1..169812

/organism="Homo sapiens"

/db_xref="taxon:9606"

/chromosome="X"

/clone="RP11-150F24"

/clone_lib="RPI1-11.1"

12..569

/note="match: GSS: Em:AQ375615"

/note="2 copies 36 mer 90% conserved"

misc_feature

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

repeat_region

```

/note="CpG island"
24009..24384 repeat: matches 310. .694 of consensus"
/note="LIM3e repeat: matches 310. .694 of consensus"
complement(24313..24743)
/note="match: GSS: Em:AQ923340"
25462..25711
/note="MIR repeat: matches 2. .256 of consensus"
25838..25939
/note="MIR repeat: matches 6. .106 of consensus"
26420..26566
/note="MIR repeat: matches 2. .151 of consensus"
28132..28302
/note="MIR repeat: matches 64. .238 of consensus"
29706..29835
/note="L2 repeat: matches 2606. .2746 of consensus"
30126..30458
/note="MIR2 repeat: matches 2. .344 of consensus"
30873..31184
/note="AluX repeat: matches 1. .312 of consensus"
34418..34503
/note="LIP3 repeat: matches 6061. .6146 of consensus"
34518..34851
/note="MIR2 repeat: matches 1. .344 of consensus"
35308..35457
/note="MIR repeat: matches 1. .162 of consensus"
35828..36039
/note="MIR repeat: matches 7. .226 of consensus"
36274..36349
/note="19 copies 4 mer ttc 76% conserved"
36353..36642
/note="AluX repeat: matches 1. .291 of consensus"
37753..37919
/note="FRAM repeat: matches -1. .165 of consensus"
38928..39134
/note="L2 repeat: matches 2467. .2703 of consensus"
39127..39319
/note="L2 repeat: matches 2031. .2228 of consensus"
39546..39726
/note="MER5A repeat: matches 1. .186 of consensus"
39738..40910
/note="Charliela repeat: matches 1. .1258 of consensus"
40911..41435
/note="LIP5 repeat: matches 5616. .6143 of consensus"
41436..41674
/note="Charliela repeat: matches 1258. .207 of consensus"
41675..41942
/note="AluY repeat: matches 1. .283 of consensus"
41943..42098
/note="Charliela repeat: matches 207. .1455 of consensus"
42634..42699
/note="MSTB repeat: matches 356. .426 of consensus"
43609..43659
/note="L2 repeat: matches 2696. .2746 of consensus"
45090..45187
/note="L2 repeat: matches 2606. .2705 of consensus"
45672..46211
/note="LIM4 repeat: matches 5700. .6295 of consensus"
46808..47107
/note="AluJb repeat: matches 1. .301 of consensus"
47190..47271
/note="HY1 repeat: matches 28. .111 of consensus"
47355..47455
/note="MER63 repeat: matches 5. .734 of consensus"
47525..47693
/note="MIR repeat: matches 3. .196 of consensus"
47826..47978
/note="match: GSS: Em:AQ136922"
47985..48294
/note="match: GSS: Em:AQ136922"
48203..50340
/note="LIM1 repeat: matches -1389. .1172 of consensus"
50335..51398

```

```

/note="LIP2 repeat: matches 1679. .2716 of consensus"
51399..51743
/note="AluJb repeat: matches 1. .305 of consensus"
51744..52940
/note="LIP2 repeat: matches 2716. .3982 of consensus"
52917..54922
/note="LIP2 repeat: matches 4138. .6146 of consensus"
54936..57273
/note="LIM3 repeat: matches 3951. .6304 of consensus"
57453..58059
/note="LIMB3 repeat: matches 5276. .5875 of consensus"
58056..58804
/note="LIP10 repeat: matches 5104. .5833 of consensus"

Query Match      38.0%; Score 674.4; DB 9; Length 169812;
Best Local Similarity 99.9%; Pred. No. 1.9e-143;
Matches 675; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 74 CCGAGGAGCTGCATCTCGCGCAACCTGTGTGCTGAGCTACGTGCTCTTCCACCTCGCGGCGACCTGCTCAAG 193
Db 23909 CCGAGGAGCTGCATCTCGCGCAACCTGTGTGCTGAGCTACGTGCTCTTCCACCTCGCGGCGACCTGCTCAAG 23968

Qy 134 TAGCTCAGCTCCCGAGTCTCACTTCTTCCACCTCGCGGCGACCTGCTCAAG 193
Db 23969 TAGCTCAGCTCCCGAGTCTCACTTCTTCCACCTCGCGGCGACCTGCTCAAG 24028

Qy 194 ACCAGGCTCTGCCAAGCGCTAGGAGGCGCGTCCAGAGGCGCGTAGGGAACCTGCGGAGC 253
Db 24029 ACCAGGCTCTGCCAAGCGCTAGGAGGCGCGTCCAGAGGCGCGTAGGGAACCTGCGGAGC 24088

Qy 254 GCGCGCCGCAATGGGCGCGCGCTGCGGCGCGGCTCTCTGCGCGGCTGCTGCGGCTTT 313
Db 24089 GCGCGCCGCAATGGGCGCGCGCTGCGGCGCGGCTCTCTGCGCGGCTGCTGCGGCTTT 24148

Qy 314 TCCAGATGCTGGCATCGTCTTCTGCTGCGCGCTGCTGCGGCGCGGCTGCTGCGGCTTT 373
Db 24149 TCCAGATGCTGGCATCGTCTTCTGCTGCGCGCTGCTGCGGCGCGGCTGCTGCGGCTTT 24208

Qy 374 GGGGCTGAAGCAGTGTGGACCGCGTACCTCAACGTGTCTTGGGGGTTCCGCGACACCGGA 433
Db 24209 GGGGCTGAAGCAGTGTGGACCGCGTACCTCAACGTGTCTTGGGGGTTCCGCGACACCGGA 24268

Qy 434 GTGAACGTCAGTGTGGAGCTGAGGAGGCGGTGTACGCGCAGGACTGCGCGCTG 493
Db 24269 GTGAACGTCAGTGTGGAGCTGAGGAGGCGGTGTACGCGCAGGACTGCGCGCTG 24328

Qy 494 GAGCTGTGGCTGGGCTCTGGTACCGCGCGCGCGCGCGCGCTTAAAGCTGTAAAC 553
Db 24329 GAGCTGTGGCTGGGCTCTGGTACCGCGCGCGCGCGCGCGCTTAAAGCTGTAAAC 24388

Qy 554 CCGCACACGAATTTACGCGTCCCGACCGTTTGGGGAAGCACCGGTGCAAGTCTCTTGGTTG 613
Db 24389 CCGCACACGAATTTACGCGTCCCGACCGTTTGGGGAAGCACCGGTGCAAGTCTCTTGGTTG 24448

Qy 614 GCGCTATCCACCGCGCGCGGCTGCACTTCCGACACAGATCCATCTGGCTATGAG 673
Db 24449 GCGCTATCCACCGCGCGCGGCTGCACTTCCGACACAGATCCATCTGGCTATGAG 24508

Qy 674 AGATGGGCGCTCTGAGCGCGTCTTTAACTTCCCGCGGACCCCGCAATGAGTCTATCCCC 733
Db 24509 AGATGGGCGCTCTGAGCGCGTCTTTAACTTCCCGCGGACCCCGCAATGAGTCTATCCCC 24568

Qy 734 ATGTCTACCGCGGTG 749
Db 24569 ATGTCTACCGCGGTG 24584

RESULT 9
AL591467 169863 bp DNA linear HTG 10-JUL-2001
LOCUS Homo sapiens chromosome X clone RP11-697G3, *** SEQUENCING IN
DEFINITION PROGRESS ***, in ordered pieces.
ACCESSION AL591467

```



```

VERSION      AL591467.3  GI:14348539
KEYWORDS     HTG; HTGS_PHASE2; HTGS_CANCELLED.
SOURCE       human.
ORGANISM     Homo sapiens
REFERENCE    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS      Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
TITLE        1 (bases 1 to 169863)
JOURNAL      Bird.C. Submission
COMMENT      Submitted (10-JUL-2001) Sanger Centre, Hinxton, Cambridgeshire,
            CB10 1SA, UK. E-mail enquiries: humquery@sanger.ac.uk
            requests: clonerequest@sanger.ac.uk
            On Jun 12, 2001 this sequence version replaced gi:14268300.
            ----- Genome Center
            Center: Sanger Centre
            Center code: SC
            Web site: http://www.sanger.ac.uk
            Contact: humquery@sanger.ac.uk
            ----- Project Information
            Center project name: BA697G3
            ----- Summary Statistics
            Sequencing program: XGAP4; version 4.5
            Chemistry: Dye-terminator Big Dye; 100% of reads
            Consensus quality: 157318 bases at least Q40
            Consensus quality: 157886 bases at least Q30
            Consensus quality: 158243 bases at least Q20
            Insert size: 169863; sum-of-contigs
            Insert size: 169949; 0.8% error; agarose-fp
            Quality coverage: 5.85x in Q20 bases; sum-of-contigs Quality
            coverage: 6.21x in Q20 bases; agarose-fp
            -----
            * NOTE: This is a 'working draft' sequence.
            * This sequence will be replaced
            * by the finished sequence as soon as it is available and
            * the accession number will be preserved.
FEATURES     Location/Qualifiers
             source
               1..169863
               /organism="Homo sapiens"
               /db_xref="taxon:9606"
               /chromosome="X"
               /clone="RP11-697G3"
               /clone_lib="RPC1-11.3"
             misc_feature
               1..169863
               /note="assembly fragment: 02868"
BASE COUNT   51891 a 31100 c 31417 g 55455 t
ORIGIN
Query Match      38.0%; Score 674.4; DB 2; Length 169863;
Best Local Similarity 99.9%; Pred. No. 1.9e-143;
Matches 675; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 74 CCGAGAGCTGATCTGGGCAACCTGTGTCTGACGCTAGCTGCTCTCTGCTCCGACG 133
DB 23909 CCGAGAGCTGATCTGGGCAACCTGTGTCTGACGCTAGCTGCTCTCTGCTCCGACG 23968
QY 134 TAGCTCGGAGCTCCCGAGTCTCACTCCATTCCTTCCCACTGCGCGCACCTGCTCAAG 193
DB 23969 TAGCTCGGAGCTCCCGAGTCTCACTCCATTCCTTCCCACTGCGCGCACCTGCTCAAG 24028
QY 194 ACCAGGGTCTTGCCAAAGCGCTAGGAGGCGCGTGCAGGGGCGCTAGGAACTCGCGAGC 253
DB 24029 ACCAGGGTCTTGCCAAAGCGCTAGGAGGCGCGTGCAGGGGCGCTAGGAACTCGCGAGC 24088
QY 254 GGGCGGCGCATGGGCGCGCGCTGGGCGCGGGTCTCTGCGCGGGTGGGCTGGGCTTT 313
DB 24089 GGGCGGCGCATGGGCGCGCGCTGGGCGCGGGTCTCTGCGCGGGTGGGCTGGGCTTT 24148
QY 314 TCCAGATTGCTGGCATGGTGTCTTCTGCTGGCCCTGAGTCCGAGGACACCGGTTCCCGG 373
DB 24149 TCCAGATTGCTGGCATGGTGTCTTCTGCTGGCCCTGAGTCCGAGGACACCGGTTCCCGG 24208
QY 374 GGGGCTGAAGAGTGTGACCGCGTACCTCAACGTGTCTTGGCGGGTTCCGCAACACGGA 433

```

```

DB 24209 GGGGCTGAAGCAGTGTGACCGCGTACCTCAACGTGTCTTGGCGGGTTCCGCAACACGGA 24268
QY 434 GTGAACCCGTACCGTGTGGGAGCTGAGCGAGGAGGCGGTGTACGGCCAGACTCGCGCTG 493
DB 24269 GTGAACCCGTACCGTGTGGGAGCTGAGCGAGGAGGCGGTGTACGGCCAGACTCGCGCTG 24328
QY 494 GAGCCTGTGGTGGGCTCTGTGACCGCCGACCGGCGCGGGCGCTTAAAGCCTGTAAAC 553
DB 24329 GAGCCTGTGGTGGGCTCTGTGACCGCCGACCGGCGCGGGCGCTTAAAGCCTGTAAAC 24388
QY 554 CGGCACACGAATTTTCCACGCTGCCACCGCTTTGGGGAAGCACCGTGCAGAGTCTCTTGGT 613
DB 24389 CGGCACACGAATTTTCCACGCTGCCACCGCTTTGGGGAAGCACCGTGCAGAGTCTCTTGGT 24448
QY 614 GCCCTCATCCAAACCGCGCGGGGCTGACCTTTCGACAGCAAGATCCATCTCTGGCTTATGAG 673
DB 24449 GCCCTCATCCAAACCGCGCGGGGCTGACCTTTCGACAGCAAGATCCATCTCTGGCTTATGAG 24508
QY 674 AGATGGGCTCTGGAGCGCTCATCTTTAACTTCCCGGAGCCGCAATGAGTGCATCCGC 733
DB 24509 AGAGGGGCGCTGAGGAGCGCTCATCTTTAACTTCCCGGAGCCGCAATGAGTGCATCCGC 24568
QY 734 ATGTCTCACCCCGGGTG 749
DB 24569 ATGTCTCACCCCGGGTG 24584

RESULT 10
AX071980 LOCUS AX071980 404 bp DNA linear PAT 25-JAN-2001
DEFINITION Sequence 2452 from Patent WO0102568.
ACCESSION AX071980
VERSION AX071980.1 GI:12582331
KEYWORDS human.
SOURCE human.
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
          1 (bases 1 to 404)
          Williams,D.T., Escobedo,J., Innis,M.A., Garcia,P.D., Klinger,J.,
          Kassam,A., Reinhard,C., Randazzo,F., Kennedy,G.C., Pot,D.,
          Lamson,G., Drmanac,R., Crkenjakov,R., Drmanac,S., Dickson,M.,
          Labat I., Lechkowitz,D., Kita,D., Garcia,V. and Strache-Crain,B.
          Human genes and gene expression products
          Patent: WO 0102568-A 2452 11-JAN-2001;
          CHIRON CORPORATION (US) ; HYSEQ, INC. (US)
FEATURES     Location/Qualifiers
             source
               1..404
               /organism="Homo sapiens"
               /db_xref="taxon:9606"
BASE COUNT   134 a 81 c 90 g 99 t
ORIGIN
Query Match      22.1%; Score 392.2; DB 6; Length 404;
Best Local Similarity 99.0%; Pred. No. 2.8e-79;
Matches 394; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1194 ACAAGACTTGGCCCATGTGCAAAATGTGACATACTCAAGCTTTGGGAATTGAGGTGATG 1253
DB 7 AGAGGACTTGGCCCATGTGCAAAATGTGACATACTCAAGCTTTGGGAATTGAGGTGATG 66
QY 1254 TTGAAGATGATCAGTGTCTTTTCAAGTCCCTGTATCCAAATATCTAATAGTGCCT 1313
DB 67 TTGAAGATGATCAGTGTCTTTTCAAGTCCCTGTATCCAAATATCTAATAGTGCCT 126
QY 1314 CTTCCCATGAAGAGGATATTCGACGAGACCGCATCATCTGGATATGCTTCAGTACAGG 1373
DB 127 CTTCCCATGAAGAGGATATTCGACGAGACCGCATCATCTGGATATGCTTCAGTACAGG 186
QY 1374 GAACAGATGAACCGGCTCTGGAGGAACACGTCAGTCAACAAATGAAAGTCTACAGCTGG 1433
DB 187 GAACAGATGAACCGGCTCTGGAGGAACACGTCAGTCAACAAATGAAAGTCTACAGCTGG 246

```


QY 1434 TAAACCATGAAGCAAAATTCGTGGCAGTGGATGTTATTCCTCATGTNGACAACCCAACT 1493
 Db 247 TAAACCATGAAGCATATTCGTGGCAGTGGATGTTATTCCTCATGTNGACAACCCAACT 306
 QY 1494 TTGAAGAGAGCAAACTCTTAATCAAGAGACTGCTGTTGAGAAATTAATCTTAAATC 1553
 Db 307 TTGAAGAGAGCAAACTCTTAATCAAGAGACTGCTGTTGAGAAATTAATCTTAAATC 366
 QY 1554 TGTGTAATAGAAAATCTTGAACCATTTAGTAATAACAGA 1591
 Db 367 TGTGTAATAGAAAATCTTGAACCATTTAGTAATAACAGA 404
 RESULT 11
 AX341568
 LOCUS
 DEFINITION Sequence 1815 from Patent WO0196388. PAT 10-JAN-2002
 ACCESSION AX341568
 VERSION AX341568.1 GI:18137550
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Jiang, Y., Harlocker, S.L. and Secrist, H.
 TITLE Compositions and methods for the therapy and diagnosis of colon cancer
 JOURNAL Patent: WO 0196388-A 1815 20-DEC-2001;
 CORIXA CORPORATION (US)
 FEATURES
 source Location/Qualifiers
 1..646
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 BASE COUNT 226 a 103 c 106 g 208 t 3 others
 ORIGIN
 Query Match 21.0%; Score 372.6; DB 6; Length 646;
 Best Local Similarity 98.0%; Pred. No. 9.7e-75;
 Matches 398; Conservative 0; Mismatches 5; Indels 3; Gaps 2;
 QY 1369 ACAGGGAACAGATGAACCGCTCTGGAGAACACGTGCAGTCAACAAATGAAGTCTACA 1428
 Db 1 ACAGGGAACAGATGAACCGCTCTGGAGAACACGTGCAGTCAACAAATGAAGTCTACA 60
 QY 1429 GCTGGTAAACCATGAAGCAAAATCTGTGGCAGTGGATGTTATTCCTCATGTNGACAACCC 1488
 Db 61 GCTGGTAAACCATGAAGCAAAATCTGTGGCAGTGGATGTTATTCCTCATGTNGACAACCC 120
 QY 1489 AACCTTTGAAGAGACGAACTCCCTAATCAAGAGACTGCTGTTGAGAAATTAATCTTA 1548
 Db 121 AACCTTTGAAGAGACGAACTCCCTAATCAAGAGACTGCTGTTGAGAAATTAATCTTA 180
 QY 1549 AAATCTGTGTAATAGAAAATCTTGAACCATTTAGTAATAACAGAACTGGCAATCAGGGCT 1608
 Db 181 AAATCTGTGTAATAGAAAATCTTGAACCATTTAGTAATAACAGAACTGGCAATCAGGGCT 240
 QY 1609 AGTTTCTATTAATAATTCGTAATAATTTAATAAATAGAGTGAATCAAGTCTCAG 1668
 Db 241 AGTTTCTATTAATAATTCGTAATAATTTAATAAATAGAGTGAATCAAGTCTCAG 300
 QY 1669 ATGACTAATATATGCTATAGTTAAATTCGCTTAAATAATTTAACTGTTAACTTTT 1728
 Db 301 ATGACTAATATATGCTATAGTTAAATTCGCTTAAATAATTTAACTGTTAACTTTT 358
 QY 1729 CCNCAAACTCATTAATAATTTTTCATAGGCAAGTTTCTCTCAG 1774
 Db 359 CCA-CAAACTCATTAATAATTTTTCATAGGCAAGTTTCTCTCAG 403
 RESULT 12
 AX396961/c

LOCUS
 DEFINITION Sequence 1176 from Patent WO0212328. PAT 18-MAY-2002
 ACCESSION AX396961
 VERSION AX396961.1 GI:21067708
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS King, G.E., Mesgher, M.J., Xu, J. and Secrist, H.
 TITLE Compositions and methods for the therapy and diagnosis of colon cancer
 JOURNAL Patent: WO 0212328-A 1176 14-FEB-2002;
 CORIXA CORPORATION (US)
 FEATURES
 source Location/Qualifiers
 1..435
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 BASE COUNT 147 a 62 c 69 g 157 t
 ORIGIN
 Query Match 17.5%; Score 310; DB 6; Length 435;
 Best Local Similarity 97.4%; Pred. No. 2e-60;
 Matches 336; Conservative 0; Mismatches 6; Indels 3; Gaps 2;
 QY 1430 CTGTTAAACCATGAAGCAAAATCTGTGGCAGTGGATGTTATTCCTCATGTNGACAACCCA 1489
 Db 435 CTGTTAAACCATGAAGCAAAATCTGTGGCAGTGGATGTTATTCCTCATGTNGACAACCCA 376
 QY 1490 ACCTTTGAAGAGACGAACTCCCTAATCAAGAGACTGCTGTTGAGAAATTAATCTTAA 1549
 Db 375 ACCTTTGAAGAGACGAACTCCCTAATCAAGAGACTGCTGTTGAGAAATTAATCTTAA 316
 QY 1550 AATCTGTGTAATAGAAAATCTTGAACCATTTAGTAATAACAGAACTGCCATCAGGCTTA 1609
 Db 315 AATCTGTGTAATAGAAAATCTTGAACCATTTAGTAATAACAGAACTGCCATCAGGCTTA 256
 QY 1610 GTTCTTATTAATAATTTGGATAAAATTTAATAAAGAGTGTATCTGAAAGTGCTCAGA 1669
 Db 255 GTTCTTATTAATAATTTGGATAAAATTTAATAAAGAGTGTATCTGAAAGTGCTCAGA 196
 QY 1670 TGACTAATATATGCTATAGTTAAATTCGCTTAAATAATTTAACTGTTAACTTTTTC 1729
 Db 195 TGACTAATATATGCTATAGTTAAATTCGCTTAAATAATTTAACTGTTAACTTTTTC 138
 QY 1730 CACAAACTCATTAATAATTTTTCATAGGCAAGTTTCTCTCAG 1774
 Db 137 CA-CAAACTCATTAATAATTTTTCATAGGCAAGTTTCTCTCAG 94
 RESULT 13
 AX115936/c
 LOCUS
 DEFINITION Sequence 195263 bp DNA linear HTG 20-JUN-2002
 ACCESSION AX115936
 VERSION AC115936.3 GI:21490425
 KEYWORDS HTG; HTGS_PHASE2; HTGS_DRAFT; HTGS_FULLTOP.
 SOURCE house mouse.
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 REFERENCE 1 (bases 1 to 195263)
 AUTHORS Birren, B., Linton, L., Nusbaum, C. and Lander, E.
 TITLE Mus musculus, clone RP24-545D3
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 195263)
 AUTHORS Birren, B., Linton, L., Nusbaum, C., Lander, E., Ali, A., Allen, N.,
 Anderson, S., Barna, N., Bastien, V., Bloom, T., Boguslavsky, L.,
 Boukhgalter, B., Brown, A., Camarata, J., Campopiano, A., Chang, J.,
 Chazaro, B., Choepel, Y., Collangelo, M., Collins, S., Collymore, A.,
 Cook, A., Cooke, P., DeArelano, K., Dewar, K., Diaz, J.S., Dodge, S.,

Faro, S., Ferreira, P., FitzHugh, W., Gage, D., Galagan, J., Gardyna, S., Ginde, S., Gord, S., Goyette, M., Graham, L., Grand-Pierre, N., Hagos, B., Horton, L., Hulme, W., Iliev, I., Johnson, R., Jones, C., Kamas, A., Karatas, A., Kells, C., Lacroque, K., Lamazares, R., Landers, T., Lehoczy, J., Levine, R., Lindblad-Toh, K., Liu, G., MacLean, C., Macdonald, P., Major, J., Marquis, N., Matthews, C., McCarthy, M., McEwan, P., McKernan, K., Meldrim, J., Meneus, L., Mihova, T., Mlenga, V., Murphy, T., Naylor, J., Nguyen, C., Nicol, R., Norbu, C., Norman, C.H., O'Connor, T., O'Donnell, P., O'Neill, D., Oliver, J., Peterson, K., Phunkhang, P., Pierre, N., Pollara, V., Raymond, C., Retta, R., Rieback, M., Riley, R., Rise, C., Rogov, P., Roman, J., Rosetti, M., Roy, A., Santos, R., Schauer, S., Schupback, R., Seaman, S., Severy, P., Spencer, B., Stange-Thomann, N., Stojanovic, N., Strauss, N., Subramanian, A., Tallamas, J., Tesfaye, S., Theodore, J., Topham, K., Travers, M., Travis, N., Trigglio, J., Vassiliev, H., Viel, R., Vo, A., Wilson, B., Wu, X., Wyman, D., Ye, W.J., Young, G., Zainoun, J., Zembek, L., Zimmer, A. and Zody, M.

Direct Submission
Submitted (22-MAR-2002) Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA
3 (bases 1 to 195263)

REFERENCE
AUTHORS
Birten, B., Linton, L., Nuebaum, C., Lander, E., Ali, A., Allen, N., Anderson, S., Barna, N., Bastien, V., Bloom, T., Boguelavkiy, L., Boukhgalter, B., Brown, A., Camarata, J., Campopiano, A., Chang, J., Chazaro, B., Choepel, Y., Collangelo, M., Collins, S., Collymore, A., Cook, A., Cooke, P., DeArellano, K., Dewar, K., Diaz, J.S., Dodge, S., Faro, S., Ferreira, P., FitzGerald, M., FitzHugh, W., Gage, D., Galagan, J., Gardyna, S., Ginde, S., Gord, S., Goyette, M., Graham, L., Grand-Pierre, N., Hagos, B., Horton, L., Hulme, W., Iliev, I., Johnson, R., Jones, C., Kamat, A., Karatas, A., Kells, C., Lacroque, K., Lamazares, R., Landers, T., Lehoczy, J., Levine, R., Kells, C., Lacroque, K., Liu, G., MacLean, C., Macdonald, P., Major, J., Marquis, N., Matthews, C., McCarthy, M., McEwan, P., McKernan, K., Meldrim, J., Meneus, L., Mihova, T., Mlenga, V., Murphy, T., Naylor, J., Nguyen, C., Nicol, R., Norbu, C., Norman, C.H., O'Connor, T., O'Donnell, P., O'Neill, D., Oliver, J., Peterson, K., Phunkhang, P., Pierre, N., Pollara, V., Raymond, C., Retta, R., Rieback, M., Riley, R., Rise, C., Rogov, P., Roman, J., Rosetti, M., Roy, A., Santos, R., Schauer, S., Schupback, R., Seaman, S., Severy, P., Spencer, B., Stange-Thomann, N., Stojanovic, N., Strauss, N., Subramanian, A., Tallamas, J., Tesfaye, S., Theodore, J., Topham, K., Travers, M., Travis, N., Trigglio, J., Vassiliev, H., Viel, R., Vo, A., Wilson, B., Wu, X., Wyman, D., Ye, W.J., Young, G., Zainoun, J., Zembek, L., Zimmer, A. and Zody, M.

Direct Submission
Submitted (20-JUN-2002) Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA
On Jun 20, 2002 this sequence version replaced gi:21431255.
All repeats were identified using RepeatMasker:
Smit, A.F.A. & Green, P. (1996-1997)
http://ftp.genome.washington.edu/RM/RepeatMasker.html

Center: Whitehead Institute/ MIT Center for Genome Research
Web site: <http://www-seq.wi.mit.edu>
Contact: sequence_submission@genome.wi.mit.edu
----- Project Information
Center project name: L24918
Center clone name: 545.D.3
----- Summary Statistics
Sequencing vector: Plasmid; n/a; 100% of reads
Chemistry: Dye-terminator Big Dye; 100% of reads
Assembly program: Phrap; version 0.960731
Consensus quality: 190111 bases at least Q40
Consensus quality: 192623 bases at least Q30
Consensus quality: 193567 bases at least Q20
Insert size: 194000; agarose-ff
Insert size: 194063; sum-of-contigs
Quality coverage: 7.4 in Q20 bases; agarose-ff
Quality coverage: 7.4 in Q20 bases; sum-of-contigs

* NOTE: This is a 'working draft' sequence. It currently
* consists of 13 contigs. Gaps between the contigs
* are represented as runs of N. The order of the pieces

* is believed to be correct as given, however the sizes
* of the gaps between them are based on estimates that have
* been provided by the submitter.
* This sequence will be replaced
* by the finished sequence as soon as it is available and
* the accession number will be preserved.
* 1 1669: contig of 1669 bp in length
* 1670 1769: gap of 100 bp
* 1770 2684: contig of 915 bp in length
* 2685 2784: gap of 100 bp
* 2785 6907: contig of 4123 bp in length
* 6908 7007: gap of 100 bp
* 7008 9245: contig of 2238 bp in length
* 9246 9345: gap of 100 bp
* 9346 12194: contig of 2849 bp in length
* 12195 12294: gap of 100 bp
* 12295 20535: contig of 8241 bp in length
* 20536 20635: gap of 100 bp
* 20636 28882: contig of 8247 bp in length
* 28883 28982: gap of 100 bp
* 28983 43950: contig of 14968 bp in length
* 43951 44050: gap of 100 bp
* 44051 69397: contig of 25347 bp in length
* 69398 69497: gap of 100 bp
* 69498 31792: contig of 22295 bp in length
* 31793 91892: gap of 100 bp
* 91893 118569: contig of 26677 bp in length
* 118570 118669: gap of 100 bp
* 118670 150554: contig of 31885 bp in length
* 150555 150654: gap of 100 bp
* 150655 195263: contig of 44609 bp in length.

FEATURES

Location/Qualifiers
source
1..195263
/organism="Mus musculus"
/db_xref="taxon:10090"
/clone="RP24-545D3"
/clone_lib="RPGI-24 Male Mouse BAC"
misc_feature
1..1669
/note="assembly_fragment"
misc_feature
1770..2684
/note="assembly_fragment"
misc_feature
2785..6907
/note="assembly_fragment"
misc_feature
7008..9245
/note="assembly_fragment"
misc_feature
9346..12194
/note="assembly_fragment"
misc_feature
12295..20535
/note="assembly_fragment"
misc_feature
20636..28882
/note="assembly_fragment"
misc_feature
28983..43950
/note="assembly_fragment"
misc_feature
44051..69397
/note="assembly_fragment"
misc_feature
69498..91792
/note="assembly_fragment"
misc_feature
91893..118569
/note="assembly_fragment"
misc_feature
118670..150554
/note="assembly_fragment"
misc_feature
150655..195263
/note="assembly_fragment"
BASE COUNT 58269 a 38652 c 38418 g 58724 t 1200 others
ORIGIN

Query Match 15.8%; Score 280.4; DB 2; Length 195263;
Best Local Similarity 60.8%; Pred. No. 4.6e-53;
Matches 546; Conservative 0; Mismatches 316; Indels 36; Gaps 4;
QY 434 GTGAACCGTACGTGTGGGAGCTGAGCGGCGGTGTACGGCCGAGCTCGCGCTG 493
|||||
Db 179183 GGGAAACCGTACGTGTGTGAGAGTGGGGAGACCGGGGTCTTCGGAAGAGCTCCATCTTG 179124

```

QY 494 GAGCCTGTGGTGGGTCCTGGTACCGCCGCGAGCGGGCCCGGCGCTTAAACGCGCTTAAAC 553
D 179123 AAGAGATAGCAGGAGTGTGTGTGCCACACAGAGGG---AAAAATTCAAAATGCTTGTGAT 179067
QY 554 CCGCACACAGAAATTCACGGTGCCCGACGGTTTGGGGAGACCGTGGCAAGTCTCTTGGTTG 613
D 179066 CCCAATACCACTTTTATCTCTGCCACGG-----AACAAAGAGCCCTGGATC 179022
QY 614 GCCCTCATCAACCGCGCGGGGGTGCACCTTCCGACAGCAAGATCCATCTGGCTTATGAG 673
D 179021 GCACTCATTAAC---GGGAGGTTGTGCTTCCACACAGAAAATTAAGGTGGCATCTGAG 178965
QY 674 AGATGGGGTCTGGAGCGCTGCTTTAACTTCCCGGGACCGCGAATGAGTCAATCCCG 733
D 178964 CACGAGCCACAGAGAGTGCATCTAATTTCCCAAGTACTGCGCAACCAAGGTTTTCGCC 178905
QY 734 ATGTCTCACCGGGTGCAGTAGACATTTGTCATATGATCGGCAATCTGAAAGGCACA 793
D 178904 ATGTCTCACAGGGTTTGAAGACATCGTTGTAGTTATGATTTGTAACATCAAGATGATG 178845
QY 794 AAAATCTGCAATCTTCAAGAGGCGATCAAGTGCACAAATGTCATAGAGTAGGAA 853
D 178844 GAGATTTTGCATTTAATTCGAAGGAGTTCATGTTACAGTCATGTTGGAGTGGGAAGA 178785
QY 854 AAACATGGCCCTGGGTGAATCACTATTCAATTTTTTCTGTTCTGTCCTTTTAT 913
D 178784 AAACATGTCTATTGGCTGAATCACTA-----TTTTGTCTCTTTATGATG 178740
QY 914 ATTACGGCGGCACTGTGGGCTATTTTATCTTTTATCTGCTCGAAGGCTACGGAATGCA 973
D 178739 GTCAACCGCCGACGTTAGCATATTTTCACTTTTATCACTTCGGAGACTTTGGTGGCA 178680
QY 974 AGACCTCAAGCAGGAGCAGAGCAATTAAGCAGATGCTAAAAAGCTATTGGAAG 1033
D 178679 AGAATTTGGAACAGAGATGGAAGCGATTAAACAGAGAGCTCAAGAAAGCTTTTGGCAG 178620
QY 1034 CTTCAACTACGACACTGAACACAGGAGACAGGAATTTGGCCCTGATGAGATAGTTGT 1093
D 178619 CTGCAAGTTCAGTATTAAAGAAGGGATGAAGAGTTAATCAATGTCGACACTGT 178560
QY 1094 GCTGTGTCATTAATTTATTAACCAAAATGATTTGGTAGCATCTTTAAAGTCAACCAT 1153
D 178559 GTCACTGCTTTGAAGCCTATAAGCCTTAATGAATAGTTCCGATTTCTCACTGCAAACT 178500
QY 1154 ATTTTCCATAGCATGTTGTGACCCATGCTGTTTAAACACAGACTTCCCGCATGTGC 1213
D 178499 TTTTCCACAGAATTTGATTTGACCCCTGGATTCTAGCCCAAGCAGCATGCCCATGTGC 178440
QY 1214 AAATGTGCATACCTCAAGCTTTTGGGAATTTGAGGTGATTTGAAGATGATCAGTGTCT 1273
D 178439 AAATGTGCATTTGAAAGCTTGGGATTCAGATGACATTTGAGGATGGACAGACTCT 178380
QY 1274 TTCAAGTCCCTGTATCAATGAATATCTAATAGTGCCTTCCCATGAAGAGGATA 1331
D 178379 CTGCAAGTCTGATGTCAATGAATTTGCCGGAACCTTTGACCCGGAAGAGAGA 178322

RESULT 14
AC111461/c
LOCUS AC111461 167021 bp DNA linear HTG 13-JUL-2002
DEFINITION Rattus norvegicus clone CH230-213C21, *** SEQUENCING IN PROGRESS
***, 75 unordered pieces.
AC111461
AC111461.2 GI:21736011
VERSION HTG; HTGS_PHASE1.
KEYWORDS Norway rat.
SOURCE Rattus norvegicus
ORGANISM Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
Rattus.
REFERENCE 1 (bases 1 to 167021)
AUTHORS Muzny,D.M., Adams,C., Adio-Oduola,B., Ali-osman,F.R., Allen,C.,

```

Allebrooke, S.L., Amaratunga, H.C., Are, J.R., Ayele, M., Banks, T., Barbra, J., Benton, J., Bimge, K., Blankenburg, K., Bonnin, D., Bouck, J., Bowie, S., Brieva, M., Brown, E., Brown, M., Bryant, N.P., Buhay, C., Burch, P., Burrell, C., Burrell, K.L., Byrd, N.C., Carron, T.F., Carter, M., Cavazos, S.R., Chacko, J., Chavez, D., Chen, G., Chen, R., Chen, Z., Chowdhry, I., Christopoulos, C., Cleveland, C.D., Cox, C., Coyle, M.D., Dathorne, S.R., David, R., Davila, M.L., Davis, C., Davy-Carroll, L., Dederich, D.A., Delaney, K.R., Delgado, O., Denn, A.L., Ding, Y., Dinh, H.H., Douthwaite, K.J., Draper, H., Dugan-Rocha, S., Durbin, N.C., Earnhart, C., Edgar, D., Edwards, C.C., Elhaj, C., Escotto, M., Falls, T., Farraguto, D., Flagg, N., Ford, J., Foster, P., Frantz, P., Gabisi, A., Gao, J., Garcia, A., Garner, T., Garza, N., Gill, R., Girelli, U.H., Guevara, W., Gunatillane, P., Hale, S., Hamilton, K., Harris, C., Harris, K., Hart, M., Havlak, P., Hawes, A., Hernandez, J., Hernandez, O., Hodgson, A., Hogues, M., Holloway, C., Hollins, B., Homsi, F., Howard, S., Huber, J., Huly, S., Hume, J., Jackson, L.E., Jacobson, B., Jia, Y., Johnson, R., Jolivet, S., Joudah, S., Karlsson, E., Kelly, S., Khan, U., King, L., Korvah, J., Kovar, C., Kratovic, J., Kureshi, A., Landry, N., Leal, B., Lewis, L.C., Lewis, L., Li, J., Li, Z., Lichtarge, O., Lieu, C., Liu, J., Liu, W., Loubege, H., Lozano, R.J., Lu, X., Lucier, A., Lucier, R., Luna, R., Ma, J., Maheshwari, M., Mapua, P., Martin, R., Martindale, A., Martinez, E., Massey, E., Mawhiney, E., McLeod, M.P., Meador, M., Mei, G., Metzker, M., Miner, G., Miner, Z., Mitchell, T., Mohabbat, K., Morgan, M., Morris, S., Moser, M., Neal, D., Newton, J., Newton, N., Nguyen, A., Nguyen, N., Nguyen, N., Nickerson, E., Nwokenkwo, S., Ogih, M., Okwodu, G., Ogunyeye, N., Oviado, R., Pace, A., Payton, B., Peery, J., Perez, L., Peters, L., Pickens, R., Primus, E., Pu, L.L., Quiles, M., Ren, Y., Rives, M., Rojas, A., Rojibokan, I., Rolfe, M., Ruiz, S., Savary, G., Scherer, S., Scott, G., Shen, H., Shoohtari, N., Sleson, I., Sodergren, E., Sonaika, T., Sparks, A., Stanley, H., Stone, H., Sutton, A., Svatek, A., Taber, P., Tamerisa, A., Tamerisa, K., Tang, H., Tansey, J., Taylor, C., Taylor, T., Telford, B., Thomas, N., Thomas, S., Umani, K., Vasquez, L., Vera, V., Villalon, D., Vinson, R., Wang, Q., Wang, S., Ward-Moore, S., Warren, R., Washington, C., Watlington, S., Williams, G., Williamson, A., Wlezyk, R., Wooden, S., Worley, K., Wu, C., Wu, Y., Zhou, J., Zorrilla, S., Nelson, D., Weinstock, G., and Gibbs, R.

Direct Submission
Unpublished
2 (bases 1 to 167021)
Worley, K.C.
Direct Submission
Submitted (19-FEB-2002) Human Genome Sequencing Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
3 (bases 1 to 167021)
Worley, K.C.
Direct Submission
Submitted (13-JUL-2002) Human Genome Sequencing Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
On Jul 12, 2002 this sequence version replaced gi:18701226.

----- Genome Center
Center: Baylor College of Medicine
Center code: BCM
Web site: <http://www.hgsc.bcm.tmc.edu/>
Contact: hgsc-help@bcm.tmc.edu
----- Project Information
Center project name: GMJK
Center clone name: CH230-213C21
----- Summary Statistics
Sequencing vector: Plasmid;
Chemistry: Dye-terminator Big Dye; 100% of reads
Assembly program: Phrap; version 0.990329
Consensus quality: 89039 bases at least Q40
Consensus quality: 93636 bases at least Q30
Consensus quality: 97431 bases at least Q20

* NOTE: Estimated insert size may differ from sequence length
* (see http://www.hgsc.bcm.tmc.edu/docs/Genbank_draft_data.html).
* NOTE: This is a 'working draft' sequence. It currently

* consists of 75 contigs. The true order of the pieces
 * is not known and their order in this sequence record is
 * arbitrary. Gaps between the contigs are represented as
 * runs of N, but the exact sizes of the gaps are unknown.
 * This record will be updated with the finished sequence
 * as soon as it is available and the accession number will
 * be preserved.

* 1 1200: contig of 1200 bp in length
 * 1201 1300: gap of unknown length
 * 1301 2480: contig of 1180 bp in length
 * 2481 2580: gap of unknown length
 * 2581 4294: contig of 1714 bp in length
 * 4295 4394: gap of unknown length
 * 4395 5589: contig of 1195 bp in length
 * 5590 5689: gap of unknown length
 * 5690 7039: contig of 1350 bp in length
 * 7040 7139: gap of unknown length
 * 7140 8161: contig of 1022 bp in length
 * 8162 9786: gap of unknown length
 * 9787 9885: gap of unknown length
 * 9887 11075: contig of 1189 bp in length
 * 11076 11175: gap of unknown length
 * 11176 12487: contig of 1312 bp in length
 * 12488 12587: gap of unknown length
 * 12588 13739: contig of 1152 bp in length
 * 13740 13839: gap of unknown length
 * 13840 15104: contig of 1265 bp in length
 * 15105 15204: gap of unknown length
 * 15205 16606: contig of 1402 bp in length
 * 16607 16706: gap of unknown length
 * 16707 18097: contig of 1391 bp in length
 * 18098 18197: gap of unknown length
 * 18198 19766: contig of 1569 bp in length
 * 19767 19866: gap of unknown length
 * 19867 21735: contig of 1869 bp in length
 * 21736 21835: gap of unknown length
 * 21836 22871: contig of 1036 bp in length
 * 22872 22971: gap of unknown length
 * 22972 24060: contig of 1089 bp in length
 * 24061 24160: gap of unknown length
 * 24161 25579: contig of 1419 bp in length
 * 25580 25679: gap of unknown length
 * 25680 27146: contig of 1467 bp in length
 * 27147 27246: gap of unknown length
 * 27247 28388: contig of 1142 bp in length
 * 28389 28488: gap of unknown length
 * 28489 30073: contig of 1585 bp in length
 * 30074 30173: gap of unknown length
 * 30174 31407: contig of 1234 bp in length
 * 31408 31507: gap of unknown length
 * 31508 33049: contig of 1542 bp in length
 * 33050 33149: gap of unknown length
 * 33150 34856: contig of 1707 bp in length
 * 34857 34956: gap of unknown length
 * 34957 36203: contig of 1247 bp in length
 * 36204 36303: gap of unknown length
 * 36304 38026: contig of 1723 bp in length
 * 38027 38126: gap of unknown length
 * 38127 39131: contig of 1005 bp in length
 * 39132 39231: gap of unknown length
 * 39232 40881: contig of 1650 bp in length
 * 40882 40981: gap of unknown length
 * 40982 42222: contig of 1241 bp in length
 * 42223 42322: gap of unknown length
 * 42323 43979: contig of 1657 bp in length
 * 43980 44079: gap of unknown length
 * 44080 45706: contig of 1627 bp in length
 * 45707 45806: gap of unknown length
 * 45807 47463: contig of 1657 bp in length
 * 47464 47563: gap of unknown length
 * 47564 49070: contig of 1507 bp in length
 * 49071 49170: gap of unknown length

* 49171 50894: contig of 1724 bp in length
 * 50895 50994: gap of unknown length
 * 50995 52487: contig of 1493 bp in length
 * 52488 52587: gap of unknown length
 * 52588 54880: contig of 2293 bp in length
 * 54881 54980: gap of unknown length
 * 54981 57373: contig of 2393 bp in length
 * 57374 57473: gap of unknown length
 * 57474 58491: contig of 1018 bp in length
 * 58492 58591: gap of unknown length
 * 58592 59883: contig of 1292 bp in length
 * 59884 61364: gap of unknown length
 * 61365 61464: gap of unknown length
 * 61465 62900: contig of 1336 bp in length
 * 62901 64001: contig of 1501 bp in length
 * 64002 64501: gap of unknown length
 * 64502 66266: contig of 2325 bp in length
 * 66267 66926: gap of unknown length
 * 66927 67935: contig of 1009 bp in length
 * 67936 68035: gap of unknown length
 * 68036 70512: contig of 2477 bp in length
 * 70513 72597: contig of 1985 bp in length
 * 72598 72697: gap of unknown length
 * 72699 74479: contig of 1782 bp in length
 * 74480 74579: gap of unknown length
 * 74580 76830: contig of 2251 bp in length
 * 76831 76930: gap of unknown length
 * 76931 77998: contig of 2868 bp in length
 * 77999 79898: gap of unknown length
 * 79899 82654: contig of 2756 bp in length
 * 82755 84685: contig of 1931 bp in length
 * 84686 84785: gap of unknown length
 * 84786 87419: contig of 2634 bp in length
 * 87420 87519: gap of unknown length
 * 87520 89991: contig of 2472 bp in length
 * 89992 90091: gap of unknown length
 * 90092 91827: contig of 1736 bp in length

Query Match 15.7%; Score 278.4; DB 2; Length 167021;
 Best Local Similarity 60.7%; Pred. No. 1.3e-52;
 Matches 544; Conservative 0; Mismatches 316; Indels 36; Gaps 4;

QY 434 GTGAACCGTACGGTGTGGAGCTGAGCGAGGCGGTGTACGGCCAGGACTCGCGCTG 493
 DB 83860 GGGACCGCATGCTGTGACAGCTGGCGAGACTGGGTCTTCGGAGAGTCCATCTTG 83801
 QY 494 GAGCCTGTGGTGGGCTCTGTGTACCGCCCGACCGGCGCGCGCTTAAACGCTGTAA 553
 DB 83800 AAGAGAGTAGCAGGAGTAGTGTGTGCCACGAGGGGAAA---AATTCAAAATGCTGTGAC 83744
 QY 554 CGCACACGAATTCACCGTGCACCGTGTGGGGAGCACCAGTGCAGTCTCTTGGTTG 613
 DB 83743 CCCAATACAGTTTATCTCTCCCGGAA-----CAAAGAGCCCTGGATT 83699
 QY 614 GCCCTCATCCAAACCGCGGGGCTGCACCTTTCGACAGAGATCCATCTCGCTTATGAG 673
 DB 83698 GCACCATTTGAA---AGGGAGGTTGTGCTTTCACAGAAAATCAAAGTGGCATCTGAG 83642
 QY 674 AGATGGGCGTGTGAGCCGCTCATCTTTAACTTCCCGGGACCGCAATAGAGTCAATCCCC 733
 DB 83641 AATGGGGCCAGGGAGTGTATCATATAAATTTCCGGGACTGGCAACACGATTTTCCCC 83582
 QY 734 ATGCTCACCGGTGCAGTAGACATTTGTCATATCATGTCGCAATCTCTGAAGGACA 793
 DB 83581 ATGCTCACAGGGGTTTGAAGACATCGTTGTATTTATGTTGTAACGTCAAAGGATG 83522
 QY 794 AAAATTCGCAATCTATTCAAAGAGGCATACAAGTGCACAAATGGTGCATAGAGTAGGAAA 853
 DB 83521 GAGATTTTGCATTTAAATTAGGAAGGAGTCCATCTTACGGTCATGTTGAGTGGGAAGA 83462

were constructed by oligo-capping method (Sugano et al., University of Tokyo, Institute of Medical Science). Custom primer used for sequencing

```
5', end primer [CTTCTGCTTAAAGTCGG];
3', end primer [CGACCTGCAGCTCGACGACA] .
```

FEATURES

1. 1391

```
1. 1331
/organism="Macaca fascicularis"
/db_xref="taxon:9541"
/clone="QtsA-11567"
/sex="male"
/tissue_type="testis"
/clone_lib="macaque testis cDNA"
/dev_stage="adult"
198. 1328
```

2

```
156: .1528  
/codon start=1
```

T=JTP3B_II0003/

```
/product="hypothetical"
```

```
/protein_id="BAB62968.1"
```

```
/db_xref="GI:15207887"
```

```
/translation="MHLLKVGTVWF
```

SFHVGNHVLSLGETGVFGRSTI

ALIERGGCTFTOKIKVAÆKGASCO

TEI FHL IKKGVLTAMVEVGRKH

UNBPRWOPITTDI ONA EGOY OI PIV
IEIFHUIKAGVLI I AMVEVGRKH

QNRK#QLTITDLQNAFGQLQLRVA

BASE COUNT	419 a	244 c	312 g	416 t
------------	-------	-------	-------	-------

Query Match	15.2%	Score 268.8;	DB 9;	Length 1391;
Best Local Similarity	62.5%;	Pred. No. 7.3e-51;		
Matches 445; Conservative	0;	Mismatches 252;	Indels 15;	

Qy	630	GC	GGGGG	GTG	CAC	TTT	CG	CAG	A	CA	A	GAT	CC	A	CT	CG	G	T	T	A	T	G	A	G	A	G	A	T	T	G	G	G	C	T	G	G	A	689	
Db	517	GG	GGAG	TTG	T	A	C	T	T	C	A	C	A	G	A	A	A	T	T	A	A	G	T	G	C	A	G	T	G	A	G	G	A	G	C	A	T	G	576
Qy	690	CC	GT	C	A	T	C	T	T	T	A	A	C	T	T	C	C	C	G	G	A	C	C	C	A	T	G	A	G	T	C	A	T	C	C	C	G	G	749
Db	577	TG	AT	C	A	T	A	C	T	T	T	C	A	G	A	A	T	T	C	A	G	A	A	T	T	C	C	C	A	T	T	C	A	T	C	A	G	636	
Qy	750	CAG	TAG	A	CA	T	T	G	CA	A	T	C	A	T	G	C	G	CA	A	T	C	T	C	A	A	A	A	A	A	T	T	C	G	CA	A	T	C	809	
Db	637	TT	GA	GA	T	G	T	G	T	T	A	T	G	A	T	T	G	A	C	T	T	A	A	A	A	G	C	A	G	A	A	T	T	T	C	A	T	696	
Qy	810	TT	CA	A	A	G	A	G	C	A	T	A	G	T	G	T	C	A	T	A	G	A	T	A	G	A	A	A	A	A	A	A	A	A	A	A	A	869	
Db	697	TT	AA	GA	AG	G	A	G	T	T	C	T	C	A	T	A	C	A	G	C	A	T	G	T	T	G	A	G	T	T	G	A	A	A	G	C	A	756	
Qy	870	TG	AA	T	C	A	C	A	T	T	C	A	A	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	929		
Db	757	TG	AA	T	C	A	C	T	A	-----	TTT	GG	T	C	T	C	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	T	801			
Qy	930	TG	GG	C	T	A	T	T	T	A	T	C	T	T	G	C	T	C	G	A	G	C	T	A	C	G	A	A	T	G	C	A	A	G	C	T	989		
Db	802	TAG	C	A	T	T	T	C	A	T	T	A	T	C	A	T	T	A	C	A	T	T	A	C	A	T	T	T	T	T	T	A	G	C	A	G	861		
Qy	990	AC	C	A	G	A	G	C	A	A	T	T	A	A	G	C	A	G	A	T	G	C	T	A	A	A	A	A	G	C	T	A	A	A	G	C	104		
Db	862	GAT	GG	C	A	G	G	A	T	T	A	A	C	A	C	A	G	A	T	T	C	A	G	A	T	T	T	G	G	A	A	C	T	C	C	A	921		
Qy	1050	TG	AA	A	CA	AG	A	CA	AG	A	A	A	T	T	G	C	C	C	T	G	A	T	G	T	G	C	T	G	T	G	C	A	T	T	G	1109			
Db	922	T	A	A	A	G	A	G	G	A	T	A	A	T	T	C	A	A	T	G	A	G	A	T	A	G	T	A	T	T	T	G	C	T	T	G	981		
Qy	1110	TG	T	A	T	A	A	C	A	A	A	T	G	A	T	T	G	T	A	C	G	A	T	C	T	T	A	A	C	A	A	T	T	T	T	C	1169		
Db	982	AC	T	A	T	A	A	G	C	T	A	T	G	A	C	A	T	T	C	T	G	A	T	T	T	C	T	G	A	A	C	A	T	T	T	C	104		
Qy	1170	GT	TT	G	A	C	C	C	A	T	T	T	A	A	A	C	A	C	A	G	A	C	T	T	G	C	C	C	A	T	G	C	A	A	A	T	1229		
Db	1042	GA	TT	G	A	C	C	C	T	G	A	T	T	T	A	T	C	C	A	T</																			

QY	854	AAACATGGCCCTTGGTGAATCACTATTCAAATTTTTTCGTTCTGTGTCCTTTTTATT	913
Db	83461	AAACACGTCATTTGGCTGAATCATTA-----TTTTGTCTCTTTATGATC	83417
QY	914	ATTACGGCGGCAACTGTGGGCTATTTTATCTTTTATCTGCTCGAAGGCTACGGAATGCA	973
Db	83416	GTCACAACCGGCCACATTAGCANATTTTCACTTTTTCACATTTTCGGAGACTCTGGTGCGCA	83357
QY	974	AGAGCTCAAGCGAGGACGAGAGCAATTAAGGGCAGATGCTTAAAAAGCTATTGGGAAGG	1033
Db	83356	AGAATTCGAGGACAGAGATGGAAACGATTAAACAAGAGAGCTCAAGAAAGCATTTGGGCAG	83297
QY	1034	CTTCAACTATCGGCACACTGAACAGGAGAGCAAGGAATTTGGCCCTGATGGAGATAGTTGT	1093
Db	83296	CTGCAAGTTCGAATATTAAGAAGGGGGATGAGGAAGTAAGTCCAAATGCGAGACAGCTGC	83237
QY	1094	GCTGTGTCATTGGAATTGTATAAACCAAAATGATTTGGTAGCATCTTAACTGTGCAACCAT	1153
Db	83236	GTCACTCTGCTTTGAAGCCTATAGCCCTAATGAAATAGTTTCGTTATCTCACGTGCAACAT	83177
QY	1154	ATTTTCCATAGACATGTGTGACCCATGGCTGTTTAAACACAAAGCATTTGCCCATGTGC	1213
Db	83176	TTTTTTCCACAAGAAATGCAATTGACCCCTGGATTCTTAGCCCATGGGCACATGCCCATGTGC	83117
QY	1214	AAATGTGCATACACTCAAAAGCTTTTGGGAAATTGAGGTGGATGTTTGAAGATGGAATCAGTGTCT	1273
Db	83116	AAATCGACACTTCTGAAGCTCTGGGGATTCAGATGGACATTTGAGAGATGGATCAGACTCT	83057
QY	1274	TTTCAAGTCCCTGTATCCAATGAAATATCTAATAGTGTGCTCTCCCATGAAGAGGA	1329
Db	83056	CTGCAAGTCTTGATGTCAAAATGAATTTGCTGGAACTTTTTCAGCTATCGGAAGAAGA	83001

RESULT 15	AB070023	1391 bp	mRNA	linear	PRI 16-AUG-2001
LOCUS	AB070023				
DEFINITION	Macaca fascicularis testis cDNA clone:QcEA-11567, full insert sequence.				
ACCESSION	AB070023				
VERSION	AB070023.1	GI:15207886			
KEYWORDS	oligo capping; fis (full insert sequence).				
SOURCE	Macaca fascicularis adult male testis cDNA to mRNA, clone lib:macaque testis cDNA library QcEA clone:QcEA-11567.				
ORGANISM	Macaca fascicularis	Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Cercopithecoidea; Cercopithecinae; Macaca.			
REFERENCE	1	Hashimoto, K., Osada, N., Hida, M., Kusuda, J., Tanuma, R., Hirai, M., Terao, K. and Sugano, S.			
AUTHORS	1	Isolation of novel full-length cDNA clones from macaque testis cDNA libraries			
TITLE	2	(bases 1 to 1391)			
JOURNAL	Hashimoto, K., Osada, N., Hida, M., Kusuda, J. and Sugano, S.				
REFERENCE	2	Submitted (14-AUG-2001) Katsuyuki Hashimoto, National Institute of Infectious Diseases, Division of Genetic Resources; 23-1, Toyama 1-chome, Shinjuku-ku, Tokyo 162-8640, Japan			
AUTHORS	2	(E-mail: khashihen@nig.go.jp, URL: http://www.nih.go.jp/yoken/genebank/, Tel: 81-3-5285-1111 (ex. 2120), Fax: 81-3-5285-1181)			
TITLE	2	Lab host: TOP10			
JOURNAL	2	Vector: pME185-FL3 (Acc. No. AB009864)			
REFERENCE	2	R. Sites: DraIII (CACTGTGTG)			
AUTHORS	2	R. Sites: DraIII (CACTGTGTG)			
TITLE	2	Description: 1st strand cDNA was primed with an oligo (dT) primer [ATGTCGCTTTTTTTTTTTTTTTT]; double-stranded cDNA was synthesized using specific 5' and 3' primers and amplified by PCR. The PCR product was digested with SfiI and size selection was performed to exclude fragments <1.5kb. The SfiI-digested PCR product was cloned into distinct draIII sites of pME185-FL3. XhoI sites just outside the DraIII sites can be used to isolate the cDNA insert. Libraries			
JOURNAL	2				
COMMENT					

GenCore version 5.1.4_p5_4578
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 26, 2003, 00:41:20 ; Search time 284 Seconds
(without alignments)

14067.060 Million cell updates/sec

Title: US-09-854-300-7

Perfect score: 1774

Sequence: 1 agctggagctccacggcgggt.....ataggcaagtctctctcag 1774

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 2185239 seqs, 1125999159 residues

Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : N Geneseq 101002:*

- 1: /SID22/gcgdata/geneseq/geneseq-emb1/NA1980.DAT:*
- 2: /SID22/gcgdata/geneseq/geneseq-emb1/NA1981.DAT:*
- 3: /SID22/gcgdata/geneseq/geneseq-emb1/NA1982.DAT:*
- 4: /SID22/gcgdata/geneseq/geneseq-emb1/NA1983.DAT:*
- 5: /SID22/gcgdata/geneseq/geneseq-emb1/NA1984.DAT:*
- 6: /SID22/gcgdata/geneseq/geneseq-emb1/NA1985.DAT:*
- 7: /SID22/gcgdata/geneseq/geneseq-emb1/NA1986.DAT:*
- 8: /SID22/gcgdata/geneseq/geneseq-emb1/NA1987.DAT:*
- 9: /SID22/gcgdata/geneseq/geneseq-emb1/NA1988.DAT:*
- 10: /SID22/gcgdata/geneseq/geneseq-emb1/NA1989.DAT:*
- 11: /SID22/gcgdata/geneseq/geneseq-emb1/NA1990.DAT:*
- 12: /SID22/gcgdata/geneseq/geneseq-emb1/NA1991.DAT:*
- 13: /SID22/gcgdata/geneseq/geneseq-emb1/NA1992.DAT:*
- 14: /SID22/gcgdata/geneseq/geneseq-emb1/NA1993.DAT:*
- 15: /SID22/gcgdata/geneseq/geneseq-emb1/NA1994.DAT:*
- 16: /SID22/gcgdata/geneseq/geneseq-emb1/NA1995.DAT:*
- 17: /SID22/gcgdata/geneseq/geneseq-emb1/NA1996.DAT:*
- 18: /SID22/gcgdata/geneseq/geneseq-emb1/NA1997.DAT:*
- 19: /SID22/gcgdata/geneseq/geneseq-emb1/NA1998.DAT:*
- 20: /SID22/gcgdata/geneseq/geneseq-emb1/NA1999.DAT:*
- 21: /SID22/gcgdata/geneseq/geneseq-emb1/NA2000.DAT:*
- 22: /SID22/gcgdata/geneseq/geneseq-emb1/NA2001A.DAT:*
- 23: /SID22/gcgdata/geneseq/geneseq-emb1/NA2001B.DAT:*
- 24: /SID22/gcgdata/geneseq/geneseq-emb1/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1773	99.9	1774	AAI72095	Human GRAIL cDNA.
2	1662.8	93.7	2773	AAAI5995	Human protein clon
3	1662.8	93.7	2796	AAI72321	ISIGP-4 cDNA. Hom
4	1431.4	80.7	2876	AAS42511	Human cDNA encodin
5	1278.2	72.1	1284	AAAI5985	Human protein clon
6	1178.8	66.4	2306	AAS25884	Human cDNA encodin
7	1167.2	65.8	1249	ABL90796	Human polynucleoti
8	1166	65.7	2145	AAI72094	Mouse GRAIL cDNA.
9	1157.6	65.3	1250	AAS26340	Human cDNA encodin

10	1106.8	62.4	1287	24	ABK12983	Mouse goliath cDNA
11	1052.4	59.3	1287	24	ABK12992	Synthetic goliath
12	1042.8	58.8	1287	24	ABK12990	Synthetic goliath
13	1042.8	58.8	1287	24	ABK12991	Synthetic goliath
14	1019.4	57.5	1135	22	AAI59292	Human polynucleoti
15	998.6	56.3	1287	24	ABK12989	Synthetic goliath
16	977.2	55.1	1287	24	ABK12988	Synthetic goliath
17	972.4	54.8	1287	24	ABK12987	Synthetic goliath
18	655.2	36.9	737	22	AAI61078	Human polynucleoti
19	497.2	28.0	502	24	ABN19991	Human ORFX polynuc
20	392.2	22.1	404	22	AAF66696	Novel human polynu
21	372.6	21.0	646	24	ABL38226	Human colon tumour
22	310	17.5	435	24	ABK5625	cDNA encoding colo
23	254.8	14.4	1355	21	AAA87765	Human secreted pro
24	254.8	14.4	1355	22	AAF64047	cDNA encoding huma
25	243.8	13.7	918	23	AAS70124	DNA encoding novel
26	210.2	11.8	2826	24	ABL90797	Human polynucleoti
27	209	11.8	1200	22	AAF94484	Human hydrophobic
28	209	11.8	1527	22	AAF94494	Human full-length
29	209	11.8	2005	22	AAK94499	Human secreted pro
30	209	11.8	2063	19	AAV43601	Human full-length
31	209	11.8	2452	22	AAK94373	Human secreted pro
32	194.8	11.0	1869	22	ABA09101	Human secreted pro
33	194.8	11.0	1869	22	AAK51507	Human polynucleoti
34	194.8	11.0	1869	22	AAK52491	Human polynucleoti
35	191.8	10.8	1708	23	AAK76863	DNA encoding novel
36	180.8	10.2	3615	24	ABK36205	cDNA sequence #596
37	178.8	10.1	631	21	AACT76002	Human ORFX ORF1557
38	149.2	8.4	1322	19	AAV43616	Human secreted pro
39	148.8	8.4	1260	24	ABK12986	Mouse gl cDNA sequ
40	147.6	8.3	1253	19	AAV40387	Human zinc binding
41	147.6	8.3	1257	22	AAF94418	Human hydrophobic
42	147.6	8.3	1433	22	AAF94428	Human hydrophobic
43	147.6	8.3	1489	24	ABL55072	Human cDNA sequenc
44	147.6	8.3	1515	24	ABL90798	Human polynucleoti
45	147.6	8.3	1546	24	ABL55094	Human cDNA sequenc

ALIGNMENTS

RESULT 1

AAI72095
ID AAI72095 standard; cDNA; 1774 BP.

XX AC AAI72095;

XX DT 25-MAR-2002 (first entry)

XX DE Human GRAIL cDNA.

XX KW Murine; human; GRAIL; atenuation; tyrosine; phosphorylation;
antigenic stimulation; interleukin-2; gene therapy; polymorphism; IL-2;
autoimmune disease; tumour cell; cancer; transplant rejection; ss.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers

263..1547

/*tag= a

/product= "GRAIL"

XX PN WO200185943-A1.

XX PD 15-NOV-2001.

XX PP 11-MAY-2001; 2001WO-US15385.

XX PR 11-MAY-2000; 2000US-203513P.

XX PA (STRD) UNIV LELAND STANFORD JUNIOR.

XX PI Ford GS, Bloom D, Fathman CG;

Db 1441 TGAAGCAATTCCTGCGAGTGGATGTTATTCCTCATGTGNGACAACCCAACTTTGAGA 1500
 QY 1501 AGACGAACTCTTAATCAAGAGACTGCTGTTCGAGAAATTAATCTTAAATCTGTGTA 1560
 Db 1501 AGACGAACTCTTAATCAAGAGACTGCTGTTCGAGAAATTAATCTTAAATCTGTGTA 1560
 QY 1561 ATAGAAACTTGACCAATTAAGTAAATACAGAACTGCCAATCAGGGCTAGTTTCTATTAA 1620
 Db 1561 ATAGAAACTTGACCAATTAAGTAAATACAGAACTGCCAATCAGGGCTAGTTTCTATTAA 1620
 QY 1621 TAAATTCGATAAATTAATAAATAAGAGTGATCTGAAAAGTCTCAGATGACTAATATT 1680
 Db 1621 TAAATTCGATAAATTAATAAATAAGAGTGATCTGAAAAGTCTCAGATGACTAATATT 1680
 QY 1681 ATGCTATAGTTAAATGGCTAAATAATTAACCTGTTAACTTTTTCACCAACTCA 1740
 Db 1681 ATGCTATAGTTAAATGGCTAAATAATTAACCTGTTAACTTTTTCACCAACTCA 1740
 QY 1741 TTATAATATTTTTCATAGGCAAGTTTCTCTCAG 1774
 Db 1741 TTATAATATTTTTCATAGGCAAGTTTCTCTCAG 1774

RESULT 2
 ID AAA15995 standard; cDNA; 2773 BP.
 AC AAA15995;
 XX
 DT 12-JUN-2000 (first entry)
 XX
 DE Human protein clone HP10574 full length coding sequence.
 XX
 KW Human protein; hydrophobic domain; nutritional source; haematopoiesis;
 KW cytokine production; cell proliferation; cell differentiation;
 KW immune deficiency; infectious disease; autoimmune disorder; asthma;
 KW multiple sclerosis; systemic lupus erythematosus; rheumatoid arthritis;
 KW allergic reaction; osteoporosis; osteoarthritis; periodontal disease;
 KW nervous system disorder; Alzheimer's disease; Parkinson's disease;
 KW Huntington's disease; liver fibrosis; lung fibrosis; reperfusion injury;
 KW systemic cytokine damage; tissue differentiation; contraceptive; stroke;
 KW coagulation disorder; myocardial infarction; inflammatory condition;
 KW septic shock; sepsis; ischaemia; reperfusion injury; arthritis; tumour;
 KW nephritis; therapy; ss.
 XX
 OS Homo sapiens.
 XX
 FN W0200005367-A2.
 XX
 PD 03-FEB-2000.
 XX
 PF 22-JUL-1999; 99WO-JF03929.
 XX
 PR 24-JUL-1998; 98JP-0208820.
 PR 07-AUG-1998; 98JP-0224105.
 PR 25-AUG-1998; 98JP-0238116.
 PR 09-SEP-1998; 98JP-0254736.
 PR 29-SEP-1998; 98JP-0275505.
 XX
 PA (SAGA) SAGAMI CHEM RES CENT.
 PA (PROT-) PROTEGENE INC.
 XX
 PI Kato S, Kimura T;
 XX
 DR WPI; 2000-182694/16.
 DR P-PSDB; AAY94897.
 XX
 XX Novel human proteins having hydrophobic domains useful for treating
 PT osteoporosis, Alzheimer's disease, Parkinson's disease, asthma,
 PT multiple sclerosis, rheumatoid arthritis, cancer, anaemia, and stroke -
 XX
 PS Claim 4; Page 348-351; 351pp; English.
 XX

CC This sequence encodes a human protein of the invention, which has
 CC hydrophobic domains. The DNA sequences can be used as a probe or as a
 CC genetic marker. The protein can also be used as a marker, and to identify
 CC potential genetic disorders. The DNA and protein can also be used as
 CC nutritional sources or supplements. The protein exhibits cytokine, cell
 CC proliferation, cell differentiation activities and induces production of
 CC other cytokines in certain cell populations. The protein also exhibits
 CC immune stimulating or immune suppressing activity. It can be used in the
 CC treatment of various immune deficiencies and disorders, and to treat
 CC infectious diseases caused by viral, bacterial, fungal or other
 CC infections. The protein is also used for treating autoimmune disorders
 CC such as multiple sclerosis, systemic lupus erythematosus, and rheumatoid
 CC arthritis. It is also useful in the treatment of allergic reactions and
 CC conditions such as asthma, and in immune suppression after organ
 CC transplantation. The protein is useful in regulation of haematopoiesis
 CC and consequently in the treatment of myeloid or lymphoid cell
 CC deficiencies. It is also used in compositions for tissue growth or
 CC regeneration. The protein is also used in the treatment of osteoporosis
 CC or osteoarthritis and in the treatment of periodontal disease and other
 CC tooth repair processes. The protein is used in the treatment of nervous
 CC system disorders such as Alzheimer's disease, Parkinson's disease, and
 CC Huntington's disease. They are useful for protection or regeneration and
 CC treatment of lung or liver fibrosis, reperfusion injury in various
 CC tissues, and conditions resulting from systemic cytokine damage. They are
 CC also used for promoting or inhibiting tissue differentiation. They are
 CC also used as contraceptives since they exhibit activin or inhibin related
 CC activities and as a fertility inducing therapeutic. They are used for
 CC treating various coagulation disorders and in treatment and prevention of
 CC conditions resulting from coagulation activities e.g. myocardial
 CC infarction or stroke. They also acts as receptors, receptor ligands or
 CC inhibitors or agonists of receptor/ligand interactions. They are used to
 CC treat inflammatory conditions such as septic shock, sepsis, ischaemia
 CC reperfusion injury, arthritis, and nephritis. They can be used to
 CC prevent tumours.
 XX
 SQ Sequence 2773 BP; 803 A; 545 C; 617 G; 808 T; 0 other;
 Query Match 93.7%; Score 1662.8; DB 21; Length 2773;
 Best Local Similarity 99.4%; Pred. No. 0;
 Matches 1690; Conservative 0; Mismatches 8; Indels 3; Gaps 2;
 QY 74 CGAGAGAGCTGATCTGGCGCAACTGTGCTGCTGACGCTAGCTCTCTCGCTCCGACG 133
 Db 22 CGAGAGAGCTGATCTGGCGCAACTGTGCTGCTGACGCTAGCTCTCTCGCTCCGACG 81
 QY 134 TAGCTCGCAGCTCCCGAGTCTCACTCCATTCTTCCACCTCGCGGCGACCTGCTCAAG 193
 Db 82 TAGCTCGCAGCTCCCGAGTCTCACTCCATTCTTCCACCTCGCGGCGACCTGCTCAAG 141
 QY 194 ACCAGGCTCTGCGCAAGCGCTAGGAGGCGCGTCCAGGGGCGCTAGGGAACCTGGGAGC 253
 Db 142 ACCAGGCTCTGCGCAAGCGCTAGGAGGCGCGTCCAGGGGCGCTAGGGAACCTGGGAGC 201
 QY 254 GCGCGCGCATGGGGCGCGCGCTGGGGCGCGGGTCTCTCTCCCGCGGTGGCTGGCGGCTTT 313
 Db 202 GCGCGCGCATGGGGCGCGCGCTGGGGCGCGGGTCTCTCTCCCGCGGTGGCTGGCGGCTTT 261
 QY 314 TCCAGATTGCTGGCATGCTGCTTCTGCTGCGCCCTGAGTCCGCGAGGACACCGGTTCCCGG 373
 Db 262 TCCAGATTGCTGGCATGCTGCTTCTGCTGCGCCCTGAGTCCGCGAGGACACCGGTTCCCGG 321
 QY 374 GGGGCTGAAGCAGTGTGGACCGCGTACCTCAACGTGTCTCTGGCGGTTCCCGACACGGGA 433
 Db 322 GGGGCTGAAGCAGTGTGGACCGCGTACCTCAACGTGTCTCTGGCGGTTCCCGACACGGGA 381
 QY 434 GTGAACCTGCTGGGTGGAGCTGAGCGAGGAGGCGTGTGTACGCGCAGGACTCGCGCGTGT 493
 Db 382 GTGAACCTGCTGGGTGGAGCTGAGCGAGGAGGCGTGTGTACGCGCAGGACTCGCGCGTGT 441
 QY 494 GAGCCTGTGGGTGGGTCTCTGTGTACCGCCCGACCGGGCCCGGGGCGCTTTAAACGCTGTAA 553
 Db 442 GAGCCTGTGGGTGGGTCTCTGTGTACCGCCCGACCGGGCCCGGGGCGCTTTAAACGCTGTAA 501

QY 554 CGCACACGAATTTTCAACGGTGGCCACCGTTTGGGGAAGCACCCTGCAAGTCTCTTGTTG 613
DQ 502 CGCACACGAATTTTCAACGGTGGCCACCGTTTGGGGAAGCACCCTGCAAGTCTCTTGTTG 561
QY 614 GGCCTCATCCAAACGGGGGGGGCTGCACCTTCCGAGACAAGATCCATCTGGCTTATGAG 673
DQ 562 GGCCTCATCCAAACGGGGGGGGCTGCACCTTCCGAGACAAGATCCATCTGGCTTATGAG 621
QY 674 AGATGGGGCTCTGGAGCGCTCATCTTTAACTTCCCGGGGACCCGCAATGAGTTCATCCCC 733
DQ 622 AGAGGGGGCTCTGGAGCGCTCATCTTTAACTTCCCGGGGACCCGCAATGAGTTCATCCCC 681
QY 734 ATGTCTACCGGGTGCAGTAGACATTTGTCATATCATATGATCGCAATCTGAAAGGCACA 793
DQ 682 ATGTCTACCGGGTGCAGTAGACATTTGTCATATCATATGATCGCAATCTGAAAGGCACA 741
QY 794 AAAATTTCTGCAATCTATTCAAGAGGCAATACAGTGCATGATGATGATGATGATGATGAT 853
DQ 742 AAAATTTCTGCAATCTATTCAAGAGGCAATACAGTGCATGATGATGATGATGATGATGAT 801
QY 854 AAAATTTCTGCAATCTATTCAAGAGGCAATACAGTGCATGATGATGATGATGATGATGAT 913
DQ 802 AAAATTTCTGCAATCTATTCAAGAGGCAATACAGTGCATGATGATGATGATGATGATGAT 861
QY 914 ATTACGGGGCAACTGTGGGCTATTTTATCTTTTATCTGCTCGAAGGCTACGGAATGCA 973
DQ 862 ATTACGGGGCAACTGTGGGCTATTTTATCTTTTATCTGCTCGAAGGCTACGGAATGCA 921
QY 974 AGAGTCTCAAGCAGGAGCAGGCAATTAAGGCGAGATGCTAAAAAGCTATTGGAAGG 1033
DQ 922 AGAGTCTCAAGCAGGAGCAGGCAATTAAGGCGAGATGCTAAAAAGCTATTGGAAGG 981
QY 1034 CTTCAACTACGACACTGAAACCAAGGAGCAAGGAAATTTGGCCCTGATGGAGATAGTTGT 1093
DQ 982 CTTCAACTACGACACTGAAACCAAGGAGCAAGGAAATTTGGCCCTGATGGAGATAGTTGT 1041
QY 1094 GCTGTGTGATTTGATTTTAAACCAATGATTTGTTGACGATCTTAAAGTGCACCAAT 1153
DQ 1042 GCTGTGTGATTTGATTTTAAACCAATGATTTGTTGACGATCTTAAAGTGCACCAAT 1101
QY 1154 ATTTTCCATAAGACATGTTTGAACCATGGCTGTTTAAACCAAGCAAGCTTGGCCCATGTGC 1213
DQ 1102 ATTTTCCATAAGACATGTTTGAACCATGGCTGTTTAAACCAAGCAAGCTTGGCCCATGTGC 1161
QY 1214 AAATGTGACATCTCAAGCTTTGGGAATTTGAGTGGATGTTGAAGATGATGATGATGAT 1273
DQ 1162 AAATGTGACATCTCAAGCTTTGGGAATTTGAGTGGATGTTGAAGATGATGATGATGAT 1221
QY 1274 TTACAAGTCCCTGATCCAAATGAAATATCTAATAGTGGCTCTCCCATGAAGAGATAAT 1333
DQ 1222 TTACAAGTCCCTGATCCAAATGAAATATCTAATAGTGGCTCTCCCATGAAGAGATAAT 1281
QY 1334 CGCAGGAGACCGCATCATCTGGATATGTTTCAAGTACAGGGAACAGATGAACCCGCTGTG 1393
DQ 1282 CGCAGGAGACCGCATCATCTGGATATGTTTCAAGTACAGGGAACAGATGAACCCGCTGTG 1341
QY 1394 GAGGAACAGTGCAGTCAACAATGAAATGCTACAGCTGGTAAACCATGAAGCAAAATCT 1453
DQ 1342 GAGGAACAGTGCAGTCAACAATGAAATGCTACAGCTGGTAAACCATGAAGCAAAATCT 1401
QY 1454 GTGGCAGTGGATGTTTATCTCATGTNGACACACCAACCTTTGAAGAGAGCAAACTCCT 1513
DQ 1402 GTGGCAGTGGATGTTTATCTCATGTNGACACACCAACCTTTGAAGAGAGCAAACTCCT 1461
QY 1514 AATCAAGACATCTGTTGCGAATAATTAATCTTAAATCTGTGTAAATAGAAACTTGA 1573
DQ 1462 AATCAAGACATCTGTTGCGAATAATTAATCTTAAATCTGTGTAAATAGAAACTTGA 1521
QY 1574 ACCATTAGTAATAACAGAACTGCCAATCAGGGCCCTAGTTTCTTATTAATAATTTGATAAA 1633
DQ 1522 ACCATTAGTAATAACAGAACTGCCAATCAGGGCCCTAGTTTCTTATTAATAATTTGATAAA 1581
QY 1634 TTTAATAAATAAGAGTGATGATACTGAAAGTGTCTCAGATGACTAATAATTATGCTATAGTTAA 1693

DQ 1582 TTTAATAAATAAGAGTGATGATACTGAAAGTGTCTCAGATGACTAATAATTATGCTATAGTTAA 1641
QY 1694 AATGCTTTAAAAATATTTAACTGTTAACTTTTTCACCAAACTCATTATAATATTTT 1753
DQ 1642 A--TGCTTAAAAATATTTAACTGTTAACTTTTTCCTCA--CAAACTCATTATAATATTTT 1698
QY 1754 CATAGGCAAGTTTCTCTCTCAG 1774
DQ 1699 CATAGGCAAGTTTCTCTCTCAG 1719
RESULT 3
AAI72321
ID AAI72321 standard; cDNA; 2796 BP.
XX AAI72321;
AC AAI72321;
XX 15-APR-2002 (first entry)
XX ISIGP-4 cDNA.
XX Human; intracellular signalling protein; ISIGP; gene; cell proliferation;
KW autoimmune; inflammation; gastrointestinal disorder;
KW reproductive disorder; developmental disorder; ss.
XX Homo sapiens.
XX Key Location/Qualifiers
FT CDS 217..1503
FT /*tag= a
FT /product= "ISIGP-4"
XX WO200194391-A2.
XX 13-DEC-2001.
XX 07-JUN-2001; 2001WO-US18595.
XX 08-JUN-2000; 2000US-210582P.
XX 16-JUN-2000; 2000US-212443P.
XX (INCY-) INCYTE GENOMICS INC.
XX Yue H, He A, Nguyen DB, Yao MG, Bandman O, Burford N, Tang YT;
PI Xu Y, Hatalia A, Azimzai Y, Wallia NK;
XX WPI; 2002-154564/20.
DR P-PSDB; AAB47874.
XX New human intracellular signaling protein and polynucleotides useful
PT for diagnosing, treating or preventing cell proliferative,
PT autoimmune/inflammatory, gastrointestinal, reproductive and
PT developmental disorders -
XX Claim 5; Page 104; 106pp; English.
XX The sequences given in AAI72318-22 encode novel human intracellular
CC signalling proteins (ISIGP). The polynucleotides and ISIGP proteins
CC may be used for the diagnosis, treatment or prevention of cell
CC proliferative, autoimmune/inflammatory, gastrointestinal, reproductive
CC and developmental disorders. The protein encoded by this sequence has
CC homology to mouse gl-related zinc finger protein.
XX Sequence 2796 BP; 821 A; 548 C; 620 G; 807 T; 0 other;
SQ
Query Match 93.7%; Score 1662.8; DB 24; Length 2796;
Best Local Similarity 99.4%; Pred. No. 0;
Matches 1690; Conservative 0; Mismatches 8; Indels 3; Gaps 2;
QY 74 CCAGAGAGTGCATCTGCGGCAACCTGTGTGCTGACGCTACGTGCTCTGCGTCCGAGC 133
DQ 28 CCAGAGAGTGCATCTGCGGCAACCTGTGTGCTGACGCTACGTGCTCTGCGTCCGAGC 87

QY 134 TAGCTGCGAGCTCCCGAGTCTCACTCCATTCCTTCCCACTTGGCGCGCACTGCTCTCAAG 193
 Db 88 TAGCTGCGAGCTCCCGAGTCTCACTCCATTCCTTCCCACTTGGCGCGCACTGCTCTCAAG 147
 QY 194 ACCAGGGTCTGCTCAAGCGCTAGGAGGGCGGTGCGAGGGCGCTAGGGAATGCGGAGC 253
 Db 148 ACCAGGGTCTGCTCAAGCGCTAGGAGGGCGGTGCGAGGGCGCTAGGGAATGCGGAGC 207
 QY 254 GCGCGGCCATGAGGGCGCGGCTGCGGCGCGGGTCTCTCGCGGGGTGGCTGCGGCTTT 313
 Db 208 GCGCGGCCATGAGGGCGCGGCTGCGGCGCGGGTCTCTCGCGGGGTGGCTGCGGCTTT 267
 QY 314 TCCAGATTGCTGSCATGCTGCTTCTGCTGCGCTGAGTCGAGTCGAGACACCGGGTCCCGG 373
 Db 268 TCCAGATTGCTGSCATGCTGCTTCTGCTGCGCTGAGTCGAGTCGAGACACCGGGTCCCGG 327
 QY 374 GGGGCTGAAGACAGTGTGGACCGGCTACCTCAAGCTGCTCGCGGGTCCCGCACACGGGA 433
 Db 328 GGGGCTGAAGACAGTGTGGACCGGCTACCTCAAGCTGCTCGCGGGTCCCGCACACGGGA 387
 QY 434 GTGAACCGTACGCTGTGGAGCTGAGCGAGGAGGGCGGTGACGCGCAGGACTCGCGCTG 493
 Db 388 GTGAACCGTACGCTGTGGAGCTGAGCGAGGAGGGCGGTGACGCGCAGGACTCGCGCTG 447
 QY 494 GAGCTGTGGCTGGGCTCTGCTACCGCGCGACCGGCGCGGGCGCTTAAACCGCTGTAAAC 553
 Db 448 GAGCTGTGGCTGGGCTCTGCTACCGCGCGACCGGCGCGGGCGCTTAAACCGCTGTAAAC 507
 QY 554 CCGCACACGAATTTACGGTGGCGGCTTGGGGAAGCACCGTGTCAAGTCTCTTGGTTG 613
 Db 508 CCGCACACGAATTTACGGTGGCGGCTTGGGGAAGCACCGTGTCAAGTCTCTTGGTTG 567
 QY 614 GCCTCATCAACCGCGGGGGCTGCACCTTGCAGACAAGATCCATCGCTTATGAG 673
 Db 568 GCCTCATCAACCGCGGGGGCTGCACCTTGCAGACAAGATCCATCGCTTATGAG 627
 QY 674 AGATGGCGTCTGGAGCGTCTCTTAACTTCCCGGACCGCAATGAGTCTATCCCC 733
 Db 628 AGAGGGCGTCTGGAGCGTCTCTTAACTTCCCGGACCGCAATGAGTCTATCCCC 687
 QY 734 ATGCTCACCGGGTGCAGTAGACATTTGTCATCATGATCGGCAATCTGAAAGGCACA 793
 Db 688 ATGCTCACCGGGTGCAGTAGACATTTGTCATCATGATCGGCAATCTGAAAGGCACA 747
 QY 794 AAAATTCTGCAATCTATTCAAGAGGCNTACAAAGTGACAAATGGTCTAGAGGAAA 853
 Db 748 AAAATTCTGCAATCTATTCAAGAGGCNTACAAAGTGACAAATGGTCTAGAGGAAA 807
 QY 854 AAACATGGCCCTTGGGTGAATCACTATTCAATTTTTTCTGTTCTGTCCTTTTATT 913
 Db 808 AAACATGGCCCTTGGGTGAATCACTATTCAATTTTTTCTGTTCTGTCCTTTTATT 867
 QY 914 ATTACGGCGCAACTGTGGCTATTTTATCTTTATCTGCTCGAAGGCTACGGAATGCA 973
 Db 868 ATTACGGCGCAACTGTGGCTATTTTATCTTTATCTGCTCGAAGGCTACGGAATGCA 927
 QY 974 AGAGCTCAAGCAGGAGCAGAGGCAATTAAGGCGAGTGTCTAAAGAGCTATTGGAAGG 1033
 Db 928 AGAGCTCAAGCAGGAGCAGAGGCAATTAAGGCGAGTGTCTAAAGAGCTATTGGAAGG 987
 QY 1034 CTTCAACTACGCACACTGAAACAAGGAGACAAGGAATTTGGCCCTGATCGAGATAGTTGT 1093
 Db 988 CTTCAACTACGCACACTGAAACAAGGAGACAAGGAATTTGGCCCTGATCGAGATAGTTGT 1047
 QY 1094 GCTGTGTCAATTGAATTGATATAACCAAAATGATTTGGTACGATCTTAAACGTCGAACCAT 1153
 Db 1048 GCTGTGTCAATTGAATTGATATAACCAAAATGATTTGGTACGATCTTAAACGTCGAACCAT 1107
 QY 1154 ATTTTCCATAAGACATGCTGTGACCCATGCTGTTTAAACACAGACTTTGCCCATGTGC 1213
 Db 1108 ATTTTCCATAAGACATGCTGTGACCCATGCTGTTTAAACACAGACTTTGCCCATGTGC 1167

QY 1214 AAATGTGACATATCAAAAGCTTTGGAAATTTAGGTGGATGTTGAAGATGGATCAGTGTCT 1273
 Db 1168 AAATGTGACATATCAAAAGCTTTGGAAATTTAGGTGGATGTTGAAGATGGATCAGTGTCT 1227
 QY 1274 TTACAGTCTCCTGTATCCAAATGAATATCTAATAGTGCCTCTCCCATGAGAGGATAAT 1333
 Db 1228 TTACAGTCTCCTGTATCCAAATGAATATCTAATAGTGCCTCTCCCATGAGAGGATAAT 1287
 QY 1334 CGCAGCGAGACCGCATCATCTGGATATGCTTCAGTACAGGGAACAGATGAACCGCTCTG 1393
 Db 1288 CGCAGCGAGACCGCATCATCTGGATATGCTTCAGTACAGGGAACAGATGAACCGCTCTG 1347
 QY 1394 GAGGAACACGTGACGTCAACAAATGAAAGTCTACAGCTGTAAACCATGAAGCAAAATCT 1453
 Db 1348 GAGGAACACGTGACGTCAACAAATGAAAGTCTACAGCTGTAAACCATGAAGCAAAATCT 1407
 QY 1454 GTGCGCTGGATGTTATTCCTCATGTGACCAACCCACCTTTCAAGAGACGAACCTCT 1513
 Db 1408 GTGCGCTGGATGTTATTCCTCATGTGACCAACCCACCTTTCAAGAGACGAACCTCT 1467
 QY 1514 AATCAAGAGACTGCTGTTTCGAGAAATTTAAATCTTTAAATCTGTGTAAATAGAAACTTGA 1573
 Db 1468 AATCAAGAGACTGCTGTTTCGAGAAATTTAAATCTTTAAATCTGTGTAAATAGAAACTTGA 1527
 QY 1574 ACCATTAGTAATAACAGAACTGCAATCAGGGCTAGTTTCTATTATAAATTTGGATAAA 1633
 Db 1528 ACCATTAGTAATAACAGAACTGCAATCAGGGCTAGTTTCTATTATAAATTTGGATAAA 1587
 QY 1634 TTTAATAAATAAGAGTGACTGAAAGTCTCAGATGACTAATATTTATGCTATAGTTAA 1693
 Db 1588 TTTAATAAATAAGAGTGACTGAAAGTCTCAGATGACTAATATTTATGCTATAGTTAA 1647
 QY 1694 AATGGCTTAAAAATATTTAACTGTTTAACTTTTCCACCAAACTCATTTATAATATTTT 1753
 Db 1648 A--TGGCTTAAAAATTTAACTGTTTAACTTTTTCCTCA--CAAACTCATTTATAATATTTT 1704
 QY 1754 CATAGGCAAGTTTCTCTCAG 1774
 Db 1705 CATAGGCAAGTTTCTCTCAG 1725

RESULT 4

AAS42511
 ID AAS42511 standard; cDNA; 2876 BP.

XX AAS42511;

XX 18-DEC-2001 (first entry)

XX Human cDNA encoding an mdt protein, clone LI:757439.1:2000MAY01.

Human; molecules for disease detection and treatment; mdt; ss;
 Antiartherosclerotic; hepatotropic; antipsoriatic; antidiabetic; cytotostatic;
 immunosuppressive; antidiabetic; antiashtatic; neuroprotective;
 osteopathic; antiarthritic; cell proliferative disorder;
 arteriosclerosis; cirrhosis; psoriasis; cancer; adenocarcinoma;
 leukemia; breast cancer; autoimmune disorder; AIDS;
 acquired immunodeficiency syndrome; Addison's disease;
 diabetes mellitus; asthma; multiple sclerosis; osteoarthritis.

XX Homo sapiens.

XX WO200162922-A2.

XX 30-AUG-2001.

XX 21-FEB-2001; 2001WO-US05896.

XX 24-FEB-2000; 2000US-0185213.

XX 16-MAY-2000; 2000US-0205232.

XX 17-MAY-2000; 2000US-0205285.

XX 17-MAY-2000; 2000US-0205286.

XX 17-MAY-2000; 2000US-0205287.

QY 1664 CTCAGATGACTAATATTGCTATAGTTAAATGCTTAAATATTTAACTTTAACT 1723
 |||||
 Db 1653 CTCAGATGACTAATATTGCTATAGTTAAATGCTTAAATATTTAACTTTAACT 1710
 |||||
 QY 1724 TTTTCCACCAACTCATTATAATATTTTTCATAGGCAAGTTTCTCTCAG 1774
 |||||
 Db 1711 TTTTCCCA-CAAACTCATATAATATTTTTCATAGGCAAGTTTCTCTCAG 1760
 |||||

RESULT 5

AAAL15985

ID AAA15985 standard; cDNA; 1284 BP.

XX

AC AAA15985;

XX

DT 12-JUN-2000 (first entry)

XX

DE Human protein clone HP10574 coding sequence.

XX

KW Human protein; hydrophobic domain; nutritional source; haematopoiesis;
 KW cytokine production; cell proliferation; cell differentiation;
 KW immune deficiency; infectious disease; autoimmune disorder; asthma;
 KW multiple sclerosis; systemic lupus erythematosus; rheumatoid arthritis;
 KW allergic reaction; osteoporosis; osteoarthritis; periodontal disease;
 KW nervous system disorder; Alzheimer's disease; Parkinson's disease;
 KW Huntington's disease; liver fibrosis; lung fibrosis; reperfusion injury;
 KW systemic cytokine damage; tissue differentiation; contraceptive; stroke;
 KW coagulation disorder; myocardial infarction; inflammatory condition;
 KW septic shock; sepsis; ischaemia; reperfusion injury; arthritis; tumour;
 KW nephritis; therapy; ss.

OS Homo sapiens.

XX

PN WO200005367-A2.

XX

XX 03-FEB-2000.

XX

PD 22-JUL-1999; 99WO-JP03929.

XX

PF 24-JUL-1998; 98JP-0208820.

XX

PR 07-AUG-1998; 98JP-0224105.

XX

PR 25-AUG-1998; 98JP-0238116.

XX

PR 09-SEP-1998; 98JP-0254736.

XX

PR 29-SEP-1998; 98JP-0275505.

XX

XX (SAGA) SAGAMI CHEM RES CENT.

PA (PROT-) PROTEGENE INC.

FA

XX Kato S, Kimura T;

PI

XX WPI: 2000-182694/16.

XX

DR P-PSDB; AAY94897.

XX

Novel human proteins having hydrophobic domains useful for treating
 osteoporosis, Alzheimer's disease, Parkinson's disease, asthma,
 multiple sclerosis, rheumatoid arthritis, cancer, anaemia, and stroke -

XX

PS Claim 3; Page 330; 351pp; English.

XX

This sequence encodes a human protein of the invention, which has
 hydrophobic domains. The DNA sequences can be used as a probe or as a
 genetic marker. The protein can also be used as a marker, and to identify
 potential genetic disorders. The DNA and protein can also be used as
 nutritional sources or supplements. The protein exhibits cytokine, cell
 proliferation, cell differentiation activities and induces production of
 other cytokines in certain cell populations. The protein also exhibits
 immune stimulating or immune suppressing activity. It can be used in the
 treatment of various immune deficiencies and disorders, and to treat
 infectious diseases caused by viral, bacterial, fungal or other
 infections. The protein is also used for treating autoimmune disorders
 such as multiple sclerosis, systemic lupus erythematosus, and rheumatoid
 arthritis. It is also useful in the treatment of allergic reactions and

CC conditions such as asthma, and in immune suppression after organ
 CC transplantation. The protein is useful in regulation of haematopoiesis
 CC and consequently in the treatment of myeloid or lymphoid cell
 CC deficiencies. It is also used in compositions for tissue growth or
 CC regeneration. The protein is also used in the treatment of osteoporosis
 CC or osteoarthritis and in the treatment of periodontal disease and other
 CC tooth repair processes. The protein is used in the treatment of nervous
 CC system disorders such as Alzheimer's disease, Parkinson's disease, and
 CC Huntington's disease. They are useful for protection or regeneration and
 CC treatment of lung or liver fibrosis, reperfusion injury in various
 CC tissues, and conditions resulting from systemic cytokine damage. They are
 CC also used for promoting or inhibiting tissue differentiation. They are
 CC also used as contraceptives since they exhibit activin or inhibin related
 CC activities and as a fertility inducing therapeutic. They are used for
 CC treating various coagulation disorders and in treatment and prevention of
 CC conditions resulting from coagulation activities e.g. myocardial
 CC infarction or stroke. They also acts as receptors, receptor ligands or
 CC inhibitors or agonists of receptor/ligand interactions. They are used to
 CC treat inflammatory conditions such as septic shock, sepsis, ischaemia
 CC reperfusion injury, arthritis, and nephritis. They can be used to
 CC prevent tumours.

SQ Sequence 1284 BP; 323 A; 305 C; 352 G; 304 T; 0 other;

Query Match 72.1%; Score 1278.2; DB 21; Length 1284;

Best Local Similarity 99.7%; Pred. No. 0;

Matches 1280; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 263 ATGGGGGCGCGCCCTGGGGCGGGGCTCTCTGCGCGGTGGTGGGCTTTCCAGATTG 322

Db 1 ATGGGGGCGCGCCCTGGGGCGGGGCTCTCTGCGCGGTGGTGGGCTTTCCAGATTG 60

QY 323 CTGGGATGTTGTTCTCTGCTGGCCCTGAGTCCGAGGACCCCGTTCCTGGGGGGCTGAA 382

Db 61 CTGGGATGTTGTTCTCTGCTGGCCCTGAGTCCGAGGACCCCGTTCCTGGGGGGCTGAA 120

QY 383 GCAGTGTGGACCGCGTACTCAACGTGTCCTGGGGGTTCGCGACACGGGAGTGAACGT 442

Db 121 GCAGTGTGGACCGCGTACTCAACGTGTCCTGGGGGTTCGCGACACGGGAGTGAACGT 180

QY 443 ACGGTGTGGGAGCTGAGGAGGAGGCGGTGTACCGCCAGGAGCTCCCGCTGGAGGCTGTG 502

Db 181 ACGGTGTGGGAGCTGAGGAGGAGGCGGTGTACCGCCAGGAGCTCCCGCTGGAGGCTGTG 240

QY 503 GCTGGGGTCTTGTTACCGCCCGACGGGCGCGGCGCTTAAACGCTGTAAACCCGACACG 562

Db 241 GCTGGGGTCTTGTTACCGCCCGACGGGCGCGGCGCTTAAACGCTGTAAACCCGACACG 300

QY 563 AATTTACGGTGTCCCAACGGTTTGGGGAGAGCACCGTGCAAGTCTCTTGGTTGGCCCTCATC 622

Db 301 AATTTACGGTGTCCCAACGGTTTGGGGAGAGCACCGTGCAAGTCTCTTGGTTGGCCCTCATC 360

QY 623 CAACGGCGGGGGCTGCACCTTCGACAGCAAGATCCATCTGGCTTATGAGAGATGGCG 682

Db 361 CAACGGCGGGGGCTGCACCTTCGACAGCAAGATCCATCTGGCTTATGAGAGATGGCG 420

QY 683 TCTGGAGCGGTCTCTTTAACTTCCCGGGGACCCGCAATGAGGTCTATCCCATGTCTCAC 742

Db 421 TCTGGAGCGGTCTCTTTAACTTCCCGGGGACCCGCAATGAGGTCTATCCCATGTCTCAC 480

QY 743 CCGGTTGCAAGTAGACATTTGTTGCAATCATGATCGGCAATCTGAAAGGCACAAAAATTCG 802

Db 481 CCGGTTGCAAGTAGACATTTGTTGCAATCATGATCGGCAATCTGAAAGGCACAAAAATTCG 540

QY 803 CAATCTATTCAAAGAGGCATCAAGTGTCAATGGTTCATAGAGTAGAGGAAAAAATGC 862

Db 541 CAATCTATTCAAAGAGGCATCAAGTGTCAATGGTTCATAGAGTAGAGGAAAAAATGC 600

QY 863 CCTTGGGTGATCACTATTCAATTTTTTCTGTTCTGTTCTTTTATTATTACGGCG 922

Db 601 CCTTGGGTGATCACTATTCAATTTTTTCTGTTCTGTTCTTTTATTATTACGGCG 660

QY 923 GCAACTGTGGGCTATTTTATCTTTTCTCTGCTCGAAGGCTACGGAATGCAAGAGCTCAA 982

Db 661 GCAACTGTGGGCTATTTATCTTTTATCTCTGCTGCAAGGCTACGGAATGCAAGGCTCAA 720
Qy 983 AGCAGGAAGCAGAGGCAATTAAGGCAGATGCTAAAAAGCTATTGGAAGGCTTCAACTA 1042
Db 721 AGCAGGAAGCAGAGGCAATTAAGGCAGATGCTAAAAAGCTATTGGAAGGCTTCAACTA 780
Qy 1043 CGCACACTGAACAAGGAGACAAGGAAATTTGGCCCTGTATGAGATAGTTGTGTGTGC 1102
Db 781 CGCACACTGAACAAGGAGACAAGGAAATTTGGCCCTGTATGAGATAGTTGTGTGTGC 840
Qy 1103 ATTGAATTGTATAAACCAATGATTTGTGTAGCATCTTTAAGTGCAACCATATTTTCAT 1162
Db 841 ATTGAATTGTATAAACCAATGATTTGTGTAGCATCTTTAAGTGCAACCATATTTTCAT 900
Qy 1163 AAGACATGTTTGACCCCATGCTGTTAAACAACAAGACTTGGCCCATGTGCAAAATGTGAC 1222
Db 901 AAGACATGTTTGACCCCATGCTGTTAAGACACAGGACTTGGCCCATGTGCAAAATGTGAC 960
Qy 1223 ATACTCAAGCTTTGGGAATTGAGGTGATGTTGAAGATGATCAGTGTCTTTACAAGTC 1282
Db 961 ATACTCAAGCTTTGGGAATTGAGGTGATGTTGAAGATGATCAGTGTCTTTACAAGTC 1020
Qy 1283 CCTGTATCCAAATGAATATCTAATAGTGCTCTCCCATGAAGAGATAATCGCAGCGAG 1342
Db 1021 CCTGTATCCAAATGAATATCTAATAGTGCTCTCCCATGAAGAGATAATCGCAGCGAG 1080
Qy 1343 ACCGATCATCTGGATATCTTCACTAGCAGGAAACAGATGAACCGCCCTCTGGAGGAACAC 1402
Db 1081 ACCGATCATCTGGATATCTTCACTAGCAGGAAACAGATGAACCGCCCTCTGGAGGAACAC 1140
Qy 1403 GTGCAGTCAACAAATGAAGTCTACAGCTGTGTAAACCATGAGCAAAATCTGTGCGCATG 1462
Db 1141 GTGCAGTCAACAAATGAAGTCTACAGCTGTGTAAACCATGAGCAAAATCTGTGCGCATG 1200
Qy 1463 GATGTTATTCCTCATGTNGACACCCCAACCTTTGAAGAGACGAACTCCTAATCAAGAG 1522
Db 1201 GATGTTATTCCTCATGTNGACACCCCAACCTTTGAAGAGACGAACTCCTAATCAAGAG 1260
Qy 1523 ACTGCTGTTCGAGAAATTAATCT 1546
Db 1261 ACTGCTGTTCGAGAAATTAATCT 1284

RESULT 6
AAS25884
ID AAS25884 standard; cDNA; 2306 BP.
AC AAS25884;
XX
XX
DT 07-NOV-2001 (first entry)
XX
DE Human cDNA encoding a novel secreted protein, Seq ID 63.
XX
XX Human; immunosuppressive; antiarthritic; ss; antirheumatic;
KW cytostatic; cardiant; vasotropic; cerebroprotective; nootropic;
KW neuroprotective; antibacterial; virucide; fungicide; ophthalmological;
KW vulnary; secreted protein; rheumatoid arthritis;
KW hyperproliferative disorder; cardiovascular disorder; cardiac arrest;
KW cerebrovascular disorder; cerebral ischaemia; angiogenesis;
KW nervous system disorder; Alzheimer's disease; infection; ocular disorder;
KW corneal infection; wound healing; epithelial cell proliferation;
KW skin ageing; food additive; preservative; antiproliferative.
XX
OS Homo sapiens.
XX
XX WO20015322-A2.
PN
XX
XX 02-AUG-2001.
PD
XX
XX 17-JAN-2001; 2001WO-US01341.
PF
XX
XX 31-JAN-2000; 2000US-0179065.
PR

PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.

Db 612 GCAACCATATTTTCATAGACATGTGTGACCCATGGCTTTAGAACACAGGACTTGC 671
 Qy 1206 CCATGTGCAATGTGACATCTCAAGCTTTTGGAAATGAGGTGGATGTTGAAGATGGAT 1265
 Db 672 CCATGTGCAATGTGACATCTCAAGCTTTTGGAAATGAGGTGGATGTTGAAGATGGAT 731
 Qy 1266 CAGTGTCTTTACAGTCCCTGTATCCCAATGAATATCTTATAGTGCCTCCCTCCATGAAG 1325
 Db 732 CAGTGTCTTTACAGTCCCTGTATCCCAATGAATATCTTATAGTGCCTCCCTCCATGAAG 791
 Qy 1326 AGGATAATCGCAGGAGACCCATCATCTGGATATGCTTCCAGTACAGGGAACAGATGAAC 1385
 Db 792 AGGATAATCGCAGGAGACCCATCATCTGGATATGCTTCCAGTACAGGGAACAGATGAAC 851
 Qy 1386 CGCCTCTGGAGGACACGTGAGTCAACAAATGAAGTCTACAGCTGGTAAACCATGAAG 1445
 Db 852 CGCCTCTGGAGGACACGTGAGTCAACAAATGAAGTCTACAGCTGGTAAACCATGAAG 911
 Qy 1446 CAAATTTCTGTGAGTGGATGTTATCTCTCATGTNGACAACCCCAACCTTTGAAGAAGACG 1505
 Db 912 CAAATTTCTGTGAGTGGATGTTATCTCTCATGTNGACAACCCCAACCTTTGAAGAAGACG 971
 Qy 1506 AAACCTCTTAATCAAGAGACTGCTGTTCGAGAAATTAATCTTAAATCTGTGTAATAGA 1565
 Db 972 AAACCTCTTAATCAAGAGACTGCTGTTCGAGAAATTAATCTTAAATCTGTGTAATAGA 1031
 Qy 1566 AAACCTTGAACTTAGTAATACAGACTGCAATCAGGCTAGTCTTCTATTAATAAT 1625
 Db 1032 AAACCTTGAACTTAGTAATACAGACTGCAATCAGGCTAGTCTTCTATTAATAAT 1091
 Qy 1626 TGGATAAATTTAATAAATAAGAGTGATCTGAAAGTGTCTCAGATGACTAATATTATGCT 1685
 Db 1092 TGGATAAATTTAATAAATAAGAGTGATCTGAAAGTGTCTCAGATGACTAATATTATGCT 1151
 Qy 1686 ATAGTAAATGGCTTAAATAATTTAACTGTAACTGTTAACTTTTCCACCAACTCATTATA 1745
 Db 1152 ATAGTAAAT--TGGCTTAAATAATTTAACTGTAACTTTTCCCA--CAAACTCATTATA 1208
 Qy 1746 ATATTTTTCATAGGCAAGTTCCTCTCAG 1774
 Db 1209 ATATTTTTCATAGGCAAGTTCCTCTCAG 1237

RESULT 7

ABL90796
 ID ABL90796 standard; cDNA; 1249 BP.
 XX AC ABL90796;
 XX DT 24-MAY-2002 (first entry)
 XX DE Human polynucleotide SEQ ID NO 1358.
 XX KW Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;
 KW antiallergic; hepatotropic; antidiabetic; antiinflammatory; antiulcer;
 KW vulnary; anticonvulsant; antibacterial; antifungal; antiparasitic;
 KW cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;
 KW neurological disease; infection; human; secreted protein; gene; ss.
 XX OS Homo sapiens.
 XX PN WO200190304-A2.
 XX PD 29-NOV-2001.
 XX PF 18-MAY-2001; 2001WO-US16450.
 XX PR 19-MAY-2000; 2000US-205515P.
 XX PA (HUMA-) HUMAN GENOME SCI INC.
 XX PI Birse CE, Rosen CA;

XX WPI; 2002-122018/16.
 DR P-PDB; ABB90387.
 XX Novel 1405 isolated polypeptides, useful for diagnosis, treatment and
 PT prevention of neural, immune system, muscular, reproductive,
 PT gastrointestinal, pulmonary, cardiovascular, renal and proliferative
 PT disorders -
 XX Claim 4; SEQ ID NO 1358; 2081pp + Sequence Listing; English.
 XX The invention relates to novel genes (ABL89449-ABL90853) and proteins
 CC (ABB9040-ABB90444) useful for preventing, treating or ameliorating
 CC medical conditions e.g. by protein or gene therapy. The genes are
 CC isolated from a range of human tissues disclosed in the specification.
 CC The nucleic acids, proteins, antibodies and (ant)agonists are useful
 CC in the diagnosis, treatment and prevention of: (a) cancer, e.g. breast
 CC and ovarian cancer and other cancers of the adrenal gland, bone, bone
 CC marrow, breast, gastrointestinal tract, liver, lung, or urogenital;
 CC (b) immune disorders e.g. Addison's disease, allergies, autoimmune
 CC haemolytic anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's
 CC disease, multiple sclerosis, rheumatoid arthritis and ulcerative
 CC colitis; (c) cardiovascular disorders such as myocardial ischaemias;
 CC (d) wound healing; (e) neurological diseases e.g. cerebral anoxia and
 CC epilepsy; and (f) infectious diseases such as viral, bacterial, fungal
 CC and parasitic infections.
 CC Note: The sequence data for this patent did not form part of the
 CC printed specification, but was obtained in electronic format directly
 CC from WIPO at ftp.wipo.int/pub/published_pat_sequences.
 XX Sequence 1249 BP; 379 A; 258 C; 273 G; 335 T; 4 other;

Query Match

Best Local Similarity 65.8%; Score 1167.2; DB 24; Length 1249;
 Matches 1206; Conservative 1; Mismatches 11; Indels 4; Gaps 3

Qy 547 CTGTAAACCGCACAGCAATTTTCCAGTGTCCACGGTTTGGGGAAGACCGTCAAGTCTC 606
 Db 18 CTGTAAACCGCACAGCAATTTTCCAGTGTCCACGGTTTGGGGAAGACCGTCAAGTCTC 77
 Qy 607 TTGTTTGGCCCTCATCCACGGCGGGGCTGACCTTCGCAGACAAGATCCATCTGCG 666
 Db 78 TTGTTTGGCCCTCATCCACGGCGGGGCTGACCTTCGCAGACAAGATCCATCTGCG 137
 Qy 667 TTATGAGAGATGGGCTCTGGAGCCGTCACTTTAACTTCCCGGAGCCCGCAATGAGGT 726
 Db 138 TTATGAGAGAGGGGGCTCTGGAGCCGTCACTTTAACTTCCCGGAGCCCGCAATGAGGT 197
 Qy 727 CATCCCCATGTCTCACCCGGGTGCAGTAGACATTTGTCATCATGCGCAATCTGAA 786
 Db 198 CATCCCCATGTCTCACCCGGGTGCAGTAGACATTTGTCATCATGCGCAATCTGAA 257
 Qy 787 AGGCACAAAAATTTCTGCAATCTATTCAAGAGGCATACAAAGTGACAATGGTCATAGAAGT 846
 Db 258 AGGCACAAAAATTTCTGCAATCTATTCAAGAGGCATACAAAGTGACAATGGTCATAGAAGT 317
 Qy 847 AGGAAAAAACAATGGCCCTTGGGTGAACTCACTATTCAATTTTTTCTGTGTGCTT 906
 Db 318 AGGAAAAAACAATGGCCCTTGGGTGAACTCACTATTCAATTTTTTCTGTGTGCTT 377
 Qy 907 TTTTATTATTACGGGGCAACTGTGGGCTATTATTATCTTTTATCTGTCTGCGAAGGCTACG 966
 Db 378 TTTTATTATTACGGGGCAACTGTGGGCTATTATTATCTTTTATCTGTCTGCGAAGGCTACG 437
 Qy 967 GAATGCAAGAGCTCAAGAGCAGGAAGCAGAGGCAATTTAAAGGAGATGCTAAAAAGCTAT 1026
 Db 438 GAATGCAAGAGCTCAAGAGCAGGAAGCAGAGGCAATTTAAAGGAGATGCTAAAAAGCTAT 497
 Qy 1027 TGGAAAGCTTCAACTACGCACACTGAAACAAGAGACAAGG-AAATTGGCCCTGATGGAG 1085
 Db 498 TGGAAAGCTTCAACTACGCACACTGAAACAAGAGACAAGGKAAATTTGGCCCTGATGGAG 557
 Qy 1086 ATAGTTGTGTGTGTCATTGAATTGTATAAAACCAAAATGATTTGGTACGCATCTTAACGT 1145

Db 584 TGAAGCCCGTCTCCGGGGTCTGCTACCGCCCGACGGGCCCGGGCGCTCAACGCCGTGTA 643
Qy 552 ACCCGCACACGAATTTACGGTCCCGACGGTTTGGGGAAGCAGCGTGCAAGTCTCTTGTT 611
Db 644 ACCCGCACACGAATTTACGGTCCCGACGGTTTGGGGAAGCAGCGTGCAAGTCTCTTGTT 703
Qy 612 TGGCCCTCATCAACGGGGGGGGCTGCACCTTTGCGCAGACAAGATCCATCTGCTTATG 671
Db 704 TGGCCCTCATCAACGGGGGGGGCTGCACCTTTGCGCAGACAAGATCCATCTGCTTATG 763
Qy 672 AGAGATGGGCGTCTGGAGCGGTGATCTTTTAACTTTCCCGGGGACCCGCAATGAGGTATCC 731
Db 764 AGAGAGGGGCTTCTGGAGCGGTGATCTTTTAACTTTCCCGGGGACCCGCAATGAGGTATCC 823
Qy 732 CCATGCTCACCCGGGGTGCATGACATGTTGCAATCATGATCGGCAATCTGAAAGGCA 791
Db 824 CCATGCTCACCCGGGGTGCATGACATGTTGCAATCATGATGCGCAATCTGAAAGGAA 883
Qy 792 CAAAAATTTCTCAATCTATTCAAGAGGACATCAAGTGACAAATGGTCAATGAAAGTAGGGA 851
Db 884 CAAAAATTTCTCAGTCTATTCAAGAGGACATCAAGTGACAAATGGTCAATGAAAGTAGGGA 943
Qy 852 AAAAAATGCGCCCTTGGGTGGAATCACTATTCAATTTTTCGTTCTGTCCTTTTCA 911
Db 944 AAAAAATGCGCCCTTGGGTGGAATCACTATTCAATTTTTCGTTCTGTCCTTTTCA 1003
Qy 912 TTATTACGGCGCAACTGTGGCTATTATTATCTTTTATCTTCTGCTCGAAGGCTACGGAATG 971
Db 1004 TAAATTCGGGCAACCGTGGCTATTTCATCTTTTATCTGCTCGAAGATTACGAATG 1063
Qy 972 CAAGAGCTCAAGCAGGAGGAGGCAATTAAGGCGGAGATGCTTAAAGAGCTTATGGA 1031
Db 1064 CAAGAGCTCAAGCAGGAGGAGGCAATTAAGGCGGAGATGCTTAAAGAGCTTATGGA 1123
Qy 1032 GCGTTCAACTACGACACTGAAACAGGAGACAGGAATTTGGCCCTGATGGAGATAGTT 1091
Db 1124 AGCTTCAGTGGCGACCTTGAAACAGGAGACAGGAATTTGGCCCTGATGGAGATAGTT 1183
Qy 1092 GTGCTGTGCAATGGAATGTTATAAACCAATGATTTGGTACGATCTTAAACGTGCAACC 1151
Db 1184 GTGCTGTGCAATGGAATGTTATAAACCAATGATTTGGTACGATCTTAAACGTGCAACC 1243
Qy 1152 ATATTTTCATAGACATGCTTGACCCATGGCTGTTTAAACACAGACATTTGCCCATGT 1211
Db 1244 ATATTTTCATAGACATGCTTGACCCATGGCTGTTTAAACACAGACATTTGCCCATGT 1303
Qy 1212 GCAATGTGACATCTCAAGCTTTTGGGAATTTGAGGTGGATGTTGAAGATGGATCAGTGT 1271
Db 1304 GCAAGTGTGACATCTCAAGCTTTTGGGAATTTGAGGTGGATGTTGAAGATGGATCAGTGT 1363
Qy 1272 CTTTCAAGTCCCTGTATCCAAATGAATATCTAATAGTGGCTCTCCATGAAGAGGATA 1331
Db 1364 CTTTCAAGTCCCTGTATCTAATGAAGATCTAATAGTGGCTCTCCATGAAGAGGATA 1423
Qy 1332 ATCGCAGCAGACCGCATCATCTGGATATGCTTTCAGTACAGGGAACAGATGAACCGCTC 1391
Db 1424 GTCCGAGTGAAGTGCATCATCTGGATATGCTTTCAGTACAGGGAACAGATGAACCGCTC 1483
Qy 1392 TGGAGGAACCGTGACATCAACAAATGAAGTCTACAGTGGTAAACCATGAAGCAAAAT 1451
Db 1484 TGGAGGAACATGCGCAGTCAAGAAATGAAAATCTACAGTGGTAAACCATGAAGCAAAAT 1543
Qy 1452 CTGTGCGAGTGGATGTTATCTCTCATGTTGACAAACCCACCTTTGAAGAGACGAAATC 1511
Db 1544 CTGTGCGAGTGGATGTTATCTCTCATGTTGACAAACCCACCTTTGAAGAGATGAATC 1603
Qy 1512 CTAATCAAGAGACTGCTGTTTCGAGAAATTAATCTTT - AAAATCTGTGTAATAGAAAAT 1570
Db 1604 CTGATCAAGAGGAGCTGTTTCGGGAGTTAATCTTAAATCTGTGTCATAGAAAAT 1663
Qy 1571 TGAACCAATTAG - TAAATAAGAACTGCCAATCAGGGCCTAGTTT - CTATTAATAAATGG 1628
Db 1664 TGAACCGTTAGTTTAAACAGGAGCTGCCAATCAGGGCCTAGTTTACTATGATGAATGAACTGG 1723

Qy 1629 ATAAATTTAAATAAAGAGTGATGACTGAAGTGCTCAGATGACTAATATTATGCTATA 1688
Db 1724 GTAAA--CGTAAACAAGAATGATGACTGAAGTGCTGAGGTAATTTATATTACTATA 1780
Qy 1689 GTTAAATGGCTTAAAAATATTTAACTGTTTAACTTTTCCCAACAACTCAATTATAA 1748
Db 1781 GTTAAA--TGGCTTAAACATAATTTACCCAGTACCGTTTT--CCACAAACTCACCATAACG 1836
Qy 1749 TTTTTCATAGGCAAGTTTCCTCT 1771
Db 1837 TTTTTCATAGGCAAGTTTCCTCT 1859
RESULT 9
AAS26340
ID AAS26340 standard; cDNA; 1250 BP.
XX
AC AAS26340;
XX
DT 07-NOV-2001 (first entry)
XX
DE Human cDNA encoding a novel secreted protein, Seq ID 519.
XX
KW Human; immunosuppressive; antiarthritic; ss; antirheumatic;
cytostatic; cardiant; vasotropic; cerebroprotective; nootropic;
neuroprotective; antibacterial; virucide; fungicide; ophthalmological;
vulnerary; secreted protein; rheumatoid arthritis;
hyperproliferative disorder; cardiovascular disorder; cardiac arrest;
cerebrovascular disorder; cerebral ischaemia; angiogenesis;
nervous system disorder; Alzheimer's disease; infection; ocular disorder;
corneal infection; wound healing; epithelial cell proliferation;
skin ageing; food additive; preservative; antiproliferative.
OS Homo sapiens.
XX
XX
PN WO200155322-A2.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01341.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-019874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 11-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225477.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.

PR 22-AUG-2000; 2000US-0226681.
 PR 22-AUG-2000; 2000US-0226868.
 PR 22-AUG-2000; 2000US-0227182.
 PR 23-AUG-2000; 2000US-0227009.
 PR 30-AUG-2000; 2000US-0228924.
 PR 01-SEP-2000; 2000US-0228287.
 PR 01-SEP-2000; 2000US-0229343.
 PR 01-SEP-2000; 2000US-0229344.
 PR 01-SEP-2000; 2000US-0229345.
 PR 05-SEP-2000; 2000US-0229509.
 PR 05-SEP-2000; 2000US-0229513.
 PR 06-SEP-2000; 2000US-0230437.
 PR 06-SEP-2000; 2000US-0230438.
 PR 08-SEP-2000; 2000US-0231242.
 PR 08-SEP-2000; 2000US-0231243.
 PR 08-SEP-2000; 2000US-0231244.
 PR 08-SEP-2000; 2000US-0231413.
 PR 08-SEP-2000; 2000US-0231414.
 PR 08-SEP-2000; 2000US-0233080.
 PR 08-SEP-2000; 2000US-0233081.
 PR 12-SEP-2000; 2000US-02331968.
 PR 14-SEP-2000; 2000US-0233297.
 PR 14-SEP-2000; 2000US-0233398.
 PR 14-SEP-2000; 2000US-0233399.
 PR 14-SEP-2000; 2000US-0233400.
 PR 14-SEP-2000; 2000US-0234401.
 PR 14-SEP-2000; 2000US-0233063.
 PR 14-SEP-2000; 2000US-0233064.
 PR 14-SEP-2000; 2000US-0233065.
 PR 21-SEP-2000; 2000US-0234223.
 PR 21-SEP-2000; 2000US-0234274.
 PR 25-SEP-2000; 2000US-0234997.
 PR 25-SEP-2000; 2000US-0234998.
 PR 26-SEP-2000; 2000US-0235484.
 PR 27-SEP-2000; 2000US-0235834.
 PR 27-SEP-2000; 2000US-0235836.
 PR 29-SEP-2000; 2000US-0236327.
 PR 29-SEP-2000; 2000US-0236367.
 PR 29-SEP-2000; 2000US-0236368.
 PR 29-SEP-2000; 2000US-0236369.
 PR 29-SEP-2000; 2000US-0236370.
 PR 02-OCT-2000; 2000US-0236802.
 PR 02-OCT-2000; 2000US-0237037.
 PR 02-OCT-2000; 2000US-0237038.
 PR 02-OCT-2000; 2000US-0237039.
 PR 02-OCT-2000; 2000US-0237040.
 PR 13-OCT-2000; 2000US-0239935.
 PR 13-OCT-2000; 2000US-0239937.
 PR 20-OCT-2000; 2000US-0240960.
 PR 20-OCT-2000; 2000US-0241221.
 PR 20-OCT-2000; 2000US-0241785.
 PR 20-OCT-2000; 2000US-0241786.
 PR 20-OCT-2000; 2000US-0241787.
 PR 20-OCT-2000; 2000US-0241808.
 PR 20-OCT-2000; 2000US-0241809.
 PR 20-OCT-2000; 2000US-0241826.
 PR 01-NOV-2000; 2000US-0244617.
 PR 08-NOV-2000; 2000US-0246474.
 PR 08-NOV-2000; 2000US-0246475.
 PR 08-NOV-2000; 2000US-0246476.
 PR 08-NOV-2000; 2000US-0246477.
 PR 08-NOV-2000; 2000US-0246478.
 PR 08-NOV-2000; 2000US-0246523.
 PR 08-NOV-2000; 2000US-0246524.
 PR 08-NOV-2000; 2000US-0246525.
 PR 08-NOV-2000; 2000US-0246526.
 PR 08-NOV-2000; 2000US-0246527.
 PR 08-NOV-2000; 2000US-0246528.
 PR 08-NOV-2000; 2000US-0246532.
 PR 08-NOV-2000; 2000US-0246609.
 PR 08-NOV-2000; 2000US-0246610.
 PR 08-NOV-2000; 2000US-0246611.
 PR 08-NOV-2000; 2000US-0246613.

PR 17-NOV-2000; 2000US-0249207.
 PR 17-NOV-2000; 2000US-0249208.
 PR 17-NOV-2000; 2000US-0249209.
 PR 17-NOV-2000; 2000US-0249210.
 PR 17-NOV-2000; 2000US-0249211.
 PR 17-NOV-2000; 2000US-0249212.
 PR 17-NOV-2000; 2000US-0249213.
 PR 17-NOV-2000; 2000US-0249214.
 PR 17-NOV-2000; 2000US-0249215.
 PR 17-NOV-2000; 2000US-0249216.
 PR 17-NOV-2000; 2000US-0249217.
 PR 17-NOV-2000; 2000US-0249218.
 PR 17-NOV-2000; 2000US-0249244.
 PR 17-NOV-2000; 2000US-0249245.
 PR 17-NOV-2000; 2000US-0249264.
 PR 17-NOV-2000; 2000US-0249265.
 PR 17-NOV-2000; 2000US-0249297.
 PR 17-NOV-2000; 2000US-0249299.
 PR 17-NOV-2000; 2000US-0249300.
 PR 01-DEC-2000; 2000US-0250160.
 PR 01-DEC-2000; 2000US-0250391.
 PR 05-DEC-2000; 2000US-0251030.
 PR 05-DEC-2000; 2000US-0251988.
 PR 05-DEC-2000; 2000US-0256719.
 PR 06-DEC-2000; 2000US-0251479.
 PR 08-DEC-2000; 2000US-0251856.
 PR 08-DEC-2000; 2000US-0251868.
 PR 08-DEC-2000; 2000US-0251869.
 PR 08-DEC-2000; 2000US-0251989.
 PR 08-DEC-2000; 2000US-0251990.
 PR 11-DEC-2000; 2000US-0254097.
 PR 05-JAN-2001; 2001US-0256978.
 XX XX

(HUMA-) HUMAN GENOME SCI INC.

Rosen CA, Barash SC, Ruben SM;

WPI; 2001-488783/53.

P-PSDB; AAU16353.

New nucleic acid molecules encoding 461 human secreted proteins for diagnosing, preventing, treating or ameliorating medical conditions and used as food additives or preservatives -

Claim 1; SEQ ID No 519; 980pp; English.

The invention relates to isolated nucleic acid molecules and their encoded secreted proteins. The nucleic acids and proteins are used to prevent, treat or ameliorate a medical condition in e.g. humans, mice, rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used in diagnosing a pathological condition or susceptibility to a pathological condition. Antibodies to the proteins can also be used in alleviating symptoms associated with the disorders and in diagnostic immunoassays e.g. radioimmunoassays or enzyme linked immunosorbant assays (ELISA). Disorders which are diagnosed or treated include autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g. neoplasms of the breast or liver, cardiovascular disorders e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia, angiogenesis, nervous system disorders e.g. Alzheimer's disease, infections caused by bacteria, viruses and fungi and ocular disorders e.g. corneal infection, and many other disorders listed in the specification. The polypeptides can also be used to aid wound healing and epithelial cell proliferation, to prevent skin aging due to sunburn, to maintain organs before transplantation, for supporting cell culture of primary tissues, to regenerate tissues and in chemotaxis. The polypeptides can also be used as a food additive or preservative to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors and other nutritional components. The present sequence encodes a novel secreted protein of the invention.

Query Match 65.3%; Score 1157.6; DB 22; Length 1250;
 Best Local Similarity 98.8%; Pred. No. 8.9e-312;

Matches 1208; Conservative 0; Mismatches 10; Indels 5; Gaps 4;

QY 547 CTGTAAACCCGACACGAAATTCACGGTGGCCCGCCAGGTTTGGGGAAGACACCGTGCAGATCTC 606
Db 18 CTGTAAACCCGACACGAAATTCACGGTGGCCCGCCAGGTTTGGGGAAGACACCGTGCAGATCTC 77
QY 607 TTGTTGGCCCTCATCAACGCGCGGGGCTGCACCTTCGACAGCAAGATCATCTGGC 666
Db 78 TTGTTGGCCCTCATCAACGCGCGGGGCTGCACCTTCGACAGCAAGATCATCTGGC 137
QY 667 TTATGAGAGATGGGCGTCTGGAGCCGTCATCTTTAACTCCCGGGACCCGCAATGAGGT 726
Db 138 TTATGAGAGATGGGCGTCTGGAGCCGTCATCTTTAACTCCCGGGACCCGCAATGAGGT 197
QY 727 CATCCCATGTCTCACCCGGGTGAGTAGACATTTGTTGCAATCATGATCGGCAATCTGAA 786
Db 198 CATCCCATGTCTCACCCGGGTGAGTAGACATTTGTTGCAATCATGATCGGCAATCTGAA 257
QY 787 AGGCACAAAATTTCTGCAATCTATTAAGAGGCAATCAAGTGACAAATGTCATAGAAGT 846
Db 258 AGGCACAAAATTTCTGCAATCTATTAAGAGGCAATCAAGTGACAAATGTCATAGAAGT 317
QY 847 AGGGAJAAAAACATCGCCCTGGGTGAATCACTATTCAA-TTTTTTTCGTTCTGTGTCCT 905
Db 318 AGGGAJAAAAACATCGCCCTGGGTGAATCACTATTCAA-TTTTTTTCGTTCTGTGTCCT 377
QY 906 TTTTATTATTACCGCGCAACTGTGGCTATTTTATCTTTTATTTCTGCTCGAAGGCTAC 965
Db 378 TTTTATTATTACCGCGCAACTGTGGCTATTTTATCTTTTATTTCTGCTCGAAGGCTAC 437
QY 966 GGAATGCAAGAGCTCAAGCAGGAGGAGCAGAGGCAATTTAAAGGCAGATGCTAAAAAGCTA 1025
Db 438 GGAATGCAAGAGCTCAAGCAGGAGGAGCAGAGGCAATTTAAAGGCAGATGCTAAAAAGCTA 497
QY 1026 TTGGAAGCTTCAACTACGACACTGAAACAAAGGAGCAAGG-AAATTGGCCCTGTATGGA 1084
Db 498 TTGGAAGCTTCAACTACGACACTGAAACAAAGGAGCAAGG-AAATTGGCCCTGTATGGA 557
QY 1085 GATAGTTGTGTGTGTGATGAATTTGTATAAACCAATGATTTGGTACGATCTTTAAG 1144
Db 558 GATAGTTGTGTGTGTGATGAATTTGTATAAACCAATGATTTGGTACGATCTTTAAG 617
QY 1145 TGCACCAATATTTTCCATACGACATGTTGACCCATGGCTTTAAACCAACAGACTTGC 1204
Db 618 TGCACCAATATTTTCCATACGACATGTTGACCCATGGCTTTAAACCAACAGACTTGC 677
QY 1205 CCCATGTGCAATGTGACATCTCAAAAGCTTTGGGAAATGAGTGGATGTTGAAGATGGA 1264
Db 678 CCCATGTGCAATGTGACATCTCAAAAGCTTTGGGAAATGAGTGGATGTTGAAGATGGA 737
QY 1265 TCAGTGTCTTTACAGTCCCTGTATCCAAATGAATATCTAATAGTGGCTCTCCCATGAA 1324
Db 738 TCAGTGTCTTTACAGTCCCTGTATCCAAATGAATATCTAATAGTGGCTCTCCCATGAA 797
QY 1325 GAGGATAATCGCAGCGACCGCATCATCTGGATATGTTTCAGTACAGGGAACAGATGAA 1384
Db 798 GAGGATAATCGCAGCGACCGCATCATCTGGATATGTTTCAGTACAGGGAACAGATGAA 857
QY 1385 CGCCCTCTGGAGGACACGTCAGTCAACAAATGAAGTCTACAGTGGTAAACCATGAA 1444
Db 858 CGCCCTCTGGAGGACACGTCAGTCAACAAATGAAGTCTACAGTGGTAAACCATGAA 917
QY 1445 GCAAAATCTGTGGCAGTGGATGTTATTCCTCATGTNGACACCCCACTTTGAGAGAGAC 1504
Db 918 GCAAAATCTGTGGCAGTGGATGTTATTCCTCATGTNGACACCCCACTTTGAGAGAGAC 977
QY 1505 GAAATCTCTAATCAAGAGACTGCTGTTTCAGAGAAATTAATCTTAAATCTGTGTAATAG 1564
Db 978 GAAATCTCTAATCAAGAGACTGCTGTTTCAGAGAAATTAATCTTAAATCTGTGTAATAG 1037
QY 1565 AAAATCTGACCATTAATTAACAGAACTGCCAATCAGGCGCTAGTTCTTAATTAATAA 1624
Db 1038 AAAATCTGACCATTAATTAACAGAACTGCCAATCAGGCGCTAGTTCTTAATTAATAA 1097

QY 1625 TTGGATAAATTTAATAAAATAAGAGTGATAGTCACTGAAAGTGCTCAGATGACTAATATTATGC 1684
Db 1098 TTGGATAAATTTAATAAAATAAGAGTGATAGTCACTGAAAGTGCTCAGATGACTAATATTATGC 1157
QY 1685 TATAGTTAAATGCGCTTAAATAATTTAACTGTTAACTTTTTCACCAAACTCATAT 1744
Db 1158 TATAGTTAAA--TGCTTAAATAATTTAACTGTTAACTTTTTCCTCA--CAAACTCATAT 1214
QY 1745 AATATTTTTCATAGGCAAGTTTC 1767
Db 1215 AATATTTTTCATAGGCAATTTTC 1237

RESULT 10

ABK12983
ID ABK12983 standard; cDNA; 1287 BP.
AC ABK12983;
DT 23-APR-2002 (first entry)
XX Mouse goliath cDNA sequence.
DE Mouse; goliath protein; antiangiogenic; vasotropic; gene therapy;
KW dosage form; angiogenesis; neurogenesis; tumour; vascularisation;
KW cancer; ischaemia; neuroblastoma; neurodegenerative disease;
KW unrecovered nerve trauma; gene; ss.
OS Mus sp.
XX
FH Key Location/Qualifiers
FT CDS 1..1287
FT /*tag= a
FT /product= "Mouse_goliath_protein"

WO200193681-A1.

13-DEC-2001.

01-JUN-2001; 2001WO-US18000.

02-JUN-2000; 2000US-0586398.

(REGC) UNIV CALIFORNIA.

Harland R, Baker JC;

WPI; 2002-147637/19.

P-PSDB; AAU74918.

New compositions comprising goliath proteins, useful for modulating angiogenesis or neurogenesis in mammals e.g. for preventing or treating undesirable vascularisation of a tumour, ischaemia or neurodegenerative disease

Examples; Page 38; 45pp; English.

The present invention relates to a new pharmaceutical composition that comprises a goliath polypeptide in dosage form. The goliath polypeptide has a sequence identity of at least 75% to the protein sequences (AAU74918-AAU74921) fully defined in the specification. The composition is useful for modulating angiogenesis or neurogenesis in mammals, particularly in humans or mice. Specifically, the composition is useful for the prophylactic and/or therapeutic treatment of excess angiogenesis e.g. undesirable vascularisation of a tumour or insufficient angiogenesis e.g. ischaemia, excess neurogenesis e.g. neuroblastoma or insufficient neurogenesis e.g. neurodegenerative disease or unrecovered nerve trauma. The present nucleic acid sequence encodes the mouse goliath protein that was used in the invention for modulating angiogenesis or neurogenesis.

Sequence 1287 BP; 308 A; 320 C; 359 G; 300 T; 0 other;

Query Match 62.4%; Score 1106.8; DB 24; Length 1287;
 Best Local Similarity 91.2%; Pred. No. 1.3e-297;
 Matches 1174; Conservative 0; Mismatches 113; Indels 0; Gaps 0;

QY 263 ATGGGGCGCGCTGGGGCGGGGCTCTCTGCGCGGGTGGCTGGCGCTTTTCCAGATTG 322
 DB 1 ATGGGGCGCGCGGGGATCGGGTCTACTGCGCGGGCGCTGCGGAGCTGCCCGGCTA 60

QY 323 CTGGCATGSGTCTCTGCTGGCCCTAGTTCGACAGCCACCGGTTCCGGGGGGGTGAA 382
 DB 61 CTGGCTGGTGTCTCTCTGCTGGCTGAGTTCGACAGCGCGCGGTTCCCGGGAGCGGAA 120

QY 383 GCAGTGTGGACCGGTACCTCAACGTGTCTGCGGGTTCGCGACAGCGGAGTGAACGT 442
 DB 121 GCGTGTGGACCGGTACCTCAACGTGTCTGCGGGTTCGCGACAGCGGAGTGAACCG 180

QY 443 ACGTGTGGAGCTGACGCGAGGAGGCGTGTACGCGCAGCACTCGCGCGTGGAGCGTGTG 502
 DB 181 ACGGTGTGGAGCTGAGCGAGGAGGCGGTGTACGCGCAGCACTCGCGCGTGGAGCGGCTC 240

QY 503 GCTGGGCTCTGTGACCGCGCGACGCGGCGCGGCGCTTAAACGCTGTAAACCGCACAG 562
 DB 241 TCCGGGCTCTGTGACCGCGCGACGCGGCGCGGCGCTCAACGCTGTAAACCGCACAC 300

QY 563 AATTTCACGCTGCCACGGTTTGGGGAAGCACCGTGCAGTCTCTTGTGGCGCTCATC 622
 DB 301 AATTTCACGCTGCCACGGTTTGGGGAAGCACCGTGCAGTCTCTTGTGGCGCTCATC 360

QY 623 CAACGCGCGCGGCGCTGCACCTTCGACAGCAAGATCCATCTGGCTTATGAGAGATGGGG 682
 DB 361 CAACGCGGTGGAGCTGCACCTTCGCGGACAGATCCATCTGGCTTACAGAGAGGGCT 420

QY 683 TCTGGAGCGTCACTTTTAACTTCCCGGACCCGCAATGAGTCAATCCCATGTCTAC 742
 DB 421 TCTGGAGCGTCACTTTTAACTTCCCGGACCCGCAATGAGTCAATCCCATGTCTAC 480

QY 743 CCGGTCGAGTACACATTTGTGCAATCATGATCGGCAATCTGAAAGGCAAAAATTCG 802
 DB 481 CCGGTCGAGTACACATTTGTGCAATCATGATCGGCAATCTGAAAGGCAAAAATTCG 540

QY 803 CAATCTATTCAAGAGGCATACAAAGTGAATGCTCATAGAGTAGGGGAAAAAATGCG 862
 DB 541 CAGTCTATTCAAGAGGCATACAAAGTGAATGCTCATAGAGTAGGGGAAAAAATGCG 600

QY 863 CTTGGGTGAATCACTATTCAATTTTTCGTTTCTGTGCTCTTTTATTAATACGGCG 922
 DB 601 CTTGGGTGAATCACTATTCAATTTTTCGTTTCTGTGCTCTTTTATTAATACGGCA 660

QY 923 GCAACTGTGGCTATTATTATCTTTTATCTGCTCGAAGGCTACGGAATCAAGAGCTCAA 982
 DB 661 GCAACTGTGGCTATTATTATCTTTTATCTGCTCGAAGGCTACGGAATCAAGAGCTCAA 720

QY 983 AGCAGGAAGCAGAGGCAATTAAGGCGAGATGCTTAAAGAAAGCTATTGGAAGGCTTCACTA 1042
 DB 721 AGCAGGAAGCAGAGGCAATTAAGGCGAGATGCTTAAAGAAAGCTATTGGAAGGCTTCACTA 780

QY 1043 CGCACACTGAAACAGAGGACAGGAAATGGCGCTGATGGAGATAGTGTGCTGTGTC 1102
 DB 781 CGCACACTGAAACAGAGGACAGGAAATGGCGCTGATGGAGATAGTGTGCTGTGTC 840

QY 1103 ATTGAATGTATAAACCAATGATTTGGTACGATCTTAACTGCGCAACCATATTTTCCAT 1162
 DB 841 ATTGAATGTATAAACCAATGATTTGGTACGATCTTAACTGCGCAACCATATTTTCCAT 900

QY 1163 AAGCATGTGTGACCCATGGCTTTAAACACAAGACTTGGCCCATGTGCAAAATGTGAC 1222
 DB 901 AAGCATGTGTGACCCATGGCTTTAAACACAAGACTTGGCCCATGTGCAAAATGTGAC 960

QY 1223 ATACTCAAGCTTTGGGAATTTAGGTGGATGTTGAAGATGGATCAGTGTCTTACAGTC 1282
 DB 961 ATACTCAAGCTTTGGGAATTTAGGTGGATGTTGAAGATGGATCAGTGTCTTACAGGTT 1020

QY 1283 CCTGTATCCAAATGAATATCTAATAGTGCCTCTCCCATGAAGAGGATATCGAGCGAG 1342
 DB 1021 CCTGTATCCAAATGAAGCATCTAATAGTGCCTCTCCCATGAAGAGGACAGTCGAGTGAG 1080

QY 1343 ACCGCATCATCTGATATGCTTACGTACAGGAAACAGATGAACCGCCTCTGGAGGAACAC 1402
 DB 1081 ACTGCATCATCTGATATGCTTACGTACAGGAAACAGATGAACCGCCTCTGGAGGAACAT 1140

QY 1403 GTGCAGTCAACAAATGAAAGTCTACAGCTGGTAAACCATGAAGCAAAATCTGTGGCAGTG 1462
 DB 1141 GCGCAGTCAGCAAAATGAAATCTACAGCTGGTAAACCATGAAGCAAAATCTGTGGCAGTG 1200

QY 1463 GATGTATTCTCATGTGACCAACCAACCTTTGAAGAACAGCAAACTCTTAATCAAGAG 1522
 DB 1201 GATGTATTCTCATGTGACCAACCAACCTTTGAAGAACAGCAAACTCTTAATCAAGAG 1260

QY 1523 ACTGCTGTTGAGAAATTAATCTTAA 1549
 DB 1261 GCAGCTGTTGGGAGATTAATCTTAA 1287

RESULT 11

ABK12992

ID ABK12992 standard; DNA; 1287 BP.

XX ABK12992;

AC ABK12992;

DT 23-APR-2002 (first entry)

XX Synthetic goliath DNA sequence #6.

DE Goliath protein; antiangiogenic; vasotropic; gene therapy;

XX dosage form; angiogenesis; neurogenesis; tumour; vascularisation;

KW cancer; ischaemia; neuroblastoma; neurodegenerative disease;

KW unrecovered nerve trauma; ds.

XX Synthetic.

OS WO200193681-A1.

PN 13-DEC-2001.

PD 01-JUN-2001; 2001WO-US18000.

XX 02-JUN-2000; 2000US-0586398.

XX (REGC) UNIV CALIFORNIA.

XX Harland R, Baker JC;

XX WPI; 2002-147637/19.

XX New compositions comprising goliath proteins, useful for modulating

XX angiogenesis or neurogenesis in mammals e.g. for preventing or

XX treating undesirable vascularisation of a tumour, ischaemia or

XX neurodegenerative disease

XX Disclosure; Page 42; 45pp; English.

XX The present invention relates to a new pharmaceutical composition that

XX comprises a goliath polypeptide in dosage form. The goliath polypeptide

XX has a sequence identity of at least 75% to the protein sequences

XX (AAU74918-AAU74921) fully defined in the specification. The composition

XX is useful for modulating angiogenesis or neurogenesis in mammals,

XX particularly in humans or mice. Specifically, the composition is useful

XX for the prophylactic and/or therapeutic treatment of excess angiogenesis

XX e.g. undesirable vascularisation of a tumour or insufficient angiogenesis

XX e.g. ischaemia, excess neurogenesis e.g. neuroblastoma or insufficient

XX neurogenesis e.g. neurodegenerative disease or unrecovered nerve trauma.

XX The present nucleic acid sequence represents synthetic DNA sequence #6

XX that is one of several artificial goliath nucleic acids (ABK12987-

XX ABK12992) used in the invention for modulating angiogenesis or

XX neurogenesis.

Db	961	ATTCTCAAAGCTCTGGGAATTGAGTGGATGTAGAGATGATCAGTGTCTTTACAAGTT	102
Qy	1283	CCTGTATCCAATGAATATCTTAATAGTCCTCTCCCATGAAGAGGATAATCGCAGCGAG	1342
Db	1021	CCTGTTTCCAATGAAGCATCTTAATACGGCTCTCCCATGAAGAGACAGTCTCGCAGTGAG	1080
Qy	1343	ACCGCATCATCTCGGATATGCTTCAGTACAGGGAACAGATGAACCGCTCTCGAGGAAACAC	1402
Db	1081	ACTGCGATCATCTGGATATCGCTCAGTACAAGGAGCAGAGGAGCCACCTCTCGAGGAAACAT	1140
Qy	1403	GTGCAGTCAACAAATGAAAAGTCTACAGCTGGTGTAACCAATGAAGCAAAATTCGTGGCAGTG	1462
Db	1141	CGCGAGTCAGCAAAATGAAAATCTACAGCTGGTGTAACCAATGAAGCAAAATTCGTGGCAGTG	1200
Qy	1463	GATGTTATTTCCTCATGTNGACAAACCACTTTGAAGAGAGCAAAACTCCTTAATCAAGAG	1522
Db	1201	GATGTTGTATACCCCATGTTGACAAACCTTACCTTTGAAGAGAGATGACACTCCTGATCAAGAG	1260
Qy	1523	ACTGCTGTTTCGAGAAAATTAATCTTTAA	1549
Db	1261	CGCGCTGTTTCGGAGATTAAATCTTTAA	1287
RESULT	12		
ABK12990			
ID	ABK12990	standard; DNA; 1287 BP.	
AC	ABK12990;		
XX			
DT	23-APR-2002	(first entry)	
XX			
DE		Synthetic goliath DNA sequence #4.	
XX			
KW		Goliath protein; antiangiogenic; vasotrophic; gene therapy;	
KW		dosage form; angiogenesis; neurogenesis; tumour; vascularisation;	
KW		cancer; ischaemia; neuroblastoma; neurodegenerative disease;	
KW		uncovered nerve trauma; ds.	
XX			
OS		Synthetic.	
XX			
PN	WO200193681-A1.		
XX			
PD	13-DEC-2001.		
XX			
PF	01-JUN-2001; 2001WO-US18000.		
XX			
PR	02-JUN-2000; 2000US-0586398.		
XX			
PA	(REGC) UNIV CALIFORNIA.		
XX			
PI	Harland R, Baker JC;		
XX			
DR	WPI; 2002-147637/19.		
XX			
PT	New compositions comprising goliath proteins, useful for modulating		
PT	angiogenesis or neurogenesis in mammals e.g. for preventing or		
PT	treating undesirable vascularisation of a tumour, ischaemia or		
PT	neurodegenerative disease		
XX			
PS	Disclosure; Page 41; 45pp; English.		
XX			
CC	The present invention relates to a new pharmaceutical composition that		
CC	comprises a goliath polypeptide in dosage form. The goliath polypeptide		
CC	has a sequence identity of at least 75% to the protein sequences		
CC	(AAU74918-AAU74921) fully defined in the specification. The composition		
CC	is useful for modulating angiogenesis or neurogenesis in mammals,		
CC	particularly in humans or mice. Specifically, the composition is useful		
CC	for the prophylactic and/or therapeutic treatment of excess angiogene		
CC	e.g. undesirable vascularisation of a tumour or insufficient angiogen		
CC	e.g. ischaemia, excess neurogenesis e.g. neuroblastoma or insufficien		
CC	neurogenesis e.g. neurodegenerative disease or uncovered nerve trauma		
CC	The present nucleic acid sequence represents synthetic DNA sequence #		
CC	that is one of several artificial goliath nucleic acids (ABK12987-		

CC ABK12992) used in the invention for modulating angiogenesis or
 CC neurogenesis.
 XX
 SQ Sequence 1287 BP; 312 A; 321 C; 356 G; 298 T; 0 other;
 Query Match 58.8%; Score 1042.8; DB 24; Length 1287;
 Best Local Similarity 88.1%; Pred. No. 8.7e-280;
 Matches 1134; Conservative 0; Mismatches 153; Indels 0; Gaps 0;
 QY 263 ATGGGGCGCGCGCTGGGGCGGGGCTCTCTCGCGGGGTGGCTGCGGCTTTTCCAGATTG 322
 Db 1 ATGGGGCGCGCGCGGGATAGGGGTCTACTGCGCGGTGGCTGCGAGCTGCCCGCTTA 60
 QY 323 CTGGCATGTGCTTCCTGCTGGCCCTGAGTCCGACGACCGCGGTTCCCGGGGGCTGAA 382
 Db 61 CTGGCTTGGGTGCTTCTGCTGCTGAGTCCACACGCGCCCGGTTCCCGTGGAGCCGAA 120
 QY 383 GCAGTGTGGACCGGTACCTCAACGCTGCTCTGGCGGGTTCGACACGCGAGTGAACCGT 442
 Db 121 GCGGTGTGACCGGTACCTCAACGCTGCTCTGGCGGGTTCGACACGCGAGTGAACCGC 180
 QY 443 ACGGTGTGGAGCTGAGCGAGGAGGGGTGTTACGCGCAGACTTCGCGCTGGAGCTGTG 502
 Db 181 ACTGTGTGGAGCTGAGCGAGGAGGGGTGTTACGCGCAGACTTCGCGCTGGAGCCAGTC 240
 QY 503 GCTGGGTCTGCTTACCGCGGACGGGCGCGGGCGCTTAAACGCTGTAACCGGACAGC 562
 Db 241 TCGGGGTCTGCTTCCGCGGACGGGCGCGGGCGCTTAAACGCTGTAACCGGACAGC 300
 QY 563 AATTTCACGTCGCCACGGTTTGGGGAAGCACCGTGTCAAGTCTCTTGGTTGGCCCTCATC 622
 Db 301 AATTTCACGTCGCCACGGTTTGGGGAAGCACCGTGTCAAGTCTCTTGGTTGGCCCTCATC 360
 QY 623 CAACGCGCGGGGCTGCATCTTCGACAGCAAGATCCATCTGCTTATGAGAGATGGCG 682
 Db 361 CAGCGCGTGGAGCTGCATCTTCGACAGCAAGATCCATCTGCTTATGAGAGATGGCG 420
 QY 683 TCTGGACCGTCTATCTTTAACTTCCCGGACCGGCAATGAGTGCATCCCACTGTCTAC 742
 Db 421 TCTGGACCGTCTATCTTTAACTTCCCGGACCGGCAATGAGTGCATCCCACTGTCTAC 480
 QY 743 CCGGGTGCAGTACATTTGTGCAATCATGATCGGCAATCTGAAAGGCAAAAAATTTCTG 802
 Db 481 CCGGGTCCCGGGACATTTGTGCAATCATGATTTGGCAATCTGAAAGGCAAAAAATTTCTG 540
 QY 803 CAATCTATTCAAGAGGCATCAAGTGACAAATGTCATAGAGTAGGGAAGAAACATGGC 862
 Db 541 CATTTCTATTCAAGAGGCATCCAAGTCAATGTCATGGAAGTAGGGAAGAAACAAAGC 600
 QY 863 CTTGGGTGAATCACTATTCAATTTTTCGTTCTGTCCTTTTATTATTATTCAGCGG 922
 Db 601 CTTGGGTGAATCACTATTCAATTTTTCGTTCTGTCCTTTTATTATTATTCAGCGG 660
 QY 923 GCAACTGGGCTATTTTATCTTTTATTTCTGCTCGAAGGCTACGGAATCAAGAGCTCAA 982
 Db 661 GCAACCGTAGCTATTTTATCTTTTATTTCTGCTCGAAGGCTACGGAATCAAGAGCTCAA 720
 QY 983 AGCAGGAGCAGAGGCAATTAAGGCGAGATGCTTAAAAAGCTATTGAGGCTTCAACTA 1042
 Db 721 AGGAGGAGCAGAGGCGAGTAAAGGCGAGATGCTTAAAAAGCTATTGAGGAGCTTCACTG 780
 QY 1043 CGCACACTGAAACAAGGAGACAGGAATTTGGCCCTGATGAGATAGTTGCTGTGTGC 1102
 Db 781 CGCACTTTGAACAGGAGGACAGGAATTTGGACCTGATGAGATAGTTGCTGTGTGC 840
 QY 1103 ATTGAATGTATAAACCAATGATTTGGTACGATCTTAAACGTCACCAATATTTTCCAT 1162
 Db 841 ATTGAGCTCTATAAGCAAAATGATTTGGTGGCATCTTAACCTGAAATCATATTTTCCAT 900
 QY 1163 AAGACATGCTGTGACCATGGCTTTAAACACAGACTTGGCCCATGTGCAATGTGAC 1222
 Db 901 AATACATGTGTGGACCGCTGCTTTTAGAACACAGGACGCTGSCCCCATGTGCAAGTGAGAC 960

QY 1223 ATACTCAAGCTTTGGGAATTGAGGTGGATGTTGAAAGATGGATCAGTGTCTTTCAAGTC 1282
 Db 961 ATTTCTCAAGCTCTTGGAAATTGAGGTGGATGTTGAAAGATGGATCAGTGTCTTTCAAGTT 1020
 QY 1283 CCGTATATCAATGAAATATCTAATAGTGCCTCTCCCATGAAGAGGATAATCGCAGCGAG 1342
 Db 1021 CCGTATATCAATGAAATATCTAATAGTGCCTCTCCCATGAAGAGGATAATCGCAGCGAG 1080
 QY 1343 ACCGATCATCTGATATGCTTACGTACAGGAAACAGATGAACCCCTCTTGAGGAAACAC 1402
 Db 1081 ACGGATCATCTGATATGCTTACGTACAGGAAACAGATGAACCCCTCTTGAGGAAACAC 1140
 QY 1403 GTGCAGTCAACAAATGAAAGTCTACAGTGTAAACCATGAAGCAAAATCTGTGGCAGTG 1462
 Db 1141 GCGCAGTCAACAAATGAAAGTCTACAGTGTAAACCATGAAGCAAAATCTGTGGCAGTG 1200
 QY 1463 GATGTTATTCCTCATGTNGACAACCCCACTTTTGAAGAAGACGAAATCTCTTAATCAAGAG 1522
 Db 1201 GATGTTATTCCTCATGTNGACAACCCCACTTTTGAAGAAGACGAAATCTCTTAATCAAGAG 1260
 QY 1523 ACTGCTGTTCGAGAAATTAATCTTAA 1549
 Db 1261 GCTGCTGTTCGAGAAATTAATCTTAA 1287

RESULT 13

ABK12991
 ID ABK12991 standard; DNA; 1287 BP.

XX ABK12991;

DT 23-APR-2002 (first entry)

XX Synthetic goliath DNA sequence #5.

XX Goliath protein; antiangiogenic; vasotropic; gene therapy;
 dosage form; angiogenesis; neurogenesis; tumour; vascularisation;
 cancer; ischaemia; neuroblastoma; neurodegenerative disease;
 unrecovered nerve trauma; ds.

OS Synthetic.

XX WO200193681-A1.

XX 13-DEC-2001.

XX 01-JUN-2001; 2001WO-US18000.

XX 02-JUN-2000; 2000US-0586398.

XX (REGC) UNIV CALIFORNIA.

XX Harland R, Baker JC;

XX WPI; 2002-147637/19.

XX New compositions comprising goliath proteins, useful for modulating
 angiogenesis or neurogenesis in mammals e.g. for preventing or
 treating undesirable vascularisation of a tumour, ischaemia or
 neurodegenerative disease

PS Disclosure; Page 41-42; 45pp; English.

XX The present invention relates to a new pharmaceutical composition that
 comprises a goliath polypeptide in dosage form. The goliath polypeptide
 has a sequence identity of at least 75% to the protein sequences
 (AAU74918-AAU74921) fully defined in the specification. The composition
 is useful for modulating angiogenesis or neurogenesis in mammals,
 particularly in humans or mice. Specifically, the composition is useful
 for the prophylactic and/or therapeutic treatment of excess angiogenesis
 e.g. undesirable vascularisation of a tumour or insufficient angiogenesis
 e.g. ischaemia, excess neurogenesis e.g. neuroblastoma or insufficient
 neurogenesis e.g. neurodegenerative disease or unrecovered nerve trauma.

CC The present nucleic acid sequence represents synthetic DNA sequence #5
 CC that is one of several artificial glioth nucleic acids (ABK12987-
 CC ABK12992) used in the invention for modulating angiogenesis or
 CC neurogenesis.
 XX

Sequence 1287 BP; 312 A; 321 C; 356 G; 298 T; 0 other;

Query Match 58.8%; Score 1042.8; DB 24; Length 1287;
 Best Local Similarity 88.1%; Pred. No. 8.7e-280;
 Matches 1134; Conservative 0; Mismatches 153; Indels 0; Gaps 0;

QY 263 ATGGGGCGCGCGCTGGGGCGGGGTCTCCCTGCGCGCGGTGCTGCGCTTTTCCAGATTG 322
 DB 1 ATGGGGCGCGCGCGGGATTGCGGTCTACTGCGCGCGCGCTGCGAGCTGCCCGACTA 60
 QY 323 CTGGCATGGTCTCTGCTGCGCTGAGTCCGCGAGGACCCCGGTTCCTGGGGGGCTGAA 382
 DB 61 CTGGCTTGGTCTGCTTCTGCTCTGAGTCTCTACGGCCCGGTTCCTGGGAGCGGAA 120
 QY 383 GCAGTGTGAGCGCGTAACTCAAGTGTCTGGCGGGTTCGCGACACGGGAGTGAACCGT 442
 DB 121 GCGGTGTGAACCGCGTACTCAACGTGTCTGGCGGGTTCGCGCATACGGAGTGAACCGC 180
 QY 443 ACGGTGTGGAGCTCAGCGAGGAGGGCGTGTACGCCAGGACTCGCGCTGGAGCCTGTG 502
 DB 181 ACCGTGTGGAGCTGAGCGAGAGAGGGCGTGTACGCCAGGACTCGCGCTGGAGCCTGTG 240
 QY 503 GCTGGGGTCTCTGGTACCCCGACCGGGCCCGGGCGCTTAACGGCTGTAAACCCGACACG 562
 DB 241 TCCGGGGTCTCTGGTCCCGCGGACCGGGCCCGGAGCGCTCAACGCTGTGAACCGCACAC 300
 QY 563 AATTTTCAAGTGTCCCAAGTGTGGGGAAGACCGGTGCAAGTCTCTTGGTTGGCCCTCATC 622
 DB 301 AATTTTCAAGTGTCCCAAGTGTGGGGAAGACCGGTGCAAGTCTCTTGGTTGGCCCTCATC 360
 QY 623 CAACGCGGGGGGTGACACCTTCGACAGCAAGATCCATCTGGCTTATGAGAGATGGCG 682
 DB 361 CAGCGGTGTGAGGTGACCTTCGCGGACAAAGATCCACCTGGCTTCAGAGAGAGAGCT 420
 QY 683 TCTGAGCGGTCTATCTTTAACTTCCCGGGACCGCAATGAGGTCTATCCCATGCTCAAC 742
 DB 421 TCTGAGCGGTCTATCTTTAACTTCCCGGGACCGCAATGAGGTCTATCCCATGCTCAAC 480
 QY 743 CCGGTGTGAGTGTGCAATCTGCAATCATGATCGGCAATCTGAAGGCACAAATCTG 802
 DB 481 CCGGTGTGAGGAGATGTTGCAATGATGATGCAATCTGCAATCTGAATGGAACAAATCTG 540
 QY 803 CAATCTATTCAAAGAGGCATACAAGTGTCAATGGTCTAGAGTAGGGAAAAAATCATGGC 862
 DB 541 CACTCTATTCAAAGAGGCATACAAGTGTCAATGGTCTAGAGTAGGGAAAAAATCATGGC 600
 QY 863 CTTGGGTGAATCACTAATTTTTCGTTTCTGTTCTGTTCTTTTATTATTACGGCG 922
 DB 601 CTTGGGTGAATCACTAATTTTTCGTTTCTGTTCTGTTCTTTTATTATTACGGCA 660
 QY 923 GCAACTGTGGCTATTATCTTTTATTCTGCTGCAAGCTACGGAATGCAAGCTCAA 982
 DB 661 GCACCGTTGGCTATTATCTTTTACTCTGCTGCAAGTATGCAAGTATGCAAGCTCAA 720
 QY 983 AGCAGAGCAGAGGCAATTAAGGCAGATGCTAAAGAAAGCTATTGGAAGGCTTCAACTA 1042
 DB 721 AGGAGGAGCAGAGGAGTAAAGGCAGATGCTAAAGCGTATTGGAAGCTTCAACTG 780
 QY 1043 CGCACACTGAAAGAGGACAGGAATTTGGCCCTGATGAGATAGTGTGCTGTGTC 1102
 DB 781 CGCACCTTGAACAGGGAGACAGGAATTTGGTCTGATGAGATAGTGTGCTGTGTC 840
 QY 1103 ATTGAATTTGTAACCAATGATTTGGTACGCATCTTAACGTGCAACCATATTTTCCAT 1162
 DB 841 ATTGAGCTATATAAGCAATGATTTGGTGGCATCTTAACCTGTAAATCATATTTTCCAT 900
 QY 1163 AAGACATGTTGACCCATGGCTGTTTAAACACAGACTTGGCCCATGTGCAAAATGTGAC 1222

DB 901 AACACATGTGTGGACCCCGTGACTTTTGAACACAGGACGTCGCCCATGTGCAAGTGTGAC 960
 QY 1223 ATACTCAAAGCTTTTGGGAATTGAGGTGATGTTGAAGATGGATCAGTGTCTTTTACAAGTC 1282
 DB 961 ATTTCTCAAAGCTCTCGGAATTGAGGTGATGTAGAGATGGATCAGTGTCTGTACAAGTT 1020
 QY 1283 CTGTATCAATGAATATCTAATAGTGCCTCTCCCATGAAGAGGATAATCGCAGCGAG 1342
 DB 1021 CCTGTTCTTAATGAAGCATCTAATACCGCTCTTCCCATGAAGAGACAGTCGCAAGTGA 1080
 QY 1343 ACGCATCATCTGGATATGCTTCAGTACAGGGAACAGATGAACCGCTCTTGAGGAACAC 1402
 DB 1081 ACGCATCATCTGGATATGCTTCAGTACAGGAGCAGACGACCCACCTCTTGAGGAACAT 1140
 QY 1403 GTGCACTCAACAAATGAAAGTCTACAGCTGGTAAACCAATGAAGCAAAATTCCTGTGCA 1462
 DB 1141 GCGAGTCAGCAAGAAAGAAATCTACAGCTGGTTAAACCATGAAGCAAAATTCCTGTG 1200
 QY 1463 GATGTTATCTCATGTGACCAACCAACCTTTGAAGAGAGCAAACTCTTAATCAAGAG 1522
 DB 1201 GATGTTGTAACCCCATGTTGACAAACCGGACCTTTGAAGAGAGATGATACCTCTGATCA 1260
 QY 1523 ACTGCTGTTGCGAGAAATTAATCTTAA 1549
 DB 1261 GCGCTGTTGCGAGATTAAATCTTAA 1287

RESULT 14

AAI59292
 ID AAI59292 standard; cDNA; 1135 BP.
 XX AAI59292;
 AC AAI59292;
 XX
 XX 22-OCT-2001 (first entry)
 DT
 XX Human polynucleotide SEQ ID NO 1495.
 DE
 XX Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
 KW peripheral nervous system; neuropathy; central nervous system; CNS;
 KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
 KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
 KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
 KW leukaemia; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200153312-A1.
 XX
 XX 26-JUL-2001.
 XX
 XX 26-DEC-2000; 2000WO-US34263.
 XX
 XX 21-JAN-2000; 2000US-0488725.
 PR 25-APR-2000; 2000US-0552317.
 PR 09-JUL-2000; 2000US-0598042.
 PR 19-JUL-2000; 2000US-0620312.
 PR 03-AUG-2000; 2000US-0653450.
 PR 14-SEP-2000; 2000US-0662191.
 PR 19-OCT-2000; 2000US-0693036.
 PR 29-NOV-2000; 2000US-0727344.
 XX
 XX (HYSE-) HYSEQ INC.
 XX
 XX Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
 PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
 PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
 XX WPI; 2001-442253/47.
 DR P-PSDB; AAM40136.
 XX
 XX Novel nucleic acids and polypeptides, useful for treating disorders
 PT such as central nervous system injuries -
 XX

Claim 1; SEQ ID NO 1495; 10078pp; English.

The invention relates to human nucleic acids (AA157798-AA161369) and the encoded polypeptides (AA38642-AA42213) with neurotrophic, immunosuppressant and cytostatic activity. The polynucleotides are useful in gene therapy. A composition containing a polypeptide or polynucleotide of the invention may be used to treat diseases of the peripheral nervous system, such as peripheral nervous injuries, peripheral neuropathy and localised neuropathies and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager Syndrome. Other uses include the utilisation of the activities such as: Immune system suppression, Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic and thrombolytic activity, cancer diagnosis and therapy, drug screening, assays for receptor activity, arthritis and inflammation, leukaemias and C.N.S disorders.

Note: The sequence data for this patent did not form part of the printed specification.

Query Match 57.5%; Score 1019.4; DB 22; Length 1135;

Best Local Similarity 99.0%; Pred. No. 2.7e-273;

Matches 1057; Conservative 0; Mismatches 7; Indels 4; Gaps 3;

QY 708 CCGGACCCGCAATGAGGTATCCCATGTCTCACC CGG3TGCA-CTAGACATTTGTGCA 766
 Db 26 CCGGACCCGCAATGAGGTATCCCATGTCTCACC CGG3TGCACTAGACATTTGTGCA 85
 QY 767 ATCATGATCGGCAATCTGAAGGACAAAAATCTGCAATCTATCCAAAGAGGCAACAA 826
 Db 86 ATCATGATCGGCAATCTGAAGGACAAAAATCTGCAATCTATCCAAAGAGGCAACAA 145
 QY 827 GTGCAATGTCATAGAGTGAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 886
 Db 146 GTGCAATGTCATAGAGTGAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 205
 QY 887 TTTTTCGTTCTGTGTCCTTTTATTTATTTACGGGGCAACTGTGGGCTATTTATCTTT 946
 Db 206 TTTTTCGTTCTGTGTCCTTTTATTTATTTACGGGGCAACTGTGGGCTATTTATCTTT 265
 QY 947 TATTCTCTCGAAGGCTACCGAATGCAAGAGCTCAAGAGGAGGAGGAGGAGGAGGAGG 1006
 Db 266 TATTCTCTCGAAGGCTACCGAATGCAAGAGCTCAAGAGGAGGAGGAGGAGGAGGAGG 325
 QY 1007 GCAGATGCTAAAAAGCTATTGGAAGGCTTCAACTAGCACTGAAACAAAGAGGACAAG 1066
 Db 326 GCAGATGCTAAAAAGCTATTGGAAGGCTTCAACTAGCACTGAAACAAAGAGGACAAG 385
 QY 1067 GAAATTCGGCTGATGGAGATAGTTGCTGTGTCGATGAAATGTTATTAACCAATGAT 1126
 Db 386 GAAATTCGGCTGATGGAGATAGTTGCTGTGTCGATGAAATGTTATTAACCAATGAT 445
 QY 1127 TTGTTAGCGATCTTAACGTCGAACCAATATTTCCATAAGACATGTGTGACCCATGGCTG 1186
 Db 446 TTGTTAGCGATCTTAACGTCGAACCAATATTTCCATAAGACATGTGTGACCCATGGCTG 505
 QY 1187 TTAACACACAGACTTCCCGCATGTGCAATGTGACATCTCAAGCTTTGGGAATGAG 1246
 Db 506 TTAACACACAGACTTCCCGCATGTGCAATGTGACATCTCAAGCTTTGGGAATGAG 565
 QY 1247 GTGATGTTGAAGTGGATGATGCTCTTTTACAAAGTCCCTGTATCCCAATGAATATCTAAT 1306
 Db 566 GTGATGTTGAAGTGGATGATGCTCTTTTACAAAGTCCCTGTATCCCAATGAATATCTAAT 625
 QY 1307 AGTGCCTCTCCCATGAAGAGGATAATGCGAGGAGACCGCATCATCTGATATGCTTCA 1366
 Db 626 AGTGCCTCTCCCATGAAGAGGATAATGCGAGGAGACCGCATCATCTGATATGCTTCA 685
 QY 1367 GTACAGGGAACAGATGACCGCTCTCTGAGGGAACAGCTGCGAGTCAACAAATGAAGTCTA 1426
 Db 686 GTACAGGGAACAGATGACCGCTCTCTGAGGGAACAGCTGCGAGTCAACAAATGAAGTCTA 745

QY 1427 CAGTGTGTAACCATGAAGCAAAATCTGTGGCAGTGAATGTTATCTCATGTGACAAAC 1486
 Db 746 CAGTGTGTAACCATGAAGCAAAATCTGTGGCAGTGAATGTTATCTCATGTGACAAAC 805
 QY 1487 CCAACCTTTTGAAGAGACGAAACTCTTAATCAAGAGACTCTGTTGAGAAATTAATCT 1546
 Db 806 CCAACCTTTTGAAGAGACGAAACTCTTAATCAAGAGACTCTGTTGAGAAATTAATCT 865
 QY 1547 TAAATCTGTGTAATAGAAAACTTGAACCATTAAGTAATAACAGAACTGCAATCAGGGC 1606
 Db 866 TAAATCTGTGTAATAGAAAACTTGAACCATTAAGTAATAACAGAACTGCAATCAGGGC 925
 QY 1607 CTAGTTTCTAATTAATAATTTGGAATAATTAATAAAGAGTGAATCTGAAAGTGCTC 1666
 Db 926 CTAGTTTCTAATTAATAATTTGGAATAATTAATAAAGAGTGAATCTGAAAGTGCTC 985
 QY 1667 AGATGACTAATATATGCTATAGTTAAATGGCTTAAATATTAATAATTAATCTTAACTTT 1726
 Db 986 AGATGACTAATATATGCTATAGTTAAATGGCTTAAATATTAATAATTAATCTTAACTTT 1043
 QY 1727 TTCCACCAAACTCATTATAATATTTTTCATAGGCAAGTTTCTCTCTCAG 1774
 Db 1044 TTCCA-CAAACTCATTATAATATTTTTCATAGGCAAGTTTCTCTCTCAG 1090
 RESULT 15
 ABK12989
 ID ABK12989 standard; DNA; 1287 BP.
 XX
 AC ABK12989;
 XX
 DT 23-APR-2002 (first entry)
 XX
 DE Synthetic goliath DNA sequence #3.
 XX
 KW Goliath protein; antiangiogenic; vasotropic; gene therapy;
 KW dosage form; angiogenesis; neurogenesis; tumour; vascularisation;
 KW cancer; ischaemia; neuroblastoma; neurodegenerative disease;
 KW unrecovered nerve trauma; ds.
 XX
 OS Synthetic.
 XX
 PN WO200193681-A1.
 XX
 PD 13-DEC-2001.
 XX
 PF 01-JUN-2001; 2001WO-US18000.
 XX
 PR 02-JUN-2000; 2000US-0586398.
 XX
 PA (REGC) UNIV CALIFORNIA.
 XX
 PI Harland R, Baker JC;
 XX
 DR WPI; 2002-147637/19.
 XX
 PT New compositions comprising goliath proteins, useful for modulating
 PT angiogenesis or neurogenesis in mammals e.g. for preventing or
 PT treating undesirable vascularisation of a tumour, ischaemia or
 PT neurodegenerative disease -
 XX
 PS Disclosure; Page 40-41; 45pp; English.
 CC
 CC The present invention relates to a new pharmaceutical composition that
 CC comprises a goliath polypeptide in dosage form. The goliath polypeptide
 CC has a sequence identity of at least 75% to the protein sequences
 CC (AAU74918-AAU74921) fully defined in the specification. The composition
 CC is useful for modulating angiogenesis or neurogenesis in mammals,
 CC particularly in humans or mice. Specifically, the composition is useful
 CC for the prophylactic and/or therapeutic treatment of excess angiogenesis
 CC e.g. undesirable vascularisation of a tumour or insufficient angiogenesis
 CC e.g. ischaemia, excess neurogenesis e.g. neuroblastoma or insufficient
 CC neurogenesis e.g. neurodegenerative disease or unrecovered nerve trauma.

CC The present nucleic acid sequence represents synthetic DNA sequence #3
CC that is one of several artificial goliath nucleic acids (ABK12987-
CC ABK12992) used in the invention for modulating angiogenesis or
CC neurogenesis.
XX

SQ Sequence 1287 BP; 308 A; 320 C; 355 G; 304 T; 0 other;

Query Match 56.3%; Score 999.6; DB 24; Length 1287;
Best Local Similarity 86.0%; Pred. No. 9.5e-268;
Matches 1107; Conservative 0; Mismatches 180; Indels 0; Gaps 0;

```
Qy 263 ATGGGGCGCGCGCTGCGGGCGGGGCTCTCTGCGCGGGTGGCTGGCTTTTCCAAATGG 322
Db 1 ATGGGGCGCGCGCGGGATGCGGGCTCTAAATGCGCGGGTGGCTGGCGCGCTGCCGGCTA 60
Qy 323 CTGCATGGTGGCTCTCTGCTGGCGCTCAGTCCGCGAGCACCGGTTCCCGGGGGGCTGAA 382
Db 61 CTGCATGGTGGCTCTCTGCGCCCTGAGTCCGCGCAGGTTCCCGTGAGGCGGAC 120
Qy 383 GCACTGTGGACCGCGTACCTCAACGCTGCTCTGGCGGGTCCGCAACGCGAGTGAACCGT 442
Db 121 GCCGTGTGGACCGCGTAACTCAACGTTTCTGGCGCGTTCGCGCAGACCGGAGTAAACCGC 180
Qy 443 ACGTGTGGAGCTGACGAGGAGGGCGGTGTACGGCCAGGACTCGCGCGCTGGAGCGCTGTG 502
Db 181 ACTGTGTGGACCTGAGCGAGGAGGGCGGTATACGGCCATGACTCGCGCCCTGGAGCGGTC 240
Qy 503 GCTGGGGTCTCTGTTACCGCGCGACCGCGCGGGCGCTTAAACGCTGTAAACCGCACACG 562
Db 241 TCCGGAGTCTGGTTCGCGCGGACGCGCGCGGGCGCTCAAGCGCTGTATCCGCGACCC 300
Qy 563 AATTTCAGGTGCGCAACGGTTTGGGGAAGCAACCGTGCAGTCTCTTGGTTGGCCCTCATC 622
Db 301 AATTTCAGGTGCGCACAGTTTGGGGTAGCACCGTCCAAAGTATCTGTTGGCACTCATC 360
Qy 623 CAACGCGCGGGGCTGCACCTTCGCGACAGCAAGATCCATCTGGCTTATGAGAGATGGGG 682
Db 361 CATCGGTGGCGGTGCACGTTTCGCGAAGAATCCATCTGGCTTCGAGAGAGGGGCT 420
Qy 683 TCTGAGCGGTCACTCTTTAACTTCCCGGGACCGCGCAATGAGTCAATCCCGCTGTCTCAC 742
Db 421 TCTGAGCGGTCACTTTTAACTTCCCTGGGACCGCGCAATGAAGTCACTCCCTATGTCTCAC 480
Qy 743 CCGGTGCGAGTAGACATTTGCGAATCATGATCGGCAATCTGAAGGCAACAAAAATTCG 802
Db 481 CCGGTGCGGGGGACATAGTTGCAATATGATTCGCAATCTGAAGGGAAACAAAAATTCG 540
Qy 803 CAATCTATTCAAAGAGGCATCAAGTGACATGGTCAATAGAGTAGGGAAGAAACATGGC 862
Db 541 CATCTATTCAAGAGGCATCGAAGTCAATGGTCAATTGAAGTAGGCAAGAAACAGGGC 600
Qy 863 CTTGGGTGAATCACTATTCAATTTTTTTTCTGTTCTGTCCTTTTATTTATTTACGGCG 922
Db 601 CTTGAGTGAATCACTATTCAATCTTCTGTCGTGTCGTCACTTTTCACTTTATTTACGGCC 660
Qy 923 GCAACTGTGGGCTATTTTATCTTTTATTTCTGCTCGAAGCTACGGAATGCAAGAGCTCAA 982
Db 661 GCAACCTGTGGGCTATTTTATCTTTTATTTCTGCTCGAGATTACGGAATGCAAGAGCTCAA 720
Qy 983 AGCAGGAAGCAGAGGCAATTAAGGCAGATGCTAAAAAGCTATTGGAAGGCTTCAAATA 1042
Db 721 AGTAGGAAGCAGAGGCAATTGAAGGCAGAGCTAAAAATGCTATTGGCAAGCTTCAGCTG 780
Qy 1043 CGCACTGTAACAGAGGAGACAGGAATTTGGCCCTGATGAGATAGTTGTGCTGTGTC 1102
Db 781 CGCACTGTAACAGAGGAGACAGGAATTTGGGCGCTGATGAGATAGTTGTGCTGTGTC 840
Qy 1103 ATTGAATTGTATAAACCAATGATTTGTGCTAGCATCTTAAAGTCAACCATATTTTCCAT 1162
Db 841 ATTGAGCTGTATAGGCAATGATTTTGTGGCATCTTAACTGGAATCATATATTCAT 900
Qy 1163 AAGACATGTGTTGACCCCATGGCTGTAAACACAAAGACTTGGCCCATGTGCAATGTGAC 1222
Db 1163 AAGACATGTGTTGACCCCATGGCTGTAAACACAAAGACTTGGCCCATGTGCAATGTGAC 1222
```

```
Db 901 AATACATGTGTCGACCGTGGCTTTTAGAAACACAGGACTTGCCTCATCTGCAAGTGGGAC 960
Qy 1223 ATACTCAAAGCTTTGGGAATTTGAGGTGGATGTTGAAGATGGATCAGTGTCTTTTACAAGTC 1282
Db 961 ATTTCTAAAGCTCTTGGAAATTTGACGTGGATGTTGAAGATGGATCAGTGTCTTTACAAGTC 1020
Qy 1283 CCTGTATCCAAATGAAATATCTTAATAGTGCCTCTCCCATGAAAGAGGATAATTCGAGCGAG 1342
Db 1021 CCTGTTTCGAATGAAGCATCTAATACTGCTCTCTCCCATGAAGAGGACAGTCCGAAGTGAG 1080
Qy 1343 ACCGCATCATCTCGATATGCTTCAGTACAGGACACAGATGAACCGCTCTGGAGGAACAC 1402
Db 1081 ACTGCATCATCCGATATGCGTCAAGAGGACGATGAGCCACCCCTGGAGGACAT 1140
Qy 1403 GTGCAGTCAACAAATGAAAGTCTACAGCTGTAAACCATGAAGCAAAATTTCTGTGGCAGTG 1462
Db 1141 GCGCAATCAGCAATGAATAATCTCCAGTGTGTAACCATGAAGCAAAATTTCTGTGGCCGTC 1200
Qy 1463 GATGTTATTCCTCATGTGACCAACCCAACTTTGAAAGAGCAAACTCTCTAATCAAGAG 1522
Db 1201 GATGTTGTGCCCCATGTAGACAACTTACCTTTGACGAAGATGAGACTCTCTGAAACAAGAG 1260
Qy 1523 ACTGCTGTTTCGAGAAATTTAAATCTTAA 1549
Db 1261 GCTGCTGTTTCGAGATTTAAGTCTTAA 1287
```

Search completed: April 26, 2003, 01:03:20
Job time : 299 secs

GenCore version 5.1.4.p5.4578
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 26, 2003, 02:27:30 ; Search time 145 Seconds
(without alignments)
13312.692 Million cell updates/sec

Title: US-09-854-300-7

Perfect score: 1774

Sequence: 1 agctggagctccacgggt.....ataggcaagttctctctag 1774

Scoring table: IDENTITY NUC

Gapop 10_0 , Gapext 1.0

Searched: 709820 seqs, 544064369 residues

Total number of hits satisfying chosen parameters: 1419640

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- Published Applications NA:*
- 1: /cgn2_6/ptodata/1/pubpna/US07_PUBCOMB.seq:*
 - 2: /cgn2_6/ptodata/1/pubpna/PCT_NEW_PUB.seq:*
 - 3: /cgn2_6/ptodata/1/pubpna/US06_PUB.seq:*
 - 4: /cgn2_6/ptodata/1/pubpna/US06_PUBCOMB.seq:*
 - 5: /cgn2_6/ptodata/1/pubpna/US07_NEW_PUB.seq:*
 - 6: /cgn2_6/ptodata/1/pubpna/PCTUS_PUBCOMB.seq:*
 - 7: /cgn2_6/ptodata/1/pubpna/US08_NEW_PUB.seq:*
 - 8: /cgn2_6/ptodata/1/pubpna/US08_PUBCOMB.seq:*
 - 9: /cgn2_6/ptodata/1/pubpna/US09_NEW_PUB.seq:*
 - 10: /cgn2_6/ptodata/1/pubpna/US09_PUBCOMB.seq:*
 - 11: /cgn2_6/ptodata/1/pubpna/US10_NEW_PUB.seq:*
 - 12: /cgn2_6/ptodata/1/pubpna/US10_PUBCOMB.seq:*
 - 13: /cgn2_6/ptodata/1/pubpna/US60_NEW_PUB.seq:*
 - 14: /cgn2_6/ptodata/1/pubpna/US60_PUBCOMB.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1178.8	66.4	2306	10	US-09-764-864-63
2	1157.6	65.3	1250	9	US-09-764-864-519
3	372.6	21.0	643	9	US-10-046-935-1815
4	372.6	21.0	643	9	US-09-878-178-1815
5	372.6	21.0	643	9	US-10-146-502-1815
6	310	17.5	435	10	US-09-920-300A-1176
7	310	17.5	435	12	US-10-033-528-1176
8	274.6	15.5	387	10	US-09-983-965-5551
9	224.6	12.7	616	9	US-10-060-038-25
10	214.4	12.1	374	10	US-09-983-965-4662
11	209	11.3	2063	10	US-09-935-390A-1
12	201.2	11.3	392	10	US-09-983-965-5467
13	187.4	10.6	340	10	US-09-783-590-3523
14	180.8	10.2	3615	9	US-09-822-846-596
15	149.2	8.4	1322	10	US-09-935-390A-16
16	132.6	7.5	619	10	US-09-764-864-485
17	132	7.4	508	9	US-09-918-995-21070
18	117.2	6.6	463	10	US-09-864-761-11364
19	112.8	6.4	826	10	US-09-822-849A-90

ALIGNMENTS

RESULT 1

US-09-764-864-63

; Sequence 63, Application US/09764864

; Patent No. US20020132753A1

; GENERAL INFORMATION:

; APPLICANT: Rosen et al.

; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies

; FILE REFERENCE: PTZ23

; CURRENT APPLICATION NUMBER: US/09/764,864

; CURRENT FILING DATE: 2001-01-17

; Prior application data removed - consult PALM or file wrapper

; NUMBER OF SEQ ID NOS: 1792

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 63

; LENGTH: 2306

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-764-864-63

Query Match 66.4%; Score 1178.8; DB 10; Length 2306;

Best Local Similarity 99.0%; Pred. No. 4.1e-311;

Matches 1217; Conservative 0; Mismatches 8; Indels 4; Gaps 3;

Qy	547	CTGTAAACCGCACACGAATTTTCACGGTCCACCGTTGGGGAAGCACCGTGAAGTCTC	606
Db	12	CTGTAAACCGCACACGAATTTTCACGGTCCACCGTTGGGGAAGCACCGTGAAGTCTC	71
Qy	607	TTGGTTGGCCCTCATCAACGCGCGGGGGCTGCACCTTCGACACAAGATCCATCTGGC	666
Db	72	TTGGTTGGCCCTCATCAACGCGCGGGGGCTGCACCTTCGACACAAGATCCATCTGGC	131
Qy	667	TTATGAGATGGGGCTGTGGAGCCGTCATCTTTAACTCCCGGGACCCGCAATGAGGT	726
Db	132	TTATGAGATGGGGCTGTGGAGCCGTCATCTTTAACTCCCGGGACCCGCAATGAGGT	191
Qy	727	CATCCCATGTCACCCGGGTGCAGTAGACATTTGTCATATGATCGGCAATCTGAA	786
Db	192	CATCCCATGTCACCCGGGTGCAGTAGACATTTGTCATATGATCGGCAATCTGAA	251
Qy	787	AGGCACAAAATCTTCAATCTATTCAAGAGGCATACAAAGTGAATGGTCTATAGAAGT	846
Db	252	AGGCACAAAATCTTCAATCTATTCAAGAGGCATACAAAGTGAATGGTCTATAGAAGT	311

Sequence 5079, Ap
Sequence 1328, Ap
Sequence 27944, A
Sequence 240, App
Sequence 23, Appl
Sequence 7, Appl
Sequence 484, App
Sequence 36, Appl
Sequence 79, Appl
Sequence 81, Appl
Sequence 222, App
Sequence 222, App
Sequence 344, App
Sequence 182, App
Sequence 182, App
Sequence 404, App
Sequence 466, App
Sequence 40, Appl
Sequence 148, App
Sequence 16, Appl
Sequence 686, App
Sequence 231, App
Sequence 32, Appl
Sequence 32, Appl
Sequence 103, App

QY 847 AGGAAAAACATGGCCCTTGGGTGAATCACTATTCAA-TTTTTCCTGTTCTGTGCTCT 905
Db 312 AGGAAAAACATGGCCCTTGGGTGAATCACTATTCAA-TTTTTCCTGTTCTGTGCTCT 371
QY 906 TTTTATATTATTAACGGGGCAACTGTGGCTATTTTATCTTTTATCTTCTGTCGAAGCTAC 965
Db 372 TTTTATATTATTAACGGGGCAACTGTGGCTATTTTATCTTTTATCTTCTGTCGAAGCTAC 431
QY 966 GGAATGCAAGAGCTCAAGCAGGAGCAAGGCAATTAAGGCAGATGCTTAAAGAGCTA 1025
Db 432 GGAATGCAAGAGCTCAAGCAGGAGCAAGGCAATTAAGGCAGATGCTTAAAGAGCTA 491
QY 1026 TTGGAAGCTTTCAACTACGCACTGTAAGCAAGGAGCAAGGAAATTTGGCCCTGTATGGAG 1085
Db 492 TTGGAAGCTTTCAACTACGCACTGTAAGCAAGGAGCAAGGAAATTTGGCCCTGTATGGAG 551
QY 1086 ATAGTTGTGCTGTGCAATTTGAATTTGTATTAACCAATGATTTGGTACGCATCTTAACGT 1145
Db 552 ATAGTTGTGCTGTGCAATTTGAATTTGTATTAACCAATGATTTGGTACGCATCTTAACGT 611
QY 1146 GCAACCATATTTTCCATAAGACATGTGTTGACCCATGGCTTTTAAACCAACAGACTTGGC 1205
Db 612 GCAACCATATTTTCCATAAGACATGTGTTGACCCATGGCTTTTAAACCAACAGACTTGGC 671
QY 1206 CCATGTGCAAAATGTGACATCTCAAGCTTTGGGAAATTTGAGTGGATTTGAAGATGGAT 1265
Db 672 CCATGTGCAAAATGTGACATCTCAAGCTTTGGGAAATTTGAGTGGATTTGAAGATGGAT 731
QY 1266 CAGTGTCTTTTACAGTCCCTGTATCCAAATGAATATCTAATAGTGGCTCTCCCATGAAG 1325
Db 732 CAGTGTCTTTTACAGTCCCTGTATCCAAATGAATATCTAATAGTGGCTCTCCCATGAAG 791
QY 1326 AGGATAATTCGAGGAGACCGCATCTCGATATGCTTCAGTACAGGGAACAGATGAAC 1385
Db 792 AGGATAATTCGAGGAGACCGCATCTCGATATGCTTCAGTACAGGGAACAGATGAAC 851
QY 1386 CGCCTCTGAGGAAACAGCTGAGTCAACAAATGAAGTCTACAGCTGGTAAACCATGAAG 1445
Db 852 CGCCTCTGAGGAAACAGCTGAGTCAACAAATGAAGTCTACAGCTGGTAAACCATGAAG 911
QY 1446 CAATTCCTGTGGAGTGGATTTATCTCATGTGACACCAACCTTTGAGAGAGAG 1505
Db 912 CAATTCCTGTGGAGTGGATTTATCTCATGTGACACCAACCTTTGAGAGAGAG 971
QY 1506 AAATCTCTTAATCAAGAGACTGCTGTTTCGAGAAATTAATCTTAAATCTGTGTAATAGA 1565
Db 972 AAATCTCTTAATCAAGAGACTGCTGTTTCGAGAAATTAATCTTAAATCTGTGTAATAGA 1031
QY 1566 AAATCTCTTAATCAAGAGACTGCTGTTTCGAGAAATTAATCTTAAATCTGTGTAATAGA 1625
Db 1032 AAATCTCTTAATCAAGAGACTGCTGTTTCGAGAAATTAATCTTAAATCTGTGTAATAGA 1091
QY 1626 TGGATAAATTTAATAAATAAGAGTGTATCTGAAAGTCTCAGATGACTAATATTATGCT 1685
Db 1092 TGGATAAATTTAATAAATAAGAGTGTATCTGAAAGTCTCAGATGACTAATATTATGCT 1151
QY 1686 ATAGTTAAATGGCTTAAATAATTTAACTGTTAACTTTTTCACCAAACTCATATA 1745
Db 1152 ATAGTTAAATTTGCTTAAATAATTTAACTGTTAACTTTTTCACCAAACTCATATA 1208
QY 1746 ATATTTTTCATAGGCAAGTTTCTCTCTCAG 1774
Db 1209 ATATTTTTCATAGGCAAGTTTCTCTCTCAG 1237

RESULT 2

US-09-764-864-519
; Sequence 519, Application US/09764864
; Patent No. US20020132753A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies

FILE REFERENCE: PT223
; CURRENT APPLICATION NUMBER: US/09/764,864
; CURRENT FILING DATE: 2001-01-17
; Prior application data removed - consult PALM or file wrapper
; NUMBER OF SEQ ID NOS: 1792
; SOFTWARE: Patent in Ver. 2.0
; SEQ ID NO 519
; LENGTH: 1250
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (540)
; OTHER INFORMATION: n equals a.t.g, or g
; NAME/KEY: SITE
; LOCATION: (1242)
; OTHER INFORMATION: n equals a.t.g, or c
US-09-764-864-519

Query Match 65.3%; Score 1157.6; DB 10; Length 1250;
Best Local Similarity 98.8%; Pred. No. 1.7e-305;
Matches 1208; Conservative 0; Mismatches 10; Indels 5; Gaps 4;

QY 547 CTGTAAACCGCACACAGAAATTTACGGTGCCTCCACGGTTTGGGAGACACCGTCAAGTCTC 606
Db 18 CTGTAAACCGCACACAGAAATTTACGGTGCCTCCACGGTTTGGGAGACACCGTCAAGTCTC 77
QY 607 TTGGTTGGCCCTCATCAACGCGCGGGGGCTGCACCTTCGACACAAAGATCCATCTGGC 666
Db 78 TTGGTTGGCCCTCATCAACGCGCGGGGGCTGCACCTTCGACACAAAGATCCATCTGGC 137
QY 667 TTATGAGAGATGGCGCTCTGGAGCGCTCATCTTTAACTTCCCGGGGACCGCAATAGGT 726
Db 138 TTATGAGAGAGGGCGCTCTGGAGCGCTCATCTTTAACTTCCCGGGGACCGCAATAGGT 197
QY 727 CATCCCATGCTCTCACCGGGTGCAGTAGACATTTGTCATCATGATCGCAATCTGAA 786
Db 198 CATCCCATGCTCTCACCGGGTGCAGTAGACATTTGTCATCATGATCGCAATCTGAA 257
QY 787 AGGCACAAAAATCTGCAATCTATTCAAAGAGGCATACAAGTGAACAATGGTCAATAGAT 846
Db 258 AGGCACAAAAATCTGCAATCTATTCAAAGAGGCATACAAGTGAACAATGGTCAATAGAT 317
QY 847 AGGAAAAACATGGCCCTTGGGTGAATCACTATTCAA-TTTTTCCTGTTCTGTGCTCT 905
Db 318 AGGAAAAACATGGCCCTTGGGTGAATCACTATTCAA-TTTTTCCTGTTCTGTGCTCT 377
QY 906 TTTTATTTATTTACGGCGGCAACTGTGGCTATTTTATCTTTTATCTGCTCGAAGGCTAC 965
Db 378 TTTTATTTATTTACGGCGGCAACTGTGGCTATTTTATCTTTTATCTGCTCGAAGGCTAC 437
QY 966 GGAATGCAAGAGCTCAAGCAGGAGCAAGGCAATTAAGGCAGATGCTTAAAGAGCTA 1025
Db 438 GGAATGCAAGAGCTCAAGCAGGAGCAAGGCAATTAAGGCAGATGCTTAAAGAGCTA 497
QY 1026 TTGGAAGCTTTCAACTACGCACTGTAAGCAAGGAGCAAGGAAATTTGGCCCTGTATGGAG 1084
Db 498 TTGGAAGCTTTCAACTACGCACTGTAAGCAAGGAGCAAGGAAATTTGGCCCTGTATGGAG 557
QY 1085 GATAGTTGTGCTGTGCAATTTGAATTTGTATTAACCAATGATTTGGTACGCATCTTAACG 1144
Db 558 GATAGTTGTGCTGTGCAATTTGAATTTGTATTAACCAATGATTTGGTACGCATCTTAACG 617
QY 1145 TGCAACCATATTTTCCATAAGACATGTTGACCCATGGCTTTTAAACCAACAGACTTGC 1204
Db 618 TGCAACCATATTTTCCATAAGACATGTTGACCCATGGCTTTTAAACCAACAGACTTGC 677
QY 1205 CCATGTGCAAAATGTGACATCTCAAGCTTTGGGAAATTTGAGGAGGATGTTGAAGATGGA 1264
Db 678 CCATGTGCAAAATGTGACATCTCAAGCTTTGGGAAATTTGAGGAGGATGTTGAAGATGGA 737
QY 1265 TCAGTGTCTTTACAGTCCCTGTATCCAAATGAATATCTAATAGTGGCTCTCCCATGAA 1324

Db 738 TCAGTGTCTTTACAGTCCCTGTATCAATGAATATCTAATAGTCCCTCCCATGAA 797
Qy 1325 GAGGATATCCAGCGAGACCGCATCATCTGGATATCTTCAGTACAGGGAACAGATGAA 1384
Db 798 GAGGATATCCAGCGAGACCGCATCATCTGGATATCTTCAGTACAGGGAACAGATGAA 857
Qy 1385 CCGCTCTGGAGGAACACGTGCAGTCAACAAATGAAAGTCTACAGCTGGTAAACCATGAA 1444
Db 858 CCGCTCTGGAGGAACACGTGCAGTCAACAAATGAAAGTCTACAGCTGGTAAACCATGAA 917
Qy 1445 GCAATCTCGGCGAGTGGATGTTATCTCTCATCTGACGACCAACCTTTGAAGAGAC 1504
Db 918 GCAATCTCGGCGAGTGGATGTTATCTCTCATCTGACGACCAACCTTTGAAGAGAC 977
Qy 1505 GAAACTCCTAATCAAGAGACTGCTGTTTCGAGAAATTAATCTTAAATCTGTGTAATAG 1564
Db 978 GAAACTCCTAATCAAGAGACTGCTGTTTCGAGAAATTAATCTTAAATCTGTGTAATAG 1037
Qy 1565 AAACTTGAACCATAGTAATAACAGAACTGCCAATCAGGCGCTAGTTCTATTATATAA 1624
Db 1038 AAACTTGAACCATAGTAATAACAGAACTGCCAATCAGGCGCTAGTTCTATTATATAA 1097
Qy 1625 TTGATTAATTTAATAAATAAGAGTGATCTGAAAGTGTCTCAGATGACTAATATTATGC 1684
Db 1098 TTGATTAATTTAATAAATAAGAGTGATCTGAAAGTGTCTCAGATGACTAATATTATGC 1157
Qy 1685 TATAGTTAAATGGCTTAAATATTTAACTGTAACTTTTTTCCACCAACTCAATTAT 1744
Db 1158 TATAGTTAAA--TGGCTTAAATATTTAACTGTAACTTTTTTCCCA--CAAACTCAATTAT 1214
Qy 1745 AATATTTTTCATAGCAAGTTTC 1767
Db 1215 AATATTTTTCATAGCAATTTCC 1237

RESULT 3

US-10-046-935-1815

; Sequence 1815, Application US/10046935

; Patent No. US20020156011A1

; GENERAL INFORMATION:

; APPLICANT: Jiang, Yugu

; APPLICANT: Harlocker, Susan L.

; APPLICANT: Secretist, Heather

; APPLICANT: Wang, Aijun A.

; APPLICANT: Stoik, John A.

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY

; FILE REFERENCE: 210121.527C1

; CURRENT APPLICATION NUMBER: US/10/046,935

; CURRENT FILING DATE: 2002-01-15

; NUMBER OF SEQ ID NOS: 2239

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 1815

; LENGTH: 643

; TYPE: DNA

; ORGANISM: Homo sapiens

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION: 584

; OTHER INFORMATION: n = A,T,C or G

US-10-046-935-1815

Query Match 21.0%; Score 372.6; DB 9; Length 643;
Best Local Similarity 98.0%; Pred. No. 2.1e-91;
Matches 398; Conservative 0; Mismatches 5; Indels 3; Gaps 2;

Qy 1369 ACAGGGAACAGATGAACCGCTCTCGAGGAACACCGTGCAGTCAACAAATGAAAGTCTACA 1428

Db 1 ACAGGGAACAGATGAACCGCTCTCGAGGAACACCGTGCAGTCAACAAATGAAAGTCTACA 60

Qy 1429 GCTGGTAAACCATGAAGCAAAATCTGTGGCAGTGAATTTCTCTCATGTGACCAACC 1488

Db 61 GCTGGTAAACCATGAAGCAAAATCTGTGGCAGTGAATTTCTCTCATGTGACCAACC 120

Qy 1489 AACCTTTTGAAGAACGAAACTCCTAATCAAGAGACTGCTCTCGAGAAATTAATCTTA 1548
Db 121 AACCTTTTGAAGAACGAAACTCCTAATCAAGAGACTGCTCTCGAGAAATTAATCTTA 180
Qy 1549 AAATCTGTGTAATAGAAAACCTTGAAACCATTAGTAATAACAGAACTGCCAATCAGGGCCT 1608
Db 181 AAATCTGTGTAATAGAAAACCTTGAAACCATTAGTAATAACAGAACTGCCAATCAGGGCCT 240
Qy 1609 AGTTTCTTAAATTAATTTGGATAAATTTAATAAATAAGAGTGATCTCTGAAAGTGCTCAG 1668
Db 241 AGTTTCTTAAATTAATTTGGATAAATTTAATAAATAAGAGTGATCTCTGAAAGTGCTCAG 300
Qy 1669 ATGACTAATATTTATGCTATAGTTAAATGGCTTAAAAATATTTAACTGTTAACTTTTTT 1728
Db 301 ATGACTAATATTTATGCTATAGTTAAA--TGGCTTAAAAATATTTAACTGTTAACTTTTTT 358
Qy 1729 CCACCAAACTCAATTAATAATTTTTCATAGGCAAGTTTCTCTCTCAG 1774
Db 359 CCA--CAAACTCAATTAATAATTTTTCATAGGCAAGTTTCTCTCTCAG 403

RESULT 4

US-09-878-178-1815

; Sequence 1815, Application US/09878178

; Patent No. US2002017552A1

; GENERAL INFORMATION:

; APPLICANT: Jiang, Yugu

; APPLICANT: Harlocker, Susan L.

; APPLICANT: Secretist, Heather

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY

; FILE REFERENCE: 210121.527

; CURRENT APPLICATION NUMBER: US/09/878,178

; CURRENT FILING DATE: 2001-06-08

; NUMBER OF SEQ ID NOS: 2237

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 1815

; LENGTH: 643

; TYPE: DNA

; ORGANISM: Homo sapien

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION: (1)_(643)

; OTHER INFORMATION: n = A,T,C or G

US-09-878-178-1815

Query Match 21.0%; Score 372.6; DB 9; Length 643;
Best Local Similarity 98.0%; Pred. No. 2.1e-91;
Matches 398; Conservative 0; Mismatches 5; Indels 3; Gaps 2;

Qy 1369 ACAGGGAACAGATGAACCGCTCTCGAGGAACACCGTGCAGTCAACAAATGAAAGTCTACA 1428

Db 1 ACAGGGAACAGATGAACCGCTCTCGAGGAACACCGTGCAGTCAACAAATGAAAGTCTACA 60

Qy 1429 GCTGGTAAACCATGAAGCAAAATCTGTGGCAGTGAATTTCTCTCATGTGACCAACC 1488

Db 61 GCTGGTAAACCATGAAGCAAAATCTGTGGCAGTGAATTTCTCTCATGTGACCAACC 120

Qy 1489 AACCTTTTGAAGAACGAAACTCCTAATCAAGAGACTGCTCTCGAGAAATTAATCTTA 1548

Db 121 AACCTTTTGAAGAACGAAACTCCTAATCAAGAGACTGCTCTCGAGAAATTAATCTTA 180

Qy 1549 AAATCTGTGTAATAGAAAACCTTGAAACCATTAGTAATAACAGAACTGCCAATCAGGGCCT 1608

Db 181 AAATCTGTGTAATAGAAAACCTTGAAACCATTAGTAATAACAGAACTGCCAATCAGGGCCT 240

Qy 1609 AGTTTCTTAAATTAATTTGGATAAATTTAATAAATAAGAGTGATCTGAAAGTGCTCAG 1668

Db 241 AGTTTCTTAAATTAATTTGGATAAATTTAATAAATAAGAGTGATCTGAAAGTGCTCAG 300

Qy 1669 ATGACTAATATTTATGCTATAGTTAAATGGCTTAAAAATATTTAACTGTTAACTTTTTT 1728

Db 359 CCA--CAAACTCAATTAATAATTTTTCATAGGCAAGTTTCTCTCTCAG 403

Db 301 ATGACTAATATATGCTATAGTAAA--TGGCTTAAATATTTAACTGTTAACTTTT 358
Qy 1729 CCACAAACTATTAATATATTTTCATAGGCAAGTTTCCTCTCAG 1774
Db 359 CCA-CAAACTATTATAATATTTTCATAGGCAAGTTTCCTCTCAG 403

RESULT 5

US-10-146-502-1815
; Sequence 1815, Application US/10146502
; Publication No. US20030069180A1
; GENERAL INFORMATION:
; APPLICANT: Jiang, Yugu
; APPLICANT: Harlocker, Susan M.
; APPLICANT: Secrist, Heather
; APPLICANT: Wang, Aijun
; APPLICANT: Stolk, John A.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY
; TITLE OF INVENTION: AND DIAGNOSIS OF COLON CANCER
; FILE REFERENCE: 210121.527C2
; CURRENT APPLICATION NUMBER: US/10/146,502
; CURRENT FILING DATE: 2002-05-14
; NUMBER OF SEQ ID NOS: 2241
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1815
; LENGTH: 643
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 584
; OTHER INFORMATION: n = A,T,C or G
US-10-146-502-1815

Query Match 21.0%; Score 372.6; DB 9; Length 643;
Best Local Similarity 98.0%; Pred. No. 2.1e-91;
Matches 398; Conservative 0; Mismatches 5; Indels 3; Gaps 2;

Qy 1369 ACAGGGAACAGATGAACCGCCTCTGGAGGAACACGTCGACGCAACAAATGAAGTCTACA 1428
Db 1 ACAGGGAACAGATGAACCGCCTCTGGAGGAACACGTCGACGCAACAAATGAAGTCTACA 60
Qy 1429 GCTGTAAACCATGAACAAATCTGTGGCAGTGGATGTATTCCTCATGTNGACAACC 1488
Db 61 GCTGTAAACCATGAACAAATCTGTGGCAGTGGATGTATTCCTCATGTNGACAACC 120
Qy 1489 AACCTTTGAAGAGACGAAACTCCTAATCAAGAGACTGCTGTTTCGAGAAATTAATCTTA 1548
Db 121 AACCTTTGAAGAGACGAAACTCCTAATCAAGAGACTGCTGTTTCGAGAAATTAATCTTA 180
Qy 1549 AAATCTGTGTAATAGAAACTTGAACCATTAGTAATAACAGAACTGCCAATCAGGGCCT 1608
Db 181 AAATCTGTGTAATAGAAACTTGAACCATTAGTAATAACAGAACTGCCAATCAGGGCCT 240
Qy 1609 AGTTTCTATTAATAATTTGGATAAATTTAATAAATAAGAGTGATCTCAAAAGTGTCTAG 1668
Db 241 AGTTTCTATTAATAATTTGGATAAATTTAATAAATAAGAGTGATCTCAAAAGTGTCTAG 300
Qy 1669 ATGACTAATATATGCTATAGTTAAATAGCCTTAAAAATTAATTAACCTGTAACTTTTT 1728
Db 301 ATGACTAATATATGCTATAGTTAAA--TGGCTTAAATATTTAACTGTAACTTTTT 358
Qy 1729 CCACCAACTCATTATTAATATTTTCATAGGCAAGTTTCCTCTCAG 1774
Db 359 CCA-CAAACTATTATAATATTTTCATAGGCAAGTTTCCTCTCAG 403

RESULT 6

US-09-920-300A-1176/c
; Sequence 1176, Application US/09920300A
; Patent No. US20020136728A1
; GENERAL INFORMATION:
; APPLICANT: King, Gordon E.

; APPLICANT: Meagher, Madeleine Joy
; APPLICANT: Xu, Jiangchun
; APPLICANT: Secrist, Heather
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY
; TITLE OF INVENTION: AND DIAGNOSIS OF COLON CANCER
; FILE REFERENCE: 210121.547
; CURRENT APPLICATION NUMBER: US/09/920,300A
; CURRENT FILING DATE: 2001-07-31
; NUMBER OF SEQ ID NOS: 1789
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1176
; LENGTH: 435
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-920-300A-1176

Query Match 17.5%; Score 310; DB 10; Length 435;
Best Local Similarity 97.4%; Pred. No. 2e-74;
Matches 336; Conservative 0; Mismatches 6; Indels 3; Gaps 2;

Qy 1430 CTGGTAAACCATGAACAAATCTGTGGCAGTGGATGTTTCTCATGTNGACAACCCA 1489
Db 435 CTGGTAAACCATGAACAAATCTGTGGCAGTGGATGTTTCTCATGTNGACAACCCA 376
Qy 1490 ACCTTTGAAGAGACGAAACTCCTAATCAAGAGACTGCTGTTTCGAGAAATTAATCTTAA 1549
Db 375 ACCTTTGAAGAGACGAAACTCCTAATCAAGAGACTGTTTTCGAGAAATTAATCTTAA 316
Qy 1550 AATCTGTGTAATAGAAACTTGAACCATTTAGTAATAACAGAACTGCCAATCAGGSCCTA 1609
Db 315 AATCTGTGTAATAGAAACTTGAACCATTTAGTAATAACAGAACTGCCAATCAGGSCCTA 256
Qy 1610 GTTTCCTAATAAATTTGGATAAATTAATAAATAAGAGTGATCTGAAAGTGTCTCAGA 1669
Db 255 GTTTCCTAATAAATTTGGATAAATTAATAAATAAGAGTGATCTGAAAGTGTCTCAGA 196
Qy 1670 TGACTAATATATGCTATAGTTAAATGGCTTAAATATTTAACTGTAACTTTTTC 1729
Db 195 TGACTAATATATGCTATAGTTAAA--TGGCTTAAATATTTAACTGTAACTTTTTC 138
Qy 1730 CACCAAACTCATTATATATTTTTCATAGGCAAGTTTCTCTCAG 1774
Db 137 CA-CAAACTCATTATATATTTTTCATAGGCAAGTTTCTCTCAG 94

RESULT 7

US-10-033-528-1176/c
; Sequence 1176, Application US/10033528
; Patent No. US20020131971A1
; GENERAL INFORMATION:
; APPLICANT: King, Gordon E.

; APPLICANT: Meagher, Madeleine Joy
; APPLICANT: Xu, Jiangchun
; APPLICANT: Secrist, Heather
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY
; TITLE OF INVENTION: AND DIAGNOSIS OF COLON CANCER
; FILE REFERENCE: 210121.547C1
; CURRENT APPLICATION NUMBER: US/10/033,528
; CURRENT FILING DATE: 2001-12-26
; NUMBER OF SEQ ID NOS: 1896
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1176
; LENGTH: 435
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-033-528-1176

Query Match 17.5%; Score 310; DB 12; Length 435;
Best Local Similarity 97.4%; Pred. No. 2e-74;
Matches 336; Conservative 0; Mismatches 6; Indels 3; Gaps 2;

Qy 1430 CTGGTAAACCATGAACAAATCTGTGGCAGTGGATGTTTCTCATGTNGACAACCCA 1489
Db 435 CTGGTAAACCATGAACAAATCTGTGGCAGTGGATGTTTCTCATGTNGACAACCCA 376

Db 435 CTGGTAACCAATGAAGCAAAATTCGTGGCAGTGGATGTTATTCCTCATGTTGACAACCCA 376
Qy 1490 ACCTTTGAAGAGACGAACTCCCTAATCAAGAGAGCTGCTGTTCCAGAAATTAATCTTAA 1549
Db 375 ACCTTTGAAGAGACGAACTCCCTAATCAAGAGAGCTGCTGTTCCAGAAATTAATCTTAA 316
Qy 1550 AATCTGTGTAATAGAAAATGGAACCAATAGTAATAACAGAACTGCCAATCAGGGCCTA 1609
Db 315 AATCTGTGTAATAGAAAATGGAACCAATAGTAATAACAGAACTGCCAATCAGGGCCTA 256
Qy 1610 GTTCTCTATTAATTCGATGATAATTTAATAAATAGAGTGAATCACTGAAAGTCTCAGA 1669
Db 255 GTTCTCTATTAATTCGATGATAATTTAATAAATAGAGTGAATCACTGAAAGTCTCAGA 196
Qy 1670 TGACTAATATATGCTAGTAAATGGCTTAAATGCTTAAATTAATTAACCTGTTAACTTTTTC 1729
Db 195 TGACTAATATATGCTAGTAAAT--TGGCTTAAATTAATTAACCTGTTAACTTTTTC 138
Qy 1730 CACCAACTCATTAATATATTTTTCATAGGCAAGTTTCCTCTCAG 1774
Db 137 CA-CAACTCATTAATATATTTTTCATAGGCAAGTTTCCTCTCAG 94

RESULT 8

US-09-983-965-5551
; Sequence 5551, Application US/09983965
; Patent No. US20020137160A1
; GENERAL INFORMATION:
; APPLICANT: Warren, Wesley C.
; APPLICANT: Byatt, John C.
; APPLICANT: Mathialagan, Nagappan
; TITLE OF INVENTION: NUCLEIC ACID AND OTHER MOLECULES ASSOCIATED WITH LACTATION AND
; FILE REFERENCE: 37-21(10297)C
; CURRENT APPLICATION NUMBER: US/09/983,965
; CURRENT FILING DATE: 2001-10-26
; PRIOR FILING DATE: 1999-12-15
; PRIOR APPLICATION NUMBER: US 60/113,678
; PRIOR FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 5912
; SEQ ID NO 5551
; LENGTH: 387
; TYPE: DNA
; ORGANISM: Bos taurus
; FEATURE:
; NAME/KEY: (347)
; LOCATION: (347)
; OTHER INFORMATION:
; OTHER INFORMATION: Clone ID: 50-LIB34-010-Q1-E2-E6
US-09-983-965-5551

Query Match 15.5%; Score 274.6; DB 10; Length 387;
Best Local Similarity 86.8%; Pred. No. 8.5e-65;
Matches 336; Conservative 0; Mismatches 46; Indels 5; Gaps 3;

Qy 1386 CGCTCTGAGGAACACGTCGAGTCAACAAATGAAAGTCTACAGCTGGTAAACCATGAAG 1445
Db 1 CACCTTTGAGGAACATGCACACTCAGCAATGAAATCTACAGCTGGTAAACCATGAAG 60
Qy 1446 CAAATTCCTGGCAGTGGATGTTATTCCTCATGTNGACACCACTTTGAAGAGACG 1505
Db 61 CAAATTCATGCGAGTGGATGTTTCTCAGCTTGAACCAACCTTTGAGAGATG 120
Qy 1506 AAATCCTTAATCAAGAGCTGCTGTTGAGAAATTAATCTTAAATCTGTGTAATAGA 1565
Db 121 AAAGTCTCATCAGGAGACCACTGTTGAGAAATTAATCAATAATCTGTATCAGTAGA 180
Qy 1566 AAATCGAACCATTAATATACAGACTGCCAATCAGGGCCTAGTTT-CTATTAATAAA 1624
Db 181 AAACCTGAACTTTTAGTAATAACAGAACTGCCAATCAGGGCCTAGTTTACTACTAAGAA 240

Qy 1625 TTGGATAAAATTTAATAAATAAGAGTGAATCACTGAAAGTCTCAGATCACTAATATTATGC 1684
Db 241 CTGGATAAACTTAATAAATAAGAGTGAATCACTGAAAGTCTGATGACTAATATTATGC 300
Qy 1685 TATAGTTAAATGGCTTAAATAATTTAACTGTTAACTTTTCCACCAAACTCATTAAT 1744
Db 301 TATAGTTAAA--TGACTTAAATAACTAAACCTTATTAACCTTTT--CCACANACACTTAT 356
Qy 1745 AATATTTTTCATAGGCAAGTTCCTCTCT 1771
Db 357 AATGTTTTCATAGGCAAGTTCCTCTCT 383

RESULT 9

US-10-060-036-25
; Sequence 25, Application US/10060036
; Publication No. US2003007314A1
; GENERAL INFORMATION:
; APPLICANT: Benson, Darin R.
; APPLICANT: Kalos, Michael D.
; APPLICANT: Lodes, Michael J.
; APPLICANT: Persing, David H.
; APPLICANT: Hepler, William T.
; APPLICANT: Jiang, Yuhui
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY
; FILE REFERENCE: 210121.566
; CURRENT APPLICATION NUMBER: US/10/060,036
; CURRENT FILING DATE: 2002-01-30
; NUMBER OF SEQ ID NOS: 4560
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 25
; LENGTH: 616
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 594
; OTHER INFORMATION: n = A,T,C or G
US-10-060-036-25

Query Match 12.7%; Score 224.6; DB 9; Length 616;
Best Local Similarity 97.3%; Pred. No. 5.2e-51;
Matches 250; Conservative 0; Mismatches 4; Indels 3; Gaps 2;

Qy 1518 AAGAGACTGCTGTTGAGAAATTAATCTTAAATCTGTGTAATAGAAAACTTGAACCA 1577
Db 1 AAGAGACTGCTGTTGAGAAATTAATCTTAAATCTGTGTAATAGAAAACTTGAACCA 60
Qy 1578 TTAGTAATAACAGAACTGCCAATCAGGGCTAGTTTCTATTAAATTTGGATAAATTTA 1637
Db 61 TTAGTAATAACAGAACTGCCAATCAGGGCTAGTTTCTATTAAATTTGGATAAATTTA 120
Qy 1638 ATAAAAATAGAGTGAATCACTGAAAGTCTCAGATGACTAATATATGCTAGTTAAATG 1697
Db 121 ATAAAAATAGAGTGAATCACTGAAAGTCTCAGATGACTAATATATGCTAGTTAAA--T 178
Qy 1698 GCTTAAAAATTTAACTGTTAACTTTTCCACCAAACTCATTAATATATTTTTCATA 1757
Db 179 GGCTTAAAAATTTAACTGTTAACTTTTCCCA--CAAACTCATTAATATATTTTTCATA 237
Qy 1758 GGCAAGTTTCTCTCTCAG 1774
Db 238 GGCAAGTTTCTCTCTCAG 254

RESULT 10

US-09-983-965-4662
; Sequence 4662, Application US/09983965
; Patent No. US20020137160A1
; GENERAL INFORMATION:
; APPLICANT: Warren, Wesley C.
; APPLICANT: Tao, Nengbing

APPLICANT: Byatt, John C.
APPLICANT: Mathialagan, Nagappan
TITLE OF INVENTION: NUCLEIC ACID AND OTHER MOLECULES ASSOCIATED WITH LACTATION AND
FILE OF INVENTION: MUSCLE AND FAT DEPOSITION
FILE REFERENCE: 37-21(10297)C
CURRENT APPLICATION NUMBER: US/09/983,965
CURRENT FILING DATE: 2001-10-26
PRIOR APPLICATION NUMBER: US 09/465,231
PRIOR FILING DATE: 1999-12-15
PRIOR APPLICATION NUMBER: US 60/113,678
PRIOR FILING DATE: 1998-12-17
NUMBER OF SEQ ID NOS: 5912
SEQ ID NO 4662
LENGTH: 374
TYPE: DNA
ORGANISM: Bos taurus
FEATURE:
OTHER INFORMATION: Clone ID: 14-LIB34-009-Q1-E1-D5
US-09-983-965-4662

Query Match 12.1%; Score 214.4; DB 10; Length 374;
Best Local Similarity 78.2%; Pred. No. 2.3e-48;
Matches 283; Conservative 0; Mismatches 76; Indels 3; Gaps 2;
QY 75 CGAGGAGTGCATCTCGGCAACCTGTGTGTGACGTACGTGCTCTCTGCTCGGCGT 134
Db 13 CAAGGGCTTCTCTGGGCAACATCTCGGCGACGCTACGTGCGCGCGGCTCTGACCC 72
QY 135 AGCTGCGAGCTCC--CCAGTCTCACTCAATTCCTTCCCACTGCGCGGCGACCTGCTCAA 192
Db 73 AGCCCGCCGCGCGCGCGAGTCTCGTCCGCTCTCTCACTACGTGCGCGCGACCTGGCCCA 132
QY 193 GACCAAGGTCCTGCGCAAGCGCTAGGAGGCGCGTGCACAGGCGCTAGCGAACTGCGGAG 252
Db 133 GCGCGGGTCCCGCGAGAGTCCGAGAGCGCGGTGCGAGGGCCCTAGGGAACTCAGAG 192
QY 253 CGCGCGCGCATGCGGCGCGCGCTGCGTGGCGCGCGGTCTCTGCGCGCGGTGCGGCTT 312
Db 193 CGCGCATATCATGCGGCGCGCTGCGAGGCGCGGCTCTCTGCGCGCGGTGCGGCTT 252
QY 313 TTCCAGATTGCTGGCATGTGCTTCTGCTGCGCGCTGAGTCCGCGAGGACCGGTTCCCG 372
Db 253 TTCCCGATTGCTGGCATGTGCTTCTGCTGCGCGCTGAGTCCGCGAGGACCGGTTCCCG 312
QY 373 GCGGCGTGAAGCAGTGTGACCGCGCTACCTCAACGT-PTCTGGCGGTTCCGACACCG 431
Db 313 TGGAGCGGAGCGGTGTGGAGCGGTAGCTCAACGTGTCTTGGCGGTTCCGACACCG 372
QY 432 GA 433
Db 373 GA 374

RESULT 11

US-09-935-390A-1
Sequence 1, Application US/09935390A
Patent No. US200200761A1

GENERAL INFORMATION:

APPLICANT: Escobedo, Jaime

Quianjin, Hu

Garcia, Pablo

Williams, Lewis T.

Kothakota, Srinivas

TITLE OF INVENTION: Secreted Human Proteins

NUMBER OF SEQUENCES: 38

CORRESPONDENCE ADDRESS:

ADDRESSEE: Chiron Corporation

STREET: 4560 Horton Street

CITY: Emeryville

STATE: CA

COUNTRY: USA

ZIP: 94608-2916

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/935,390A
FILING DATE: 22-Aug-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/988,671
FILING DATE: 1997-12-11
ATTORNEY/AGENT INFORMATION:
NAME: Jane E. R. Potter
REGISTRATION NUMBER: 33,332
REFERENCE/DOCKET NUMBER: 1369,002
TELECOMMUNICATION INFORMATION:
TELEPHONE: (510) 923-2718
TELEFAX: (510) 655-3542
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 2063 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-935-390A-1

Query Match 11.8%; Score 209; DB 10; Length 2063;
Best Local Similarity 54.6%; Pred. No. 2.1e-46;
Matches 507; Conservative 0; Mismatches 410; Indels 12; Gaps 4;

QY 339 TGCTGGCCCTGAGTCCGCGAGGACCCCGTTCCCGGGGGCTGAAAGCAGTGTGACCGCGT 398
Db 180 TGCTGGCCCTGCGCCCTGTGCTGCGCGCGCGCGCGCGGCTCTCGAGTGTCTCGG 239
QY 399 ACCTCAACAGTGTCTCTGGCGGGTTCGCCACACGCGAGTGAACCGTACGCTGGGAGCTGA 458
Db 240 CCGT---GGTAAACATCGAGTACGTGGACCCGCGACCAACCTGACGGTGTGAGCGTCT 296
QY 459 GCAGAGGAGCGGTACGCGCAGGACTCGCGCGCTGAGAGCTGTGGCTGGGGTCTCTGGTAC 518
Db 297 CGAGAGTGGCCGCTTGGCGGACAGCTCGCCCAAGAGAGGGCGGCGCATGGCTGTGGCG 356
QY 519 CGCCCGACGCGCGCGCGCGCTTAAACGCTGTAAACCGCACACGAATTTACCGTGGCCCA 578
Db 357 TCCCGTGGCGCGCGCGCGAGACTCGAGGGCTGCGCGCGCGCGCGCTTCTTCTGCTGC 416
QY 579 CGGTTTGGGGAAGCAACGTCGAAGTCTCTTGGTTGGCCCTCATCCACGCGCGGGGGCT 638
Db 417 CCGAGCGCGCGCGCGCGCGCGCGCTGGGCTGGGCTGGGCTGGGCTGGGCTGGGCT 473
QY 639 GCACCTTCGCGACAGATCCATCTGGCTTATGAGAGATGGGCTCTGGAGCGCTCATCT 698
Db 474 GCACCTTCAGGACAGGTGCTGTGGCGCGCGGAGGAAACGCTCTGGCGCTGTCTCT 533
QY 699 TTAACCTTCGCGGACCGGCAATGAGTCACTCCCATGTCTCACCGGGTGGAGTAGACA 758
Db 534 ACAATGAGGAGCGCTACGGGAACATCACCTTGGCCCATGTCTCACCGGGGAACAGGAAATA 593
QY 759 TTGTTGCAATCATGATCGGCAATCTGAAAGGACAAAAATTTGCAATCTATTCAAAGAG 818
Db 594 TAGTGGCTATTATGATTAGCTATCCAAAAGAGAGAAATTTGGAGCTGGTGCAAAAAG 653
QY 819 GCATACAGTGACAAATGGTATAGAGTATAGGAAAAAATGCGCCCTTGGGTGAAATCAC- 877
Db 654 GAATTCAGTAAACGATGACCATAGGGGTTGGCACCCCGCATGTACAGAGTTCATCAGCG 713
QY 878 --TATTCAATTTTTCGTTTCTGTGCTCTTTTATTATTATACGCGCGCAACTGTGGCT 935
Db 714 GTCAGTCTGTGGTGTGTTGGGCCATTGCGCTTCATCCCATGATGATTATCTCTGTAGCCT 773

QY 936 ATTTTATCTTTTATCTGCTGAGGCTACGGAATGCAAGAGCTCAAAGCAGGAAGCAGA 995
Db 774 GGCTAATAATTTTACTATATACACAGCGTTTCTATATATCTGCTCTCAGATTGGAACTCAGA 833
QY 996 GGCAATTTAAAGGCAGATGCTTAAAGAGCTATTGGAAGGCTTCAACTACGCACACTGAAC 1055
Db 834 GCATAGAAA--AGAACTAGAAAGTTATTGGCCAGCTTCTACTTCATCTGTAAGC 890
QY 1056 AAGGAGACAGGAAATGGCCCTGATGGAGATAGTTGTCTGTGTCATTTGAATTTGATA 1115
Db 891 ATGGAGAAAAGGAATGATGTTGATGCTGAAATTTGTGCACTGTGTTGAATTTCA 950
QY 1116 ACCCAATGATTTGGTACGCTTCACTTAACTGCAACCAATTTTTCATAGACATGTTG 1175
Db 951 AAGTAAGGATATTTATAGAAATTTGCCATGCAAGCATATTTTTCATAGAATATGATTG 1010
QY 1176 ACCCATGGCTGTTAAACACAGACTTGGCCCATGTCCTGCAATGTGACATCTCAAGCTT 1235
Db 1011 ACCCATGGCTTTTGGATCACGACATGTCCTGCAATGTGTAATTTGATGTCATCAAGCCC 1070
QY 1236 TGGGAATGAGTGGATGTTGTAAGATGGA 1264
Db 1071 TAGGATATTGGGAGAGAGCTGGGATGTA 1099

RESULT 12

US-09-983-965-5467
; Sequence 5467, Application US/09983965
; Patent No. US20020137160A1
; GENERAL INFORMATION:
; APPLICANT: Warren, Wesley C.
; APPLICANT: Rao, Nengbing
; APPLICANT: Byatt, John C.
; APPLICANT: Mathialagan, Nagappan
; TITLE OF INVENTION: NUCLEIC ACID AND OTHER MOLECULES ASSOCIATED WITH LACTATION AND
; FILE REFERENCE: 37-21(10297)C
; CURRENT APPLICATION NUMBER: US/09/983,965
; CURRENT FILING DATE: 2001-10-26
; PRIOR APPLICATION NUMBER: US 09/465,231
; PRIOR FILING DATE: 1999-12-15
; PRIOR APPLICATION NUMBER: US 60/113,678
; PRIOR FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 5912
; SEQ ID NO 5467
; LENGTH: 392
; TYPE: DNA
; ORGANISM: Bos taurus
; FEATURE:
; OTHER INFORMATION: Clone ID: 46-LIB34-036-Q1-E1-D10
US-09-983-965-5467

Query Match 11.3%; Score 201.2; DB 10; Length 392;
Best Local Similarity 80.3%; Pred. No. 9.3e-45;
Matches 285; Conservative 0; Mismatches 64; Indels 6; Gaps 4;

QY 1418 GAAAGTCTACAGCTGTTAAACCATGAAGCAATTTCTGTCGAGTGGATGTTATCTCTAT 1477
Db 1 GAAATCTCAGCTGGTAACCATGAAGCAATTTCTGTCGAGTGGATGTTATCTCTAC 60
QY 1478 GTNGACAACCAACCTTTGAAGAGAGCAAACTCTCTAATCAAGAGACTGCTGTTCGAGAA 1537
Db 61 GTTGACAACCAACCTTTGAAGAGAGATGAAGTCTCTGATCAGGAAC-AATGTCAGAA 119
QY 1538 ATTAATCTTAAATCTGTGTAATAGAAAATTGGAACCATTAGTAATTAACAGAACTGCC 1597
Db 120 ATTAATCTTAAATCTGTGTAATAGAAAATTGGAACCATTAGTAATTAACAGAACTGCC 179
QY 1598 AATC-AGGGCTAGTTCTTATTAAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1656
Db 180 AATCAAGGGCCAATTTTACAAACAAGGGAATGGGTAACCTTTAATTAATTAAGAGACT 239
QY 1657 GAAAGTCTCAGATGACTAATATATATGCTATAGTTAAAAATGGCTTAAAAATATTTAACT 1716

Db 240 GAAATGCTGATATGACTAATAATATGCTATAGTTAAA--TGACTTTAAAATACTAAACCT 297
QY 1717 GTTAACTTTTCCACCAACTCATTAATATATTTTTCATAGCAAGTTTCTCT 1771
Db 298 ATTAACCTTTT--CCACAAACACATTATAAAGTTTTTTCATAGCAAAATTTCTCT 350

RESULT 13

US-09-783-590-3523
; Sequence 3523, Application US/09783590
; Patent No. US20020110850A1
; GENERAL INFORMATION:
; APPLICANT: Dillon, Patrick J.
; APPLICANT: Haseltine, William A.
; APPLICANT: Li, Haodong
; APPLICANT: Rosen, Craig A.
; APPLICANT: Ruben, Steven M.
; TITLE OF INVENTION: Human Genes, Sequences, and Expression Products 16.2
; FILE REFERENCE: PO-16.2C1
; CURRENT APPLICATION NUMBER: US/09/783,590
; CURRENT FILING DATE: 2000-02-15
; PRIOR APPLICATION NUMBER: 08/420,856
; PRIOR FILING DATE: 1995-04-12
; PRIOR APPLICATION NUMBER: 08/346,731
; PRIOR FILING DATE: 1994-11-21
; NUMBER OF SEQ ID NOS: 12485
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3523
; LENGTH: 340
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (205)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (220)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (221)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (244)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (265)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (294)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (318)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (326)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (332)
; OTHER INFORMATION: n equals a,t,g, or c
; NAME/KEY: misc feature
; LOCATION: (333)
; OTHER INFORMATION: n equals a,t,g, or c
US-09-783-590-3523

Query Match 10.6%; Score 187.4; DB 10; Length 340;
Best Local Similarity 97.0%; Pred. No. 5e-41;
Matches 191; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 1203 GCCCATGTGCAATGTGACATCTCAAGCTTTGGGAATTTGAGTGGATGTTGAAGATG 1262
Db 1 GGACAGGGGCAATGTGACATCTCAAGCTTTGGGAATTTGAGTGGATGTTGAAGATG 60

QY 1263 GATCAGTGTCTTTACAAAGTCCCTGTATCCAAATATCTAATAGTGCCTCCTCCGATG 1322
DB 61 GATCAGTGTCTTTACAAAGTCCCTGTATCCAAATATCTAATAGTGCCTCCTCCGATG 120
QY 1323 AACAGGATATCCAGCGAGACCGCATCATCTGGATATCTTTCAGTACAGGGAACAGATG 1382
DB 121 AACAGGATATCCAGCGAGACCGCATCATCTGGATATCTTTCAGTACAGGGAACAGATG 180
QY 1383 AACCGCTCTGGAGGAA 1399
DB 181 AACCGCTCTGGAGGTA 197

RESULT 14

US-09-822-846-596
; Sequence 596, Application US/09822846
; Publication No. US20030027139A1
; GENERAL INFORMATION:
; APPLICANT: Jacobs, Kenneth
; APPLICANT: McCoy, John M.
; APPLICANT: LaVallie, Edward R.
; APPLICANT: Collins-Racie, Lisa A.
; APPLICANT: Evans, Cheryl
; APPLICANT: Merberg, David
; APPLICANT: Treacy, Maurice
; APPLICANT: Agostino, Michael J.
; APPLICANT: Steininger II, Robert J.
; APPLICANT: Bowman, Michael R.
; APPLICANT: Spaulding, Vikki
; APPLICANT: Wong, Gordon G.
; APPLICANT: Clark, Hilary
; APPLICANT: Fectel, Kim
; APPLICANT: Howes, Steven H.
; APPLICANT: Resnick, Richard J.
; APPLICANT: Gulukota, Kamalakara
; APPLICANT: Graham, James R.
; APPLICANT: Genetics Institute, Inc.
; TITLE OF INVENTION: POLYNUCLEOTIDES ENCODING NOVEL SECRETED PROTEINS
; FILE REFERENCE: GIN 6400
; CURRENT APPLICATION NUMBER: US/09/822,846
; CURRENT FILING DATE: 2001-03-29
; PRIOR APPLICATION NUMBER: 60/195,605
; PRIOR FILING DATE: 2000-04-06
; NUMBER OF SEQ ID NOS: 629
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 596
; LENGTH: 3615
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-822-846-596

Query Match 10.2%; Score 180.8; DB 9; Length 3615;
Best Local Similarity 57.2%; Pred. No. 1.5e-38;
Matches 348; Conservative 0; Mismatches 257; Indels 3; Gaps 1;
QY 653 AAGATCCATCTGGCTTATGAGAGATGGCGGTCTGAGCGGTCACTTAACTTCCCGGG 712
DB 1 AAGATCCGGAAGCGGCTCTCTGAGAACCGCTCAGCGGTGGTCACTTCAACGGTGGTCC 60
QY 713 ACCCGCAATGAGTTCATCCCATGTCTCACCGGGTGGAGTAGACATTTGTGCAATCATG 772
DB 61 AACACCAAGAGACCATCACATGCCACCGGGGTGAGAGACATCGTGGCCATATG 120
QY 773 ATCGGCAATCTGAAGGCAAAAAATCTGCAATCTATTCAAAGGCAATCAAGTGACA 832
DB 121 ATTCTGAGCCAAAGGGAAGAGATAGTAAGCCCTGCTGGAAGAAACATCACCGTGACA 180
QY 833 ATGGTCATAGATAGGGA---AAAAATGCGCCCTTGGGTGAATCACTATTCAATTTT 889
DB 181 ATGTACATCACCATCGGAACCGGAACTTGGAGAATATGTAGCCGCACTTCGGTTGTG 240
QY 890 TTCGTTTCTGTCTCTTTTATTATTATACGGCGGCAACTGTGGGCTATTTTATCTTTAT 949

DB 241 TTTGTCTCCATCTCTTTCATTTGCTGATGATCATTTTCCCTCGCATGGCTCGTCTTTTAT 300
QY 950 TCTGCTCGAAGGCTACGGAATGCAAGAGCTCAAAGCAGAGAGGCAATTTAAAGGCA 1009
DB 301 TACATCCAGAGGTTTCGATATGCAAAATGCCAGGGATAGGAACACAGCGCGACTGGGGAT 360
QY 1010 GATGCTAAAAAGCTATTGGAAGGCTTCAACTACGCACACTGAAACAAAGAGAGCAAGGAA 1069
DB 361 GCAGCAAGAAAGGCATCAGCAAACTCCAGATCAGAGCCATCAAGAAGGGTGACAAGGAA 420
QY 1070 ATTGGCCCTGATGGAGATAGTTGTGCTGTGTCATTAATTGATTAATCAATGATTTG 1129
DB 421 ACAGAGTCTGATTTTGACAACTGTGCAGTTTGTATTGAAGGGTACAAAGCCCAATGCGTT 480
QY 1130 GTAGCATCTTAAGCTGCAACCATATTTTCCATAAGACATGTCTTGACCCATGGCTGTTA 1189
DB 481 GTCCGGATCTGCGCTCCCGGCATCTTTTCCAAAGTCTGTGTTGACCCCTGGCTTCTA 540
QY 1190 AAACAAGAGCTTGGCCCATGTGCAAAATGTGACATCTCAAAGCTTTGGGAATGAGGTG 1249
DB 541 GACCATGTACTGTCCCATGTGCAAGATGAACATTTCTTAAAGCCCTAGGGATCCCGCC 600
QY 1250 GATGTTGA 1257
DB 601 AATGCCGA 608

RESULT 15
US-09-935-390A-16
; Sequence 16, Application US/09935390A
; Patent No. US20020076761A1
; GENERAL INFORMATION:
; APPLICANT: Escobedo, Jaime
; Quianjin, Hu
; Garcia, Pablo
; Williams, Lewis T.
; Kothakota, Srinivas
; TITLE OF INVENTION: Secreted Human Proteins
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Chiron Corporation
; STREET: 4560 Horton Street
; CITY: Emeryville
; STATE: CA
; COUNTRY: USA
; ZIP: 94608-2916
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/935,390A
; FILING DATE: 22-Aug-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/988,671
; FILING DATE: 1997-12-11
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane E. R. Potter
; REGISTRATION NUMBER: 33,332
; REFERENCE/DOCKET NUMBER: 1369.002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (510) 923-2718
; TELEFAX: (510) 655-3542
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1322 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 16:

GenCore version 5.1.4.p5.4578
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 26, 2003, 00:58:15 ; Search time 57 seconds
(without alignments)
9544.642 Million cell updates/sec

Title: US-09-854-300-7

Perfect score: 1774

Sequence: 1 agctggagctccaccgcgt.....ataggcaagttctctctcag 1774

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 441362 seqs, 153338381 residues

Total number of hits satisfying chosen parameters: 882724

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Issued Patents NA:*

1: /cgn2_6/prodata/1/ina/5A COMB.seq:*

2: /cgn2_6/prodata/1/ina/5B COMB.seq:*

3: /cgn2_6/prodata/1/ina/6A COMB.seq:*

4: /cgn2_6/prodata/1/ina/6B COMB.seq:*

5: /cgn2_6/prodata/1/ina/PCUS COMB.seq:*

6: /cgn2_6/prodata/1/ina/backfiles1.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	147.6	8.3	1253	2	US-08-786-606-6
2	77	4.3	912	2	US-09-090-567-3
3	76.4	4.3	2605	2	US-08-680-395-4
4	73.8	4.2	1378	1	US-08-075-533-20
5	73.8	4.2	1378	2	US-08-948-176-20
6	73.8	4.2	1378	5	PCT-US91-09160-20
7	73.8	4.2	1556	4	US-09-043-937A-3
8	73.8	4.2	1568	4	US-09-043-937A-1
9	73.2	4.1	1543	4	US-09-227-357-26
10	73	4.1	1545	4	US-09-227-357-125
11	73	4.1	1585	4	US-09-183-861-54
12	73	4.1	1585	4	US-09-022-765-54
13	73	4.1	2775	1	US-08-730-771-1
14	73	4.1	2775	4	US-09-060-208-1
15	73	4.1	3089	1	US-08-472-934-5
16	73	4.1	3089	2	US-08-323-460A-5
17	73	4.1	3089	2	US-08-461-146C-5
18	73	4.1	3089	3	US-08-461-145C-5
19	73	4.1	3089	4	US-08-628-829-9
20	73	4.1	3328	4	US-08-960-048-1
21	71.4	4.0	2045	4	US-08-795-088A-1
22	71	4.0	625	4	US-09-288-143-17
23	70.4	4.0	2085	2	US-08-668-128B-7
24	70.4	4.0	2085	2	US-08-905-445-7
25	69.4	3.9	633	4	US-08-818-112-6
26	69.4	3.9	633	4	US-08-818-111-6
27	69.4	3.9	633	4	US-09-056-556-6

Sequence 6, Appli
Sequence 101, App
Sequence 96, Appl
Sequence 101, App
Sequence 96, Appl
Sequence 1, Appli
Sequence 107, App
Sequence 4, Appli
Sequence 108, App
Sequence 14, Appl
Sequence 14, Appl
Sequence 5, Appli
Sequence 9, Appli
Sequence 6, Appli
Sequence 6, Appli
Sequence 1, Appli
Sequence 1, Appli

69.4 3.9 633 4 US-09-072-596-6
500 4 US-08-818-112-101
500 4 US-08-818-111-96
500 4 US-09-056-556-101
500 4 US-09-072-596-96
2418 4 US-09-285-379-1
33 33 2327 4 US-09-149-476-107
66.2 3.7 3023 4 US-09-308-022-4
66 3.7 752 4 US-08-976-259-108
66 3.7 849 3 US-08-646-538-14
66 3.7 849 4 US-09-503-222-14
66 3.7 1924 4 US-09-424-283-5
66 3.7 1958 4 US-09-215-221-9
66 3.7 2961 4 US-08-446-935-6
66 3.7 3699 3 US-08-646-538-6
66 3.7 3699 4 US-09-503-222-6
66 3.7 3792 2 US-08-992-334-1
66 3.7 3792 3 US-08-302-752-1

ALIGNMENTS

RESULT 1
US-08-786-606-6
; Sequence 6, Application US/08786606
; Patent No. 5861495
; GENERAL INFORMATION:
; APPLICANT: Hillman, Jennifer L.
; APPLICANT: Au-Young, Janice
; APPLICANT: Coleman, Roger
; APPLICANT: Goll, Surya K.
; TITLE OF INVENTION: NOVEL HUMAN ZINC-BINDING
; TITLE OF INVENTION: PROTEINS
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Incyte Pharmaceuticals, Inc.
; STREET: 3174 Porter Drive
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/786,606
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Billings, Lucy RJ
; REGISTRATION NUMBER: 36,749
; REFERENCE/DOCKET NUMBER: PF-0173 US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-855-0555
; TELEFAX: 415-845-4166
; TELEX:
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1253 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-786-606-6

Query Match 8.3%; Score 147.6; DB 2; Length 1253;
Best Local Similarity 55.9%; Pred. No. 2.6e-31;
Matches 301; Conservative 0; Mismatches 234; Indels 3; Gaps 1;

QY 720 ATGAGTCAATCCCATGCTCACCCTGGTGCAGTAGACATTTGTTGCAATCATGATCGCA 779
 Db 242 AGGAGCCAGTTACCATGACTCATCCAGCACTGGAGATATTTATTTGCTGTCAATGAACAG 301
 QY 780 ATCTCAAAAGGACAAAATTTCTGCAATCTATTCAAAGAGGACATCAAGTGACATGTCTCA 839
 Db 302 AATTGAGGGTAAGGATATTTGATTAATCTGGAGAAAACATCTCTGTACAAATGACAA 361
 QY 840 TAGAAGTAGGGAAGAAAACATGGCCCTTGGG---TGAATCACTATTCAATTTTTTTTCTGTTT 896
 Db 362 TAGCTGTGGAACCTGAAATGCCACCGAAGAACTTTCAGCCGTGGCTCTCTAGTCTTCGTGT 421
 QY 897 CTGTCTCTCTTTTATTTATTTAAGGCGCAACTGTGGGCTATTTTATCTTTTATTTCTGCTC 956
 Db 422 CAATATCTTTTATTTGTTTGTATTTATTTCTTCCAGCATGCTCATATTCTACTTCTATTC 481
 QY 957 GAAGCTACGGAATCCAGAGCTCAAGCAGGAGAGAGCAATTAAGAGCAGATGCTA 1016
 Db 482 AGAAGATCAGGTACAAATGACGCGACAGAACCCAGCTCGTCTCGAGATGCAGCA 541
 QY 1017 ABAAGCTATTGGAAGGCTTCAACTACGCACCTGAACAGGAGAGCAAGGAATTTGGCC 1076
 Db 542 AGAAGCCATCATGTAATTTGACACACGAGACAGTAAAGAGGGTGACAGGAATCTGACC 601
 QY 1077 CTGATGGAGATAGTTGTGTGTGCTGCTGATTTGAATTTATAAACCAAAATGATTTGGTAGCGCA 1136
 Db 602 CAGACTTTGATCAATTTGTCAGTCTGCATAGAGAGCTATAAGCAGATGATGTGTCGAA 661
 QY 1137 TCTTAAGTGAACCATATTTTCCATAGACATGTTTGACCCATGGCTGTTAAACACA 1196
 Db 662 TTCTCCCTGCAAGCATGTTTTCCAAATCTCGTGGTGGATCCCTGGCTTTAGTGAACATT 721
 QY 1197 AGACTTGGCCCATGTGCAATCTGCATATCTCAAACTCTTGGGAATTTGGAGTTGAGTGT 1254
 Db 722 GTACCTGTCTATGTGCAAACTTATATATTGAAGGCCCTGGGAATTTGCGGAATTT 779

RESULT 2

US-09-090-567-3
 ; Sequence 3, Application US/09090567
 ; Patent No. 5989549
 ; GENERAL INFORMATION:
 ; APPLICANT: Sullivan, Robert
 ; APPLICANT: Brub, Bruno
 ; APPLICANT: Lgar, Christine
 ; APPLICANT: Gaudreault, Christian
 ; TITLE OF INVENTION: Acrosomal Sperm Protein And
 ; NUMBER OF SEQUENCES: 5
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Swabey Ogilvy Renault
 ; STREET: 1600 - 1981 McGill College
 ; CITY: Montreal
 ; STATE: QC
 ; COUNTRY: Canada
 ; ZIP: H3A 2Y3
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Diskette
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: Windows
 ; SOFTWARE: FastSeq for Windows Version 2.0b
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/09/090,567
 ; FILING DATE:
 ; CLASSIFICATION:
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER:
 ; FILING DATE:
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Murphy, Kevin P.
 ; REGISTRATION NUMBER: 26,674
 ; REFERENCE/DOCKET NUMBER: 13045-2"US" FC/CC

; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: 514-845-7126
 ; TELEFAX: 514-288-8389
 ; TELEX:

; INFORMATION FOR SEQ ID NO: 3:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 912 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: cDNA
 ; FEATURE:
 ; US-09-090-567-3

Query Match 4.3%; Score 77; DB 2; Length 912;
 Best Local Similarity 94.1%; Pred. No. 1-le-11;
 Matches 80; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1 AGCTGAGCTCCACCGCGTGGCGCGCTCTAGAACTAGTGGATCCCCCGGGCTGCAGG 60
 Db 7 AGCTGAGCTCCACCGCGTGGCGCGCTCTAGAACTAGTGGATCCCCCGGGCTGCAGG 66
 QY 61 AATTGGCAGCAGCCGAGGAGCTGC 85
 Db 67 AATTGGCAGCAGCCGAGGAGCTGC 91

RESULT 3

US-08-680-395-4
 ; Sequence 4, Application US/08680395
 ; Patent No. 5892010
 ; GENERAL INFORMATION:
 ; APPLICANT: Gray, Joe W.
 ; APPLICANT: Collins, Colin
 ; APPLICANT: Hwang, Soo-in
 ; APPLICANT: Godfrey, Tony
 ; APPLICANT: Kowbel, David
 ; APPLICANT: Rommens, Johanna
 ; TITLE OF INVENTION: Genes from the 20q13 Amplicon and Their
 ; NUMBER OF SEQUENCES: 40
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Townsend and Townsend and Crew LLP
 ; STREET: Two Embarcadero Center, Eighth Floor
 ; CITY: San Francisco
 ; STATE: California
 ; COUNTRY: USA
 ; ZIP: 94111-3834
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: PatentIn Release #1.0, Version #1.30
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/680,395
 ; FILING DATE: 15-JUL-1996
 ; CLASSIFICATION: 435
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Bastian, Kevin L.
 ; REGISTRATION NUMBER: 34,774
 ; REFERENCE/DOCKET NUMBER: 023070-0689000US
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (415) 576-0200
 ; TELEFAX: (415) 576-0300
 ; INFORMATION FOR SEQ ID NO: 4:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 2605 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: cDNA
 ; FEATURE:
 ; NAME/KEY:

LOCATION: 1..2605
OTHER INFORMATION: /note="cdna clone cc43 of 4 kb
transcript"
US-08-680-395-4

Query Match 4.3%; Score 76.4; DB 2; Length 2605;
Best Local Similarity 80.9%; Pred. No. 2.8e-11;
Matches 89; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
QY 1 AGCTGGAGCTCCACCGCGTGGCGCGCTCTAGAACTAGTGGATCCCCCGGCTGCAGG 60
DB 36 AGCTGGAGCTCCACCGCGTGGCGCGCTCTAGAACTAGTGGATCCCCCGGCTGCAGG 95
QY 61 AATTCGGCAGCAGCGGAGGAGTGCATCTCGGCAACTGTGTGCTGACG 110
DB 96 AATTCGGCAGCAGCTGGGCTACTACGATGGCGATGTTTCGAGTGCGCG 145

RESULT 4
US-08-075-533-20
Sequence 20, Application US/08075533
Patent No. 5530186
GENERAL INFORMATION:
APPLICANT: Hitz, William D.
APPLICANT: Yadav, Narendra S.
TITLE OF INVENTION: Nucleotide Sequences of Soybean Acyl-ACP
TITLE OF INVENTION: Thioesterase Genes
NUMBER OF SEQUENCES: 22
CORRESPONDENCE ADDRESS:
ADDRESSEE: E. I. du Pont de Nemours and Company
STREET: 1007 Market Street
CITY: Wilmington
STATE: Delaware
COUNTRY: U.S.A
ZIP: 19898
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/075,533
FILING DATE:
CLASSIFICATION: 800
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/631,264
FILING DATE: 20-DEC-1990
ATTORNEY/AGENT INFORMATION:
NAME: Morrissey, Bruce W.
REGISTRATION NUMBER: 30,663
REFERENCE/DOCKET NUMBER: CR-8926-A
TELECOMMUNICATION INFORMATION:
TELEPHONE: (302) 992-4927
TELEFAX: (302) 892-7949
TELEX: 835420
INFORMATION FOR SEQ ID NO: 20:
SEQUENCE CHARACTERISTICS:
LENGTH: 1378 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
ORIGINAL SOURCE:
ORGANISM: Brassica napus
US-08-075-533-20

Query Match 4.2%; Score 73.8; DB 1; Length 1378;
Best Local Similarity 97.4%; Pred. No. 1.1e-10;
Matches 75; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 AGCTGGAGCTCCACCGCGTGGCGCGCTCTAGAACTAGTGGATCCCCCGGCTGCAGG 60
DB 52 AGCTGGAGCTCCACCGCGTGGCGCGCTCTAGAACTAGTGGATCCCCCGGCTGCAGG 111

QY 61 AATTCGGCAGCAGCGGA 77
DB 112 AATTCGGCAGCAGGA 128

RESULT 5
US-08-948-176-20
Sequence 20, Application US/08948176
Patent No. 5945585
GENERAL INFORMATION:
APPLICANT: Hitz, William D.
APPLICANT: Yadav, Narendra S.
TITLE OF INVENTION: ACYL-ACP THIOESTERASES GENES
TITLE OF INVENTION: AND THEIR USE IN WATERING PLANT
TITLE OF INVENTION: OIL COMPOSITION
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: E. I. du Pont de Nemours and Company
STREET: 1007 Market Street
CITY: Wilmington
STATE: Delaware
COUNTRY: UNITED STATES OF AMERICA
ZIP: 19898
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.50 INCH
COMPUTER: IBM PC COMPATIBLE
OPERATING SYSTEM: MICROSOFT WORD FOR WINDOWS 95
SOFTWARE: MICROSOFT WORD VERSION 7.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/948,176
FILING DATE:
CLASSIFICATION: 800
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/631,264
FILING DATE: DECEMBER 20, 1990
ATTORNEY/AGENT INFORMATION:
NAME: CHRISTENBURY, LYNN M.
REGISTRATION NUMBER: 30,971
REFERENCE/DOCKET NUMBER: CR-8926-C
TELECOMMUNICATION INFORMATION:
TELEPHONE: 302-992-5481
TELEFAX: 302-773-0164
INFORMATION FOR SEQ ID NO: 20:
SEQUENCE CHARACTERISTICS:
LENGTH: 1378 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
ORIGINAL SOURCE:
ORGANISM: Brassica napus
US-08-948-176-20

Query Match 4.2%; Score 73.8; DB 2; Length 1378;
Best Local Similarity 97.4%; Pred. No. 1.1e-10;
Matches 75; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 AGCTGGAGCTCCACCGCGTGGCGCGCTCTAGAACTAGTGGATCCCCCGGCTGCAGG 60
DB 52 AGCTGGAGCTCCACCGCGTGGCGCGCTCTAGAACTAGTGGATCCCCCGGCTGCAGG 111
QY 61 AATTCGGCAGCAGCGGA 77
DB 112 AATTCGGCAGCAGGA 128

RESULT 6
PCT-US91-09160-20
Sequence 20, Application PCT/US9109160
GENERAL INFORMATION:
APPLICANT: Hitz, William D.
APPLICANT: Yadav, Narendra S.

;; TITLE OF INVENTION: Nucleotide Sequences of Soybean Acyl-ACP
;; TITLE OF INVENTION: Thioesterase Genes
;; NUMBER OF SEQUENCES: 22
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: E. I. du Pont de Nemours and Company
;; STREET: 1007 Market Street
;; CITY: Wilmington
;; STATE: Delaware
;; COUNTRY: U.S.A
;; ZIP: 19898
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: PatentIn Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: PCT/US91/09160
;; FILING DATE: 19911216
;; CLASSIFICATION:
;; PRIORITY APPLICATION DATA:
;; APPLICATION NUMBER: US 07/631,264
;; FILING DATE: 20-DEC-1990
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Morrissey, Bruce W.
;; REGISTRATION NUMBER: 30,663
;; REFERENCE/DOCKET NUMBER: CR-8926-A
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (302) 992-4927
;; TELEFAX: (302) 892-7949
;; TELEX: 835420
;; INFORMATION FOR SEQ ID NO: 20:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 1378 base pairs
;; TYPE: NUCLEIC ACID
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (genomic)
;; ORIGINAL SOURCE:
;; ORGANISM: Brassica napus
;; PCT-US91-09160-20

Query Match 4.2%; Score 73.8; DB 5; Length 1378;
Best Local Similarity 97.4%; Pred. No. 1.1e-10;
Matches 75; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 AGCTGGAGCTCCACCGCGTGGCGGCTCTAGAACTAGTGGATCCCCCGGCTGCAGG 60
Db 52 AGCTGGAGCTCCACCGCGTGGCGGCTCTAGAACTAGTGGATCCCCCGGCTGCAGG 111

QY 61 AATTCGGCAGAGCCGA 77
Db 112 AATTCGGCAGAGAGGA 128

RESULT 7
US-09-043-937A-3
; Sequence 3, Application US/09043937A
; Patent No. 6211432
; GENERAL INFORMATION:
; APPLICANT: BOUDET, ALAIN-MICHEL
; PICHON, MAGALIE
; GRIMA-PETTENATI, JACQUELINE
; BECKERT, MICHEL
; GAMAS, PASCAL
; BRIAT, JEAN-FRANCOIS
; TITLE OF INVENTION: DNA SEQUENCES CODING FOR CINNAMOYL-CoA
; REDUCTASE, AND APPLICATIONS THEREOF IN THE CONTROL OF
; LIGNIN CONTENTS IN PLANTS
; NUMBER OF SEQUENCES: 29
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHUYE, P.C.
; STREET: 110 NORTH GLEBE ROAD, 8TH FLOOR
; CITY: ARLINGTON
; STATE: VA
; COUNTRY: USA
; ZIP: 22201
; COMPUTER READABLE FORM:

;; STATE: VA
;; COUNTRY: USA
;; ZIP: 22201
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: PatentIn Release #1.0, Version #1.30
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/043,937A
;; FILING DATE: 24-Jul-1998
;; CLASSIFICATION: <Unknown>
;; PRIORITY APPLICATION DATA:
;; APPLICATION NUMBER: WO PCT/FR96/01544
;; FILING DATE: 03-OCT-1996
;; APPLICATION NUMBER: FR 95.11623
;; FILING DATE: 03-OCT-1995
;; ATTORNEY/AGENT INFORMATION:
;; NAME: SADOFF, B.J.
;; REGISTRATION NUMBER: 36,663
;; REFERENCE/DOCKET NUMBER: 1487-20
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 703-816-4000
;; TELEFAX: 703-816-4100
;; INFORMATION FOR SEQ ID NO: 3:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 1556 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: double
;; TOPOLOGY: linear
;; MOLECULE TYPE: cDNA to mRNA
;; FEATURE:
;; NAME/KEY: CDS
;; LOCATION: 195..1310
;; SEQUENCE DESCRIPTION: SEQ ID NO: 3:
US-09-043-937A-3

Query Match 4.2%; Score 73.8; DB 4; Length 1556;
Best Local Similarity 97.4%; Pred. No. 1.1e-10;
Matches 75; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 AGCTGGAGCTCCACCGCGTGGCGGCTCTAGAACTAGTGGATCCCCCGGCTGCAGG 60
Db 52 AGCTGGAGCTCCACCGCGTGGCGGCTCTAGAACTAGTGGATCCCCCGGCTGCAGG 111

QY 61 AATTCGGCAGAGCCGA 77
Db 112 AATTCGGCAGAGAGGA 128

RESULT 8
US-09-043-937A-1
; Sequence 1, Application US/09043937A
; Patent No. 6211432
; GENERAL INFORMATION:
; APPLICANT: BOUDET, ALAIN-MICHEL
; PICHON, MAGALIE
; GRIMA-PETTENATI, JACQUELINE
; BECKERT, MICHEL
; GAMAS, PASCAL
; BRIAT, JEAN-FRANCOIS
; TITLE OF INVENTION: DNA SEQUENCES CODING FOR CINNAMOYL-CoA
; REDUCTASE, AND APPLICATIONS THEREOF IN THE CONTROL OF
; LIGNIN CONTENTS IN PLANTS
; NUMBER OF SEQUENCES: 29
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHUYE, P.C.
; STREET: 110 NORTH GLEBE ROAD, 8TH FLOOR
; CITY: ARLINGTON
; STATE: VA
; COUNTRY: USA
; ZIP: 22201
; COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/043.937A
FILING DATE: 24-Jul-1998
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: WO PCT/FR96/01544
FILING DATE: 03-OCT-1996
APPLICATION NUMBER: FR 95.11623
FILING DATE: 03-OCT-1995
ATTORNEY/AGENT INFORMATION:
NAME: SADOFF, B.J.
REGISTRATION NUMBER: 36.663
REFERENCE/DOCKET NUMBER: 1487-20
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-816-4000
TELEFAX: 703-816-4100
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 1568 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: cDNA to mRNA
FEATURE:
NAME/KEY: CDS
LOCATION: 278..1306
SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-043-937A-1

Query Match 4.2%; Score 73.8; DB 4; Length 1568;

Best Local Similarity 97.4%; Pred. No. 1.1e-10;
Matches 75; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 AGCTGAGTCCACCGCGTGGCGCGCTCTAGAACTAGTGGATCCCGCGGTGCAGG 60
|||||
DB 47 AGCTGAGTCCACCGCGTGGCGCGCTCTAGAACTAGTGGATCCCGCGGTGCAGG 106
|||||

QY 61 AATTCGGCAGGCGGA 77
|||||

DB 107 AATTCGGCAGGCGGA 123
|||||

RESULT 9

US-09-227-357-26
Sequence 26, Application US/09227357
Patent No. 6342581
GENERAL INFORMATION:
APPLICANT: Fischer et al.
TITLE OF INVENTION: 123 Human Secreted Proteins
FILE REFERENCE: P2010P1
CURRENT APPLICATION NUMBER: US/09/227,357
CURRENT FILING DATE: 1999-01-08
EARLIER APPLICATION NUMBER: PCT/US98/13684
EARLIER FILING DATE: 1998-07-07
EARLIER APPLICATION NUMBER: 60/051,926
EARLIER FILING DATE: 1997-07-08
EARLIER APPLICATION NUMBER: 60/052,793
EARLIER FILING DATE: 1997-07-08
EARLIER APPLICATION NUMBER: 60/051,925
EARLIER FILING DATE: 1997-07-08
EARLIER APPLICATION NUMBER: 60/051,929
EARLIER FILING DATE: 1997-07-08
EARLIER APPLICATION NUMBER: 60/052,803
EARLIER FILING DATE: 1997-07-08
EARLIER APPLICATION NUMBER: 60/052,732
EARLIER FILING DATE: 1997-07-08
EARLIER APPLICATION NUMBER: 60/051,931
EARLIER FILING DATE: 1997-07-08
EARLIER APPLICATION NUMBER: 60/051,932

EARLIER FILING DATE: 1997-07-08
EARLIER APPLICATION NUMBER: 60/051,916
EARLIER FILING DATE: 1997-07-08
EARLIER APPLICATION NUMBER: 60/051,930
EARLIER FILING DATE: 1997-07-08
EARLIER APPLICATION NUMBER: 60/051,918
EARLIER FILING DATE: 1997-07-08
EARLIER APPLICATION NUMBER: 60/051,920
EARLIER FILING DATE: 1997-07-08
EARLIER APPLICATION NUMBER: 60/052,733
EARLIER FILING DATE: 1997-07-08
EARLIER APPLICATION NUMBER: 60/052,795
EARLIER FILING DATE: 1997-07-08
EARLIER APPLICATION NUMBER: 60/051,919
EARLIER FILING DATE: 1997-07-08
EARLIER APPLICATION NUMBER: 60/051,928
EARLIER FILING DATE: 1997-07-08
EARLIER APPLICATION NUMBER: 60/055,722
EARLIER FILING DATE: 1997-08-18
EARLIER APPLICATION NUMBER: 60/055,723
EARLIER FILING DATE: 1997-08-18
EARLIER APPLICATION NUMBER: 60/055,948
EARLIER FILING DATE: 1997-08-18
EARLIER APPLICATION NUMBER: 60/055,949
EARLIER FILING DATE: 1997-08-18
EARLIER APPLICATION NUMBER: 60/055,953
EARLIER FILING DATE: 1997-08-18
EARLIER APPLICATION NUMBER: 60/055,950
EARLIER FILING DATE: 1997-08-18
EARLIER APPLICATION NUMBER: 60/055,947
EARLIER FILING DATE: 1997-08-18
EARLIER APPLICATION NUMBER: 60/055,964
EARLIER FILING DATE: 1997-08-18
EARLIER APPLICATION NUMBER: 60/056,360
EARLIER FILING DATE: 1997-08-18
EARLIER APPLICATION NUMBER: 60/055,684
EARLIER FILING DATE: 1997-08-18
EARLIER APPLICATION NUMBER: 60/055,984
EARLIER FILING DATE: 1997-08-18
EARLIER APPLICATION NUMBER: 60/055,954
EARLIER FILING DATE: 1997-08-18
EARLIER APPLICATION NUMBER: 60/058,785
EARLIER FILING DATE: 1997-09-12
EARLIER APPLICATION NUMBER: 60/058,664
EARLIER FILING DATE: 1997-09-12
EARLIER APPLICATION NUMBER: 60/058,660
EARLIER FILING DATE: 1997-09-12
EARLIER APPLICATION NUMBER: 60/058,661
NUMBER OF SEQ ID NOS: 672
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 26
LENGTH: 1543
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: SITE
LOCATION: (69)
OTHER INFORMATION: n equals a,t,g, or c
FEATURE:
NAME/KEY: SITE
LOCATION: (717)
OTHER INFORMATION: n equals a,t,g, or c
FEATURE:
NAME/KEY: SITE
LOCATION: (899)
OTHER INFORMATION: n equals a,t,g, or c
US-09-227-357-26

Query Match 4.1%; Score 73.2; DB 4; Length 1543;
Best Local Similarity 73.8%; Pred. No. 1.7e-10;
Matches 93; Conservative 0; Mismatches 33; Indels 0; Gaps 0;

QY 11 CCACCGCGTGGCGCCCTCTAGAACTAGTGGATCCCGCGGCTGCAGGAATTCGGCAC 70
Db 99 CCACCGCGTGGCGCCCTCTAGAACTAGTGGATCCCGCGGCTGCAGGAATTCGGCAC 158
QY 71 GAGCGGAGAGTGCATCTGGCGCAACCTGTGTGCTGACGCTACGTGCTCTCTGGCTCCG 130
Db 159 GAGCGGAGAGTGCATCTGGCGCAACCTGTGTGCTGACGCTACGTGCTCTCTGGCTCCG 218
QY 131 ACGTAG 136
Db 219 CCGTTG 224

RESULT 10
US-09-227-357-125
; Sequence 125, Application US/09227357
; Patent No. 6342581
; GENERAL INFORMATION:
; APPLICANT: Fischer et al.
; TITLE OF INVENTION: 123 Human Secreted Proteins
; FILE REFERENCE: PZ010P1
; CURRENT APPLICATION NUMBER: US/09/227,357
; CURRENT FILING DATE: 1999-01-08
; EARLIER APPLICATION NUMBER: PCT/US98/13684
; EARLIER FILING DATE: 1998-07-07
; EARLIER APPLICATION NUMBER: 60/051,926
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/052,793
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/051,925
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/051,929
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/052,803
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/052,732
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/051,931
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/051,932
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/051,916
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/051,930
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/051,918
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/051,920
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/052,733
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/052,795
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/051,919
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/051,928
; EARLIER FILING DATE: 1997-07-08
; EARLIER APPLICATION NUMBER: 60/055,722
; EARLIER FILING DATE: 1997-08-18
; EARLIER APPLICATION NUMBER: 60/055,723
; EARLIER FILING DATE: 1997-08-18
; EARLIER APPLICATION NUMBER: 60/055,948
; EARLIER FILING DATE: 1997-08-18
; EARLIER APPLICATION NUMBER: 60/055,949
; EARLIER FILING DATE: 1997-08-18
; EARLIER APPLICATION NUMBER: 60/055,953
; EARLIER FILING DATE: 1997-08-18
; EARLIER APPLICATION NUMBER: 60/055,950
; EARLIER FILING DATE: 1997-08-18
; EARLIER APPLICATION NUMBER: 60/055,947
; EARLIER FILING DATE: 1997-08-18
; EARLIER APPLICATION NUMBER: 60/055,964
; EARLIER FILING DATE: 1997-08-18

; EARLIER APPLICATION NUMBER: 60/056,360
; EARLIER FILING DATE: 1997-08-18
; EARLIER APPLICATION NUMBER: 60/055,684
; EARLIER FILING DATE: 1997-08-18
; EARLIER APPLICATION NUMBER: 60/055,984
; EARLIER FILING DATE: 1997-08-18
; EARLIER APPLICATION NUMBER: 60/055,954
; EARLIER FILING DATE: 1997-08-18
; EARLIER APPLICATION NUMBER: 60/058,785
; EARLIER FILING DATE: 1997-09-12
; EARLIER APPLICATION NUMBER: 60/058,664
; EARLIER FILING DATE: 1997-09-12
; EARLIER APPLICATION NUMBER: 60/058,660
; EARLIER FILING DATE: 1997-09-12
; EARLIER APPLICATION NUMBER: 60/058,661
; EARLIER FILING DATE: 1997-09-12
; NUMBER OF SEQ ID NOS: 672
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 125
; LENGTH: 545
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (7)
; OTHER INFORMATION: n equals a,t,g, or c
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (16)
; OTHER INFORMATION: n equals a,t,g, or c
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (41)
; OTHER INFORMATION: n equals a,t,g, or c
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (42)
; OTHER INFORMATION: n equals a,t,g, or c
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (87)
; OTHER INFORMATION: n equals a,t,g, or c
US-09-227-357-125
Query Match 4.1%; Score 73; DB 4; Length 545;
Best Local Similarity 100.0%; Pred. No. 1e-10;
Matches 73; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AGCTGGAGCTCCACCGCGTGGCGCGCTCTAGAACTAGTGGATCCCGCGGCTGCAGG 60
Db 117 AGCTGGAGCTCCACCGCGTGGCGCGCTCTAGAACTAGTGGATCCCGCGGCTGCAGG 176
QY 61 AATTCGGCAGG 73
Db 177 AATTCGGCAGG 189
RESULT 11
US-09-183-861-54
; Sequence 54, Application US/09183861
; Patent No. 6365165
; GENERAL INFORMATION:
; APPLICANT: Reed, Steven G.
; APPLICANT: Campos-Neto, Antonio
; APPLICANT: Webb, John R.
; APPLICANT: Dillon, David C.
; APPLICANT: Skeiky, Yasir A.W.
; TITLE OF INVENTION: LEISHMANIA ANTIGENS FOR USE IN THE THERAPY AND
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle

STATE: Washington
COUNTRY: USA
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/183,861
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/022,765
FILING DATE: 12-FEB-1998,
ATTORNEY/AGENT INFORMATION:
NAME: Maki, David J.
REGISTRATION NUMBER: 31,392
REFERENCE/DOCKET NUMBER: 210121.420C3
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 54:
SEQUENCE CHARACTERISTICS:
LENGTH: 1585 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-09-183-861-54

Query Match 4.1%; Score 73; DB 4; Length 1585;
Best Local Similarity 100.0%; Pred. No. 1.9e-10;
Matches 73; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGCTGGAGCTCCACCGGCTGTAGAACTAGTGGATCCCCGGGCTGCAGG 60
|||||
Db 3 AGCTGGAGCTCCACCGGCTGTAGAACTAGTGGATCCCCGGGCTGCAGG 62

Qy 61 AATTCGGCAGG 73
|||||
Db 63 AATTCGGCAGG 75

RESULT 12

US-09-022-765-54
Sequence 54, Application US/09022765
Patent No. 6375955
GENERAL INFORMATION:
APPLICANT: Reed, Steven G.
APPLICANT: Campos-Neto, Antonio
APPLICANT: Webb, John R.
APPLICANT: Dillon, David C.
APPLICANT: Skeiky, Yasir A.W.
TITLE OF INVENTION: LEISHMANIA ANTIGENS FOR USE IN THE THERAPY AND
NUMBER OF SEQUENCES: 87
CORRESPONDENCE ADDRESS:
ADDRESSEE: SEED and BERRY LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/022,765
FILING DATE: 12-FEB-1998
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:

NAME: Maki, David J.
REGISTRATION NUMBER: 31,392
REFERENCE/DOCKET NUMBER: 210121.420C3
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 54:
SEQUENCE CHARACTERISTICS:
LENGTH: 1585 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-09-022-765-54

Query Match 4.1%; Score 73; DB 4; Length 1585;
Best Local Similarity 100.0%; Pred. No. 1.9e-10;
Matches 73; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGCTGGAGCTCCACCGGCTGTAGAACTAGTGGATCCCCGGGCTGCAGG 60
|||||
Db 3 AGCTGGAGCTCCACCGGCTGTAGAACTAGTGGATCCCCGGGCTGCAGG 62

Qy 61 AATTCGGCAGG 73
|||||
Db 63 AATTCGGCAGG 75

RESULT 13

US-08-730-771-1
Sequence 1, Application US/08730771
Patent No. 5780609
GENERAL INFORMATION:
APPLICANT: Marshall, Lisa
APPLICANT: Roehak, Amy
TITLE OF INVENTION: A NOVEL HUMAN B-CELL SURFACE MOLECULE
NUMBER OF SEQUENCES: 1
CORRESPONDENCE ADDRESS:
ADDRESSEE: SmithKline Beecham Corporation
STREET: 709 Swedeland Road
CITY: King of Prussia
STATE: PA
COUNTRY: USA
ZIP: 19406-2799
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA: US/08/730,771
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Han, William T
REGISTRATION NUMBER: 34,344
REFERENCE/DOCKET NUMBER: P50380
TELECOMMUNICATION INFORMATION:
TELEPHONE: 610-270-5219
TELEFAX: 610-270-5090
TELEX:
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 2775 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: NO

FRAGMENT TYPE:
ORIGINAL SOURCE:
US-08-730-771-1

Query Match 4.1%; Score 73; DB 1; Length 2775;
Best Local Similarity 100.0%; Pred. No. 2.6e-10; Indels 0; Gaps 0;
Matches 73; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGCTGGAGCTCCACCGCGGTGGCGCGCTCTAGAACTAGTGGATCCCCCGGCTGCAGG 60
Db 37 AGCTGGAGCTCCACCGCGGTGGCGCGCTCTAGAACTAGTGGATCCCCCGGCTGCAGG 96

Qy 61 AATTCGGCAGG 73
Db 97 AATTCGGCAGG 109

RESULT 14

US-09-060-208-1

; Sequence 1, Application US/09060208
; Patent No. 6221629
; GENERAL INFORMATION:
; APPLICANT: Marshall, Lisa
; APPLICANT: Roshak, Amy
; TITLE OF INVENTION: THE DNA SEQUENCE OF HUMAN RP-105
; NUMBER OF SEQUENCES: 1
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Ratner & Prestia
; STREET: P.O. Box 980
; CITY: Valley Forge
; STATE: PA
; COUNTRY: USA
; ZIP: 19482-0980

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/060,208
; FILING DATE: April 15, 1998
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Prestia, Paul F.
; REGISTRATION NUMBER: 23,031
; REFERENCE/DOCKET NUMBER: P50380-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 610-407-0700
; TELEFAX: 610-407-0701
; TELEX: 846169

; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 2775 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE:
; ORIGINAL SOURCE:
US-09-060-208-1

Query Match 4.1%; Score 73; DB 4; Length 2775;
Best Local Similarity 100.0%; Pred. No. 2.6e-10; Indels 0; Gaps 0;
Matches 73; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGCTGGAGCTCCACCGCGGTGGCGCGCTCTAGAACTAGTGGATCCCCCGGCTGCAGG 60
Db 37 AGCTGGAGCTCCACCGCGGTGGCGCGCTCTAGAACTAGTGGATCCCCCGGCTGCAGG 96

Qy 61 AATTCGGCAGG 73
Db 97 AATTCGGCAGG 109

RESULT 15

US-08-472-934-5

; Sequence 5, Application US/08472934
; Patent No. 5753446
; GENERAL INFORMATION:
; APPLICANT: JOHNSON, GARY L.
; TITLE OF INVENTION: METHOD AND PRODUCT FOR REGULATING CELL
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lahive and Cockfield
; STREET: 60 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02109

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/472,934
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/440,421
; FILING DATE: 15-May-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/354,516
; FILING DATE: 21-FEB-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 5,405,941
; FILING DATE: 15-Apr-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/323,460
; FILING DATE: 14-Oct-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/11690
; FILING DATE: 14-OCT-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/04178
; FILING DATE: 15-APR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Giulio A. Deconti, Jr. Esq.
; REGISTRATION NUMBER: 31,503
; REFERENCE/DOCKET NUMBER: CPI-004DVCP2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 227-7400
; TELEFAX: (617) 227-5941

; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 3089 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 400..2280
US-08-472-934-5

Query Match 4.1%; Score 73; DB 1; Length 3089;
Best Local Similarity 100.0%; Pred. No. 2.8e-10; Indels 0; Gaps 0;
Matches 73; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGCTGGAGCTCCACCGCGGTGGCGCGCTCTAGAACTAGTGGATCCCCCGGCTGCAGG 60
Db 37 AGCTGGAGCTCCACCGCGGTGGCGCGCTCTAGAACTAGTGGATCCCCCGGCTGCAGG 96

Db 11 AGCTGGAGCTCCACCGGCTGGCGCGCTCTAGAACTAGTGGATCCCCCGGCTGCAGG 70
Qy 61 AATTGGCAGGAG 73
Db 71 AATTGGCAGGAG 83

Search completed: April 26, 2003, 02:28:24
Job time : 63 secs

GenCore version 5.1.4.p5.4578
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 26, 2003, 00:56:15 ; Search time 1751 Seconds
(without alignments)
16408.220 Million cell updates/sec

Title: US-09-854-300-7

Perfect score: 1774

Sequence: 1 agctggagctccaccgggt.....ataggcaagttctctctcag 1774

Scoring table: IDENTITY NUC

Gapop 10.0, Gapext 1.0

Searched: 16154066 seqs, 8097743376 residues

Total number of hits satisfying chosen parameters: 32308132

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

```
EST:*
1: em_estba:*
2: em_estham:*
3: em_estin:*
4: em_estmu:*
5: em_estov:*
6: em_estpl:*
7: em_estro:*
8: em_htc:*
9: gb_est1:*
10: gb_est2:*
11: gb_htc:*
12: gb_est3:*
13: gb_est4:*
14: gb_est5:*
15: em_estfun:*
16: em_estom:*
17: gb_ges:*
18: em_ges_hum:*
19: em_ges_inv:*
20: em_ges_pln:*
21: em_ges_vrt:*
22: em_ges_fun:*
23: em_ges_mam:*
24: em_ges_mus:*
25: em_ges_other:*
26: em_ges_pro:*
27: em_ges_rtd:*
```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1205.2	67.9	1921	11 AK018582	AK018582 Mus muscu
2	1202	67.8	2741	11 AK004847	AK004847 Mus muscu
3	836.8	47.2	1954	11 BC030951	BC030951 Homo sapi
4	680.4	38.4	1806	11 BC012931	BC012931 Homo sapi
5	673.8	38.0	811	13 B1600046	B1600046 603251431
6	654.2	36.9	1000	13 B1600419	B1600419 603246458

7	644.2	36.3	676	10 AV690200	AV690200
8	641	36.1	773	13 BK010196	BK010196
9	623.4	35.1	840	11 AK008312	Mus muscu
10	622.8	35.1	1150	13 B1488609	B1488609
11	622.4	35.1	906	12 BG185370	BG185370
12	622.2	35.1	683	10 AV686169	AV686169
13	615.4	34.7	996	12 BG176206	BG176206
14	577	32.5	681	13 B1220592	B1220592
15	564.4	31.8	683	10 AV692456	AV692456
16	542.8	30.6	557	13 BM507037	BM507037
17	537.2	30.3	904	12 BF664617	BF664617
18	531.2	29.9	596	12 BF231341	BF231341
19	524.2	29.5	862	12 BF668554	BF668554
20	515.6	29.1	902	12 BG165006	BG165006
21	513.8	29.0	841	12 BF663559	BF663559
22	509.8	28.7	812	13 B1110345	B1110345
23	502.2	28.3	872	12 BF699229	BF699229
24	499.4	28.2	789	12 BF669635	BF669635
25	496	28.0	879	12 BF666897	BF666897
26	492.4	27.8	759	12 BG400279	BG400279
27	482.4	27.2	774	12 BG432146	BG432146
28	481.6	27.1	841	12 BF666680	BF666680
29	481.6	27.1	847	12 BE958515	BE958515
30	475.6	26.8	804	13 B1653069	B1653069
31	471.8	26.6	856	12 BE958087	BE958087
32	469	26.4	680	10 BE308209	BE308209
33	468.6	26.4	884	12 BF542034	BF542034
34	466.4	26.3	835	12 BE958350	BE958350
35	461.4	26.0	622	12 BF137973	BF137973
36	459.2	25.9	725	13 B1557834	B1557834
37	458.6	25.9	466	12 BF382058	BF382058
38	456.4	25.7	732	12 BF246687	BF246687
39	443.6	25.0	813	13 B1648028	B1648028
40	442.6	24.9	619	13 BG991456	BG991456
41	441.8	24.9	889	12 BG172246	BG172246
42	440	24.8	862	12 BF700761	BF700761
43	435.4	24.5	854	12 BF670202	BF670202
44	431.4	24.3	759	12 BE958295	BE958295
45	427.2	24.1	942	12 BF967109	BF967109

ALIGNMENTS

RESULT 1
AK018582
LOCUS
DEFINITION
AK018582 1921 bp mRNA linear HTC 19-JAN-2002
Mus musculus adult male cecum CDNA, RIKEN full-length enriched library, clone:9130001F19: BRAIN CDNA, CLONE MNCB-3816, SIMILAR TO AF171875 GI-RELATED ZINC FINGER PROTEIN (MUS MUSCULUS), full insert sequence.
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
AK018582
AK018582.1 GI:12858361
HTC; CAP trapper.
Mus musculus (strain: C57BL/6J) adult male cecum CDNA to mRNA, clone lib: RIKEN full-length enriched mouse cDNA library
clone: 9130001F19.
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE
1
Carninci, P. and Hayashizaki, Y.
High-efficiency full-length cDNA cloning
Meth. Enzymol. 303, 19-44 (1999)
99279253
MEDLINE
PUBMED
REFERENCE
2
Carninci, P., Shibata, Y., Hayatsu, N., Sugahara, Y., Shibata, K., Itoh, M., Konno, H., Okazaki, Y., Muramatsu, M. and Hayashizaki, Y.
Normalization and subtraction of cap-trapper-selected cDNAs to prepare full-length cDNA libraries for rapid discovery of new genes
Genome Res. 10 (10), 1617-1630 (2000)
20499374
MEDLINE


```

QY 1392 TGGAGGAACACGTCAGTCAACAAATGAAAGTCTACAGCTGGTAAACCATGAAGCAAAATT 1451
Db 1317 TGGAGGAACATGCGAGTCAGCAATGAAATCTACAGCTGGTAAACCATGAAGCAAAATT 1376
QY 1452 CTGTGGCAGTGGATGTTATTCCTCATGTGACAAACCAACCTTTGAAGAGAGCAAACTC 1511
Db 1377 CTGTGGCAGTGGATGTTATTCCTCATGTGACAAACCAACCTTTGAAGAGAGCAAACTC 1436
QY 1512 CTAATCAAGAGACTGCTGTTGCGAGAAATTAATCTTT-AAAATCTGTTAAATAGAAACT 1570
Db 1437 CTGATCAAGAGGAGCTGTTGCGAGATTAATCTTTAAATCTGTTCAATAGAAACT 1496
QY 1571 TGAACCATTAAG-ATAACACAGAACTGCCAATCAGGCGCTAGTTT-CTATTAATAAATGG 1628
Db 1497 TGAACCGTTAGTTAAACACAGGACTGCCAATCAGGCGCTAGTTTACTATGAATGAATCG 1556
QY 1629 ATAAATTAATAAATAAGAGTGAATCTGAAAGTCTCAGATGACTAAATATTATGCTATA 1688
Db 1557 GTAAA---CGTAAACCAAGAAATGATCTGAAAGTCTGAGGTAACCTTATATTATATA 1613
QY 1689 GTTAAATGCTTTAAATAATTTAACTGTTAACTTTTTCACCAAACTCATTATAATA 1748
Db 1614 GTTAAA--TGCTTAACATATTTACCCAGTACCGTTT--CCAAACTCACCATAACG 1669
QY 1749 TTTTTCATAGGCAAGTTTCCTCT 1771
Db 1670 TTTTTCATAGGCAAGTTTCCTCT 1692

RESULT 3
BC030951 1954 bp mRNA linear HTC 13-JUN-2002
LOCUS Homo sapiens, hypothetical protein FLJ23516, clone IMAGE.4280352,
DEFINITION mRNA.
ACCESSION BC030951
VERSION BC030951.1 GI:21410659
KEYWORDS HTC.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 1954)
Strausberg,R.
Direct Submission
Submitted (03-JUN-2002) National Institutes of Health, Mammalian
Gene Collection (MGC), Cancer Genomics Office, National Cancer
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
USA
NIH-MGC Project URL: http://mgc.nci.nih.gov
Contact: MGC help desk
Email: cgapbs-r@mail.nih.gov
Tissue Procurement: ATCC
cDNA Library Preparation: CLONTECH Laboratories, Inc.
DNA Sequencing Arrayed by: The I.M.A.G.E. Consortium (LLNL)
Center, Stanford University School of Medicine, Stanford, CA 94305
Web site: http://www-bhgc.stanford.edu
Contact: (Dickson, Mark) mcd@paxil.stanford.edu
Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers,
R. M.

Clone distribution: MGC clone distribution information can be found
through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov
Series: IRAL Plate: 41 Row: c Column: 10
This clone was selected for full length sequencing because it
passed the following selection criteria: matched mRNA gi: 13375696
This clone has the following problem: frame shifted.
FEATURES
Location/Qualifiers
1..1954
/organism="Homo sapiens"
/db_xref="LocusID:79589"
/db_xref="taxon:9606"

```

```

/clone="IMAGE:4280352"
/tissue type="Brain, primitive neuroectodermal"
/clone_lib="NIH MGC_56"
/lab_host="DH10B"
/notes="Vector: pDNR-LIB"
BASE COUNT 676 a 294 c 346 g 638 t
ORIGIN

```

```

Query Match 47.2%; Score 836.8; DB 11; Length 1954;
Best Local Similarity 98.7%; Pred. No. 2.3e-185;
Matches 864; Conservative 0; Mismatches 8; Indels 3; Gaps 2;

```

```

QY 900 TGTCTCTTTTATTTATTTACGCGCAACTGTGGGCTATTTATCTTTTATCTGCTCGAA 959
Db 1 TGTCTCTTTTATTTATTTACGCGCAACTGTGGGCTATTTATCTTTTATCTGCTCGAA 60
QY 960 GGCTACGGATGCAAGAGCTCAAGCAGGAAGCAGGCAATTTAAAGCGAGATCTAAAA 1019
Db 61 GGCTACGGATGCAAGAGCTCAAGCAGGAAGCAGGCAATTTAAAGCGAGATCTAAAA 120
QY 1020 AAGCTATTGGAAGGCTTCAACTACGCACACTGAAACAAAGAGACAGGAAATTTGGCCCTG 1079
Db 121 AAGCTATTGGAAGGCTTCAACTACGCACACTGAAACAAAGAGACAGGAAATTTGGCCCTG 180
QY 1080 ATGAGATAGTGTGTGTGTGATGAAATTTATATAACCAAAATGATTTGGTACGCACT 1139
Db 181 ATGAGATAGTGTGTGTGTGATGAAATTTATATAACCAAAATGATTTGGTACGCACT 240
QY 1140 TAACTGTCACCACTATTTCCATAAGACATGTGTTGACCCATGGCTGTTAAGACACAGA 1199
Db 241 TAACTGTCACCACTATTTCCATAAGACATGTGTTGACCCATGGCTGTTAAGACACAGA 300
QY 1200 CTTGCCCATGTGCAAAATGTGACATCTCAAAAGCTTTGGGAATTTAGGTGATTTGAAAG 1259
Db 301 CTTGCCCATGTGCAAAATGTGACATCTCAAAAGCTTTGGGAATTTAGGTGATTTGAAAG 360
QY 1260 ATGATCAGTGTCTTTACAGTCCCTGTATCCAATGAAATATCTAATAGTCCCTCCCTCC 1319
Db 361 ATGATCAGTGTCTTTACAGTCCCTGTATCCAATGAAATATCTAATAGTCCCTCCCTCC 420
QY 1320 ATGAAGAGTAATTCGAGGAGAGACCGCATCATCTGATATGCTTCAGTACAGGGAACAG 1379
Db 421 ATGAAGAGTAATTCGAGGAGAGACCGCATCATCTGATATGCTTCAGTACAGGGAACAG 480
QY 1380 ATGAACCGCTCTTGAGGGAACACGTCGAGTCAACAAATGAAAGTCTACAGCTGGTAAACC 1439
Db 481 ATGAACCGCTCTTGAGGGAACACGTCGAGTCAACAAATGAAAGTCTACAGCTGGTAAACC 540
QY 1440 ATGAAGCAAAATCTGTGGCAGTGGATGTTATCTCATGTGACAAACCAACCTTTGAG 1499
Db 541 ATGAAGCAAAATCTGTGGCAGTGGATGTTATCTCATGTGACAAACCAACCTTTGAG 600
QY 1500 AAGACGAACTCTTAATCAAGAGACTGCTGTTGAGGAAATTTAAATCTTAAATCTGTGTA 1559
Db 601 AAGACGAACTCTTAATCAAGAGACTGCTGTTGAGGAAATTTAAATCTTAAATCTGTGTA 660
QY 1560 AATGAAAACTTGAAACCAATAGTAATAACGAACTGCCAATCAGGCGCTAGTTCTATTA 1619
Db 661 AATGAAAACTTGAAACCAATAGTAATAACGAACTGCCAATCAGGCGCTAGTTCTATTA 720
QY 1620 ATAAATTCGATTAATTTTAAATAATAGAGTGATCTGATGATGCTCAGATGACTAATAT 1679
Db 721 ATAAATTCGATTAATTTTAAATAATAGAGTGATCTGATGATGCTCAGATGACTAATAT 780
QY 1680 TATGCTATAGTTAAATGGCTTAAAAATATTTAACTGTTAACTTTTTTCCACCAAACTC 1739
Db 781 TATGCTATAGTTAAA--TGGCTTAAAAATTTAACTGTTAACTTTTTTCCA-CAAACTC 837
QY 1740 ATTATAATTTTTCATAGGCAAGTTTCCTCTCAG 1774
Db 838 ATTATAATTTTTCATAGGCAAGTTTCCTCTCAG 872

```


for full-length clones and constructed using the
Cap-trapper method (Carninci, in preparation). Library
constructed by M. Brownstein (NIMH/NHGRI, National
Institutes of Health). Note: this is a NIH_MGC Library."

BASE COUNT 153 a 244 c 264 g 150 t

ORIGIN

Query Match 38.0%; Score 673.8; DB 13; Length 811;
Best Local Similarity 94.2%; Pred. No. 3.3e-147;
Matches 745; Conservative 0; Mismatches 37; Indels 9; Gaps 4;

Qy 74 CCGAGAGCTGATCTGGGCAACCTGTGTGCTGACGTACGTGCTCTGCTCCGACG 133
Db 22 CCGAGAGCTGATCTGGGCAACCTGTGTGCTGACGTACGTGCTCTGCTCCGACG 81
Qy 134 TAGCTCGCAGCTCCCGAGTCTCACTCCATTCTCTCCACCTGGCGGCACTGCTCAAG 193
Db 82 TAGCTCGCAGCTCCCGAGTCTCACTCCATTCTCTCCACCTGGCGGCACTGCTCAAG 141
Qy 194 ACCAGGTCCTGCCAAGCGCTAGGAGGCGGTGCGGCGGCGCTAGGGAACCTCGGAGC 253
Db 142 ACCA-GGTCTGCCAAGCGCTAGGAGGCGGTGCGGCGGCGCTAGGGAACCTCGGAGC 200
Qy 254 GCGCGGCGATGGGCGCGCGCTGCGGCGGCGGTCTCTCGCGGCGGTGCGGCTTT 313
Db 201 GCGCGGCGATGGGCGCGCGCTGCGGCGGCGGTCTCTCGCGGCGGTGCGGCTTT 260
Qy 314 TCCAGATTGCTGGCATGTGTCTCTGCTGGCCCTGAGTCCGCGAGGCAACCGGTTCCCGG 373
Db 261 TCCAGATTGCTGGCATGTGTCTCTGCTGGCCCTGAGTCCGCGAGGCAACCGGTTACCGG 320
Qy 374 GGGGCTGAAGAGTGTGAGCCGCTACCTCAACGTGTCTGCGCGGCTTCCGACACGGGA 433
Db 321 GGGGCTGAAGAGTGTGAGCCGCTACCTCAACGTGTCTGCGCGGCTTCCGACACGGGA 380
Qy 434 GTAAACCGTACCGTGTGGAGCTGAGCAGGAGGCGGTGTACGGCAGGACTCGCGCGTG 493
Db 381 GTAAACCGTACCGTGTGGAGCTGAGCAGGAGGCGGTGTACGGCAGGACTCGCGCGTG 440
Qy 494 GAGCCTGTGGTGGGTCTGTGTACCGCGGCGGCGGCGGCGCTTAAACGCTGTAAAC 553
Db 441 GAGCCTGTGGTGGGTCTGTGTACCGCGGCGGCGGCGGCGCTTAAACGCTGTAAAC 500
Qy 554 CCGCACCAAAATTCACGGTCCACCGTTTGGGAGACACCGTCTCAAGTCTCTGGTGTG 613
Db 501 CCGCACCAAAATTCACGGTCCACCGTTTGGGAGACACCGTCTCAAGTCTCTGGTGTG 560
Qy 614 GCCTCATCAACCGCGGGGCTGCACCTTTCGAGCAAGATCCATCTGGCTTATGAG 673
Db 561 GCCTCATCAACCGCGGGGCTGCACCTTTCGAGCAAGATCCATCTGGCTTATGAG 620
Qy 674 AGATGGGCTGTGAGCGCTCATCTTTAA--CTTCCCGGAGCCCGCAATGAG----GTC 727
Db 621 AGAGGGGCGTCTGAGCGCTCATCTTTAAACTGTCTCCCGGAGCGCGCAATGAGTCAAT 680
Qy 728 ATCCCATGTCTCACCGGCTGAGTGTGAGTGTGTTGCAATC-ATGATCGGCAATCTGA 785
Db 681 CCCCCATTGTCTCACCGGCTGAGTGTGAGTGTGTTGCAATTCATGAATTCGCAATCTG 740
Qy 786 AAGGCAAAAAATTTGCAATCTATTCAAGAGGCAATCAAGTGAATATGTTGATAGAG 845
Db 741 AAGGCAAAAAATTTGCAATCTATTCAAGAGGCAATCAAGTGAATATGTTGATAGAG 800
Qy 846 TAGGGAAAAA 856
Db 801 GTAGGGAAAAA 811

RESULT 6

BI600419

LOCUS

DEFINITION

603246458F1 NIH_MGC_96 Homo sapiens cDNA clone IMAGE:5288774 5',
mRNA sequence.

ACCESSION

BI600419 GI:15493358

VERSION

EST.

KEYWORDS

human.

SOURCE

ORGANISM

Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

NIH-MGC http://mgi.nci.nih.gov/.

National Institutes of Health, Mammalian Gene Collection (MGC)

Unpublished (1999)

Contact: Robert Strausberg, Ph.D.

Email: c9pbbs@mail.nih.gov

Tissue Procurement: Miklos Palkovits, M.D., Ph.D.

cDNA Library Preparation: Michael J. Brownstein (NHGRI), Shiraki

Toshiyuki and Piero Carninci (RIKEN)

cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)

DNA Sequencing by: Incyte Genomics, Inc.

Clone distribution: MGC clone distribution information can be

found through the I.M.A.G.E. Consortium/LLNL at:

http://image.llnl.gov

Plate: LLAM11730 row: c column: 15

High quality sequence stop: 701.

Location/Qualifiers

1..1000

/organism="Homo sapiens"

/db_xref="taxon:9606"

/clone="IMAGE:5288774"

/clone_lib="NIH_MGC_96"

/tissue_type="hypothalamus"

/lab_host="DH10B"

/note="organ: brain; Vector: pBluescriptR (modified

pBluescript KS+); Site1: BamHI; Site 2: SalI-XhoI (gtcgag

size-selected for average insert size 2.3 kb and

normalized to ROT 5. This is a primary library enriched

for full-length clones and constructed using the

Cap-trapper method (Carninci, in preparation). Library

constructed by M. Brownstein (NIMH/NHGRI, National

Institutes of Health). Note: this is a NIH_MGC Library."

BASE COUNT 206 a 299 c 321 g 174 t

ORIGIN

Query Match 36.9%; Score 654.2; DB 13; Length 1000;

Best Local Similarity 93.7%; Pred. No. 1.3e-142;

Matches 747; Conservative 0; Mismatches 43; Indels 7; Gaps 6;

Qy 74 CCGAGAGCTGATCTGGGCAACCTGTGTGCTGACGTACGTGCTCTGCTCCGACG 133
Db 22 CCGAGAGCTGATCTGGGCAACCTGTGTGCTGACGTACGTGCTCTGCTCCGACG 81
Qy 134 TAGCTCGCAGCTCCCGAGTCTCACTCCATTCTCTCCACCTGGCGGCACTGCTCAAG 193
Db 82 TAGCTCGCAGCTCCCGAGTCTCACTCCATTCTCTCCACCTGGCGGCACTGCTCAAG 141
Qy 194 ACCAGGTCCTGCCAAGCGCTAGGAGGCGGTGCGGCGGCGCTAGGGAACCTCGGAGC 253
Db 142 ACCA-GGTCTGCCAAGCGCTAGGAGGCGGTGCGGCGGCGCTAGGGAACCTCGGAGC 199
Qy 254 GCGCGGCGATGGGCGCGCGCTGCGGCGGCGGTCTCTGCGCGGCTGCTGCGGCTTT 313
Db 200 GCGCGGCGATGGGCGCGCGCTGCGGCGGCGGTCTCTGCGCGGCTGCTGCGGCTTT 259
Qy 314 TCCAGATTGCTGGCATGTGTCTCTGCTGGCCCTGAGTCCGAGGCAACCGGTTCCCGG 373
Db 260 TCCAGATTGCTGGCATGTGTCTCTGCTGGCCCTGAGTCCGAGGCAACCGGTTCCCGG 319
Qy 374 GGGGCTGAAGAGTGTGAGCCGCTACCTCAACGTGTCTCTGGCGGTTCCGACACGGGA 433
Db 320 GGGGCTGAAGAGTGTGAGCCGCTACCTCAACGTGTCTCTGGCGGTTCCGACACGGGA 379
Qy 434 GTGAACCGTACCGTGTGGAGCTGAGCAGGAGGCGGTGTACGCGCAGGACTCGCGCTG 493

Db 380 GTGAACCGTACGGTCTGGAGCTGAGCGAGGAGGCGGTGTACGGCAGGACTCGCCGCTG 439
 Qy 494 GAGCTGTGGCTGGGGTCTGTGTACCGCCGACCGGGCCGGGGCGCTTAAGCCTGTAAAC 553
 Db 440 GAGCCTGTGGCTGGGGTCTGTGTACCGCCGACCGGGCCGGGGCGCTTAAGCCTGTAAAC 499
 Qy 554 CCGCACAGCAATTTTACCGGTGCCCCACCGGTTTGGGGAAGCACCGGTGCAAGTCTCTTGG-TT 612
 Db 500 CCGCACAGCAATTTTACCGGTGCCCCACCGATTTGGGGAAGCACCGGTGCAAGTCTCTTGGTTT 559
 Qy 613 GGCCTCATTCMAACCGCGGGGGGGTGC-ACCTTCGCGAGCAAGATCATCTGGCTTATG 671
 Db 560 GGCCTCATTCMAACCGCGGGGGGGTGCACCTTCGCGAGCAAGATCATCTGGCTTATG 619
 Qy 672 AGAGATGGGCGTCTCGAGCGGTCACTTTTAACTTCCCGGAGCCGCGCAATGAGTCAATCC 731
 Db 620 AGAGAGGGGGTCTCGAGCGGTCACTTTTAACTTCCCGGAGCCGCGCAATGAGTCAAT-C 678
 Qy 732 CCATGTCTACCGCGGTGCAAGTGTGAGATTTTGAATCATGATCGGCAATCTGAAGGCA 791
 Db 679 CCATGTCTACCGCGGTGCAAGTGTGAGATTTTGAATCATGATCGGCGCCATCTGAAGGG 738
 Qy 792 CAAAATCTGCAATCTATTCAAGAGGCATACAGTCAATGTCATAGATAGGGA 851
 Db 739 CAAAATCTGCAATCTATTCAAGAG--CATACAGTGACCACCTGGTCTAGAAGTCGGGA 796
 Qy 852 AAAAAACATGGCCCTTGG 868
 Db 797 ACAACATGGCTGGGG 813

 RESULT 7
 AV690200
 LOCUS AV690200 GK Homo sapiens cDNA clone GKCA02 5', mRNA sequence.
 DEFINITION AV690200
 ACCESSION AV690200
 VERSION AV690200.1 GI:10292063
 KEYWORDS EST.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 1 (bases 1 to 676)
 Xu.X., Huang,J., Xu.Z., Qian,B., Zhu,Z., Yan,Q., Cai,T., Zhang,X.,
 Xiao,H., Qu,J., Liu,F., Huang,Q., Cheng,Z., Li,N., Du,J., Hu,W.,
 Shen,K., Lu,G., Fu,G., Zhong,M., Xu,S., Gu,W., Huang,W., Zhao,X.,
 Hu,G., Gu,J., Chen,Z. and Han,Z.
 Insight into hepatocellular carcinogenesis at transcriptome level
 by comparing gene expression profiles of hepatocellular carcinoma
 with those of corresponding noncancerous liver
 Proc. Natl. Acad. Sci. U.S.A. 98 (26), 15089-15094 (2001)
 21625106
 Contact: Zeguang Han
 Chinese National Human Genome Center at Shanghai
 351 Guo Shoujing Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai
 201203, P. R. China
 Tel: 86-21-50801919(ex.45)
 Fax: 86-21-50801922
 Email: hanzg@chgc.sh.cn
 This clone is available at CHGC in Shanghai.
 Location/Qualifiers
 1..676
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="GKCA02"
 /tissue="hepatocellular carcinoma"
 /dev_stage="Adult"
 /lab_host="SOLR"
 /note="Vector: pBluescript sk(-); Site_1: EcoRI; Site_2:
 XhoI"

BASE COUNT 94 a 223 c 231 g 125 t 3 others
 ORIGIN

Query Match 36.3%; Score 644.2; DB 10; Length 676;
 Best Local Similarity 98.1%; Pred. No. 2.8e-140;
 Matches 661; Conservative 0; Mismatches 11; Indels 2; Gaps 1;

Qy 74 CCGAGGAGCTGATCTGGCGCAACCTGTGTGTGCTGACGCTAGTGCTCTCTGGCTCCGACG 133
 Db 4 CCGAGGAGCTGATCTGGCGCAACCTGTGTGTGCTGACGCTAGTGCTCTCTGGCTCCGACG 63
 Qy 134 TAGCTCGAGCTCCCACTGCTCACTCCATTTCTTCCACCTGGCGCGCACTGCTCAAG 193
 Db 64 TAGCTCGAGCTCCCACTGCTCACTCCATTTCTTCCACCTGGCGCGCACTGCTCAAG 123
 Qy 194 ACCAGGGTCTCTCCAAAGCGCTAGGAGGGCGCTGTCAGGGGCGCTAGGGAATCGCGGAGC 253
 Db 124 ACCAGGGTCTCTCCAAAGCGCTAGGAGGGCGCTGTCAGGGGCGCTAGGGAATCGCGGAGC 183
 Qy 254 GCGCGGCCATGGGGCGCGCTGGGGCGGGGTCTCTGCGCGGTGGTGGCTT 313
 Db 184 GCGCGGCCATGGGGCGCGCTGGGGCGGGGTCTCTGCGCGGTGGTGGCTT 243
 Qy 314 TCCAGATTCTGTCGATGGTGTCTTCTGTCGCGCTGAGTCCGCGAGCGACCCGGTTCCCGG 373
 Db 244 TCCAGATTCTGTCGATGGTGTCTTCTGTCGCGCTGAGTCCGCGAGCGACCCGGTTCCCGG 303
 Qy 374 GGGGCTGAAGACGAGTGTGGACCGCGTACCTCAACGTGTCTGCGGGTTCGCGACGCGGA 433
 Db 304 GGGGCTGAAGACGAGTGTGGACCGCGTACCTCAACGTGTCTGCGGGTTCGCGACGCGGA 363
 Qy 434 GTGAACCGTACGGTGTGGAGCTGAGCGAGGAGGGGTGTACGGCGAGGACTCGCGGCTG 493
 Db 364 GTGAACCGTACGGTGTGGAGCTGAGCGAGGAGGGGTGTACGGCGAGGACTCGCGGCTG 423
 Qy 494 GAGCCTGTGGCTGGGTCTCTGCTACCGCCGAGCGGGCGGCTTAAACGCTGTAAAC 553
 Db 424 GAGCCTGTGGCTGGGTCTCTGCTACCGCCGAGCGGGCGGCTTAAACGCTGTAAAC 483
 Qy 554 CCGCACAGCAATTTACGGTGTGCGCGCGGTGGGGAAGCACCGTGTCAAGTCTCTGGTGTG 613
 Db 484 CCGCACAGCAATTTACGGTGTGCGCGCGGTGGGGAAGCACCGTGTCAAGTCTCTGGTGTG 543
 Qy 614 GCCTCATCAACCGCGGGGGCTGCACTTTCGAGACAAAGATCCATCTGGCTTATGAG 673
 Db 544 GCCTCATCAACCGCGGGGGCTGCACTTTCGAGACAAAGATCCATCTGGCTTATGAG 603
 Qy 674 AGATGGCGCTGTGGAGCGCTCATCTTTAACTTCCCGGAGCCGCAATGAGTCAATCCCC 733
 Db 604 AGAGGGCGCTGTGGAGCGCTCATCTTTTCTTCCCGGAGCCCGCATGAGTCAATNCCC 661
 Qy 734 ATGTCTACCCGGG 747
 Db 662 ATGTCTACCCGGG 675

RESULT 8
 BI601096
 LOCUS BI601096
 DEFINITION BI601096 NIH_MGC_96 Homo sapiens cDNA clone IMAGE:530380 5', mRNA sequence.
 ACCESSION BI601096
 VERSION BI601096.1 GI:15494035
 KEYWORDS EST.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 1 (bases 1 to 773)
 NIH-MGC http://img.nci.nih.gov/.
 TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
 JOURNAL Unpublished (1999)
 COMMENT Contact: Robert Strausberg, Ph.D.
 Email: cgabbs-r@mail.nih.gov
 Tissue Procurement: Miklos Palkovits, M.D., Ph.D.

cDNA Library Preparation: Michael J. Brownstein (NHGRI), Shiraki Toshiyuki and Piero Carninci (RIKEN)
 cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
 DNA Sequencing by: Incyte Genomics, Inc.
 Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at:
<http://image.llnl.gov>
 Plate: LLAM11762 row: p column: 21
 High quality sequence stop: 759.

Location/Qualifiers
 1. 773

FEATURES

source
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="IMAGE:5301380"
 /clone_lib="NIH MGC 96"
 /tissue_type="hypothalamus"
 /lab_host="DH10B"
 /note="Organ: brain; Vector: pBluescriptR (modified pBluescript KS+); Site 1: BamHI; Site 2: SalI-XhoI (gtcgag); Oligo-dT primed using primer 5'-TTTTTTTTTTTTTTVN-3', size-selected for average insert size 2.3 kb and normalized to ROT 5. This is a primary library enriched for full-length clones and constructed using the Cap-trapper method (Carninci, in preparation). Library constructed by M. Brownstein (NHGRI, National Institutes of Health). Note: this is a NIH MGC library."
 BASE COUNT 130 a 242 c 254 g 146 t 1 others
 ORIGIN

Query Match 36.1%; Score 641; DB 13; Length 773;
 Best Local Similarity 96.3%; Pred. No. 1.6e-139;
 Matches 720; Conservative 0; Mismatches 21; Indels 7; Gaps 6;
 Qy 74 CCGAGGAGCTCATCTGGGCAACCTGTGTGCTGACGCTACGTCCTCTGGTCCGAGC 133
 Db 22 CCGAGGAGCTCATCTGGGCAACCTGTGTGCTGACGCTACGTCCTCTGGTCCGAGC 81
 Qy 134 TAGCTCGAGCTCCCGAGTCTCACTCCATTCTTCCGACCTGCGCGGACCTGCTCAAG 193
 Db 82 TAGCTCGAGCTCCCGAGTCTCACTCCATTCTTCCGACCTGCGCGGACCTGCTCAAG 141
 Qy 194 ACCAGGCTCTGCAAGCGCTAGGAGGCGGCTGCGGCGGCGCTAGGAACTGCGGAGC 253
 Db 142 ACCAGGCTCTGCAAGCGCTAGGAGGCGGCTGCGGCGGCGCTAGGAACTGCGGAGC 200
 Qy 254 GCGCGCGCATGGGCGCGCCCTGGGCGCGGGTCTCTGCGCGCGGTGGCTGGCGTTT 313
 Db 201 GCGCGCGCATGGGCGCGCCCTGGGCGCGGGTCTCTGCGCGCGGTGGCTGGCGTTT 260
 Qy 314 TCCAGATTGCTGGCATGTGTCTGCTGCGCCTGAGTCGCGAGGACCGCGTTCGCGG 373
 Db 261 TCCAGATTGCTGGCATGTGTCTGCTGCGCCTGAGTCGCGAGGACCGCGTTCGCGG 320
 Qy 374 GGGGCTGAAGCAGTGTGACCGCGTACCTCAACGCTGCTCTGCGGGTTCGCGACACGGGA 433
 Db 321 GGGGCTGAAGCAGTGTGACCGCGTACCTCAACGCTGCTCTGCGGGTTCGCGACACGGGA 380
 Qy 434 GTGAACCGTAGCGTGTGGAGCTGAGCGAGGCGGTGTACGCGCAGGACTCGCGCGTG 493
 Db 381 GTGAACCGTAGCGTGTGGAGCTGAGCGAGGCGGTGTACGCGCAGGACTCGCGCGTG 440
 Qy 494 GAGCCTGTGGTGGGCTCTGTGTACCGCGGCGGCGGCGGCTTAACGCGCTGTAAAC 553
 Db 441 GAGCCTGTGGTGGGCTCTGTGTACCGCGGCGGCGGCGGCTTAACGCGCTGTAAAC 500
 Qy 554 CGGCACACGAATTTTAC -GGTGGCCACCGGTTTGGGGAAGC -ACCGTGAAGTCTCTTGG - 610
 Db 501 CGGCACACGAATTTTACCGGCTTCCACCGANTTTGGGAGAGCAACCGTGAAGTCTCTTGGT 560
 Qy 611 TTGGGCGCTCATCCAAACGGCGGGGGCTGACCTTCGCGAGACAGATCCATCTCGGCTTAT 670
 Db 561 TTGGGCGCTCATCCAAACGGCGGGGGCTGACCTTCGCGAGACAGATCCATCTCGGCTTAT 620

Qy 671 GAGAGATGGCGTCTGGAGCGCTCATCTTTAACTTCCCGGACCC--GCAATGAGGTCA 728
 Db 621 GAGAGATGGCGTCTGGAGCGCTCATCTTTAACTTCCCGGACCCCGCAATGAGGTCA 680
 Qy 729 TCCCATGTCTCACCCGGGTGAGTACATTT-GTTGCAATCATGCGCAATCTGAAA 787
 Db 681 TCCCATGTCTCACCCGGGTGAGTACATTTGTTGCAATCATGCGCAATCTGCA 740
 Qy 788 GGCACAAAAATTTCTGCAATCTATTCAA 815
 Db 741 AGGCCAAAAATTTCTGCAATCTATTCCAA 768
 RESULT 9
 AK008312
 LOCUS
 DEFINITION
 Mus musculus adult male small intestine cDNA, RIKEN full-length enriched library, clone:2010104G21.BRAIN CDNA, CLONE MNCB-3816, SIMILAR TO AFI71875 GI-RELATED ZINC FINGER PROTEIN (MUS MUSCULUS), full insert sequence.
 AK008312
 AK008312.1 GI:12842420
 VERSION
 HTCC; CAP trapper.
 KEYWORDS
 Mus musculus (strain: C57BL/6J) adult male small intestine cDNA to mRNA, clone: lib:RIKEN full-length enriched mouse cDNA library clone:2010104G21.
 SOURCE
 Mus musculus
 ORGANISM
 Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
 1
 Carninci, P. and Hayashizaki, Y.
 High-efficiency full-length cDNA cloning
 Meth. Enzymol. 303, 19-44 (1999)
 99279253
 MEDLINE
 10349636
 PUBMED
 2
 Carninci, P., Shibata, Y., Hayatsu, N., Sugahara, Y., Shibata, K., Itoh, M., Konno, H., Okazaki, Y., Muramatsu, M. and Hayashizaki, Y.
 Normalization and subtraction of cap-trapper-selected cDNAs to prepare full-length cDNA libraries for rapid discovery of new genes
 Genome Res. 10 (10), 1617-1630 (2000)
 21499374
 JOURNAL
 11042159
 MEDLINE
 3
 Shibata, K., Itoh, M., Aizawa, K., Nagaoka, S., Sasaki, N., Carninci, P., Konno, H., Akiyama, J., Nishi, K., Kitsuai, T., Tashiro, H., Itoh, M., Sumi, N., Ishii, Y., Nakamura, S., Hazama, M., Nishino, T., Harada, A., Yamamoto, R., Matsumoto, H., Sakaguchi, S., Ikegami, T., Kashiwagi, K., Fujiwara, S., Inoue, K., Togawa, Y., Izawa, M., Ohara, E., Watahiki, M., Yoneda, Y., Ishikawa, T., Ozawa, K., Tanaka, T., Matsura, S., Kawai, J., Okazaki, Y., Muramatsu, M., Inoue, Y., Kira, A., and Hayashizaki, Y.
 RIKEN integrated sequence analysis (RISA) system--384-format
 sequencing pipeline with 384 multicapillary sequencer
 Genome Res. 10 (11), 1757-1771 (2000)
 20530913
 JOURNAL
 11076861
 MEDLINE
 4
 Kawai, J., Shinagawa, A., Shibata, K., Yoshino, M., Itoh, M., Ishii, Y., Arakawa, K., Hara, A., Fukunishi, Y., Konno, H., Adachi, J., Fukuda, S., Aizawa, K., Izawa, M., Nishi, K., Kiyosawa, H., Kondo, S., Yamanaka, I., Saito, T., Okazaki, Y., Gojobori, T., Bono, H., Kasukawa, T., Saito, R., Kadota, K., Matsuda, H., Ashburner, M., Batalov, S., Casavant, T., Fleischmann, W., Gaasterland, T., Gissi, C., King, B., Kochiwa, H., Kuenli, P., Lewis, S., Matsuo, Y., Nikaado, I., Pesole, G., Quackenbush, J., Schriml, L. M., Staali, F., Suzuki, R., Tomita, M., Wagner, L., Washio, T., Sakai, K., Okido, T., Furuno, M., Aono, H., Balderelli, R., Barsh, G., Blake, J., Boffelli, D., Bojunga, N., Carninci, P., de Bonaldo, M. F., Brownstein, M. J., Bult, C., Fletcher, C., Fujita, M., Gariboldi, M., Gustincich, S., Hill, D., Hofmann, M., Hume, D. A., Kamiya, M., Lee, N. H., Lyons, P., Marchionni, L., Mashima, J., Mazzarelli, J., Mombarts, P., Nordone, P., Ring, B., Ringwald, M., Rodriguez, I., Sakamoto, N., Sasaki, H., Sato, K., Schonbach, C., Seta, T., Shibata, Y., Storch, K. F., Suzuki, H.,

source

1. 1150
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:5191785"
/clone_lib="NIH_MGC_114"
/lab_host="DH10B"

/note="Organ: brain; Vector: pCMV-SPORT6; Site_1: NotI;
Site_2: EcoRV (destroyed); RNA source anonymous pool of 6
male brains, age range 23-27 yo. Library is oligo-dT
primed and directionally cloned (EcoRV site is destroyed
upon cloning). Average insert size 1.5 kb. Insert size
range 1-3 kb. Library is normalized and enriched for
full-length clones and was constructed by C. Gruber
(Invitrogen). Research Genetics tracking code 019. Note:
this is a NIH_MGC Library."

BASE COUNT 264 a 315 c 336 g 235 t

ORIGIN

Query Match 35.1%; Score 622.8; DB 13; Length 1150;
Best Local Similarity 95.8%; Pred. No. 3.1e-135;
Matches 747; Conservative 0; Mismatches 22; Indels 11; Gaps 10;

QY 174 CTGGCGCCACCTGCTCAAGACACAGGCTCTGCGCAAGCGCTAGGAGCGCGCTGCCAGGG 233
DB |||||
QY 1 CTGGCGCCACCTGCTCAAGACCA-GTCTCTGCCAAGCGCTAGGAGCGCGCTGCCA-GG 58
DB |||||

QY 234 GCGCTAGGAACTCGGAGAGCGCGCGCATGAGGCGCGCCCTGGGGCGGGGTCTCCT 293
DB |||||

QY 59 GCGCTAGGAACTCGGAGAGCGCGCGCATGAGGCGCGCCCTGGGGCGGGGTCTCCT 118
DB |||||

QY 294 GCGCGGTGGTGGGCTTTTCCAGATTGCTGCGCATGCTGCTTCTGCTGGCCCTGATC 353
DB |||||

QY 119 GCGCGGTGGTGGGCTTTTCCAGATTGCTGCGCATGCTGCTTCTGCTGGCCCTGATC 178
DB |||||

QY 354 GCGAGCCACCGGTTTCCCG-GGGGGCTGAAGCAGTGTGAGCGCGGTACCTCAAGCTGCC 412
DB |||||

QY 179 GCGAGCCACCGGTTTCCCGTGGGGCTGAAGCAGTGTGAGCGCGGTACCTCAAGCTGCC 238
DB |||||

QY 413 TGGCGGGTTTCGCACACGGGAGTGAAACCGTTCGTTGGGAGCTGAGCGAGGGGGT 472
DB |||||

QY 239 TGGCGGGTTTCGCACACGGGAGTGAAACCGTTCGTTGGGAGCTGAGCGAGGGGGT 298
DB |||||

QY 473 TACGCCAGGACTCGCCCTCGAGCTCTGCTGGGGTCTGCTGACCGCGCGGCGCC 532
DB |||||

QY 299 TACGCCAGGACTCGCCCTCGAGCTCTGCTGGGGTCTGCTGACCGCGCGGCGCC 358
DB |||||

QY 533 GGGCGCTTAAC-GCCTGTAAACCGCACACGAAATTTACGCTGCCACGGTTTGGGAAG 591
DB |||||

QY 359 GGGCGCTTAACGCTGTAAACCGCACACGAAATTTACGCTGCCACGGTTTGGGAAG 418
DB |||||

QY 592 CACCGTGAAGTCTCTTGGTTGGCCCTCATCAAGCGCGCGGGGCTGCACCTTCGAGA 651
DB |||||

QY 419 CACCGTGAAGTCTCTTGGTTGGCCCTCATCAAGCGCGCGGGGCTGCACCTTCGAGA 478
DB |||||

QY 652 C-AAGATCATCTGCTTATGAGAGTGGGGCTCTGAGCGCTCATCTTTAACTTCCCG 710
DB |||||

QY 479 CGAAGTCCATCTGCTTATGAGAGAGGGGCTCTGAGCGCTCATCTTTAACTTCCCG 538
DB |||||

QY 711 GGACCGCAATGAGGTCTATCCCATGTCTCAACCGGGTGCAGTAGACATTTGCAATCA 770
DB |||||

QY 539 GGACCGCAATGAGGTCTATCCCATGTCTCAACCGGGTGCAGTAGACATTTGCAATCA 598
DB |||||

QY 771 TGATCGGCAATCTGAAGGCAAC-AAATTTCTGCAATCTATTCAAGAGGCATCAAGTG 829
DB |||||

QY 599 TGATCGGCAATCTGAAGGCAACAAATTTCTGCAATCTATTCAAGAGGCATCAAGTG 658
DB |||||

QY 830 ACAATGGTCAAGAGTA-GGGAAGAAACATGGCCCTTTGGGTGATC-ACTATTCAATTT 887
DB |||||

QY 659 ACAATGGTCAAGAGTACGGGAAAGAAACATGGCCCTTTCGGGTGAATCAATATTCAATA 718
DB |||||

QY 888 TTTTCGTTTC--TGTTGCTTTTATTTA-TTACGGCGGCAACTGTGGGCTATTTTATCT 944
DB |||||

QY 719 TTTTCGTAACCTGGTGTCTTTTCCCATTTACTTTACGGCGGCAACTTTGTGCGCTATTGTAT 778
DB |||||

RESULT 11

BG165370

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

BG165370 906 bp mRNA linear EST 06-PEB-2001
602346005P1 NIH_MGC_89 Homo sapiens cDNA clone IMAGE:4456033 5',
mRNA sequence.

BG165370
BG165370.1 GI:12672073

EST.
human.

Human
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

1 (bases 1 to 906)
NIH-MGC <http://mgc.nci.nih.gov/>

National Institutes of Health, Mammalian Gene Collection (MGC)
Unpublished (1999)

Contact: Robert Strausberg, Ph.D.
Email: cgapbs-remail.nih.gov

Tissue Procurement: ATCC
CDNA Library Preparation: Life Technologies, Inc.

DNA Sequencing by: Incyte Genomics, Inc.

Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
<http://image.llnl.gov>

Plate: LLAM10250 row: j column: 02
High quality sequence stop: 649.

Location/Qualifiers
1. 906

/organism="Homo sapiens"
/db_xref="taxon:9606"

/clone="IMAGE:4456033"

/clone_lib="NIH_MGC_89"

/tissue_type="hypermephroma, cell line"

/lab_host="DH10B (phage-resistant)"

/note="Organ: kidney; Vector: pCMV-SPORT6; Site_1: NotI;
Site_2: SalI; Cloned unidirectionally; oligo-dT primed.
Average insert size 1.3 kb. Library enriched for
full-length clones and constructed by Life Technologies.
Note: this is a NIH_MGC Library."

275 a 204 c 183 g 244 t

BASE COUNT

ORIGIN

Query Match 35.1%; Score 622.4; DB 12; Length 906;
Best Local Similarity 96.0%; Pred. No. 3.7e-135;
Matches 692; Conservative 0; Mismatches 22; Indels 7; Gaps 5;

QY 1058 GGGAGCAAGAAATTGGCCCTGATGGAGATAGTTGCTGTGTCGATTTGAATTGTATAA 1117
DB |||||

QY 1118 CAAATGATTTGGTAGCATCTTAACGTGCAACCATATTTTCCATAAGACATGTGTGAC 1177
DB |||||

QY 60 CCAATGA-TTGGTAGCATCTTAACGTGCAACCATATTTTCCATAAGACATGTGTGAC 118
DB |||||

QY 1178 CMTGCTGTTAAACACAAAGACTTGGCCCATGTGCAATGTGACATCTCAAGCTTTG 1237
DB |||||

QY 119 CCAATGCTGTTAAACACAAAGACTTGGCCCATGTGCAATGTGACATCTCAAGCTTTG 177
DB |||||

QY 1238 GGAATTTGAGTGGATGTTGAAGATGATCAGTGTCTTTTCAAGTCCCTGTATCCAATGAA 1297
DB |||||

QY 178 GGAATTTGAGTGGATGTTGAAGATGATCAGTGTCTTTTCAAGTCCCTGTATCCAATGAA 237
DB |||||

QY 1298 ATATCTAATAGTGCCTCTCCCATGAAGAGGATAATTCGAGCGAGACCGCATCATCTGGA 1357
DB |||||

QY 238 ATATCTAATAGTGCCTCTCCCATGAAGAGGATAATTCGAGCGAGACCGCATCATCTGGA 297
DB |||||

QY 1358 TATGCTTCAGTACAGGAAACAGATGAAACCGCTCTGGAGGACACGTCGAGTCAACAAT 1417
DB |||||

QY 298 TATGCTTCAGTACAGGAAACAGATGAAACCGCTCTGGAGGACACGTCGAGTCAACAAT 357
DB |||||

QY 1418 GAAAGTCTACAGCTGGTAAACCATGAAGCAAAATCTGTGGCAGTGGATGTTATTCCTCAT 1477
 |||||
 Db 358 GAAAGTCTACAGCTGGTAAACCATGAAGCAAAATCTGTGGCAGTGGATGTTATTCCTCAT 417
 |||||
 QY 1478 GTNGACACCCAACTTTGAAGAGACGAAATCTCTAATCAAGAGACTGTGTTGAGAA 1537
 |||||
 Db 418 GTTGACACCCAACTTTGAAGAGACGAAATCTCTAATCAAGAGACTGTGTTGAGAA 477
 |||||
 QY 1538 ATTAATCTTAAATCTGTGTAATAGAAACTTGAACCAATTAGTAATAACAGAACTGCC 1597
 |||||
 Db 478 ATTAATCTTAAATCTGTGTAATAGAAACTTGAACCAATTAGTAATAACAGAACTGCC 537
 |||||
 QY 1598 AATCAGGCTAGTCTTAAATTAATAAATTTGATATAATTAATAAATAAGAGTGAATCTG 1657
 |||||
 Db 538 AATCAGGCTAGTCTTAAATTAATAAATTTGATATAATTAATAAATAAGAGTGAATCTG 597
 |||||
 QY 1658 AATGAGCTCAGATGACTAATATGCTATAGTTAAATAGCTTAAATATTTT--AACC 1715
 |||||
 Db 598 AATGAGCTCAGATGACTAATATGCTATAGTTAAATAGCTTAAATATTTTAAACGC 657
 |||||
 QY 1716 TGTAACTTTTTCACCAAACTCAATATAATTTTTCA--TAGGCAAGTTTCTCTCTCA 1773
 |||||
 Db 658 TGTAACTTTTTCACCAAACTCAATATAATTTTTGACCAAGGCGCAGTTTCTCTCTCA 717
 |||||
 QY 1774 G 1774
 |||||
 Db 718 G 718

RESULT 12

AV686169 LOCUS 683 bp mRNA linear EST 16-JAN-2002
 DEFINITION GK Homo sapiens CDNA clone GRCA1E10 5', mRNA sequence.

ACCESSION AV686169

VERSION AV686169.1 GI:10288032

KEYWORDS EST.

SOURCE human.

ORGANISM

Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE

Xu, X., Huang, J., Xu, Z., Qian, B., Zhu, Z., Yan, Q., Cai, T., Zhang, X.,
 Xiao, H., Ou, J., Liu, F., Huang, Q., Cheng, Z., Li, N., Du, J., Hu, W.,
 Shen, K., Lu, G., Fu, G., Zhong, M., Xu, S., Gu, W., Huang, W., Zhao, X.,
 Hu, G., Gu, J., Chen, Z., and Han, Z.

Insight into hepatocellular carcinogenesis at transcriptome level
 by comparing gene expression profiles of hepatocellular carcinoma
 with those of corresponding noncancerous liver

Proc. Natl. Acad. Sci. U.S.A. 98 (26), 15089-15094 (2001)

JOURNAL

MEDLINE

COMMENT

Contact: Zeguang Han
 Chinese National Human Genome Center at Shanghai
 351 Guo Shoujing Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai
 201203, P. R. China

Tel: 86-21-50801919 (ex. 45)

Fax: 86-21-50801922

Email: hanzg@chgc.sh.cn

This clone is available at CHGC in Shanghai.

FEATURES

source

1..683
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="GKAI10"
 /clone_lib="GKC"
 /tissue_type="hepatocellular carcinoma"
 /dev_stage="Adult"
 /lab_host="SOLR"
 /note="Vector: pBluescript sk(-); Site_1: EcoRI; Site_2:
 XhoI"

BASE COUNT

ORIGIN

98 a 222 c 228 g 135 t

Query Match

35.1%; Score 622.2; DB 10; Length 683;

Best Local Similarity 97.0%; Pred. No. 4e-135;
 Matches 655; Conservative 0; Mismatches 18; Indels 2; Gaps 2;
 QY 74 CCGAGAGCTGATCTGGCGGCAACCTGTGTGCTGACGCTAGCTGCTCTGGCTCGGACG 133
 |||||
 Db 4 CCGAGAGCTGATCTGGCGGCAACCTGTGTGCTGACGCTAGCTGCTCTGGCTCGGACG 63
 |||||
 QY 134 TAGCTCGCAGCTCCCCAGCTCTCACTCCATTCCTTCCCCACCTGGCGCGCACCTGCTCAAG 193
 |||||
 Db 64 TAGCTCGCAGCTCCCCAGCTCTCACTCCATTCCTTCCCCACCTGGCGCGCACCTGCTCAAG 123
 |||||
 QY 194 ACCAGGCTCCTGCAGAGCTAGGAGGCGCGTGCACAGGCGGCTAGGGAACTGCGGAGC 253
 |||||
 Db 124 ACCAGGCTCCTGCAGAGCTAGGAGGCGCGTGCACAGGCGGCTAGGGAACTGCGGAGC 183
 |||||
 QY 254 GCGCGGCCATCGGGGCGCGCGCTGGGGCGGGGCTCTCTCGCGGGTGGCTGGCGGCTTT 313
 |||||
 Db 184 GCGCGGCCATCGGGGCGCGCGCTGGGGCGGGGCTCTCTCGCGGGTGGCTGGCGGCTTT 243
 |||||
 QY 314 TCCAGATTCTGGCATGGTGTCTTCTGTGCTGCTTCAAGTCCGACAGGACCCGGTTCCCGG 373
 |||||
 Db 244 TCCAGATTCTGGCATGGTGTCTTCTGTGCTGCTGAGTCCGACAGGACCCGGTTCCCGG 303
 |||||
 QY 374 GGGGCTGAAGCAGTGTGGACCGGCTACCTCAACGTGTCTGGGGGTTCCGACACGGGA 433
 |||||
 Db 304 GGGGCTGAAGCAGTGTGGACCGGCTACCTCAACGTGTCTGGGGGTTCCGACACGGGA 363
 |||||
 QY 434 GTGAACCTGACGCTGTGGGAGCTGAGCGAGAGGGGCTGTACGGCAGGACTCGCGCGTGG 493
 |||||
 Db 364 GTGAACCTGACGCTGTGGGAGCTGAGCGAGAGGGGCTGTACGGCAGGACTCGCGCGTGG 423
 |||||
 QY 494 GAGCTGTGGTGGGCTCTGTGTACCGCCGACGCGGCCCGGGCGCTTAAACGCTGTAAAC 553
 |||||
 Db 424 GAGCTGTGGTGGGCTCTGTGTACCGCCGACGCGGCCCGGGCGCTTAAACGCTGTAAAC 483
 |||||
 QY 554 CCGCACACGAATTTTACGGTGCACGGTGCACGGTTTGGGGAAGCACCGTGCACGCTCTCTGGTTG 613
 |||||
 Db 484 CCGCACACGAATTTTACGGTGCACGGTGCACGGTTTGGGGAAGCACCGTGCACGCTCTCTGGTTG 543
 |||||
 QY 614 GCCTCATCAACCGCGCGGGGCTGACCTTTCGACAGCAAGATCCATCTGGCTTATGAG 673
 |||||
 Db 544 GCCTCATCAACCGCGCGGGGCTGACCTTTCGACAGCAAGATCCATCTGGCTTATGAG 603
 |||||
 QY 674 -AGATGGGCTGAGAGCGCTCATCTTTAACTTCCCGGACCCGCAATGAGGTATATCC 732
 |||||
 Db 604 AAGAAGGGGCTGAGAGCGCGCATCTTTACTTTCCCGG-CCCCCAATGAGGTATATCC 662
 |||||
 QY 733 CATGTCTCAACCCCGG 747
 |||||
 Db 663 CATGTCTCAACCCCGG 677
 |||||

RESULT 13

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

BASE COUNT

ORIGIN

Query Match

35.1%;

Score 622.2;

DB 10;

Length 683;

BG176206 60233351F2 NCI_CGAP_Mam1 Mus musculus cdna clone IMAGE:4458252 5',

linear EST 06-FEB-2001

mRNA

musculus

cdna

clone

IMAGE:4458252 5',

linear

EST 06-FEB-2001

musculus

cdna

clone

IMAGE:4458252 5',

linear

EST 06-FEB-2001

musculus

cdna

clone

IMAGE:4458252 5',

linear

EST 06-FEB-2001

musculus

cdna

clone

IMAGE:4458252 5',

Mus musculus
 house mouse.
 Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

1 (bases 1 to 996)
 NIH-MGC http://mgi.nci.nih.gov/.

National Institutes of Health, Mammalian Gene Collection (MGC)

Unpublished (1999)

Contact: Robert Strausberg, Ph.D.

Email: cgabs-r@mail.nih.gov

Tissue Procurement: Gilbert Smith, Ph.D.

CDNA Library Preparation: Life Technologies, Inc.

CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)


```

Qy 681 CGTCTGAGCGCTCATCTTTAACTTCCCGGACCGCGCAATGAGTGCATCCCATGCTC 740
Db 241 CTTCTGGAGCGTCTATCTTTAACTTCCCTGGACCGCGCAATGAGTGCATCCCATGCTC 300
Qy 741 ACCCGGTGAGTAGACATTTGTCATCATGATCGGCAATCTGAAAGGCACAAAATTC 800
Db 301 ACCCGGTGAGTAGACATTTGTCATCATGATCGGCAATCTGAAAGGCACAAAATTC 360
Qy 801 TGCATCTATTCAAGAGGATCAAGTGCATCAATGCTAGAGTGGGAAACATG 860
Db 361 TGCAGTCTATTCAAGAGGATCAAGTGCATCAATGCTAGAGTGGGAAACATG 418
Qy 861 GCCCTTGGGTG-AATCACTATTCAATTTTTCGTTTCTGTCCTCTTTTATTATTAGG 919
Db 419 GCCCTTGGGTGAAATCAATTTTCTGTTTCTGTCCTCTTTTATTATTAGG 478
Qy 920 GCGCAACTGTGGCTATTTTATCTTTTATCTGTCGAAAGGCTAGGAAATGCAAGCT 979
Db 479 GCAACAACCGTGGGCTATTTTATCTTTTATCTGTCGAAAGTATGCAAGCT 538
Qy 980 CAAGCAGGAGCAGAGGCAATTAAGGCGATGCTAAAGAGCTATTGGAAGGCTTCAA 1039
Db 539 CAAGCAGGAGCAGAGGCAATTAAGGCGATGCTAAAGAGCTATTGGAAGGCTTCAA 598
Qy 1040 CTACGCACACTGAAACAAGGAGACAAGAAATTTGGCCCTGATGAGATAGTTGTGCTGTG 1099
Db 599 CTGCGCACCTTGAACAAGGAGACAAGAAATTTGGCCCTGATGAGATAGTTGTGCTGTG 658
Qy 1100 TGCATTGAATGTATAACCAA 1122
Db 659 TGCATTGAGCTCTATAAGCCAAA 681

```

RESULT 15

LOCUS AV692456 683 bp mRNA linear EST 16-JAN-2002
 DEFINITION AV692456 GK Homo sapiens cDNA clone KCBCD09 5', mRNA sequence.

ACCESSION AV692456

VERSION AV692456.1 GI:10294319

KEYWORDS EST.

SOURCE human.

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE

1 (bases 1 to 683)
 Xiao H., Qu J., Liu F., Huang Q., Cheng Z., Li N., Du J., Hu W.,

Shen K., Lu G., Fu G., Zhong M., Xu S., Gu W., Huang W., Zhao X., Hu G., Gu J., Chen Z. and Han Z.

Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma

with those of corresponding noncancerous liver

Proc. Natl. Acad. Sci. U.S.A. 98 (26), 15089-15094 (2001)

21625106

Contact: Zequang Han

Chinese National Human Genome Center at Shanghai

351 Guo Shoujing Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai

201203, P. R. China

Tel: 86-21-50801919 (ex. 45)

Fax: 86-21-50801922

Email: hanzq@chgc.sh.cn

This clone is available at CHGC in Shanghai.

FEATURES

source

1. .683

/organism="Homo sapiens"

/db_xref="taxon:9606"

/clone="GKCCBD09"

/clone_lib="GKC"

/tissue_type="hepatocellular carcinoma"

/dev_stage="Adult"

/lab_host="SOLR"

/note="vector: pBluescript sk(-); Site_1: EcoRI; Site_2: XhoI"

```

BASE COUNT 225 a 127 c 126 g 200 t 5 others
ORIGIN
Query Match 31.8%; Score 564.4; DB 10; Length 683;
Best Local Similarity 98.0%; Pred. No. 1.4e-121;
Matches 591; Conservative 0; Mismatches 9; Indels 3; Gaps 2;
Qy 1172 GTTCACCATGGCTGTTTAAACACACAGACTTGGCCCATGTGCAAAATGTGACATACCTCAA 1231
Db 1 GTTCACCATGGCTGTTTAAACACACAGACTTGGCCCATGTGCAAAATGTGACATACCTCAA 60
Qy 1232 GCTTTGGGAATGAGGTGGATGTTGAAGATGAGATCAAGTGTCTTTTACAAGTCCCTGTATCC 1291
Db 61 GCTTTGGGAATGAGGTGGATGTTGAAGATGAGATCAAGTGTCTTTTACAAGTCCCTGTATCC 120
Qy 1292 AATGAATATCTAATAGTGGCTCTCCCATGAAGAGATTAATCGACGAGAGCCGCATCA 1351
Db 121 AATGAATATCTAATAGTGGCTCTCCCATGAAGAGATTAATCGACGAGAGCCGCATCA 180
Qy 1352 TCTGGATATGCTTCAGTACAGGGAACAGATGAACCGCTCTGGAGGAACACGTCAGTCA 1411
Db 181 TCTGGATATGCTTCAGTACAGGGAACAGATGAACCGCTCTGGAGGAACACGTCAGTCA 240
Qy 1412 ACAATGAAGTCTACAGCTGGTAAACCATGAAGCAAAATCTGTGGCAGTGGATGTTATT 1471
Db 241 ACAATGAAGTCTACAGCTGGTAAACCATGAAGCAAAATCTGTGGCAGTGGATGTTATT 300
Qy 1472 CCTCATGTNGACAACCAACCTTTGAAGAGACGAAACTCTCTAATCAAGAGACTGCTGTT 1531
Db 301 CCTCATGTNGACAACCAACCTTTGAAGAGACGAAACTCTCTAATCAAGAGACTGCTGTT 360
Qy 1532 CGAGAAATTAATCTTAAATCTGTGTAATAAGAAAACTTTGAACCATTTAGTAATAACAGA 1591
Db 361 CGAGAAATTAATCTTAAATCTGTGTAATAAGAAAACTTTGAACCATTTAGTAATAACAGA 420
Qy 1592 ACTGCCAATCAGGCGCTAGTTTCTTAAATAAATGGATAAATTTAATAAATAAGAGTG 1651
Db 421 ACTGCCAATCAGGCGCTAGTTTCTTAAATAAATGGATAAATTTAATAAATAAGAGTG 480
Qy 1652 ATACTGAAAGTGTCTCAGATGACTAATATTATGCTATAGTTAAAAATGGCTTAAAAATATT 1711
Db 481 ATACTGAAAGTGTCTCAGATGACTAATATTATGCTATAGTTAAAAATGGCTTAAAAATATT 538
Qy 1712 AACCTGTTAACTTTTTTCCACCAAACTCAATTAATAATTTTTTATAGGCAAGTTTCTCT 1771
Db 539 AACCTGTTAACTTTTTTCCCA-CAAACTCAATTAATAATTTTTTATAGGCAAGTTTCTCT 597
Qy 1772 CAG 1774
Db 598 CAG 600

```

Search completed: April 26, 2003, 02:27:20

Job time : 1767 secs

GenCore version 5.1.4.p5.4578
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: April 22, 2003, 08:27:01 ; Search time 42 Seconds
(without alignments)
816.561 Million cell updates/sec

Title: US-09-854-300-8

Perfect score: 2275

Sequence: 1 MGPPGAGVSCRGCGFSRL.....PTFEDETPNQETAVREIKS 428

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 301932 seqs, 80129803 residues

Total number of hits satisfying chosen parameters: 301932

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA:*

- 1: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB_PEP.*
- 2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB_PEP.*
- 3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB_PEP.*
- 4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB_PEP.*
- 5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB_PEP.*
- 6: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB_PEP.*
- 7: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB_PEP.*
- 8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB_PEP.*
- 9: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB_PEP.*
- 10: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB_PEP.*
- 11: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB_PEP.*
- 12: /cgn2_6/ptodata/1/pubpaa/US10_PUBCOMB_PEP.*
- 13: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB_PEP.*
- 14: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB_PEP.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1134	49.8	225	10	US-09-764-864-850
2	838	36.8	165	10	US-09-764-864-1306
3	656.5	28.9	400	10	US-09-935-390A-20
4	468.5	20.6	276	10	US-09-935-390A-35
5	396	17.4	147	10	US-09-764-864-1272
6	246.5	10.8	381	9	US-09-798-889-65
7	227.5	10.0	296	10	US-09-925-300-1231
8	223	9.8	259	9	US-09-798-889-127
9	137.5	6.0	337	10	US-09-828-303-18
10	130.5	5.7	199	10	US-09-764-864-1291
11	130.5	5.7	207	10	US-09-925-302-638
12	130	5.7	461	10	US-09-764-864-1288
13	130	5.7	636	10	US-09-764-864-832
14	129.5	5.7	604	10	US-09-764-864-836
15	127.5	5.6	664	9	US-10-176-847-40
16	127.5	5.6	664	10	US-09-898-533-2
17	126.5	5.6	685	10	US-09-745-763-11
18	123.5	5.4	291	10	US-09-764-864-1293
19	118.5	5.2	171	10	US-09-764-864-840

20	118.5	5.2	171	10	US-09-764-864-1295
21	105.5	4.6	124	10	US-09-764-864-803
22	105.5	4.6	124	10	US-09-764-864-1264
23	105	4.6	155	10	US-09-925-300-1159
24	105	4.6	205	10	US-09-764-864-1260
25	105	4.6	224	10	US-09-764-864-799
26	103.5	4.5	662	10	US-09-799-777-53
27	103.5	4.5	1863	9	US-09-734-672-2
28	103.5	4.5	1863	9	US-09-734-672-4
29	103.5	4.5	1863	9	US-09-734-672-6
30	103.5	4.5	1863	9	US-09-982-828-2
31	103.5	4.5	1863	9	US-09-982-828-4
32	103.5	4.5	1863	9	US-09-982-828-6
33	103.5	4.5	1863	9	US-10-022-819-2
34	102.5	4.5	426	10	US-09-764-864-809
35	102.5	4.5	664	10	US-09-780-525-2
36	102	4.5	26926	9	US-09-759-508B-2
37	101.5	4.5	825	9	US-10-121-988-161
38	101.5	4.5	826	9	US-10-121-988-47
39	101.5	4.5	826	10	US-09-894-998-47
40	100	4.4	600	10	US-09-764-864-1282
41	100	4.4	615	10	US-09-925-301-1094
42	100	4.4	759	10	US-09-764-864-823
43	98.5	4.3	439	10	US-09-764-864-849
44	97	4.3	266	10	US-09-764-864-834
45	96.5	4.2	811	10	US-09-840-787-45

ALIGNMENTS

RESULT 1

US-09-764-864-850

; Sequence 850, Application US/09764864

; Patent No. US20020132753A1

; GENERAL INFORMATION:

; APPLICANT: Rosen et al.

; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies

; FILE REFERENCE: PT223

; CURRENT APPLICATION NUMBER: US/09/764,864

; CURRENT FILING DATE: 2001-01-17

; Prior application data removed - consult PALM or file wrapper

; NUMBER OF SEQ ID NOS: 1792

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 850

; LENGTH: 225

; TYPE: PRT

; ORGANISM: Homo sapiens

US-09-764-864-850

Query Match 49.8%; Score 1134; DB 10; Length 225;
Best Local Similarity 99.1%; Pred.No. 5.9e-106;
Matches 218; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY	209	FFVSVSFFIITAATGVGFYFYSARRLRNARQSRKQRLKADAKKAIQRLQLRTLKQDK	268
Db	6	FFVSVSFFIITAATGVGFYFYSARRLRNARQSRKQRLKADAKKAIQRLQLRTLKQDK	65
QY	269	EIGPDGDSCAVCIELKPNLVLRLTCNHFHKTCTDVPMLLKHTKTCMKCDILKALGIE	328
Db	66	EIGPDGDSCAVCIELKPNLVLRLTCNHFHKTCTDVPMLLKHTKTCMKCDILKALGIE	125
QY	329	VDVEDGSVSLQVPSVNEINSASSHEEDNRKSETASSGVASVQGTDEPPLEEHVQSTNESL	388
Db	126	VDVEDGSVSLQVPSVNEINSASSHEEDNRKSETASSGVASVQGTDEPPLEEHVQSTNESL	185
QY	389	QLNVNEANSVADVIPHVDNPTFEDETPNQETAVREIKS	428
Db	186	QLNVNEANSVADVIPHVDNPTFEDETPNQETAVREIKS	225

RESULT 2

US-09-764-864-1306

```

; Sequence 1306, Application US/09764864
; Patent No. US20020132753A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PTZ23
; CURRENT APPLICATION NUMBER: US/09/764,864
; PRIOR FILING DATE: 2001-01-17
; Prior application data removed - consult PALM or file wrapper
; NUMBER OF SEQ ID NOS: 1792
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1306
; LENGTH: 165
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (6)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-09-764-864-1306

Query Match      36.8%; Score 838; DB 10; Length 165;
Best Local Similarity 97.5%; Pred. No. 2.3e-76;
Matches 157; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 268 KEIGPDGDSACVCIYLYKNDLVRLTCNHIHFKTCVDPWLLKHKTCPCMKCDILKALGI 327
Db 5 RXIGPDGDSACVCIYLYKNDLVRLTCNHIHFKTCVDPWLLKHKTCPCMKCDILKALGI 64

QY 328 EVDVDEGVSQVLPVNSASSHEEDNRSETASSGYSVQGTDEPPLLEHVVOSTNES 387
Db 65 EVDVDEGVSQVLPVNSASSHEEDNRSETASSGYSVQGTDEPPLLEHVVOSTNES 124

QY 388 LQLVNHEANSVAVDVIPIHVDNPTFEDETFNQETAVERIKS 428
Db 125 LQLVNHEANSVAVDVIPIHVDNPTFEDETFNQETAVERIKS 165

RESULT 3
US-09-935-390A-20
; Sequence 20, Application US/09935390A
; Patent No. US20020076761A1
; GENERAL INFORMATION:
; APPLICANT: Escobedo, Jaime
; Quianjin, Hu
; Garcia, Pablo
; Williams, Lewis T.
; Kothakota, Srinivas
; TITLE OF INVENTION: Secreted Human Proteins
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Chiron Corporation
; STREET: 4560 Horton Street
; CITY: Emeryville
; STATE: CA
; COUNTRY: USA
; Zip: 94608-2916
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/935,390A
; FILING DATE: 22-Aug-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/988,671
; FILING DATE: 1997-12-11
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane E. R. Potter
; REGISTRATION NUMBER: 33,332
; REFERENCE/DOCKET NUMBER: 1369.002

```

```

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (510) 923-2718
; TELEFAX: (510) 655-3542
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 400 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: No. US20020076761A1e
; SEQUENCE DESCRIPTION: SEQ ID NO: 20:
US-09-935-390A-20

Query Match      28.9%; Score 656.5; DB 10; Length 400;
Best Local Similarity 37.9%; Pred. No. 1.8e-57;
Matches 161; Conservative 65; Mismatches 148; Indels 51; Gaps 13;

QY 7 AGVSCRGCGFSRLLCWCFLLASPOAPGSRGAEAVW-TAYLVNWSRVPHGTGNRTWEL 65
Db 8 AGVGARG-----VLALA-LLALALCVPGARGALEWFSAVVNIYVDPQT--NLTVMSV 58

QY 66 SEEGVYGQDSPLEPVAGLVPPDPGGA-LNACNPHNTFTVPTVMGSTVQVSWLALIORGG 124
Db 59 SESGRFDSSPKGAHGLGVVPWAPGDLGCGCAPDTRFFVPEP-GRGGAAPWVALVAR-G 116

QY 125 GCTPADKIHLYAYERWASGAVIFNPGPTGRNEVIMPSHPGAVIDVAIMIGNIKGTILQSIQ 184
Db 117 GCTFKDKVLVAARNASAVLYNEERYGNITLPMASHAGTGNIVIMISYPKGREILELVQ 176

QY 185 RGQVTWVIEVGKHK-GPWVNHYSIFVSVSFFIITAAVTGVYFIFYSARLRNARAQSRK 243
Db 177 KGIPVTMTIGVTRHVOEFISGQSVVFAIAFITMMIISLAWLIFYIYQRLFTYGSQIGS 236

QY 244 QRQLKADAKAIGRLQLRLTKQDKEIGPDGSDCAVCIYLYKNDLVRLTCNHIHFKTC 303
Db- 237 QSHRK-ETKVIQGLLLHTVHKEKGIDVDVAENCANCIENFKVKDRIIRILPCKHIFRIC 295

QY 304 VDPWLLKHKTCPCMKCDILKALGI---EVDVDEGVSQVLPVNSASSHEEDNRSE 360
Db 296 IDPWLDRHTCPMKCLDVIKALGYWGPBGVQEMPAPEPPGRDPAANLSLALPDDGSD 355

QY 361 TASSGYSVQGTDEPPLLEHVVOSTNESLQLVNHEANSVAVDVIPIHVDNPTFEDETFNQ 420
Db 356 DSSPPSAS-----PAESEPPQ-----DPSFKGDAGEN-- 382

QY 421 TAVRE 425
Db 383 TALLE 387

RESULT 4
US-09-935-390A-35
; Sequence 35, Application US/09935390A
; Patent No. US20020076761A1
; GENERAL INFORMATION:
; APPLICANT: Escobedo, Jaime
; Quianjin, Hu
; Garcia, Pablo
; Williams, Lewis T.
; Kothakota, Srinivas
; TITLE OF INVENTION: Secreted Human Proteins
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Chiron Corporation
; STREET: 4560 Horton Street
; CITY: Emeryville
; STATE: CA
; COUNTRY: USA
; Zip: 94608-2916
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible

```



```

US-09-798-889-127

Query Match          9.8%; Score 223; DB 9; Length 259;
Best Local Similarity 24.0%; Pred. No. 4e-14;
Matches 65; Conservative 49; Mismatches 105; Indels 52; Gaps

QY   126 CTFADKIHLAYERNWAGAVIFNPGTRNEVIMSPHG-----ADVIVAIMIGNLKGTKIL 180
      |||:|||||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
DB    6 CNFDIKVLNAQRAGYKAATLVHNDVS--DDLISMGNSDIEVLKKIDIPSVFIGESSANSJK 63
      |||:|||||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY   181 Q--SIORGIGVTMWIEVGKKHGPWNHYSIFPVSVSFFIITAATGVGYFIFYSARLRNAR 238
      |||:|||||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
DB    64 DEFTYEKGGLLIVEFS-----LPLEYLIPLFLIIVGICLLIVFMITKFVDQR 114
      |||:|||||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY   239 AOSRKORQLUKADAKAIGRLQRLTIKQGDKETGGDGSCAVCIELYKNPDLVRILTNNHI 298
      |||:|||||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
DB   115 HRARRNLRRKDQLKK----LPVHKFKKGD-----BYDVCAICLDEVEDGDKLRILPCSHA 165
      |||:|||||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY   299 FHKTCTVDPMLLX-HKTCMPCKCDILKALG-----LEVDVDGVSLSLOVPV----- 342
      |||:|||||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
DB   166 YHCCKVDPMELTKTKTCPVKCKQVFSGDSDDSDTSSOEENEVEHTPLLRLPLASVSAQ 225
      |||:|||||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY   343 -----SNEINSASSHEEDNRSEATSS 364
      |||:|||||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
DB   226 SFGALSESRSHQNMTWSSDYEDDNEDTDSS 256
      |||:|||||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 9
US-09-828-303-18
; Sequence 18, Application US/09828303
; Patent No. US20020102695A1
; GENERAL INFORMATION:
; APPLICANT: COSTA E SILVA, OSWALDO DA
; APPLICANT: BOHNERT, HANG J.
; APPLICANT: VAN THIELEN, NOCHA
; TITLE OF INVENTION: TRANSCRIPTION FACTOR STRESS-RELATED PROTEINS AND
; TITLE OF INVENTION: METHODS OF USE IN PLANTS
; FILE REFERENCE: 16313-0030
; CURRENT APPLICATION NUMBER: US/09/828,303
; CURRENT FILING DATE: 2001-08-20
; PRIOR APPLICATION NUMBER: 60/196,001
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 79
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 18
; LENGTH: 337
; TYPE: PRT
; ORGANISM: Physcomitrella patens
US-09-828-303-18

Query Match          6.0%; Score 137.5; DB 10; Length 337;
Best Local Similarity 24.4%; Pred. No. 2.5e-05;
Matches 39; Conservative 26; Mismatches 78; Indels 17; Gaps

QY   273 DGD-----SCAVCIELYKNPDLVRIL-TCNHFHKTCVDPMLLKHKTCPCMCKDILKAL 325
      |||:|||||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
DB    78 DGERAKRVPECAVCLFEFELGEGKRTLPKCDHSFHLDICDIMLHSHSTCPLCRTSV-GAD 136
      |||:|||||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY   326 GIENVDDGSV-----SLOVPVSNESINASSHEEDNRSETASSGYASVQGTDEPPLE 378
      |||:|||||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
DB   137 ETBKTEATVMQISEPPOMEAPVMGDGAPMAAMRARSRSORSRG--OLPALNSSPRG 194
      |||:|||||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY   379 EHVOQTNESLQLVNHEANSVAVDVIPIHDNPNTPEEDETEN 418
      |||:|||||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
DB   195 NSLPRTAEQGENHRRSCTSETAVAVDQQNIKYETPS 234
      |||:|||||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

RESULT 10
US-09-764-864-1291
; Sequence 1291, Application US/09764864
; Patent No. US20020132753A1
; GENERAL INFORMATION:

```

```
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PT223
; CURRENT APPLICATION NUMBER: US/09/764,864
; CURRENT FILING DATE: 2001-01-17
; Prior application data removed - consult PALM or file wrapper
; NUMBER OF SEQ ID NOS: 1792
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1291
; LENGTH: 199
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (187)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-09-764-864-1291

Query Match          5.7%; Score 130.5; DB 10; Length 199;
Best Local Similarity 33.8%; Pred. No. 5.5e-05;
Matches 24; Conservative 16; Mismatches 26; Indels 5; Gaps 1;

QY 252 KKAIGRLQLRTLKQGDKEIGPDGSCAVCIELYKPNLVRILTCNHIHFKTCVDPWLLKH 311
Db 125 KEQIDNLAMRSGENDAL-----KTCSCVITEYTEGNKLRKLPSCSHYHVCIDRWLSEN 179
QY 312 KTCPCCKCDIL 322
Db 180 STCPICRXAVL 190

RESULT 11
US-09-925-302-638
; Sequence 638, Application US/09925302
; Patent No. US20020044941A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins and Antibodies
; FILE REFERENCE: PA104
; CURRENT APPLICATION NUMBER: US/09/925,302
; CURRENT FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: PCT/US00/05918
; PRIOR FILING DATE: 2000-03-08
; PRIOR APPLICATION NUMBER: 60/124,270
; PRIOR FILING DATE: 1999-03-12
; NUMBER OF SEQ ID NOS: 896
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 638
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-925-302-638

Query Match          5.7%; Score 130.5; DB 10; Length 207;
Best Local Similarity 33.0%; Pred. No. 5.9e-05;
Matches 29; Conservative 16; Mismatches 32; Indels 11; Gaps 3;

QY 239 AGRKQRLQRLKQGDKEIGPDG-----KKAIGRLQLRTLKQGD-----SCAVCIELYKPNL 289
Db 107 SQTRLATQTEEEQRIARIGLIO--HLPKGVDPGRDGSSEKIRECVICMDFVYGP 164
QY 290 VRILTCNHIHFKTCVDPWLLKHKTCPMC 317
Db 165 IRFLPCWHIYHLDCIDDLWLRSGFTCPSC 192

RESULT 12
US-09-764-864-1288
; Sequence 1288, Application US/09764864
; Patent No. US20020132753A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
```

```
; FILE REFERENCE: PT223
; CURRENT APPLICATION NUMBER: US/09/764,864
; CURRENT FILING DATE: 2001-01-17
; Prior application data removed - consult PALM or file wrapper
; NUMBER OF SEQ ID NOS: 1792
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1288
; LENGTH: 461
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (83)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; NAME/KEY: SITE
; LOCATION: (250)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-09-764-864-1288

Query Match          5.7%; Score 130; DB 10; Length 461;
Best Local Similarity 28.7%; Pred. No. 0.00023;
Matches 33; Conservative 17; Mismatches 49; Indels 16; Gaps 3;

QY 220 AATVGY-----FIFYARRLRNAPQSRKQRLKADA-----KKAIGRLQLRTLK 264
Db 342 AEATSYVDPOFLTYMALEERLAQAMETALAHLESIAVDVEVANPPASKESIDALPEILVT 401
QY 265 QGDKEIGPDGDSCAVCIELYKPNLVRILTCNHIHFKTCVDPWLLKHKTCPMCCK 319
Db 402 EDHGAVGQE-MCCPICSEYKGEVATELPCHHYFHKPCVSIWLQSGTGPVCRC 455

RESULT 13
US-09-764-864-832
; Sequence 832, Application US/09764864
; Patent No. US20020132753A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PT223
; CURRENT APPLICATION NUMBER: US/09/764,864
; CURRENT FILING DATE: 2001-01-17
; Prior application data removed - consult PALM or file wrapper
; NUMBER OF SEQ ID NOS: 1792
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 832
; LENGTH: 836
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-764-864-832

Query Match          5.7%; Score 130; DB 10; Length 636;
Best Local Similarity 28.7%; Pred. No. 0.00039;
Matches 33; Conservative 17; Mismatches 49; Indels 16; Gaps 3;

QY 220 AATVGY-----FIFYARRLRNAPQSRKQRLKADA-----KKAIGRLQLRTLK 264
Db 517 AEATSYVDPOFLTYMALEERLAQAMETALAHLESIAVDVEVANPPASKESIDALPEILVT 576
QY 265 QGDKEIGPDGDSCAVCIELYKPNLVRILTCNHIHFKTCVDPWLLKHKTCPMCCK 319
Db 577 EDHGAVGQE-MCCPICSEYKGEVATELPCHHYFHKPCVSIWLQSGTGPVCRC 630

RESULT 14
US-09-764-864-836
; Sequence 836, Application US/09764864
; Patent No. US20020132753A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PT223
; CURRENT APPLICATION NUMBER: US/09/764,864
```


QY 158 MSHPGAVDIVAIMGNLKGTKILQSIQGIQVTWIEVCKHGPV-VNHYISFFVSVFF 216
Db 1 MTHPGGDIIVAMITELRGKILSVLEKNISVQMTIANGTRPPKNFSGSLVFSISFI 60
QY 217 IITAAVGVYFIFYSARRLRNARQKQKADAKAIGRLQLTLKQDKEIGPDGDS 276
Db 61 VLMISSAWLIFYFOKIXYTWARQNRRLGDAAKAISKUTTVTKGDKETDPDPDH 120
QY 277 CAVCIELYKPNLVRILTCHNHFHKTCDPMLLKHKTCPCMKCDILKALGI 327
Db 121 CAVCIESYKQNDVRLPCKVFKHSCVDPMLSEHCTPCMKCNILKALGI 171

RESULT 2

US-08-786-606-9
; Sequence 9, Application US/08786606
; Patent No. 5861495
; GENERAL INFORMATION:
; APPLICANT: Hillman, Jennifer L.
; APPLICANT: Au-Young, Janice
; APPLICANT: Coleman, Roger
; APPLICANT: Goli, Surya K.
; TITLE OF INVENTION: NOVEL HUMAN ZINC-BINDING
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Incyte Pharmaceuticals, Inc.
; STREET: 3174 Porter Drive
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: Fast-SEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/786.606
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Billings, Lucy RJ
; REGISTRATION NUMBER: 36,749
; REFERENCE/DOCKET NUMBER: PF-0173 US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-855-0555
; TELEFAX: 415-845-4166
; TELEX:
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 284 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; LIBRARY: GenBank
; CLONE: 157535
US-08-786-606-9

Query Match 14.5%; Score 331; DB 2; Length 284;
Best Local Similarity 34.8%; Pred. No. 2.3e-28;
Matches 80; Conservative 39; Mismatches 77; Indels 34; Gaps 5;
QY 165 DIVAIMGNLKGTKILQSIQGIQVTWIEVCKHGPV-VNHYISFFVSVFFIITAA 221
Db 14 NTAAVITYQNIQDLSLTLKQKYNVTISIEGRGVRITSSILNRTSVLFSISF--IVDD 71
QY 222 TVGYFIFYSARRLRNARQKQKADAKAIGRLQLTLKQDKEIGPDGDSCAVCI 281

Db 72 ILCWLFYIYQIRFYMQAKDQQRNLCVTKKAIMKIPTKTGKFS-DKDLSDCCAICI 130
QY 282 ELKPNLVRILTCHNHFHKTCDPMLLKHKTCPCMKCDILKALG----- 326
Db 131 EAYKFTDTRILPCKEHEFKNCIDPWLIERHTCPMKCLDLVKFYGVVGDQIYQTSPOH 190
QY 327 -----TEVDVEDGSVSLQVPVSNEISNSASSHE-EDNRSETAS 363
Db 191 TAPIASTEEVPVIWAVPHGPQLPLQASNMSSFAPSHYFQSSRSPSS 240

RESULT 3

US-08-867-057-3
; Sequence 3, Application US/08867057
; Patent No. 5840535
; GENERAL INFORMATION:
; APPLICANT: Hillman, Jennifer L.
; APPLICANT: Lal, Preeti
; APPLICANT: Shah, Purvi
; TITLE OF INVENTION: NEW ZINC RING PROTEIN
; NUMBER OF SEQUENCES: 3
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Incyte Pharmaceuticals, Inc.
; STREET: 3174 Porter Drive
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/867,057
; FILING DATE: Filed Herewith
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Billings, Lucy J.
; REGISTRATION NUMBER: 36,749
; REFERENCE/DOCKET NUMBER: PF-0311 US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-855-0555
; TELEFAX: 415-845-4166
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 381 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; LIBRARY: GenBank
; CLONE: 1321818
US-08-867-057-3

Query Match 11.1%; Score 253; DB 2; Length 381;
Best Local Similarity 24.0%; Pred. No. 2.1e-19;
Matches 84; Conservative 60; Mismatches 140; Indels 66; Gaps 14;
QY 71 YGQDSPLEPVAGVLV--PPDGPALNACPHNTNFTVPTWGSTVQVSWIALQGGGCTF 128
Db 55 FGVLPAEGLKGLFLNSKPE-----NACEP-----IAPPLRDNSSAFIVLIRR-LECNF 104
QY 129 ADKHLAYERWASGAVIFNPPGTRNEVIMSHPG-----AVDIVAIMGNLKGTKILO-- 181
Db 105 DIKVLNARAGYKAAIVHNVD--DDLISGNDIEILKKIDIPSVFGEASNSKEEF 162
QY 182 SIQRGIQVTWIEVKGKGFVNHYISFFVSVFFIITAAVTGYFIFYSARRLRNARQ 241
Db 163 TYEKGGRVLIPEFS-----LPLEVYLPFLIIVGICLILIVIFMITKFEVDHRH 213

```

QY 242 RKORQLKADAKAIGRLQLRTLKQDKEIGPDGSCAVCIELYKPNLVRILTCHNHFHK 301
Db 214 RNRRLKQDLKK-----LPVHKFKGD-----EYDVCAICLDEYEDGDKLRILPCSHAYHC 264
QY 302 TCVDPMWLK-HKTCPCMKCDILKALG-----IEVDVEDGSVSLQVPV----- 342
Db 265 KCVDPMWLTKTKTCPCVKQKVVPQSDSDTSDSQEENEVESENTPLLRPLASVSTQSGF 324
QY 343 -----SNEINSASSHEEDNRSETASSGYASVQGTDEPPPLEEHVQSTNE 386
Db 325 ALSSESHSHQNMTESEYEDDNDNDSDAES--GVNEESVVVQLQPNDE 372

RESULT 4
US-09-128-369-3
; Sequence 3, Application US/09128369
; Patent No. 5998372
; GENERAL INFORMATION:
; APPLICANT: Hillman, Jennifer L.
; APPLICANT: Lal, Preeti
; APPLICANT: Shah, Purvi
; TITLE OF INVENTION: NEW ZINC RING PROTEIN
; NUMBER OF SEQUENCES: 3
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Incyte Pharmaceuticals, Inc.
; STREET: 3174 Porter Drive
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/128,369
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/867,057
; FILING DATE: 06/02/1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Billings, Lucy J.
; REGISTRATION NUMBER: 36,749
; REFERENCE/DOCKET NUMBER: PF-0311 US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-855-0555
; TELEFAX: 415-845-4166
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 381 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; LIBRARY: GenBank
; CLONE: 1321818
US-09-128-369-3

```

```

Query Match 11.1%; Score 253; DB 2; Length 381;
Best Local Similarity 24.0%; Pred. No. 2.1e-19;
Matches 84; Conservative 60; Mismatches 140; Indels 66; Gaps 14;

QY 71 YGQDSPLEPVAGLV--PPDGPALNACNPHNTFTVTWGSTVQVSWLALIORGGCTP 128
Db 55 FGRLPAGLKGFLINSKPE-----NACEP-----IAPPLRDNSSATFIVLIRR-LDCNF 104
QY 129 ADKHLAYERWASGAVIFNPFGRNEVPMGHPG-----AVDIVAIMIGNLKGTKILO-- 181
Db 105 DIKVLNAQRAGYKAAIVHNVD--DDLISMGSDNIDELKIDIPSVFIGASANSKEEF 162
QY 182 SIQRGIQVTWIEVKKHGPWNHYSIFFVSFFIATAVTGYFIFYSARLRNARAQS 241

```

```

Db 163 TYEKGHHVVLIEFFS-----LPLEVYLIPFLIIVGICLILIVIFMITFVODRHA 213
QY 242 RKORQLKADAKAIGRLQLRTLKQDKEIGPDGSCAVCIELYKPNLVRILTCHNHFHK 301
Db 214 RNRRLKQDLKK-----LPVHKFKGD-----EYDVCAICLDEYEDGDKLRILPCSHAYHC 264
QY 302 TCVDPMWLK-HKTCPCMKCDILKALG-----IEVDVEDGSVSLQVPV----- 342
Db 265 KCVDPMWLTKTKTCPCVKQKVVPQSDSDTSDSQEENEVESENTPLLRPLASVSTQSGF 324
QY 343 -----SNEINSASSHEEDNRSETASSGYASVQGTDEPPPLEEHVQSTNE 386
Db 325 ALSSESHSHQNMTESEYEDDNDNDSDAES--GVNEESVVVQLQPNDE 372

RESULT 5
US-08-867-057-1
; Sequence 1, Application US/08867057
; Patent No. 5840535
; GENERAL INFORMATION:
; APPLICANT: Hillman, Jennifer L.
; APPLICANT: Lal, Preeti
; APPLICANT: Shah, Purvi
; TITLE OF INVENTION: NEW ZINC RING PROTEIN
; NUMBER OF SEQUENCES: 3
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Incyte Pharmaceuticals, Inc.
; STREET: 3174 Porter Drive
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/867,057
; FILING DATE: Filed Herewith
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Billings, Lucy J.
; REGISTRATION NUMBER: 36,749
; REFERENCE/DOCKET NUMBER: PF-0311 US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-855-0555
; TELEFAX: 415-845-4166
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 381 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; LIBRARY: BMARNOT02
; CLONE: 104119
US-08-867-057-1

```

```

Query Match 10.8%; Score 246.5; DB 2; Length 381;
Best Local Similarity 24.1%; Pred. No. 1.1e-18;
Matches 83; Conservative 58; Mismatches 132; Indels 71; Gaps 14;

QY 71 YGQDSPLEPVAGLV--PPDGPALNACNPHNTFTVTWGSTVQVSWLALIORGGCTP 128
Db 55 FGRLPAGLKGFLINSKPE-----NACEP-----IAPPLRDNSSATFIVLIRR-LDCNF 104
QY 129 ADKHLAYERWASGAVIFNPFGRNEVPMGHPG-----AVDIVAIMIGNLKGTKILO-- 181
Db 105 DIKVLNAQRAGYKAAIVHNVD--DDLISMGSDNIDELKIDIPSVFIGESSANSKLDEF 162

```

QY 182 SIORGQVMTVIEVGGKKGWVNHYSIFFVSFFIITAATVGYFIFYSARRLRNARAQS 241
 Db 163 TYEKGGLILVPEFS-----LPLEYLIPFLIIIVGICLILIVIFWTKFVQDRHRA 213
 QY 242 RKQRLKADAKAIGRLQLRTLKQDKEIGPDGSCAVCIELYKPNDLVRLTNCNHIFPK 301
 Db 214 RRRLRKQOLKK-----LPVHKFKKGD-----EYDVCAICLDEYEDGDKLRILPCSHAYHC 264
 QY 302 TCVDPMWLK-HKTCPCMKCDILKALG-----IEVDVEDGSYSVLOQVPV----- 342
 Db 265 KCVDPMWLTKTKTCPCVKQKVPSQSDSDTSSQSENEVEHTHTPLLRPLASVSAOSFG 324
 QY 343 -----SNEISNSASHEEDNRSETASSGYASVQGTDEPPLEEH 380
 Db 325 ALSESRHQNTMTESSDYEDDNETDSS-----DAENEINEH 361

RESULT 6

US-09-128-369-1
 ; Sequence 1, Application US/09128369
 ; Patent No. 5998372
 ; GENERAL INFORMATION:
 ; APPLICANT: Hillman, Jennifer L.
 ; APPLICANT: Lal, Preeti
 ; APPLICANT: Shah, Purvi
 ; TITLE OF INVENTION: NEW ZINC RING PROTEIN
 ; NUMBER OF SEQUENCES: 3
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Incyte Pharmaceuticals, Inc.
 ; STREET: 3174 Porter Drive
 ; CITY: Palo Alto
 ; STATE: CA
 ; COUNTRY: USA
 ; ZIP: 94304
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Diskette
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: DOS
 ; SOFTWARE: FastSeq for Windows Version 2.0
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/09/128,369
 ; FILING DATE:
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 08/867,057
 ; FILING DATE: 06/02/1997
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Billings, Lucy J.
 ; REGISTRATION NUMBER: 36,749
 ; REFERENCE/DOCKET NUMBER: PF-0311 US
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: 415-855-0555
 ; TELEFAX: 415-845-4166
 ; INFORMATION FOR SEQ ID NO: 1:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 381 amino acids
 ; TYPE: amino acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; IMMEDIATE SOURCE:
 ; LIBRARY: BMARNOT02
 ; CLONE: 104119
 US-09-128-369-1

Query Match 10.8%; Score 246.5; DB 2; Length 381;
 Best Local Similarity 24.1%; Pred. No. 1.1e-18;
 Matches 83; Conservative 58; Mismatches 132; Indels 71; Gaps 14;
 QY 71 YQDPSPLFVAGLV--PPDGFALNACNPHNTFTVPTVMSGTQVSWLAIQGGGCTF 128
 Db 55 FGVRLPAGLKGFLINSKPE-----NACEP-----IVPPVKDSSGTFVILIR-LDCNF 104
 QY 129 ADKIHAYERWASGAVIFNFFGTRENEVPMSPHG-----AVDIVAIMIGNLKGTKILQ-- 181

Db 105 DIKVLNQRAGYKAAIVHNVD-----DILISGNDIEVLKKIDIPSVFIGESSANSLKDEF 162
 QY 182 SIORGQVMTVIEVGGKKGWVNHYSIFFVSFFIITAATVGYFIFYSARRLRNARAQS 241
 Db 163 TYEKGGLILVPEFS-----LPLEYLIPFLIIIVGICLILIVIFWTKFVQDRHRA 213
 QY 242 RKQRLKADAKAIGRLQLRTLKQDKEIGPDGSCAVCIELYKPNDLVRLTNCNHIFPK 301
 Db 214 RRRLRKQOLKK-----LPVHKFKKGD-----EYDVCAICLDEYEDGDKLRILPCSHAYHC 264
 QY 302 TCVDPMWLK-HKTCPCMKCDILKALG-----IEVDVEDGSYSVLOQVPV----- 342
 Db 265 KCVDPMWLTKTKTCPCVKQKVPSQSDSDTSSQSENEVEHTHTPLLRPLASVSAOSFG 324
 QY 343 -----SNEISNSASHEEDNRSETASSGYASVQGTDEPPLEEH 380
 Db 325 ALSESRHQNTMTESSDYEDDNETDSS-----DAENEINEH 361

RESULT 7

US-09-052-089A-15
 ; Sequence 15, Application US/09052089A
 ; Patent No. 6346605
 ; GENERAL INFORMATION:
 ; APPLICANT: Lee, Soo Y.
 ; APPLICANT: Choi, Yongwon
 ; TITLE OF INVENTION: SIGNAL TRANSDUCER FOR THE TNF RECEPTOR SUPER
 ; NUMBER OF SEQUENCES: 16
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: David A. Jackson, Esq.
 ; STREET: 411 Hackensack Ave, Continental Plaza, 4th
 ; Floor
 ; CITY: Hackensack
 ; STATE: New Jersey
 ; COUNTRY: USA
 ; ZIP: 07601
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: PatentIn Release #1.0, Version #1.30
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/09/052,089A
 ; FILING DATE: 31-Mar-1998
 ; CLASSIFICATION: <Unknown>
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Jackson Esq., David A.
 ; REGISTRATION NUMBER: 26,742
 ; REFERENCE/DOCKET NUMBER: 600-1-198 CIP 1
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: 201-487-5800
 ; TELEFAX: 201-343-1684
 ; INFORMATION FOR SEQ ID NO: 15:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 50 amino acids
 ; TYPE: amino acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: peptide
 ; HYPOTHETICAL: NO
 ; FRAGMENT TYPE: internal
 ; SEQUENCE DESCRIPTION: SEQ ID NO: 15:

US-09-052-089A-15
 Query Match 6.7%; Score 152.5; DB 4; Length 50;
 Best Local Similarity 55.6%; Pred. No. 1e-09;
 Matches 25; Conservative 8; Mismatches 11; Indels 1; Gaps 1;
 QY 275 DSCAVCIELYKPNDLVRLTNCNHIFHKTCTVDPMWLK-HKTCPCMK 318
 Db 2 DVCAICLDEYEDGDKLRILPCSHAYCKVDPWLTKTKTCPCVCK 46

QY 275 DSCAVCIELYKPNLVRILTCNHIFHKTCTVDPWLLKHKTCPMCKCDILKALGIEVDVDDG 334
D 545 DVCAICVHEFTS--ARITPCNHYFHALCKRLKWLVIQOTCPMCH-----QKYYIEDDIKON 598
QY 335 SVSLQVPVNSISNSASSHEEDNRSETASSGYASVQGTDEPPLEHVVQSNESLQLVNHE 394
D 599 S-----NVSN-----NNGFI-----PPNETPEAAVREAAESDRE 628
QY 395 ANSVAVDVIPVDNPTFEEDTNPQETAVRE 425
D 629 LN-----EDDSTDCDDVQRE 644

RESULT 12

US-09-325-932A-46

; Sequence 46, Application US/09325932A
; Patent No. 6451604
; GENERAL INFORMATION:
; APPLICANT: Flinn, Barry
; APPLICANT: Lasham, Annette
; TITLE OF INVENTION: Compositions affecting programmed cell
; TITLE OF INVENTION: death and their use in the modification of forestry plant develop
; FILE REFERENCE: 1022
; CURRENT APPLICATION NUMBER: US/09/325,932A
; CURRENT FILING DATE: 1999-06-04
; NUMBER OF SEQ ID NOS: 206
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 46
; LENGTH: 199
; TYPE: PRI
; ORGANISM: Pinus radiata
US-09-325-932A-46

Query Match 5.0%; Score 114.5; DB 4; Length 199;
Best Local Similarity 44.2%; Pred. No. 0.00021;
Matches 19; Conservative 7; Mismatches 16; Indels 1; Gaps 1;
QY 273 DGDSCAVCIELYKPNLVRIL--TCNHIFHKTCTVDPWLLKHKTCT 314
D 157 DGLECAVCLCEPEENEIARLLPNCRRHNFVCEIDMWFHSHSTC 199

RESULT 13

US-08-699-103B-25

; Sequence 25, Application US/08699103B
; Patent No. 6107462
; GENERAL INFORMATION:
; APPLICANT: Rine, Jasper D.
; APPLICANT: Hampton, Randolph
; TITLE OF INVENTION: GENES AND PROTEINS CONTROLLING
; TITLE OF INVENTION: CHOLESTEROL SYNTHESIS
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESS: Fish & Richardson P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: USA
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/699,103B
; FILING DATE: 16-AUG-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,581
; FILING DATE: 17-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Green, Grant D.
; REGISTRATION NUMBER: 31,259

; REFERENCE/DOCKET NUMBER: 09272/005001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650/322-5070
; TELEFAX: 650/854-0875
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 551 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: polypeptide
US-08-699-103B-25

Query Match

Best Local Similarity 4.8%; Score 108.5; DB 3; Length 551;
Matches 34; Conservative 26; Mismatches 58; Indels 49; Gaps 6;

QY 273 DGDSCAVCIELYKPNLVRILTCNHIFHKTCTVDPWLLKHKTCPMCKCDIL 322
D 345 DDNICIICMDELIHSPNQOTWKNKPKRLPCGHILHLCLKNMERSQTCPIRLPVF 404
QY 323 KALGIEVDVDEGSVLSQVPVNSISNSASSHEEDNRSETASSGYASVQGTDEPPLEHVVQ 382
D 405 D-----EKNVVQTTFTSNDITTTQTTVDSTGIATDQGF----- 441
QY 383 STNESLQLVNHEANSVAVDVIP--HVDNPTFEEDTNPQETAVREIKS 428
D 442 --NE-----VDLLPRTTSPDIRIVPTQNTIDTLAMRTS 473

RESULT 14

US-09-229-059-25

; Sequence 25, Application US/09229059
; Patent No. 6333172
; GENERAL INFORMATION:
; APPLICANT: Rine, Jasper D.
; APPLICANT: Hampton, Randolph
; TITLE OF INVENTION: GENES AND PROTEINS CONTROLLING
; TITLE OF INVENTION: CHOLESTEROL SYNTHESIS
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESS: Fish & Richardson P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: USA
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/229,059
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/699,103
; FILING DATE: 16-AUG-1996
; APPLICATION NUMBER: 60/002,581
; FILING DATE: 17-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Green, Grant D.
; REGISTRATION NUMBER: 31,259
; REFERENCE/DOCKET NUMBER: 09272/005001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650/322-5070
; TELEFAX: 650/854-0875
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 551 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: polypeptide
US-09-229-059-25

```

      :| : : : :||| : || :|
Db 123 QALGKAEMLCSTLXKQMKYLEQQDDTKOQAEARLRLS 161

Search completed: April 22, 2003, 08:27:49
Job time : 19 secs
```

					Query Match	4.7%	Score 107.5;	DB 2;	Length 469;
					Best Local Similarity	22.6%;	Pred. No. 0.0059;		
					Matches 36;	Conservative	30;	Mismatches 82;	Indels 11; Gaps 4;
QY	277	CACVCTELKYPNDLVRLITCNHIFHKTCVDWPL--LKHKTCPMC-----KCDILKALGIEV	329			:	:	:	:
		: : : :	: : : :			:	:	:	:
Dd	7	CTICSDFFDHSRDVAACHGHTFHLQLCIQWFETAPSRTCPQCRIQGVGRKTINKLFFDL	66			:	:	:	:
QY	330	DVEDGSVSLQVPVSNEINSASSHEEDNRSETASSGYASVGQTDEDFPLEHHVQSINESIQ	389			:	:	:	:
		: : : :	: : : :			:	:	:	:
Dd	67	AQEENVLDAEFLKNGLDNVRAQSXDKDKRDSQ---VIIDTLRTDLER-NATTVWSLQ	122			:	:	:	:
QY	390	LNVNHANSVAVDVIPHVDNPTFEDETNPQBTAREIKS	428			:	:	:	:

GenCore version 5.1.4 p5 4578
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: April 22, 2003, 08:16:45 i. Search time 76 Seconds
(without alignments)
750.411 Million cell updates/sec

Title: US-09-854-300-8

Perfect score: 2275

Sequence: 1 MGPPPGAGVSCGGCGFSRL.....PTFEDETNPQETAVREIKS 428

Scoring table: BLOSUM62

Gapop 10.0, Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database:

```

1: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA2001.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA2002.DAT:*

```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query Match	Score	Length	ID	Description
1	2275	100.0	428	23	Human GRAIL. Homo
2	2255	99.1	428	21	Human protein clon
3	2255	99.1	428	23	ISIGP-4. Homo sap
4	2160	94.9	428	23	Mouse goliath prot
5	2115	93.0	428	23	Synthetic goliath
6	2111	92.8	428	23	Synthetic goliath
7	2111	92.8	428	23	Synthetic goliath
8	2110	92.7	428	23	Synthetic goliath
9	2108	92.7	428	23	Synthetic goliath
10	2106	92.6	428	23	Synthetic goliath

11	2090.5	91.9	427	23	AA047799	Mouse GRAIL. Mus
12	1364	60.0	276	22	AA040136	Human polypeptide
13	1134	49.8	225	22	AAU15897	Human novel secret
14	1027.5	45.2	294	22	AAU25459	Human mdt protein
15	838	36.8	165	22	AAU16353	Human novel secret
16	799	35.1	155	22	AA041922	Human polypeptide
17	763.5	33.6	305	22	ABG05937	Novel human diagno
18	755.5	33.2	305	21	AA025803	Human secreted pro
19	755.5	33.2	305	22	AA075389	Human secreted pro
20	656.5	28.9	400	19	AA063681	Human secreted pro
21	656.5	28.9	400	22	AA035567	Human polypeptide,
22	650.5	28.6	400	22	AA03452	Human polypeptide,
23	650.5	28.6	400	22	AA088594	Human hydrophobic
24	649.5	28.5	400	23	AB030388	Human polypeptide
25	617.5	27.1	419	22	AA088558	Human hydrophobic
26	617.5	27.1	419	23	AB077003	Human protein sequ
27	617.5	27.1	419	23	AB077025	Human protein sequ
28	617.5	27.1	419	23	AB064937	Human albumin fusi
29	617.5	27.1	419	23	AB064938	Human albumin fusi
30	617.5	27.1	419	23	AB030389	Human polypeptide
31	592.5	26.0	419	23	AAU74921	Mouse g1 protein s
32	586	25.8	462	23	AAU74919	Human goliath prot
33	551	24.2	115	23	AB030387	Human polypeptide
34	545	24.0	341	22	AB051081	Human secreted pro
35	537	23.6	312	22	AB011857	Human secreted pro
36	537	23.6	341	20	AA079358	Human protein SEQ
37	537	23.6	341	20	AA079358	Polypeptide fragme
38	532.5	23.4	210	21	AA041793	Human ORFX ORF1557
39	525	23.1	257	22	AB012676	Novel human diagno
40	468.5	20.6	276	19	AA069602	Human zinc binding
41	468.5	20.6	276	19	AA036966	Human secreted pro
42	468.5	20.6	276	23	AAU74920	Human goliath-2 pr
43	462.5	20.3	276	20	AA088996	Polypeptide fragme
44	462.5	20.3	276	22	AB051074	Human secreted pro
45	438.5	19.3	167	20	AA088995	Polypeptide fragme

ALIGNMENTS

RESULT 1

AA047800
ID AA047800 standard; Protein; 428 AA.

XX AA047800;

XX 25-MAR-2002 (first entry)

XX Human GRAIL.

XX Murine; human; GRAIL; energy; attenuation; tyrosine; phosphorylation;
antigenic stimulation; interleukin-2; gene therapy; polymorphism; IL-2;
autoimmune disease; tumour cell; cancer; transplant rejection.

XX Homo sapiens.

XX Key Location/Qualifiers

XX Domain 339..413

XX FT /label= Zinc RING finger domain

XX FT /note= "Mediates protein/protein interaction"

XX PN WO200185943-A1.

XX PD 15-NOV-2001.

XX PF 11-MAY-2001; 2001WO-US15385.

XX PR 11-MAY-2000; 2000US-203513P.

XX PA (STFD) UNIV LELAND STANFORD JUNIOR.

XX PI Ford GS, Bloom D, Fathman CG;

XX

DR WPI; 2002-055597/07.
 DR N-PSDB; AA172095.
 XX Novel nucleic acid sequences of energy associated genes, including
 PT GRAIL gene useful in the evaluation of pathophysiology or immunotherapy
 PT of cancer, autoimmune disease and transplant rejection -
 XX
 XX Claim 13; Page 47-48; 50pp; English.
 PS This sequence shows human GRAIL protein. The GRAIL gene is an
 XX energy associated gene which is upregulated during the early stages
 CC of induction of energy. GRAIL has been shown to attenuate IL-2
 CC transcription in T-cells during response to antigenic stimulation.
 CC GRAIL DNA is useful for decreasing the responsiveness of a T cell
 CC population, especially synthesis of interleukin-2 (IL-2) in response to
 CC antigenic stimulation, by up-regulating GRAIL activity in the T cell
 CC population. GRAIL DNA is useful in producing compositions that modulate
 CC induction or maintenance of energy, for gene therapy, mapping
 CC functional regions of the encoded protein, to analyse a patient sample
 CC for the presence of polymorphisms or alterations in expression of
 CC sequences associated with T cell energy, disease states, genetic
 CC predisposition to a disease state, and in studying associated
 CC physiological pathways. Modulation of the gene activity in vivo is
 CC useful for prophylactic and therapeutic purposes, such as treating
 CC autoimmune disease and to enhance immune response to tumour cells, and
 CC identification of energetic T cells. GRAIL DNA is useful in the
 CC evaluation of the pathophysiology or immunotherapy of cancer,
 CC autoimmune disease, and transplant rejection. Genetic sequences
 CC involved in energy induction are useful as markers in the evaluation of
 CC specific immunotherapies. Functional characterization of genes involved
 CC in energy induction allows the elucidation of the mechanisms of T cell
 CC energy, including the transcriptional blockade of IL-2, which may be
 CC manipulated to regulate T cell responses in human disease. Modulation
 CC of expression of GRAIL gene is useful in manipulating the anergic
 CC state. The genetic sequences find use alone or in combinations in
 CC determining the expression profile of cells relating to energy, for
 CC example in screening of candidate biologically active compounds for
 CC modulation of T cell energy. Expression of GRAIL has been found to
 CC block tyrosine phosphorylation of a protein present in T cells during
 XX activation.
 XX
 SQ Sequence 428 AA;
 Query Match 100.0%; Score 2275; DB 23; Length 428;
 Best Local Similarity 100.0%; Pred. No. 1.3e-236;
 Matches 428; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MGPPPGAGVSCRGCGFRLALAWCFLLALSPQAPGSGAEAVWTAYLNVSRVPHTVGNR 60
 DB 1 MGPPPGAGVSCRGCGFRLALAWCFLLALSPQAPGSGAEAVWTAYLNVSRVPHTVGNR 60
 QY 61 TWELSEGVGVQDSPLFVAGVLVPPDGGALNACNPHNTFTVPTWGSTVQVSWLALI 120
 DB 61 TWELSEGVGVQDSPLFVAGVLVPPDGGALNACNPHNTFTVPTWGSTVQVSWLALI 120
 QY 121 QRGCGCTFADKIHILAYERWASGAVIFNPPGTRNEVPMSPHGAVIDIVAIMIGNLKGTKIL 180
 DB 121 QRGCGCTFADKIHILAYERWASGAVIFNPPGTRNEVPMSPHGAVIDIVAIMIGNLKGTKIL 180
 QY 181 QSIQRIQVTVWIEVKGKGPWVNHYSIFFVSFFIITAATVGFYFYSARRLRNARAQ 240
 DB 181 QSIQRIQVTVWIEVKGKGPWVNHYSIFFVSFFIITAATVGFYFYSARRLRNARAQ 240
 QY 241 SRKQRLKADAKKAIGRLQLRTLKGDKIEIGPDGSCAVCIYELKPNDLVRLTCNHFH 300
 DB 241 SRKQRLKADAKKAIGRLQLRTLKGDKIEIGPDGSCAVCIYELKPNDLVRLTCNHFH 300
 QY 301 KTCVDPWLLKHKTCPMKCKDILKALGIEVDVDSVSLQVPVSEINSASSHEEDNRSE 360
 DB 301 KTCVDPWLLKHKTCPMKCKDILKALGIEVDVDSVSLQVPVSEINSASSHEEDNRSE 360
 QY 361 TASSGVVSVQGTDEPPELHEHVQSTNESLQVNVHEANSVAVDVIPHVDNPTFEEDTPNOE 420
 DB 361 TASSGVVSVQGTDEPPELHEHVQSTNESLQVNVHEANSVAVDVIPHVDNPTFEEDTPNOE 420

DB 361 TASSGVVSVQGTDEPPELHEHVQSTNESLQVNVHEANSVAVDVIPHVDNPTFEEDTPNOE 420
 QY 421 TAVREIKS 428
 DB 421 TAVREIKS 428
 RESULT 2
 AAY94897
 ID AAY94897 standard; Protein; 428 AA.
 AC AAY94897;
 DT 12-JUN-2000 (first entry)
 DE Human protein clone HP10574.
 KW Human protein; hydrophobic domain; nutritional source; haematopoiesis;
 KW cytokine production; cell proliferation; cell differentiation;
 KW immune deficiency; infectious disease; autoimmune disorder; asthma;
 KW multiple sclerosis; systemic lupus erythematosus; rheumatoid arthritis;
 KW allergic reaction; osteoporosis; osteoarthritis; periodontal disease;
 KW nervous system disorder; Alzheimer's disease; Parkinson's disease;
 KW Huntington's disease; liver fibrosis; lung fibrosis; reperfusion injury;
 KW systemic cytokine damage; tissue differentiation; inflammatory condition;
 KW coagulation disorder; myocardial infarction; septic shock; stroke;
 KW septic shock; sepsis; ischaemia; reperfusion injury; arthritis; tumour;
 KW nephritis; therapy.
 OS Homo sapiens.
 PN WO200005367-A2.
 PD 03-FEB-2000.
 XX 22-JUL-1999; 99WO-JP03929.
 XX 24-JUL-1998; 98JP-0208820.
 PR 07-AUG-1998; 98JP-0224105.
 PR 25-AUG-1998; 98JP-0238116.
 PR 09-SEP-1998; 98JP-0254736.
 PR 29-SEP-1998; 98JP-0275505.
 XX (SAGA) SAGAMI CHEM RES CENT.
 PA (PROT-) PROTEGENE INC.
 XX Kato S, Kimura T;
 DR WPI; 2000-182694/16.
 XX Novel human proteins having hydrophobic domains useful for treating
 PT osteoporosis, Alzheimer's disease, Parkinson's disease, asthma,
 PT multiple sclerosis, rheumatoid arthritis, cancer, anaemia, and stroke -
 PS Claim 1; Page 323-324; 351pp; English.
 XX This sequence represents a human protein of the invention, which has
 CC hydrophobic domains. The DNA sequences can be used as a probe or as a
 CC genetic marker. The protein can also be used as a marker, and to identify
 CC potential genetic disorders. The DNA and protein can also be used as
 CC nutritional sources or supplements. The protein exhibits cytokine, cell
 CC proliferation, cell differentiation activities and induces production of
 CC other cytokines in certain cell populations. The protein also exhibits
 CC immune stimulating or immune suppressing activity. It can be used in the
 CC treatment of various immune deficiencies and disorders, and to treat
 CC infectious diseases caused by viral, bacterial, fungal or other
 CC infections. The protein is also used for treating autoimmune disorders
 CC such as multiple sclerosis, systemic lupus erythematosus, and rheumatoid
 CC arthritis. It is also useful in the treatment of allergic reactions and
 CC conditions such as asthma, and in immune suppression after organ
 CC transplantation. The protein is useful in regulation of haematopoiesis
 CC and consequently in the treatment of myeloid or lymphoid cell
 CC deficiencies. It is also used in compositions for tissue growth or

CC regeneration. The protein is also used in the treatment of osteoporosis
 CC or osteoarthritis and in the treatment of periodontal disease and other
 CC tooth repair processes. The protein is used in the treatment of nervous
 CC system disorders such as Alzheimer's disease, Parkinson's disease, and
 CC Huntington's disease. They are useful for protection or regeneration and
 CC treatment of lung or liver fibrosis, reperfusion injury in various
 CC tissues, and conditions resulting from systemic cytokine damage. They are
 CC also used for promoting or inhibiting tissue differentiation. They are
 CC also used as contraceptives since they exhibit activin or inhibin related
 CC activities and as a fertility inducing therapeutic. They are used for
 CC treating various coagulation disorders and in treatment and prevention of
 CC conditions resulting from coagulation activities e.g. myocardial
 CC infarction or stroke. They also acts as receptors, receptor ligands or
 CC inhibitors or agonists of receptor/ligand interactions. They are used to
 CC treat inflammatory conditions such as septic shock, sepsis, ischaemia
 CC reperfusion injury, arthritis, and nephritis. They can be used to
 CC prevent tumours.
 XX
 SQ Sequence 428 AA;

Query Match 99.1%; Score 2255; DB 21; Length 428;
 Best Local Similarity 99.3%; Pred. No. 1.9e-234;
 Matches 425; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 MGPPPGAGVSCRGCGFSRLLCWCFLLALSPQAPGSRGAEAVMTAYLVNSWRVPHGTGVR 60
 DB 1 MGPPPGAGVSCRGCGFSRLLCWCFLLALSPQAPGSRGAEAVMTAYLVNSWRVPHGTGVR 60
 QY 61 TWELSEGVYQDSPLPVGAVLVPPDGPALNACNPHNTFTVPTVMGSTVQVSLALI 120
 DB 61 TWELSEGVYQDSPLPVGAVLVPPDGPALNACNPHNTFTVPTVMGSTVQVSLALI 120
 QY 121 QRGCGCTFADKIHLAYERWASGAVIFNPGTRNEVPMSPHGAVDIVAIMGNLKGTKIL 180
 DB 121 QRGCGCTFADKIHLAYERWASGAVIFNPGTRNEVPMSPHGAVDIVAIMGNLKGTKIL 180
 QY 181 QSIQRGQVTWVIEVGKKGFWNNHYSIFFVSVPFFITTAATVGYTFYSARLRNARAQ 240
 DB 181 QSIQRGQVTWVIEVGKKGFWNNHYSIFFVSVPFFITTAATVGYTFYSARLRNARAQ 240
 QY 241 SRQRQLKADAKKAIQRLQRTLKQDKEIGPDGDSCAVCIYKPNDLVRLTNCNHFH 300
 DB 241 SRQRQLKADAKKAIQRLQRTLKQDKEIGPDGDSCAVCIYKPNDLVRLTNCNHFH 300
 QY 301 KTCVDPMLLKHKTCPMKCKDILKALGIEVDVDSVLSQVPVSNISNSASSHEEDNRSE 360
 DB 301 KTCVDPMLLKHKTCPMKCKDILKALGIEVDVDSVLSQVPVSNISNSASSHEEDNRSE 360
 QY 361 TASSGYASVQGTDEPPLEEHVQSTNESLQLVNHEANSVAVDVIPIHVDNPTFEEDTPNQE 420
 DB 361 TASSGYASVQGTDEPPLEEHVQSTNESLQLVNHEANSVAVDVIPIHVDNPTFEEDTPNQE 420
 QY 421 TAVREIKS 428
 DB 421 TAVREIKS 428

RESULT 3

AAB47874
 ID AAB47874 standard; Protein; 428 AA.

XX
 AC AAB47874;

XX
 DT 15-APR-2002 (first entry)

XX
 DE ISIGP-4.

XX Human; intracellular signalling protein; ISIGP; gene; autoimmune;
 KW cell proliferation; inflammation; gastrointestinal disorder;
 KW reproductive disorder; developmental disorder.

XX OS Homo sapiens.

XX

Key	Location/Qualifiers
Peptide	1..41
FT	/label= Signal_peptide
FT	/note= "identified using HMW and SPSCAN"
FT	10
FT	/note= "potentially O-phosphorylated"
FT	48
FT	/note= "potentially N-glycosylated"
FT	50
FT	/note= "potentially O-phosphorylated"
FT	59
FT	/note= "potentially N-glycosylated"
FT	61
FT	/note= "potentially O-phosphorylated"
FT	75
FT	/note= "potentially O-phosphorylated"
FT	101
FT	/note= "potentially N-glycosylated"
FT	127
FT	/note= "potentially O-phosphorylated"
FT	151
FT	/note= "potentially O-phosphorylated"
FT	206..229
FT	/label= Transmembrane domain
FT	/note= "identified using HMW"
FT	230
FT	/note= "potentially O-phosphorylated"
FT	241
FT	/note= "potentially O-phosphorylated"
FT	262
FT	/note= "potentially O-phosphorylated"
FT	273..323
FT	/label= Zinc_finger_C3CH4_type
FT	/note= "identified using BLAST_DOMO"
FT	273..328
FT	/label= Zinc_finger_C3CH4_type
FT	/note= "identified using PROFILESSCAN"
FT	277..317
FT	/label= Zinc_finger_C3CH4_type
FT	/note= "identified using HMW_PPFAM"
FT	292..306
FT	/label= PHD_finger
FT	/note= "identified using BLIMPS_PPFAM"
FT	302
FT	/note= "potentially O-phosphorylated"
FT	351
FT	/note= "potentially O-phosphorylated"
FT	352
FT	/note= "potentially O-phosphorylated"
FT	357
FT	/note= "potentially N-glycosylated"
FT	383
FT	/note= "potentially O-phosphorylated"
FT	385
FT	/note= "potentially N-glycosylated"
FT	410
FT	/note= "potentially O-phosphorylated"
XX	WO200194391-A2.
PN	13-DEC-2001.
XX	07-JUN-2001; 2001WO-US18595.
XX	08-JUN-2000; 2000US-210582P.
PR	16-JUN-2000; 2000US-212443P.
XX	(INCY-) INCYTE GENOMICS INC.
PA	Yue H, He A, Nguyen DB, Yao MG, Bandman O, Burford N, Tang YT;
PI	Xu Y, Hafalla A, Azimzai Y, Walia NK;
XX	WPI; 2002-154564/20.
DR	

DR N-PSDB; AAU72321.

XX New human intracellular signaling protein and polynucleotides useful
 PT for diagnosing, treating or preventing cell proliferative,
 PT autoimmune/inflammatory, gastrointestinal, reproductive and
 PT developmental disorders -

XX
 PS Claim 1; Page 99-100; 106pp; English.

XX The sequences given in ABA47871-75 show novel human intracellular
 CC signalling proteins (ISIGP). The polynucleotides and ISIGP proteins
 CC may be used for the diagnosis, treatment or prevention of cell
 CC proliferative, autoimmune/inflammatory, gastrointestinal, reproductive
 CC and developmental disorders. This protein has homology to the mouse
 CC gl-related zinc finger protein.

XX
 SQ Sequence 428 AA;

Query Match 99.1%; Score 2255; DB 23; Length 428;
 Best Local Similarity 99.3%; Pred. No. 1.9e-234;
 Matches 425; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1 MGPPPGAGVSCRGCGFSRLLAFCFLALSPQAPGSRGAENVMTAYLNVSWRVPHGTGVR 60
 Db 1 MGPPPGAGVSCRGCGFSRLLAFCFLALSPQAPGSRGAENVMTAYLNVSWRVPHGTGVR 60

Qy 61 TWELSEGVYQDPSLEPVAGVLVPPDGPALNACNPHNTFTVPTVMGSTVQVSWLALI 120
 Db 61 TWELSEGVYQDPSLEPVAGVLVPPDGPALNACNPHNTFTVPTVMGSTVQVSWLALI 120

Qy 121 QRGGGCTPADKIHILAYERWASGAVIFNPPGTRNEVIMPSHPGAVDIIVAIMIGNLKGTKIL 180
 Db 121 QRGGGCTPADKIHILAYERWASGAVIFNPPGTRNEVIMPSHPGAVDIIVAIMIGNLKGTKIL 180

Qy 181 QSIORGIOVTWIEVGKKGHPWNVHSIFVSVSFFIITATVGYFIFYSARLRNARAQ 240
 Db 181 QSIORGIOVTWIEVGKKGHPWNVHSIFVSVSFFIITATVGYFIFYSARLRNARAQ 240

Qy 301 KTCVDPWLLKHTCPMKCDILKALGIEVDVSDGSVLSQVPSNEISNSASSHEEDNRSE 360
 Db 301 KTCVDPWLLKHTCPMKCDILKALGIEVDVSDGSVLSQVPSNEISNSASSHEEDNRSE 360

Qy 361 TASSGYASVQGTDEPPELHEHVQSTNESLQVNHANSVAVDVI PHVDNPTFEDETNPQE 420
 Db 361 TASSGYASVQGTDEPPELHEHVQSTNESLQVNHANSVAVDVI PHVDNPTFEDETNPQE 420

Qy 421 TAVREIKS 428
 Db 421 TAVREIKS 428

RESULT 4
 AAU74918
 ID AAU74918 standard; Protein; 428 AA.

XX
 AC AAU74918;
 XX
 DT 23-APR-2002 (first entry)
 XX
 DE Mouse goliath protein sequence.

XX Mouse; goliath protein; antiangiogenic; vasotropic; gene therapy;
 KW dosage form; angiogenesis; neurogenesis; tumour; vascularisation;
 KW cancer; ischaemia; neuroblastoma; neurodegenerative disease;
 KW unrecovered nerve trauma.

XX
 OS Mus sp.
 XX
 FH Key Location/Qualifiers

FT Peptide 20..32 /label= Signal_sequence
 FT Protein 33..428 /label= Mature_goliath_protein
 FT Domain 33..205 /label= Extracellular_N_terminal_domain
 FT Domain 206..225 /label= Transmembrane_domain
 FT Domain 226..428 /label= Intracellular_C_terminal_domain
 FT Domain 277..317 /label= C3H2C3_ring_finger_motif
 PN WO200193681-A1.
 XX 13-DEC-2001.
 XX
 PF 01-JUN-2001; 2001WO-US18000.
 XX
 PR 02-JUN-2000; 2000US-0586398.
 XX
 PA (REGC) UNIV CALIFORNIA.
 XX
 PI Harland R, Baker JC;
 XX
 DR WPI; 2002-147637/19.
 XX
 DR N-PSDB; ASK12983.
 XX
 XX New compositions comprising goliath proteins, useful for modulating
 PT angiogenesis or neurogenesis in mammals e.g. for preventing or
 PT treating undesirable vascularisation of a tumour, ischaemia or
 PT neurodegenerative disease -
 XX
 PS Claim 1; Page 29-30; 45pp; English.

XX The present invention relates to a new pharmaceutical composition that
 CC comprises a goliath polypeptide in dosage form. The goliath polypeptide
 CC has a sequence identity of at least 75% to the protein sequences
 CC (AAU74918-AAU74921) fully defined in the specification. The composition
 CC is useful for modulating angiogenesis or neurogenesis in mammals,
 CC particularly in humans or mice. Specifically, the composition is useful
 CC for the prophylactic and/or therapeutic treatment of excess angiogenesis
 CC e.g. undesirable vascularisation of a tumour or insufficient angiogenesis
 CC e.g. ischaemia, excess neurogenesis e.g. neuroblastoma or insufficient
 CC neurogenesis e.g. neurodegenerative disease or unrecovered nerve trauma.
 CC The present amino acid sequence represents the mouse goliath protein
 CC that was used in the invention for modulating angiogenesis or
 CC neurogenesis.

XX
 SQ Sequence 428 AA;

Query Match 94.9%; Score 2160; DB 23; Length 428;
 Best Local Similarity 94.6%; Pred. No. 3.5e-224;
 Matches 405; Conservative 10; Mismatches 13; Indels 0; Gaps 0;

Qy 1 MGPPPGAGVSCRGCGFSRLLAFCFLALSPQAPGSRGAENVMTAYLNVSWRVPHGTGVR 60
 Db 1 MGPPPGAGVSCRGCGFSRLLAFCFLALSPQAPGSRGAENVMTAYLNVSWRVPHGTGVR 60

Qy 61 TWELSEGVYQDPSLEPVAGVLVPPDGPALNACNPHNTFTVPTVMGSTVQVSWLALI 120
 Db 61 TWELSEGVYQDPSLEPVAGVLVPPDGPALNACNPHNTFTVPTVMGSTVQVSWLALI 120

Qy 121 QRGGGCTPADKIHILAYERWASGAVIFNPPGTRNEVIMPSHPGAVDIIVAIMIGNLKGTKIL 180
 Db 121 QRGGGCTPADKIHILAYERWASGAVIFNPPGTRNEVIMPSHPGAVDIIVAIMIGNLKGTKIL 180

Qy 181 QSIORGIOVTWIEVGKKGHPWNVHSIFVSVSFFIITATVGYFIFYSARLRNARAQ 240
 Db 181 QSIORGIOVTWIEVGKKGHPWNVHSIFVSVSFFIITATVGYFIFYSARLRNARAQ 240

Qy 241 SRKQRLKADAKKAIKRLQLRTLKQDKEIGPDGSCAVCIELYKPNDLVRLTNCNHFH 300
 Db 241 SRKQRLKADAKKAIKRLQLRTLKQDKEIGPDGSCAVCIELYKPNDLVRLTNCNHFH 300

Db 241 SRKORQLKADAKKAIGKQLRLTKQGDKEIGPDGDSCAVCIELYKPNDLVRLITCNHIFH 300
 Qy 301 KTCVDPMLLKHKTCPCMKCDILKALGIEVDVDSVSLQVPVSNEISNSASSHEEDNRSE 360
 Db 301 KTCVDPMLLEHRTCPMKCDILKALGIEVDVDSVSLQVPVSNEASNTASPHEDSRSE 360
 Qy 361 TASSGYASVQGTDEPPLEEHVQSTNESLQLVNHEANSVADVIPHVDNPTFEDETPDOE 420
 Db 361 TASSGYASVQADEPPLEEHQAQSANENLQLVNHEANSVADVIPHVDNPTFEDETPDOE 420
 Qy 421 TAVREIKS 428
 Db 421 AAVREIKS 428

RESULT 5
 AAU74927
 ID AAU74927 standard; Protein; 428 AA.
 XX
 AC AAU74927;
 XX
 XX 23-APR-2002 (first entry)
 DT
 DE
 DE
 XX
 XX Synthetic goliath protein sequence #6.
 XX
 KW Goliath protein; antiangiogenic; vasotropic; gene therapy;
 KW dosage form; angiogenesis; neurogenesis; tumour; vascularisation;
 KW cancer; ischaemia; neuroblastoma; neurodegenerative disease;
 KW unrecovered nerve trauma.
 XX
 OS Synthetic.
 XX
 XX W0200193681-A1.
 PN
 PD 13-DEC-2001.
 XX
 XX 01-JUN-2001; 2001WO-US18000.
 XX
 XX 02-JUN-2000; 2000US-0586398.
 PR
 XX
 PA (REGC) UNIV CALIFORNIA.
 XX
 XX Harland R, Baker JC;
 PI
 XX WPI; 2002-147637/19.
 XX
 DR
 XX New compositions comprising goliath proteins, useful for modulating
 PT angiogenesis or neurogenesis in mammals e.g. for preventing or
 PT treating undesirable vascularisation of a tumour, ischaemia or
 PT neurodegenerative disease -
 XX
 XX Disclosure; Page 37-38; 45pp; English.
 PS
 XX The present invention relates to a new pharmaceutical composition that
 CC comprises a goliath polypeptide in dosage form. The goliath polypeptide
 CC has a sequence identity of at least 75% to the protein sequences
 CC (AAU74918-AAU74921) fully defined in the specification. The composition
 CC is useful for modulating angiogenesis or neurogenesis in mammals,
 CC particularly in humans or mice. Specifically, the composition is useful
 CC for the prophylactic and/or therapeutic treatment of excess angiogenesis
 CC e.g. undesirable vascularisation of a tumour or insufficient angiogenesis
 CC e.g. ischaemia, excess neurogenesis e.g. neuroblastoma or insufficient
 CC neurogenesis e.g. neurodegenerative disease or unrecovered nerve trauma.
 CC The present amino acid sequence represents synthetic goliath protein #6
 CC that is one of several artificial goliath proteins (AAU74922-AAU74927)
 CC used in the invention for modulating angiogenesis or neurogenesis.
 XX
 SQ Sequence 428 AA;

Query Match 93.0%; Score 2115; DB 213; Length 428;
 Best Local Similarity 92.8%; Pred. No. 2.6e-219;
 Matches 397; Conservative 11; Mismatches 20; Indels 0; Gaps 0;

Qy 1 MGPPPGAGVSCRGCGPSRLLAWCFILALSPQAPGSRGAENVMTAYLNVSHRVPHTGVNR 60
 Db 1 MGPPPGIGVYCRGCGGAARLLAWCFLLALSPHAFGSRGAENVMTAYLNVGWRVPHTGVNR 60
 Qy 61 TWELSEBEGVYQDSPLPEPVAGVLVPPDGPALNACNPHNTFTVPTVMGSTVQVSWLALI 120
 Db 61 TWELSEBEGVYQDSPLPEPVAGVLVPPDGPALNACNPHNTFTVPTVMGSTVQVSWLALI 120
 Qy 121 ORGGGCTPADKIHILAYERWASGAVIFNPPGTRNEVIMSHPGAVDIIVAIMIGNLKGTKIL 180
 Db 121 ORGGGCTPADKIHILASERGASGAVIFNPPGIRNEVIMSHPGAGDIIVAIMIGNLKGTKIL 180
 Qy 181 OSIORGIOVTWVIEVGKKGPMVNHYSITFFVSVSFFIITATVGYFIFYSARRLRNARAQ 240
 Db 181 OSIORGIOVTWVIEVGKKGPMVNHYSITFFVSVSFFIITATVGYFIFYSARRLRNARAQ 240
 Qy 241 SRKORQLKADAKKAIGKQLRLTKQGDKEIGPDGDSCAVCIELYKPNDLVRLITCNHIFH 300
 Db 241 SRKORQLKADLKAIGKQLRLTKQGDKEIGPDGDSCAVCIELYKPNDLVRLITCNHIFH 300
 Qy 301 KTCVDPMLLKHKTCPCMKCDILKALGIEVDVDSVSLQVPVSNEISNSASSHEEDNRSE 360
 Db 301 MTCVDPMLLEHRTCPMKCDILKALGIEVDVDSVSLQVPVSNEASNTANPHEDSRSE 360
 Qy 361 TASSGYASVQGTDEPPLEEHVQSTNESLQLVNHEANSVADVIPHVDNPTFEDETPDOE 420
 Db 361 TASSGYASVQADEPPLEEHQAQSANENLQLVNHEANSVADVIPHVDNPTFEDETPDOE 420
 Qy 421 TAVREIKS 428
 Db 421 AAVREIKS 428

RESULT 6
 AAU74922
 ID AAU74922 standard; Protein; 428 AA.
 XX
 AC AAU74922;
 XX
 XX 23-APR-2002 (first entry)
 DT
 DE
 DE
 XX Synthetic goliath protein sequence #1.
 XX
 KW Goliath protein; antiangiogenic; vasotropic; gene therapy;
 KW dosage form; angiogenesis; neurogenesis; tumour; vascularisation;
 KW cancer; ischaemia; neuroblastoma; neurodegenerative disease;
 KW unrecovered nerve trauma.
 XX
 OS Synthetic.
 XX
 PN W0200193681-A1.
 PD 13-DEC-2001.
 XX
 XX 01-JUN-2001; 2001WO-US18000.
 XX
 XX 02-JUN-2000; 2000US-0586398.
 XX
 XX (REGC) UNIV CALIFORNIA.
 XX
 XX Harland R, Baker JC;
 PI
 XX WPI; 2002-147637/19.
 XX
 PT New compositions comprising goliath proteins, useful for modulating
 PT angiogenesis or neurogenesis in mammals e.g. for preventing or
 PT treating undesirable vascularisation of a tumour, ischaemia or
 PT neurodegenerative disease -
 XX
 XX Disclosure; Page 32-33; 45pp; English.
 PS
 XX The present invention relates to a new pharmaceutical composition that
 CC comprises a goliath polypeptide in dosage form. The goliath polypeptide

AAU74923;
 23-APR-2002 (first entry)
 Synthetic gliath protein sequence #2.
 Gliath protein; antiangiogenic; vasotropic; gene therapy;
 dosage form; angiogenesis; neurogenesis; tumour; vascularisation;
 cancer; ischaemia; neuroblastoma; neurodegenerative disease;
 unrecovered nerve trauma.
 Synthetic.
 WO200193681-A1.
 13-DEC-2001.
 01-JUN-2001; 2001WO-US18000.
 02-JUN-2000; 2000US-0586398.
 (REGC) UNIV CALIFORNIA.
 Harland R, Baker JC;
 WPI; 2002-147637/19.
 New compositions comprising gliath proteins, useful for modulating
 angiogenesis or neurogenesis in mammals e.g. for preventing or
 treating undesirable vascularisation of a tumour, ischaemia or
 neurodegenerative disease
 Disclosure; Page 33-34; 45pp; English.
 The present invention relates to a new pharmaceutical composition that
 comprises a gliath polypeptide in dosage form. The gliath polypeptide
 has a sequence identity of at least 75% to the protein sequences
 (AAU74918-AAU74921) fully defined in the specification. The composition
 is useful for modulating angiogenesis or neurogenesis in mammals,
 particularly in humans or mice. Specifically, the composition is useful
 for the prophylactic and/or therapeutic treatment of excess angiogenesis
 e.g. undesirable vascularisation of a tumour or insufficient angiogenesis
 e.g. ischaemia, excess neurogenesis e.g. neuroblastoma or insufficient
 neurogenesis e.g. neurodegenerative disease or unrecovered nerve trauma.
 The present amino acid sequence represents synthetic gliath protein #2
 that is one of several artificial gliath proteins (AAU74922-AAU74927)
 used in the invention for modulating angiogenesis or neurogenesis.
 Sequence 428 AA;
 Query Match 92.7%; Score 2110; DB 23; Length 428;
 Best Local Similarity 92.8%; Pred. No. 8.9e-219;
 Matches 397; Conservative 11; Mismatches 20; Indels 0; Gaps 0;
 1 MGPPPGAGVSCRGCGFSRLLAWCFLLALSPQAGSRGAEAVMTAYLNVSRVPHGTGVR 60
 1 MGPPPGIGYVCGGCGAARLLAWCFLLALSPHAFSGRGAETAYLNVSRVPHGTGVR 60
 61 TWELSEGVGQDSPLPVPAGVLVPPDGPALNACNPHNTPTVTWGSTVQVSWLALI 120
 61 TWELSEGVGQDSPLPVPAGVLVPPDGPALNACNPHNTPTVTWGSTVQVSWLALI 120
 121 QRGGCTFADKIHLYERWASGAVIFNPPGTRNEVPMHSPGAVDIIVAIMIGNLKGTKIL 180
 121 QRGGCTFADKIHLYERWASGAVIFNPPGTRNEVPMHSPGAVDIIVAIMIGNLKGTKIL 180
 181 QSIQRGIQVTWVIEVKKHGPMWNHYSIFVSVSFFIITAATVGYFYSARRLRNARAQ 240
 181 QSIQRGIQVTWVIEVKKHGPMWNHYSIFVSVSFFIITAATVGYFYSARRLRNARAQ 240
 241 SRKQRLKADAKAIGRLQLRTLKQDKEIGPDGSCAVCIELYPKNDLVRLTCNHFH 300
 241 SRKQRLKADGKKAIGRLQLRTLKQDKEIGPDGSCAVCIELYPKNDLVRLTCNHFH 300

301 KTCVDPWLLKHTCPMCKCDILKALGIEVDVSDGVSLSQVPSNEISNSASSHEEDNRSE 360
 301 GTCVDPWLLKHTCPMCKCDILKALGIEVDVSDGVSLSQVPSNEASNTAIPHEEDSRSE 360
 361 TASSGYASVQGTDEPPLPEEHVQSTNESLQVNVNHEANSVAVDVIPIHVDNPTFEEDETPNOE 420
 361 TASSGYASVQGADEPPLPEEHAQSANENLQVNVNHEANSVAVKVPVHDVNDPTFEEDETPNOE 420
 421 TAVREIKS 428
 421 AAVREIKS 428
 RESULT 9
 AAU74926
 ID AAU74926 standard; Protein; 428 AA.
 XX
 AC AAU74926;
 XX
 DT 23-APR-2002 (first entry)
 XX
 DE Synthetic gliath protein sequence #5.
 XX
 KW Gliath protein; antiangiogenic; vasotropic; gene therapy;
 KW dosage form; angiogenesis; neurogenesis; tumour; vascularisation;
 KW cancer; ischaemia; neuroblastoma; neurodegenerative disease;
 KW unrecovered nerve trauma.
 XX
 OS Synthetic.
 XX
 PN WO200193681-A1.
 XX
 PD 13-DEC-2001.
 XX
 PF 01-JUN-2001; 2001WO-US18000.
 XX
 PR 02-JUN-2000; 2000US-0586398.
 XX
 PA (REGC) UNIV CALIFORNIA.
 XX
 PI Harland R, Baker JC;
 XX
 DR WPI; 2002-147637/19.
 XX
 PT New compositions comprising gliath proteins, useful for modulating
 PT angiogenesis or neurogenesis in mammals e.g. for preventing or
 PT treating undesirable vascularisation of a tumour, ischaemia or
 PT neurodegenerative disease
 XX
 PS Disclosure; Page 36-37; 45pp; English.
 XX
 CC The present invention relates to a new pharmaceutical composition that
 CC comprises a gliath polypeptide in dosage form. The gliath polypeptide
 CC has a sequence identity of at least 75% to the protein sequences
 CC (AAU74918-AAU74921) fully defined in the specification. The composition
 CC is useful for modulating angiogenesis or neurogenesis in mammals,
 CC particularly in humans or mice. Specifically, the composition is useful
 CC for the prophylactic and/or therapeutic treatment of excess angiogenesis
 CC e.g. undesirable vascularisation of a tumour or insufficient angiogenesis
 CC e.g. ischaemia, excess neurogenesis e.g. neuroblastoma or insufficient
 CC neurogenesis e.g. neurodegenerative disease or unrecovered nerve trauma.
 CC The present amino acid sequence represents synthetic gliath protein #5
 CC that is one of several artificial gliath proteins (AAU74922-AAU74927)
 CC used in the invention for modulating angiogenesis or neurogenesis.
 XX
 SQ Sequence 428 AA;
 Query Match 92.7%; Score 2108; DB 23; Length 428;
 Best Local Similarity 92.8%; Pred. No. 1.5e-218;
 Matches 397; Conservative 11; Mismatches 20; Indels 0; Gaps 0;
 1 MGPPPGAGVSCRGCGFSRLLAWCFLLALSPQAGSRGAEAVMTAYLNVSRVPHGTGVR 60

Db 1 MGPPPGVYCRGGCGAARLLAWCFLLALSPHAPSGRGAEEVMTAYLVNFWRPHTGVNR 60
QY 61 TWELSEEGVYQDSPLPVPVAGVLPDPGPGALNACNPHNTFTVTVWGSTVQVSWLALI 120
Db 61 TWELSEEGVYQDSPLPVPVAGVLPDPGPGALNACNPHNTFTVTVWGSTVQVSWLALI 120
QY 121 QRGGGCTFADKIHLYERWASGAVIFNPFPGTRNEVPMSPHAGVDIVAIMIGNLKGTKIL 180
Db 121 QRGGGCTFADKIHLYERWASGAVIFNPFGRNEVPMSPHAGVDIVAIMIGNLKGTKIL 180
QY 181 QSTQGIQVTWIEVCKKHGPMWNYHSIFVSVSPFIITAAATVGYFIFYSARRLRNARQ 240
Db 181 QSTQGIQVTWIEVCKKHGPMWNYHSIFVSVSPFIITAAATVGYFIFYSARRLRNARQ 240
QY 241 SRKQRLKADAKKAIKQLRLTKQDKEIGPDGSCAVCIELYKPNLVLRLTCNHIFH 300
Db 241 SRKQRLKADAKKAIKQLRLTKQDKEIGPDGSCAVCIELYKPNLVLRLTCNHIFH 300
QY 301 KTCVDPWLLKHTCPMKCDILKALGIEVDVSGSVLQVPSNEISASHEEDNRSE 360
Db 301 LTCVDPWLLKHTCPMKCDILKALGIEVDVSGSVLQVPSNEASNTAMPHEEDSRSE 360
QY 361 TASSGVASVQGTDEPPLEHVSQTNESLQVNHANSVAVDVI PHVDNPTFEDETPNOE 420
Db 361 TASSGVASVQGTDEPPLEHVSQTNESLQVNHANSVAVDVI PHVDNPTFEDETPNOE 420
QY 421 TAVREIKS 428
Db 421 AAVREIKS 428
RESULT 10
AAU74924
ID AAU74924 standard; Protein; 428 AA.
XX AC AAU74924;
XX DT 23-APR-2002 (first entry)
XX DE Synthetic gliath protein sequence #3.
XX KW Gliath protein; antiangiogenic; vasotropic; gene therapy;
KW dosage form; angiogenesis; neurogenesis; tumour; vascularisation;
KW cancer; ischaemia; neuroblastoma; neurodegenerative disease;
KW unrecovered nerve trauma.
XX OS Synthetic.
XX PN WO200193681-A1.
XX PD 13-DEC-2001.
XX PF 01-JUN-2001; 2001WO-US18000.
XX PR 02-JUN-2000; 2000US-0586398.
XX PA (REGC) UNIV CALIFORNIA.
XX PI Harland R, Baker JC;
XX DR WPI; 2002-147637/19.
XX PT New compositions comprising gliath proteins, useful for modulating
PT angiogenesis or neurogenesis in mammals e.g. for preventing or
PT treating undesirable vascularisation of a tumour, ischaemia or
PT neurodegenerative disease -
XX PS Disclosure; Page 34-35; 45pp; English.
XX CC The present invention relates to a new pharmaceutical composition that
CC comprises a gliath polypeptide in dosage form. The gliath polypeptide
CC has a sequence identity of at least 75% to the protein sequences

CC (AAU74918-AAU74921) fully defined in the specification. The composition
is useful for modulating angiogenesis or neurogenesis in mammals,
CC particularly in humans or mice. Specifically, the composition is useful
for the prophylactic and/or therapeutic treatment of excess angiogenesis
CC e.g. undesirable vascularisation of a tumour or insufficient angiogenesis
CC e.g. ischaemia, excess neurogenesis e.g. neuroblastoma or insufficient
CC neurogenesis e.g. neurodegenerative disease or unrecovered nerve trauma.
CC The present amino acid sequence represents synthetic gliath protein #3
CC that is one of several artificial gliath proteins (AAU74922-AAU74927)
CC used in the invention for modulating angiogenesis or neurogenesis.
XX SQ Sequence 428 AA;
Query Match 92.6%; Score 2116; DB 23; Length 428;
Best Local Similarity 92.8%; Pred. No. 2.4e-218;
Matches 397; Conservative 10; Mismatches 21; Indels 0; Gaps 0;
QY 1 MGPPPGVYCRGGCGFSLALWCFLLALSPHAPSGRGAEEVMTAYLVNFWRPHTGVNR 60
Db 1 MGPPPGVYCRGGCGAARLLAWCFLLALSPHAPSGRGAEEVMTAYLVNFWRPHTGVNR 60
QY 61 TWELSEEGVYQDSPLPVPVAGVLPDPGPGALNACNPHNTFTVTVWGSTVQVSWLALI 120
Db 61 TWELSEEGVYQDSPLPVPVAGVLPDPGPGALNACNPHNTFTVTVWGSTVQVSWLALI 120
QY 121 QRGGGCTFADKIHLYERWASGAVIFNPFGRNEVPMSPHAGVDIVAIMIGNLKGTKIL 180
Db 121 QRGGGCTFADKIHLYERWASGAVIFNPFGRNEVPMSPHAGVDIVAIMIGNLKGTKIL 180
QY 181 QSTQGIQVTWIEVCKKHGPMWNYHSIFVSVSPFIITAAATVGYFIFYSARRLRNARQ 240
Db 181 QSTQGIQVTWIEVCKKHGPMWNYHSIFVSVSPFIITAAATVGYFIFYSARRLRNARQ 240
QY 241 SRKQRLKADAKKAIKQLRLTKQDKEIGPDGSCAVCIELYKPNLVLRLTCNHIFH 300
Db 241 SRKQRLKADAKKAIKQLRLTKQDKEIGPDGSCAVCIELYKPNLVLRLTCNHIFH 300
QY 301 KTCVDPWLLKHTCPMKCDILKALGIEVDVSGSVLQVPSNEISASHEEDNRSE 360
Db 301 LTCVDPWLLKHTCPMKCDILKALGIEVDVSGSVLQVPSNEASNTAMPHEEDSRSE 360
QY 361 TASSGVASVQGTDEPPLEHVSQTNESLQVNHANSVAVDVI PHVDNPTFEDETPNOE 420
Db 361 TASSGVASVQGTDEPPLEHVSQTNESLQVNHANSVAVDVI PHVDNPTFEDETPNOE 420
QY 421 TAVREIKS 428
Db 421 AAVREIKS 428
RESULT 11
AAU74924
ID AAU74924 standard; Protein; 427 AA.
XX AC AAU74924;
XX DT 25-MAR-2002 (first entry)
XX DE Mouse GRAIL.
XX KW Murine; human; GRAIL; energy; attenuation; tyrosine; phosphorylation;
KW antigenic stimulation; interleukin-2; gene therapy; polymorphism; IL-2;
KW autoimmune disease; tumour cell; cancer; transplant rejection.
XX OS Mus musculus.
XX FH Key Location/Qualifiers
FT Domain 339..413
FT /label= zinc_RING_finger_domain
FT /note= "Mediates protein/protein interaction"
XX PN WO200185943-A1.

PD 15-NOV-2001.
 XX 11-MAY-2001; 2001WO-US15385.
 XX 11-MAY-2000; 2000US-203513P.
 XX (STRD) UNIV LELAND STANFORD JUNIOR.
 PA Ford GS, Bloom D, Fathman CG;
 XX MPI; 2002-055597/07.
 XX N-PSDB; AAI72094.
 PT Novel nucleic acid sequences of anergy associated genes, including
 PT GRAIL gene useful in the evaluation of pathophysiology or immunotherapy
 PT of cancer, autoimmune disease and transplant rejection -
 XX Claim 13; Page 44-45; 50pp; English.
 XX This sequence shows murine GRAIL protein. The GRAIL gene is an
 CC anergy associated gene which is upregulated during the early stages
 CC of induction of anergy. GRAIL has been shown to attenuate IL-2
 CC transcription in T-cells during response to antigenic stimulation.
 CC GRAIL DNA is useful for decreasing the responsiveness of a T cell
 CC population, especially synthesis of interleukin-2 (IL-2) in response to
 CC antigenic stimulation, by up-regulating GRAIL activity in the T cell
 CC population. GRAIL DNA is useful in producing compositions that modulate
 CC induction or maintenance of anergy, for gene therapy, mapping
 CC functional regions of the encoded protein, to analyse a patient sample
 CC for the presence of polymorphisms or alterations in expression of
 CC sequences associated with T cell anergy, disease states, genetic
 CC predisposition to a disease state, and in studying associated
 CC physiological pathways. Modulation of the gene activity in vivo is
 CC useful for prophylactic and therapeutic purposes, such as treating
 CC autoimmune disease and to enhance immune response to tumour cells, and
 CC identification of anergic T cells. GRAIL DNA is useful in the
 CC evaluation of the pathophysiology or immunotherapy of cancer,
 CC autoimmune disease, and transplant rejection. Genetic sequences
 CC involved in anergy induction are useful as markers in the evaluation of
 CC specific immunotherapies. Functional characterization of genes involved
 CC in anergy induction allows the elucidation of the mechanisms of T cell
 CC anergy, including the transcriptional blockade of IL-2, which may be
 CC manipulated to regulate T cell responses in human disease. Modulation
 CC of expression of GRAIL gene is useful in manipulating the anergic
 CC state. The genetic sequences find use alone or in combinations in
 CC determining the expression profile of cells relating to anergy, for
 CC example in screening of candidate biologically active compounds for
 CC modulation of T cell anergy. Expression of GRAIL has been found to
 CC block tyrosine phosphorylation of a protein present in T cells during
 CC activation.
 XX Sequence 427 AA;

Query Match
 Best Local Similarity 91.9%; Score 2090.5; DB 23; Length 427;
 Matches 395; Conservative 11; Mismatches 21; Indels 1; Gaps 1;

QY 1 MGPPPGAGVSCGCGFRLLAWCFLLALSPQAGSGAEAVWTAYLVNSWRVPHGTGVR 60
 Db 1 MGPPPGIGVYCRGGGARLLAWCFLLALSPHAPGSGAEAVWTAYLVNSWRVPHGTGVT 60
 QY 61 TWELSEGVYQDSPLPVGVLVPPDPGALNACNHTNFTVPTWGSTVQVSWLALI 120
 Db 61 RC-GAEREVYQDSPLPVGVLVPPDPGALNACNHTNFTVPTWGSTVQVSWLALI 119
 QY 121 QRGGGCTFADKIHLEWASGAVIFNPGTRNEVIMSHPCGAVDIVAIMGNLKGTKIL 180
 Db 120 QRGGGCTFADKIHLEWASGAVIFNPGTRNEVIMSHPCGAGDIVAIMGNLKGTKIL 179
 QY 181 QSIQRGIQVMTWIEVKKGHPWNHYSIFVSVSFFIITAAATVGVFFIYSARRLRNARQ 240
 Db 180 QSIQRGIQVMTWIEVKKGHPWNHYSIFVSVSFFIITAAATVGVFFIYSARRLRNARQ 239

QY 241 SRKQRLKADAKAIGRLQLRTLKQGDKEIGPDGDSCAVCIELYKPNDLVRLTCNHIFH 300
 Db 240 SRKQRLKADAKAIGRLQLRTLKQGDKEIGPDGDSCAVCIELYKPNDLVRLTCNHIFH 299
 QY 301 KTCVDPWLLKHTCPMKCKDILKALGIEVDVDSGVSLOVPVSNISNSASHEEDNRSE 360
 Db 300 KTCVDPWLLKHTCPMKCKDILKALGIEVDVDSGVSLOVPVSNISNSASHEEDNRSE 359
 QY 361 TASSGYASVQGTDEPPLEHVSQSTNESLQLVNHEANSVAVDVIPHVDNPTFEEDTPOE 420
 Db 360 TASSGYASVQGTDEPPLEHVSQSTNESLQLVNHEANSVAVDVIPHVDNPTFEEDTPOE 419
 QY 421 TAVREIKS 428
 Db 420 AAVREIKS 427

RESULT 12
 AAM40136
 ID AAM40136 standard; Protein; 276 AA.
 XX
 AC AAM40136;
 XX
 DT 22-OCT-2001 (first entry)
 XX
 DE Human polypeptide SEQ ID NO 3281.
 XX
 KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
 KW peripheral nervous system; neuropathy; central nervous system; CNS;
 KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
 KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
 KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
 KW leukaemia.
 XX
 OS Homo sapiens.
 XX
 PN WO200153312-A1.
 XX
 PD 26-JUL-2001.
 XX
 PF 26-DEC-2000; 2000WO-US34263.
 XX
 PR 21-JAN-2000; 2000US-0488725.
 PR 25-APR-2000; 2000US-0552317.
 PR 09-JUL-2000; 2000US-0598042.
 PR 19-JUL-2000; 2000US-0620312.
 PR 03-AUG-2000; 2000US-0653450.
 PR 14-SEP-2000; 2000US-0662191.
 PR 19-OCT-2000; 2000US-0693036.
 PR 29-NOV-2000; 2000US-0727344.
 XX
 (HYSE-) HYSEQ INC.
 XX
 PA Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
 PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
 PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
 XX
 DR WPI; 2001-442253/47.
 DR N-PSDB; AAI59292.
 XX
 PT Novel nucleic acids and polypeptides, useful for treating disorders
 XX such as central nervous system injuries -
 PS Example 5; SEQ ID NO 3281; 10078pp; English.
 XX
 CC The invention relates to human nucleic acids (AAI57798-AAI61369) and
 CC the encoded polypeptides (AAM38642-AA42213) with nootropic,
 CC immunosuppressant and cytostatic activity. The polynucleotides are useful
 CC in gene therapy. A composition containing a polypeptide or polynucleotide
 CC of the invention may be used to treat diseases of the peripheral nervous
 CC system, such as peripheral nervous injuries, peripheral neuropathy and
 CC localised neuropathies and central nervous system diseases, such as
 CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic

CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
 CC utilisation of the activities such as: Immune system suppression,
 CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
 CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
 CC assays for receptor activity, arthritis and inflammation, leukaemias and
 CC C.N.S disorders.
 CC Note: The sequence data for this patent did not form part of the printed
 CC specification.

XX Sequence 276 AA;

Query Match 60.0%; Score 1364; DB 22; Length 276;
 Best Local Similarity 99.2%; Pred No² 2e-138;
 Matches 263; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 164 VDVAIMGNLKGTKILQSGIQRGIVQTMVIEVGKXGPMVNHYSIFFVSFFIITAATV 223

Db 12 VDVAIMGNLKGTKILQSGIQRGIVQTMVIEVGKXGPMVNHYSIFFVSFFIITAATV 71

QY 224 GYFIFYSARLRNARASQKQKADAKAIGRLQRLTKQGDKEIGPDGDSACVCTEL 283

Db 72 GYFIFYSARLRNARASQKQKADAKAIGRLQRLTKQGDKEIGPDGDSACVCTEL 131

QY 284 YKENDLVRILTCNHFHKTCDPWLKHKTCPMCKDILKALGIEVDVDSVSIQVPVS 343

Db 132 YKENDLVRILTCNHFHKTCDPWLLEHRTCPMKCDILKALGIEVDVDSVSIQVPVS 191

QY 344 NEISNASSHEEDNRSETASSGYASVQGTDEPPLEHVQSTNESLQLVNHANSVAVDVI 403

Db 192 NEISNASSHEEDNRSETASSGYASVQGTDEPPLEHVQSTNESLQLVNHANSVAVDVI 251

QY 404 PHVDNPTFEDETPTNOETAVRIKS 428

Db 252 PHVDNPTFEDETPTNOETAVRIKS 276

RESULT 13

AAU15897

ID AAU15897 standard; Protein; 225 AA.

AC AAU15897;

DT 07-NOV-2001 (first entry)

DE Human novel secreted protein, Seq ID 850.

XX Human; immunosuppressive; antiarthritic; antirheumatic;
 KW cytostatic; cardiant; vasotropic; cerebroprotective; nootropic;
 KW neuroprotective; antibacterial; virucide; fungicide; ophthalmological;
 KW vulnary; secreted protein; rheumatoid arthritis;
 KW hyperproliferative disorder; cardiovascular disorder; cardiac arrest;
 KW cerebrovascular disorder; cerebral ischaemia; angiogenesis;
 KW nervous system disorder; Alzheimer's disease; infection; ocular disorder;
 KW corneal infection; wound healing; epithelial cell proliferation;
 KW skin ageing; food additive; preservative; antiproliferative.

OS Homo sapiens.

XX WO200155322-A2.

PN 02-AUG-2001.

PD 17-JAN-2001; 2001WO-US01341.

PF 31-JAN-2000; 2000US-0179065.

XX 04-FEB-2000; 2000US-0180628.

PR 24-FEB-2000; 2000US-0184664.

PR 02-MAR-2000; 2000US-0186350.

PR 16-MAR-2000; 2000US-0189874.

PR 17-MAR-2000; 2000US-0190076.

PR 18-APR-2000; 2000US-0198123.

PR 19-MAY-2000; 2000US-0205515.

PR 07-JUN-2000; 2000US-0209467.

PR 29-JUN-2000; 2000US-0214886.
 PR 30-JUN-2000; 2000US-0215135.
 PR 07-JUL-2000; 2000US-0216647.
 PR 07-JUL-2000; 2000US-0216880.
 PR 11-JUL-2000; 2000US-0217487.
 PR 14-JUL-2000; 2000US-0217496.
 PR 14-JUL-2000; 2000US-0218290.
 PR 26-JUL-2000; 2000US-0220963.
 PR 14-AUG-2000; 2000US-0224518.
 PR 14-AUG-2000; 2000US-0224519.
 PR 14-AUG-2000; 2000US-0225213.
 PR 14-AUG-2000; 2000US-0225214.
 PR 14-AUG-2000; 2000US-0225267.
 PR 14-AUG-2000; 2000US-0225268.
 PR 14-AUG-2000; 2000US-0225270.
 PR 14-AUG-2000; 2000US-0225447.
 PR 14-AUG-2000; 2000US-0225757.
 PR 14-AUG-2000; 2000US-0225758.
 PR 14-AUG-2000; 2000US-0225759.
 PR 18-AUG-2000; 2000US-0226279.
 PR 22-AUG-2000; 2000US-0226681.
 PR 22-AUG-2000; 2000US-0226868.
 PR 22-AUG-2000; 2000US-0227182.
 PR 23-AUG-2000; 2000US-0227009.
 PR 30-AUG-2000; 2000US-0228924.
 PR 01-SEP-2000; 2000US-0229287.
 PR 01-SEP-2000; 2000US-0229343.
 PR 01-SEP-2000; 2000US-0229344.
 PR 01-SEP-2000; 2000US-0229345.
 PR 05-SEP-2000; 2000US-0229509.
 PR 05-SEP-2000; 2000US-0229513.
 PR 06-SEP-2000; 2000US-0230437.
 PR 06-SEP-2000; 2000US-0230438.
 PR 08-SEP-2000; 2000US-0231242.
 PR 08-SEP-2000; 2000US-0231243.
 PR 08-SEP-2000; 2000US-0231244.
 PR 08-SEP-2000; 2000US-0231413.
 PR 08-SEP-2000; 2000US-0231414.
 PR 08-SEP-2000; 2000US-0232080.
 PR 08-SEP-2000; 2000US-0232081.
 PR 12-SEP-2000; 2000US-0231968.
 PR 14-SEP-2000; 2000US-0232397.
 PR 14-SEP-2000; 2000US-0232398.
 PR 14-SEP-2000; 2000US-0232399.
 PR 14-SEP-2000; 2000US-0232400.
 PR 14-SEP-2000; 2000US-0232401.
 PR 14-SEP-2000; 2000US-0233063.
 PR 14-SEP-2000; 2000US-0233064.
 PR 14-SEP-2000; 2000US-0233065.
 PR 21-SEP-2000; 2000US-0234223.
 PR 21-SEP-2000; 2000US-0234274.
 PR 25-SEP-2000; 2000US-0234997.
 PR 25-SEP-2000; 2000US-0234998.
 PR 26-SEP-2000; 2000US-0235484.
 PR 27-SEP-2000; 2000US-0235834.
 PR 27-SEP-2000; 2000US-0235836.
 PR 29-SEP-2000; 2000US-0236327.
 PR 29-SEP-2000; 2000US-0236367.
 PR 29-SEP-2000; 2000US-0236368.
 PR 29-SEP-2000; 2000US-0236369.
 PR 29-SEP-2000; 2000US-0236370.
 PR 02-OCT-2000; 2000US-0236802.
 PR 02-OCT-2000; 2000US-0237037.
 PR 02-OCT-2000; 2000US-0237038.
 PR 02-OCT-2000; 2000US-0237039.
 PR 02-OCT-2000; 2000US-0237040.
 PR 13-OCT-2000; 2000US-0239935.
 PR 13-OCT-2000; 2000US-0239937.
 PR 20-OCT-2000; 2000US-0240960.
 PR 20-OCT-2000; 2000US-0241221.
 PR 20-OCT-2000; 2000US-0241785.

PR 20-OCT-2000; 2000US-0241786.
 PR 20-OCT-2000; 2000US-0241787.
 PR 20-OCT-2000; 2000US-0241808.
 PR 20-OCT-2000; 2000US-0241809.
 PR 20-OCT-2000; 2000US-0241826.
 PR 01-NOV-2000; 2000US-0244617.
 PR 08-NOV-2000; 2000US-0246474.
 PR 08-NOV-2000; 2000US-0246475.
 PR 08-NOV-2000; 2000US-0246476.
 PR 08-NOV-2000; 2000US-0246477.
 PR 08-NOV-2000; 2000US-0246478.
 PR 08-NOV-2000; 2000US-0246523.
 PR 08-NOV-2000; 2000US-0246524.
 PR 08-NOV-2000; 2000US-0246525.
 PR 08-NOV-2000; 2000US-0246526.
 PR 08-NOV-2000; 2000US-0246527.
 PR 08-NOV-2000; 2000US-0246528.
 PR 08-NOV-2000; 2000US-0246532.
 PR 08-NOV-2000; 2000US-0246609.
 PR 08-NOV-2000; 2000US-0246610.
 PR 08-NOV-2000; 2000US-0246611.
 PR 08-NOV-2000; 2000US-0246613.
 PR 17-NOV-2000; 2000US-0249207.
 PR 17-NOV-2000; 2000US-0249208.
 PR 17-NOV-2000; 2000US-0249209.
 PR 17-NOV-2000; 2000US-0249210.
 PR 17-NOV-2000; 2000US-0249211.
 PR 17-NOV-2000; 2000US-0249212.
 PR 17-NOV-2000; 2000US-0249213.
 PR 17-NOV-2000; 2000US-0249214.
 PR 17-NOV-2000; 2000US-0249215.
 PR 17-NOV-2000; 2000US-0249216.
 PR 17-NOV-2000; 2000US-0249217.
 PR 17-NOV-2000; 2000US-0249218.
 PR 17-NOV-2000; 2000US-0249219.
 PR 17-NOV-2000; 2000US-0249224.
 PR 17-NOV-2000; 2000US-0249225.
 PR 17-NOV-2000; 2000US-0249265.
 PR 17-NOV-2000; 2000US-0249266.
 PR 17-NOV-2000; 2000US-0249297.
 PR 17-NOV-2000; 2000US-0249299.
 PR 17-NOV-2000; 2000US-0249299.
 PR 17-NOV-2000; 2000US-0249300.
 PR 01-DEC-2000; 2000US-0250160.
 PR 01-DEC-2000; 2000US-0250391.
 PR 05-DEC-2000; 2000US-0251030.
 PR 05-DEC-2000; 2000US-0251988.
 PR 05-DEC-2000; 2000US-0256719.
 PR 06-DEC-2000; 2000US-0251479.
 PR 08-DEC-2000; 2000US-0251856.
 PR 08-DEC-2000; 2000US-0251868.
 PR 08-DEC-2000; 2000US-0251869.
 PR 08-DEC-2000; 2000US-0251989.
 PR 11-DEC-2000; 2000US-0251990.
 PR 11-DEC-2000; 2000US-0254097.
 PR 05-JAN-2001; 2001US-0259678.
 (HUMA-) HUMAN GENOME SCI INC.
 Rosen CA, Barash SC, Ruben SM;
 WPI; 2001-488783/53.
 DR N-PSDB; AAS25884.
 New nucleic acid molecules encoding 461 human secreted proteins for
 diagnosing, preventing, treating or ameliorating medical conditions and
 used as food additives or preservatives -
 Claim 11; SEQ ID No 850; 980pp; English.
 The invention relates to isolated nucleic acid molecules and their
 encoded secreted proteins. The nucleic acids and proteins are used to
 prevent, treat or ameliorate a medical condition in e.g. humans, mice,
 rabbits, goats, horses, cats, dogs, chickens or sheep. They
 are also used in diagnosing a pathological condition or susceptibility

CC to a pathological condition. Antibodies to the proteins can also
 CC be used in alleviating symptoms associated with the disorders and in
 CC diagnostic immunoassays e.g. radioimmunoassays or enzyme linked
 CC immunoassay (ELISA). Disorders which are diagnosed or treated
 CC include autoimmune diseases e.g. rheumatoid arthritis,
 CC hyperproliferative disorders e.g. neoplasms of the breast or liver,
 CC cardiovascular disorders e.g. cardiac arrest, cerebrovascular disorders
 CC e.g. cerebral ischaemia, angiogenesis, nervous system disorders e.g.
 CC Alzheimer's disease, infections caused by bacteria, viruses and fungi
 CC and ocular disorders e.g. corneal infection, and many other
 CC disorders listed in the specification. The polypeptides can also
 CC be used to aid wound healing and epithelial cell proliferation, to
 CC prevent skin aging due to sunburn, to maintain organs before
 CC transplantation, for supporting cell culture of primary tissues, to
 CC regenerate tissues and in chemotaxis. The polypeptides can also be used
 CC as a food additive or preservative to increase or decrease storage
 CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
 CC minerals, cofactors and other nutritional components. The present
 CC sequence represents a novel secreted protein of the invention.

Query Match 49.8%; Score 1134; DB 22; Length 225;
 Best Local Similarity 99.1%; Pred. No. 1.le-113;
 Matches 218; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 209 FVVSFFIITATGCFYFYSARRLRNARQSRQRLKADAKKAIQRLTLKQGDK 268
 DB 6 FVVSFFIITATGCFYFYSARRLRNARQSRQRLKADAKKAIQRLTLKQGDK 65
 QY 269 EIGPDGSCAVCIELYKPNLDVRLITCNHIFHKTCDPMLLKHKTCPMCKDILKALGIE 328
 DB 66 EIGPDGSCAVCIELYKPNLDVRLITCNHIFHKTCDPMLLKHKTCPMCKDILKALGIE 125
 QY 329 VDVEDGSVSLQVPVSNEISNSASSHEEDNRSETASGVASVQGTDEPPLEHVQSTNESL 388
 DB 126 VDVEDGSVSLQVPVSNEISNSASSHEEDNRSETASGVASVQGTDEPPLEHVQSTNESL 185
 QY 389 QLVNHEANSVAVDVIPHDVNPTEDETPNQETAVREIKS 428
 DB 186 QLVNHEANSVAVDVIPHDVNPTEDETPNQETAVREIKS 225

RESULT 14

AAU25459

ID AAU25459 standard; Protein; 294 AA.

XX AAU25459;

XX 18-DEC-2001 (first entry)

XX Human mddt protein from clone LI:757439.1:2000MAY01.

Human; molecules for disease detection and treatment; mddt;
 KW Antiarteriosclerotic; hepatotropic; antipsoriatic; cytostatic;
 KW immunosuppressive; antidiabetic; antiasthmatic; neuroprotective;
 KW osteopathic; antiarthritic; cell proliferative disorder;
 KW arteriosclerosis; cirrhosis; psoriasis; cancer; adenocarcinoma;
 KW leukaemia; breast cancer; autoimmune disorder; AIDS;
 KW acquired immunodeficiency syndrome; Addison's disease;
 KW diabetes mellitus; asthma; multiple sclerosis; osteoarthritis.

XX Homo sapiens.

XX WO200162922-A2.

XX 30-AUG-2001.

XX 21-FEB-2001; 2001WO-US05896.

XX 24-FEB-2000; 2000US-0185213.

XX 16-MAY-2000; 2000US-0205232.

XX 17-MAY-2000; 2000US-0205285.

XX 17-MAY-2000; 2000US-0205286.

XX 17-MAY-2000; 2000US-0205287.

PR 17-MAY-2000; 2000US-0205323.
 PR 17-MAY-2000; 2000US-0205324.
 XX (INCY-) INCYTE GENOMICS INC.
 XX Panzer SR, Spiro PA, Banville SC, Shah P, Chalup MS, Chang SC;
 PI Chen A, D'Sa SA, Anshey S, Dahl CR, Dam TC, Daniels SE;
 PI Dufour GE, Flores V, Fong WT, Greenwalt LB, Hillman JL, Jones AL;
 PI Liu TF, Roseberry AM, Rosen BH, Russo FD, Stockdreher TK, Daffo A;
 PI Wright RJ, Yap PE, Yu JY, Bradley DL, Bratcher SR, Chen W;
 PI Cohen HJ, Hodgson DM, Lincoln SE, Jackson S;
 XX WPI; 2001-570631/64.
 DR N-PSDB; AAS42511.
 XX
 XX New disease detection and treatment molecule polynucleotides and
 PT polypeptides, useful for diagnosis and treatment of arteriosclerosis,
 PT cirrhosis, psoriasis, cancer, autoimmune disorders, diabetes mellitus,
 PT asthma and multiple sclerosis
 XX
 XX Claim 27; Page 170-171; 183pp; English.
 CC The invention relates to novel human molecules for disease
 CC detection and treatment (mdt proteins) and the polynucleotides encoding
 CC them. The MDDT polynucleotides and polypeptides are useful for diagnostic
 CC and therapeutic purposes e.g. to diagnose and treat cell proliferative
 CC disorders (e.g. arteriosclerosis, cirrhosis and psoriasis) cancers (e.g.
 CC adenocarcinoma, leukaemia and breast cancer) autoimmune disorders
 CC (e.g. acquired immunodeficiency syndrome (AIDS) and Addison's disease)
 CC diabetes mellitus, asthma, multiple sclerosis, osteoarthritis, and many
 CC more diseases given in the specification. The present sequence
 CC represents an mddt protein of the invention.
 XX
 SQ Sequence 294 AA;
 Query Match 45.2%; Score 1027.5; DB 22; Length 294;
 Best Local Similarity 76.1%; Pred. No. 5.5e-102;
 Matches 201; Conservative 7; Mismatches 25; Indels 31; Gaps 3;
 QY 1 MGPPPGAGVSCRGCGFSLALWCFLLALSPQAGSRGAEAVWTAYLVNSVRVHTGVNR 60
 DB 43 MGPPPGAGVSCRGCGFSLALWCFLLALSPQAGSRGAEAVWTAYLVNSVRVHTGVNR 102
 QY 61 TWELSEGVYQDSPLVAVGLVPPDPGALNACNPHNTFTVPTVWGSTVQVSWLALI 120
 DB 103 TWELSEGVYQDSPLVAVGLVPPDPGALNACNPHNTFTVPTVWGSTVQVSWLGLI 162
 QY 121 QRGCGCTFADKTHLAYERVASGAVIFNFPGTENEVTPMSPHGAVDIVAIMIGNL---KGT 177
 DB 163 QRGCGCTFADKTHLAYERVASGAVIFNFPGTENEVTPMSPHGAVDIVAIMIRQSRHKN 222
 QY 178 KILQSGRGIQVTWIEVGKXGHPVWYNH-----YSIFFVSVSFFIITAATVG 224
 DB 223 AI-----YSKRHTSDNGHRSREKTPWLGESLNFRRFLCPFLLRRATVG 267
 QY 225 YFIFYSARLRNARQSRKQRLK 248
 DB 268 YFIFYSARLRNARQSRKQRLK 291
 RESULT 15
 AAU16353
 ID AAU16353 standard; Protein; 165 AA.
 XX
 AC AAU16353;
 XX
 DT 07-NOV-2001 (first entry)
 XX Human novel secreted protein, Seq ID 1306.
 DE
 XX Human; immunosuppressive; antiarthritic; antirheumatic;
 KW cytostatic; cardiant; vasotropic; cerebroprotective; nootropic;
 KW neuroprotective; antibacterial; virucide; fungicide; ophthalmological;

KW vulnery; secreted protein; rheumatoid arthritis;
 KW hyperproliferative disorder; cardiovascular disorder; cardiac arrest;
 KW cerebrovascular disorder; cerebral ischaemia; angiogenesis;
 KW nervous system disorder; Alzheimer's disease; infection; ocular disorder;
 KW corneal infection; wound healing; epithelial cell proliferation;
 KW skin ageing; food additive; preservative; antiproliferative.
 XX Homo sapiens.
 XX WO200155322-A2.
 DN
 XX
 XX 02-AUG-2001.
 XX
 XX 17-JAN-2001; 2001WO-US01341.
 XX
 XX 31-JAN-2000; 2000US-0179065.
 PR 04-FEB-2000; 2000US-0180628.
 PR 24-FEB-2000; 2000US-0184664.
 PR 02-MAR-2000; 2000US-0186350.
 PR 16-MAR-2000; 2000US-0189874.
 PR 17-MAR-2000; 2000US-0190076.
 PR 18-APR-2000; 2000US-0198123.
 PR 19-MAY-2000; 2000US-0205515.
 PR 07-JUN-2000; 2000US-0209467.
 PR 28-JUN-2000; 2000US-0214886.
 PR 30-JUN-2000; 2000US-0215135.
 PR 07-JUL-2000; 2000US-0216647.
 PR 07-JUL-2000; 2000US-0218880.
 PR 11-JUL-2000; 2000US-0217487.
 PR 11-JUL-2000; 2000US-0217496.
 PR 14-JUL-2000; 2000US-0218290.
 PR 26-JUL-2000; 2000US-0220963.
 PR 26-JUL-2000; 2000US-0220964.
 PR 14-AUG-2000; 2000US-0224518.
 PR 14-AUG-2000; 2000US-0224519.
 PR 14-AUG-2000; 2000US-0225213.
 PR 14-AUG-2000; 2000US-0225214.
 PR 14-AUG-2000; 2000US-0225266.
 PR 14-AUG-2000; 2000US-0225267.
 PR 14-AUG-2000; 2000US-0225268.
 PR 14-AUG-2000; 2000US-0225270.
 PR 14-AUG-2000; 2000US-0225447.
 PR 14-AUG-2000; 2000US-0225757.
 PR 14-AUG-2000; 2000US-0225758.
 PR 14-AUG-2000; 2000US-0225759.
 PR 18-AUG-2000; 2000US-0226279.
 PR 22-AUG-2000; 2000US-0226681.
 PR 22-AUG-2000; 2000US-0226688.
 PR 22-AUG-2000; 2000US-0227182.
 PR 23-AUG-2000; 2000US-0227009.
 PR 30-AUG-2000; 2000US-0228924.
 PR 01-SEP-2000; 2000US-0229287.
 PR 01-SEP-2000; 2000US-0229343.
 PR 01-SEP-2000; 2000US-0229344.
 PR 01-SEP-2000; 2000US-0229345.
 PR 05-SEP-2000; 2000US-0229509.
 PR 05-SEP-2000; 2000US-0229513.
 PR 06-SEP-2000; 2000US-0230437.
 PR 06-SEP-2000; 2000US-0230438.
 PR 08-SEP-2000; 2000US-0231242.
 PR 08-SEP-2000; 2000US-0231243.
 PR 08-SEP-2000; 2000US-0231244.
 PR 08-SEP-2000; 2000US-0231413.
 PR 08-SEP-2000; 2000US-0231414.
 PR 08-SEP-2000; 2000US-0232080.
 PR 08-SEP-2000; 2000US-0232081.
 PR 12-SEP-2000; 2000US-0231968.
 PR 14-SEP-2000; 2000US-0232397.
 PR 14-SEP-2000; 2000US-0232398.
 PR 14-SEP-2000; 2000US-0232399.
 PR 14-SEP-2000; 2000US-0232400.
 PR 14-SEP-2000; 2000US-0232401.
 PR 14-SEP-2000; 2000US-0233063.

PR 14-SEP-2000; 2000US-0233064.
 PR 21-SEP-2000; 2000US-0233065.
 PR 21-SEP-2000; 2000US-0234223.
 PR 21-SEP-2000; 2000US-0234274.
 PR 25-SEP-2000; 2000US-0234997.
 PR 25-SEP-2000; 2000US-0234998.
 PR 26-SEP-2000; 2000US-0235484.
 PR 27-SEP-2000; 2000US-0235834.
 PR 27-SEP-2000; 2000US-0235836.
 PR 29-SEP-2000; 2000US-0236327.
 PR 29-SEP-2000; 2000US-0236367.
 PR 29-SEP-2000; 2000US-0236368.
 PR 29-SEP-2000; 2000US-0236369.
 PR 29-SEP-2000; 2000US-0236370.
 PR 02-OCT-2000; 2000US-0236802.
 PR 02-OCT-2000; 2000US-0237037.
 PR 02-OCT-2000; 2000US-0237038.
 PR 02-OCT-2000; 2000US-0237039.
 PR 02-OCT-2000; 2000US-0237040.
 PR 13-OCT-2000; 2000US-0239935.
 PR 13-OCT-2000; 2000US-0239937.
 PR 20-OCT-2000; 2000US-0240960.
 PR 20-OCT-2000; 2000US-0241221.
 PR 20-OCT-2000; 2000US-0241785.
 PR 20-OCT-2000; 2000US-0241786.
 PR 20-OCT-2000; 2000US-0241787.
 PR 20-OCT-2000; 2000US-0241808.
 PR 20-OCT-2000; 2000US-0241809.
 PR 20-OCT-2000; 2000US-0241826.
 PR 01-NOV-2000; 2000US-0244617.
 PR 01-NOV-2000; 2000US-0244618.
 PR 08-NOV-2000; 2000US-0246474.
 PR 08-NOV-2000; 2000US-0246475.
 PR 08-NOV-2000; 2000US-0246476.
 PR 08-NOV-2000; 2000US-0246477.
 PR 08-NOV-2000; 2000US-0246478.
 PR 08-NOV-2000; 2000US-0246523.
 PR 08-NOV-2000; 2000US-0246524.
 PR 08-NOV-2000; 2000US-0246525.
 PR 08-NOV-2000; 2000US-0246526.
 PR 08-NOV-2000; 2000US-0246527.
 PR 08-NOV-2000; 2000US-0246528.
 PR 08-NOV-2000; 2000US-0246532.
 PR 08-NOV-2000; 2000US-0246539.
 PR 08-NOV-2000; 2000US-0246600.
 PR 08-NOV-2000; 2000US-0246610.
 PR 08-NOV-2000; 2000US-0246611.
 PR 08-NOV-2000; 2000US-0246613.
 PR 17-NOV-2000; 2000US-0249207.
 PR 17-NOV-2000; 2000US-0249208.
 PR 17-NOV-2000; 2000US-0249209.
 PR 17-NOV-2000; 2000US-0249210.
 PR 17-NOV-2000; 2000US-0249211.
 PR 17-NOV-2000; 2000US-0249212.
 PR 17-NOV-2000; 2000US-0249213.
 PR 17-NOV-2000; 2000US-0249214.
 PR 17-NOV-2000; 2000US-0249215.
 PR 17-NOV-2000; 2000US-0249216.
 PR 17-NOV-2000; 2000US-0249217.
 PR 17-NOV-2000; 2000US-0249218.
 PR 17-NOV-2000; 2000US-0249219.
 PR 17-NOV-2000; 2000US-0249244.
 PR 17-NOV-2000; 2000US-0249245.
 PR 17-NOV-2000; 2000US-0249264.
 PR 17-NOV-2000; 2000US-0249265.
 PR 17-NOV-2000; 2000US-0249266.
 PR 17-NOV-2000; 2000US-0249297.
 PR 17-NOV-2000; 2000US-0249299.
 PR 17-NOV-2000; 2000US-0249300.
 PR 01-DEC-2000; 2000US-0250160.
 PR 01-DEC-2000; 2000US-0250391.
 PR 05-DEC-2000; 2000US-0251030.
 PR 05-DEC-2000; 2000US-0251988.
 PR 05-DEC-2000; 2000US-0256719.
 PR 06-DEC-2000; 2000US-0251479.
 PR 08-DEC-2000; 2000US-0251856.
 PR 08-DEC-2000; 2000US-0251868.

PR 08-DEC-2000; 2000US-0251869.
 PR 08-DEC-2000; 2000US-0251889.
 PR 08-DEC-2000; 2000US-0251990.
 PR 11-DEC-2000; 2000US-0254097.
 PR 05-JAN-2001; 2001US-0259678.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 XX
 XX Rosen CA, Barash SC, Ruben SM;
 PI MPI; 2001-488783/53.
 XX DR N-PSDB; AAS26340.
 XX
 PT New nucleic acid molecules encoding 461 human secreted proteins for
 PT diagnosing, preventing, treating or ameliorating medical conditions and
 PT used as food additives or preservatives -
 XX
 XX
 PS Claim 11; SEQ ID No 1306; 980pp; English.
 XX

The invention relates to isolated nucleic acid molecules and their encoded secreted proteins. The nucleic acids and proteins are used to prevent, treat or ameliorate a medical condition in e.g. humans, mice, rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used in diagnosing a pathological condition or susceptibility to a pathological condition. Antibodies to the proteins can also be used in alleviating symptoms associated with the disorders and in diagnostic immunoassays e.g. radioimmunoassays or enzyme linked immunosorbent assays (ELISA). Disorders which are diagnosed or treated include autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g. neoplasms of the breast or liver, cardiovascular disorders e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia, angiogenesis, nervous system disorders e.g. Alzheimer's disease, infections caused by bacteria, viruses and fungi and ocular disorders e.g. corneal infection, and many other disorders listed in the specification. The polypeptides can also be used to aid wound healing and epithelial cell proliferation, to prevent skin aging due to sunburn, to maintain organs before transplantation, for supporting cell culture of primary tissues, to regenerate tissues and in chemotaxis. The polypeptides can also be used as a food additive or preservative to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors and other nutritional components. The present sequence represents a novel secreted protein of the invention.

Query Match 36.8%; Score 838; DB 22; Length 165;

Best Local Similarity 97.5%; Pred. No. 6.6e-82;

Matches 157; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 268 KEIGPDGDSCAVCIELYKPNLVRILTCNHPHKTCTVDPWLLKHKTCPMKCDILKALGI 327

DB 5 RXIGPDGDSCAVCIELYKPNLVRILTCNHPHKTCTVDPWLLKHKTCTCPMKCDILKALGI 64

QY 328 EVDVEDGSVLSQVPVNSNELSNASSHEEDNRSETASSGVASVQGTDEPPELHVOSTNES 387

DE 65 EVDVEDGSVLSQVPVNSNELSNASSHEEDNRSETASSGVASVQGTDEPPELHVOSTNES 124

QY 388 LQLVNHANSVADVIPHVDNPTFEDETPNQETAVERIKS 428

DB 125 LQLVNHANSVADVIPHVDNPTFEDETPNQETAVERIKS 165

Search completed: April 22, 2003, 08:25:54

Job time : 78 secs

GenCore version 5.1.4.p5.4578
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: April 22, 2003, 08:22:11 ; Search time 35 Seconds

(without alignments)
2519.662 Million cell updates/sec

Title: US-09-854-300-8

Perfect score: 2275

Sequence: 1 MGPPPGAGVSCRCGCGFSRL.....PTREEDTPNQETAVERIKS 428

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 671580 seqs, 206047115 residues

Total number of hits satisfying chosen parameters: 671580

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

SPTREMBL 21.*

- 1: sp_archaea.*
- 2: sp_bacteria.*
- 3: sp_fungi.*
- 4: sp_human.*
- 5: sp_invertebrate.*
- 6: sp_mammal.*
- 7: sp_mhc.*
- 8: sp_organelle.*
- 9: sp_phage.*
- 10: sp_plant.*
- 11: sp_rodent.*
- 12: sp_virus.*
- 13: sp_vertebrate.*
- 14: sp_unclassified.*
- 15: sp_virus.*
- 16: sp_bacteriap.*
- 17: sp_archaea.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	2255	99.1	428	Q8TEB7	Q8TEB7 homo sapien
2	2213	97.3	428	Q86RF3	Q86RF3 homo sapien
3	2160	94.9	428	Q9D304	Q9D304 mus musculus
4	2159	94.9	428	Q9JUF8	Q9JUF8 mus musculus
5	2149	94.5	428	Q9DBN3	Q9DBN3 mus musculus
6	1218	53.5	237	Q9CVG1	Q9CVG1 mus musculus
7	930	40.9	376	Q95JW9	Q95JW9 macaca fasc
8	927	40.7	376	Q95K04	Q95K04 macaca fasc
9	910.5	40.0	376	Q8WVZ7	Q8WVZ7 homo sapien
10	829	36.4	316	Q9D3V4	Q9D3V4 mus musculus
11	714	31.4	156	Q9H5E4	Q9H5E4 homo sapien
12	650.5	28.6	426	Q8WU03	Q8WU03 homo sapien
13	595.5	26.2	419	Q8VEM1	Q8VEM1 mus musculus
14	592.5	26.0	419	Q9QZQ6	Q9QZQ6 mus musculus
15	586	25.8	462	Q9ULK6	Q9ULK6 homo sapien
16	468.5	20.6	276	Q9P0J9	Q9P0J9 homo sapien

17	412.5	18.1	461	5	Q8TOM7	Q8TOM7 drosophila
18	356.5	15.7	180	11	Q9CY01	Q9CY01 mus musculus
19	346	15.2	286	5	Q9W0W3	Q9W0W3 drosophila
20	327	14.4	473	5	Q76671	Q76671 caenorhabdi
21	227.5	10.0	310	10	Q9M622	Q9M622 arabidopsis
22	212	9.3	347	11	Q91XF4	Q91XF4 mus musculus
23	211.5	9.3	783	4	Q9NXXD	Q9NXXD homo sapien
24	210	9.2	350	4	Q9H6Y7	Q9H6Y7 homo sapien
25	210	9.2	536	5	Q9V120	Q9V120 drosophila
26	208	9.1	537	10	Q8S7T8	Q8S7T8 oryza sativ
27	205	9.0	424	10	Q9C8W4	Q9C8W4 arabidopsis
28	205	9.0	448	10	Q8VZ14	Q8VZ14 arabidopsis
29	204.5	9.0	431	10	Q9M0N7	Q9M0N7 arabidopsis
30	203	8.9	444	10	Q9M621	Q9M621 arabidopsis
31	203	8.9	456	5	Q9XX98	Q9XX98 caenorhabdi
32	194.5	8.5	324	4	Q9Y3V1	Q9Y3V1 homo sapien
33	191	8.4	891	4	Q9ULT6	Q9ULT6 homo sapien
34	190	8.4	378	10	Q64763	Q64763 arabidopsis
35	189.5	8.3	354	10	Q8S7D2	Q8S7D2 oryza sativ
36	185	8.1	332	10	Q9LQW2	Q9LQW2 arabidopsis
37	184.5	8.1	508	10	Q9C804	Q9C804 arabidopsis
38	184	8.1	404	10	Q9C7T5	Q9C7T5 arabidopsis
39	182.5	8.0	226	11	Q9CYM6	Q9CYM6 mus musculus
40	177	7.8	420	4	Q75866	Q75866 homo sapien
41	177	7.8	420	4	Q8WVF5	Q8WVF5 homo sapien
42	176.5	7.8	362	10	Q9LF64	Q9LF64 arabidopsis
43	172	7.6	291	10	Q9SRQ8	Q9SRQ8 arabidopsis
44	172	7.6	322	10	Q9SMQ0	Q9SMQ0 arabidopsis
45	172	7.6	356	10	Q9SS59	Q9SS59 arabidopsis

ALIGNMENTS

RESULT 1

Q8TEB7
ID Q8TEB7 PRELIMINARY; PRT; 428 AA.
AC Q8TEB7:
DT 01-JUN-2002 (Tremblrel. 21, Created)
DT 01-JUN-2002 (Tremblrel. 21, Last sequence update)
DT 01-JUN-2002 (Tremblrel. 21, Last annotation update)
DE CDNA FLJ23684 fis, clone HEP09821.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA Okitani R., Oka T., Suzuki Y., Obayashi M., Nishi T., Shibahara T.,
RA Tanaka T., Nakamura Y., Isogai T., Sugano S.;
RT "NEO human cDNA sequencing project."
RL Submitted (FEB-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AK074264; BAB85033.1; -.
SQ SEQUENCE 428 AA; 46520 MW; 32F9CDB32BF208FA CRC64;

Query Match	99.1%	Score 2255;	DB 4;	Length 428;
Best Local Similarity	99.3%	Pred. No. 9.3e-196;		
Matches 425;	Conservative	2;	Mismatches 1;	Indels 0;
Gaps	0;			
QY	1	MGPPPGAGVSCRCGCGFSRL	AWCFL	LSPQAPGSRGAEAVMTAYLVNYSWRVPHTGVNR 60
Db	1	MGPPPGAGVSCRCGCGFSRL	AWCFL	LSPQAPGSRGAEAVMTAYLVNYSWRVPHTGVNR 60
QY	61	TWELSEGVYQDSPLEPVAGVLVPPD	PGALNACNPHNTFTVPTWGSTVQVSWLAI 120	
Db	61	TWELSEGVYQDSPLEPVAGVLVPPD	PGALNACNPHNTFTVPTWGSTVQVSWLAI 120	
QY	121	QRGGGCTFADKIHLYERWASGAVL	FNPGTRNEVIMPSHPCAVDIVAIMIGLTKTL 180	
Db	121	QRGGGCTFADKIHLYERWASGAVL	FNPGTRNEVIMPSHPCAVDIVAIMIGLTKTL 180	
QY	181	QSTQRGIQVTMVIEWKKGHPWNHYS	IFVSVSFFIITATVGTGYFIFYSARRLRNARQA 240	

```

Db 181 QSIQRGIQVTVVIEVKKGGPWNHYSIFFVSUSFFIITATVGYFIFYSARLRNARAQ 240
QY 241 SRKQRLKADAKKAIGRLQLRTLKQDKETGPDGDSCAVCIELYKPNDLVRLITCNHIFH 300
Db 241 SRKQRLKADAKKAIGRLQLRTLKQDKETGPDGDSCAVCIELYKPNDLVRLITCNHIFH 300
QY 301 KTCVDPMLLKHTKTCMCKCDILKALGIEVDVDSGVSLOVPVNSINSASSHEEDNRSE 360
Db 301 KTCVDPMLLEHRTCPMCKCDILKALGIEVDVDSGVSLOVPVNSINSASSHEEDNRSE 360
QY 361 TASSGYASVQGTDEPPLEEHVQSTNESLQLVNHEANSVAVDVIPIHVDNPTFEEDTPNQ 420
Db 361 TASSGYASVQGTDEPPLEEHVQSTNESLQLVNHEANSVAVDVIPIHVDNPTFEEDTPNQ 420
QY 421 TAVREIKS 428
Db 421 TAVREIKS 428

RESULT 2
ID Q96RF3 PRELIMINARY; PRT; 428 AA.
AC Q96RF3;
DT 01-DEC-2001 (TREMBlrel. 19, Created)
DT 01-DEC-2001 (TREMBlrel. 19, Last sequence update)
DE GRAL.
DE GRAL.
GN GRAL.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Soares L.R., Fathman G.;
RT "Grail: a novel ring finger protein upregulated in anergic T cells.";
RL Submitted (JUN-2001) to the EMBL/GenBank/DBJ databases.
CC -1- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.
DR EMBL; AF394689; AAK77554.1; -.
DR InterPro; IPR003137; PA.
DR Pfam; PF02225; PA; 1.
DR Pfam; PF00097; zf-C3HC4; 1.
KW Zinc-finger.
SQ SEQUENCE 428 AA; 46491 MW; E003DBED8968E45A CRC64;

Query Match 97.3%; Score 2213; DB 4; Length 428;
Best Local Similarity 97.7%; Pred. No. 5.9e-192;
Matches 418; Conservative 2; Mismatches 8; Indels 0; Gaps 0;

QY 1 MGPPPGAGVSCRCGCGFSRLLANCFLLALSPQAPGSRGABAVMTAYLNSWRVPHGTGVR 60
Db 1 MGPLPAGVSCRCGCGFSRLLANCFLLALSPQAPGSRGABAVMTAYLNSWRVPHGTGVR 60
QY 61 TWELSEGVYQDSPLEPVGVLVPPDGPALNACNPHNTFTVPTVMGSTVOVSWLALI 120
Db 61 TWELSEGVYQDSPLEPVGVLVPPDGPALNACNPHNTFTVPTVMGSTVOVSWLALI 120
QY 121 QRGCGCTFADKIHLAYERWASGAVIFNPGTRNEVPMSPHGAVIDIVAIMGNLKGTKIL 180
Db 121 QRGCGCTFADKIHLAYERWASGAVIFNPGTRNEVPMSPHGAVIDIVAIMGNLKGTKIL 180
QY 181 QSIQRGIQVTVVIEVKKGGPWNHYSIFFVSUSFFIITATVGYFIFYSARLRNARAQ 240
Db 181 QSIQRGIQVTVVIEVKKGGPWNHYSIFFVSUSFFIITATVGYFIFYSARLRNARAQ 240
QY 241 SRKQRLKADAKKAIGRLQLRTLKQDKETGPDGDSCAVCIELYKPNDLVRLITCNHIFH 300
Db 241 SRKQRLKADAKKAIGRLQLRTLKQDKETGPDGDSCAVCIELYKPNDLVRLITCNHIFH 300
QY 301 KTCVDPMLLKHTKTCMCKCDILKALGIEVDVDSGVSLOVPVNSINSASSHEEDNRSE 360

```

```

Db 301 KTCVDPMLLEHRTCPMCKCDILKALGIEVDVDSGVSLOVPVNSINSASSHEEDNRSE 360
QY 361 TASSGYASVQGTDEPPLEEHVQSTNESLQLVNHEANSVAVDVIPIHVDNPTFEEDTPNQ 420
Db 361 TASSGYASVQGTDEPPLEEHVQSTNESLQLVNHEANSVAVDVIPIHVDNPTFEEDTPNQ 420
QY 421 TAVREIKS 428
Db 421 TAVREIKS 428

RESULT 3
ID Q9D304 PRELIMINARY; PRT; 428 AA.
AC Q9D304;
DT 01-JUN-2001 (TREMBlrel. 17, Created)
DT 01-JUN-2001 (TREMBlrel. 17, Last sequence update)
DE 1300002C13Rik protein (RIKEN CDNA 1300002C13 gene) (Zinc ring
DE finger-containing protein GRAL).
GN 1300002C13Rik.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RA Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
RA Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,
RA Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamanaka I.,
RA Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,
RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
RA Fleischnann W., Gaasterland T., Gissi C., King B., Kochiwa H.,
RA Kuehl P., Lewis S., Matsuo Y., Mikalido I., Pesole G., Quackenbush J.,
RA Schriml L.M., Staubli F., Suzuki R., Tomita M., Wagner L., Washio T.,
RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,
RA Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,
RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,
RA Gustincich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,
RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,
RA Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,
RA Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,
RA Suzuki H., Toyooka K., Wang K.H., Weitz C., Whittaker C., Wilming L.,
RA Wynshaw-Boris A., Yoshida K., Haegawa Y., Kawaji H., Kohtsuki S.,
RA Hayashizaki Y.;
RT "Functional annotation of a full-length mouse cDNA collection.";
RL Nature 409:685-690(2001).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=BREAST TUMOR;
RA Strausberg R.;
RL Submitted (JUL-2001) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RC STRALN=DBG/2;
RA Ford G.S., Bloom R.Q., Paragas V., Anandasabapathy N., Skrenta H.,
RA Ermann J., Cron R.Q., Lewis D.B., Fathman G.;
RT "GRAL: A novel gene expressed in anergic T cells that inhibits
RT NFAT/AP-1 activation and IL-2 transcription.";
RL Submitted (OCT-2001) to the EMBL/GenBank/DBJ databases.
CC -1- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.
DR EMBL; AK018562; BAB31291.1; -.
DR EMBL; BC010477; AAH10477.1; -.
DR EMBL; AF426411; AAL34514.1; -.
DR MGD; MGI:1914139; 1300002C13Rik.
DR InterPro; IPR003137; PA.
DR InterPro; IPR001841; Znf_ring.
DR Pfam; PF02225; PA; 1.
DR Pfam; PF00097; zf-C3HC4; 1.
DR SMART; SM00184; RING; 1.
KW Zinc-finger.

```

```

SQ SEQUENCE 428 AA; 46276 MW; 480DCP46CT5E238F CRC64;
Query Match 94.9%; Score 2160; DB 11; Length 428;
Best Local Similarity 94.6%; Pred. No. 3.8e-187;
Matches 405; Conservative 10; Mismatches 13; Indels 0; Gaps 0;

QY 1 MGPPPGAGVSCRGCGFSLRLAWCFLLALSPQAPGSRGAEAVMTAYLVNSWRVPHTGVNR 60
DB 1 MGPPPGIGVYCRGGCGAARLLAWCFLLALSPHAPGSRGAEAVMTAYLVNSWRVPHTGVNR 60
QY 61 TWELSEEGVYQDSPLEPVAGLVPPDPGALNACNPHNTFTVPTVMGSTVQVSWLALI 120
DB 61 TWELSEEGVYQDSPLEPVAGLVPPDPGALNACNPHNTFTVPTVMGSTVQVSWLALI 120
QY 121 ORGGGCTFADKTHLAYERWASGAVIFNPPGTRNEVTPMSHPGADVIVAIMGNLKGTKIL 180
DB 121 ORGGGCTFADKTHLAYERWASGAVIFNPPGTRNEVTPMSHPGADVIVAIMGNLKGTKIL 180
QY 181 QSIQGIQVTWIEVKGKGPWNHYSIFPVSPFIITAAATGVYFIFYSARRLRNARQ 240
DB 181 QSIQGIQVTWIEVKGKGPWNHYSIFPVSPFIITAAATGVYFIFYSARRLRNARQ 240
QY 241 SRKQRLKADAKAIGRLQLRTLKQDKEIGPDGSCAVCIELYKPNLVLRLTCNHIFH 300
DB 241 SRKQRLKADAKAIGRLQLRTLKQDKEIGPDGSCAVCIELYKPNLVLRLTCNHIFH 300
QY 301 KTCVDPMLLKHKTCPMCKDILKALGIEVDVDEGVSLSQVPSNEISASHEEDNRSE 360
DB 301 KTCVDPMLLKHKTCPMCKDILKALGIEVDVDEGVSLSQVPSNEISASHEEDNRSE 360
QY 361 TASSGVASVQGTDEPPLEEHVOSTNESLQLVNHEANSVAVDVIPHVDNPTFEDETPNOE 420
DB 361 TASSGVASVQGTDEPPLEEHVOSTNESLQLVNHEANSVAVDVIPHVDNPTFEDETPNOE 420
QY 421 TAVREIKS 428
DB 421 AAVREIKS 428

RESULT 4
Q9JUF8 PRELIMINARY; PRT; 428 AA.
ID Q9JUF8
AC Q9JUF8
DT 01-OCT-2000 (TremBLrel. 15, Created)
DT 01-OCT-2000 (TremBLrel. 15, Last sequence update)
DT 01-DEC-2001 (TremBLrel. 19, Last annotation update)
DE Brain cDNA, clone MNCB-3816, similar to AF171875 gl-related zinc
DE finger protein (Mus musculus).
GN 1300002C13RIK.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J;
RA Osada N., Kusuda J., Tanuma R., Ito A., Hirata M., Sugano S.,
RA Hashimoto K.
RT "Isolation of full-length cDNA clones from mouse brain cDNA library
RT made by oligo-capping method."
RL Submitted (APR-2000) to the EMBL/GenBank/DBSJ databases.
CC -!- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.
DR EMBL; AB041548; BAA95033.1; -
DR MGD; MGI:1914139; 1300002C13RIK.
DR InterPro; IPR003137; PA.
DR Pfam; PF02225; PA; 1.
DR SMART; SM00097; zf-C3HC4; 1.
DR SMART; SM00184; RING; 1.
SQ SEQUENCE 428 AA; 46262 MW; E13AGDCAD67DECBDC CRC64;
Query Match 94.9%; Score 2159; DB 11; Length 428;
Best Local Similarity 94.4%; Pred. No. 4.6e-187;
Matches 404; Conservative 11; Mismatches 13; Indels 0; Gaps 0;

QY 1 MGPPPGAGVSCRGCGFSLRLAWCFLLALSPQAPGSRGAEAVMTAYLVNSWRVPHTGVNR 60
DB 1 MGPPPGIGVYCRGGCGAARLLAWCFLLALSPHAPGSRGAEAVMTAYLVNSWRVPHTGVNR 60
QY 61 TWELSEEGVYQDSPLEPVAGLVPPDPGALNACNPHNTFTVPTVMGSTVQVSWLALI 120
DB 61 TWELSEEGVYQDSPLEPVAGLVPPDPGALNACNPHNTFTVPTVMGSTVQVSWLALI 120
QY 121 ORGGGCTFADKTHLAYERWASGAVIFNPPGTRNEVTPMSHPGADVIVAIMGNLKGTKIL 180
DB 121 ORGGGCTFADKTHLAYERWASGAVIFNPPGTRNEVTPMSHPGADVIVAIMGNLKGTKIL 180
QY 181 QSIQGIQVTWIEVKGKGPWNHYSIFPVSPFIITAAATGVYFIFYSARRLRNARQ 240
DB 181 QSIQGIQVTWIEVKGKGPWNHYSIFPVSPFIITAAATGVYFIFYSARRLRNARQ 240
QY 241 SRKQRLKADAKAIGRLQLRTLKQDKEIGPDGSCAVCIELYKPNLVLRLTCNHIFH 300
DB 241 SRKQRLKADAKAIGRLQLRTLKQDKEIGPDGSCAVCIELYKPNLVLRLTCNHIFH 300
QY 301 KTCVDPMLLKHKTCPMCKDILKALGIEVDVDEGVSLSQVPSNEISASHEEDNRSE 360
DB 301 KTCVDPMLLKHKTCPMCKDILKALGIEVDVDEGVSLSQVPSNEISASHEEDNRSE 360
QY 361 TASSGVASVQGTDEPPLEEHVOSTNESLQLVNHEANSVAVDVIPHVDNPTFEDETPNOE 420
DB 361 TASSGVASVQGTDEPPLEEHVOSTNESLQLVNHEANSVAVDVIPHVDNPTFEDETPNOE 420
QY 421 TAVREIKS 428
DB 421 AAVREIKS 428

RESULT 5
Q9DBN3 PRELIMINARY; PRT; 428 AA.
ID Q9DBN3
AC Q9DBN3
DT 01-JUN-2001 (TremBLrel. 17, Created)
DT 01-JUN-2001 (TremBLrel. 17, Last sequence update)
DT 01-DEC-2001 (TremBLrel. 19, Last annotation update)
DE 1300002C13RIK protein.
GN 1300002C13RIK.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=LIVER;
RC MEDLINE=21085660; PubMed=11217851;
RA Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
RA Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,
RA Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamataka I.,
RA Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,
RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
RA Fleischmann W., Gaasterland T., Gissi C., King B., Kuchiwa H.,
RA Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,
RA Schriml L.M., Staubli F., Suzuki R., Tomita M., Wagner L., Washio T.,
RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,
RA Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,
RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,
RA Gustincich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,
RA Lyons P., Marchionni L., Mashima J., Marzari J., Mombarts P.,
RA Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,
RA Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,
RA Suzuki H., Toyooka K., Wang K.H., Weitz C., Whitaker C., Wilming L.,
RA Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kohtsuki S.,
RA Hayashizaki Y.;
RT "Functional annotation of a full-length mouse cDNA collection.";
RL Nature 409:685-690(2001).

```

CC -1- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.

DR EMBL; AK004847; BAB23613.1; -;
DR MGD; MGI:1914139; 1300002C13Rik.
DR InterPro; IPR003137; PA.
DR InterPro; IPR001841; Znf_ring.
DR Pfam; PF02225; PA; 1.
DR Pfam; PF00097; zf-C3HC4; 1.
DR SMART; SM00184; RING; 1.
KW Zinc-finger.
SQ SEQUENCE 428 AA; 46292 MW; EBA2B50512828B8 CRC64;

Query Match 94.5%; Score 2149; DB 11; Length 428;
Best Local Similarity 94.2%; Pred. No. 3.7e-186;
Matches 403; Conservative 10; Mismatches 15; Indels 0; Gaps 0;

QY 1 MGPPPGAGVSCRGCGFSRLAWCFLLALSPQAPGSRGAETAYLVNSVRVPHGTGVR 60
DB 1 MGPPPGIGVYCRGCGAARLLAWCFLLALSPHAPGSRGAETAYLVNSVRVPHGTGVR 60

QY 61 TWELSEEGVYGQDSPLEPVAGLVPPDGGALNACNPHNTFTVPTVMGSTVQVSWLALI 120
DB 61 TWELSEEGVYGQDSPLEPVAGLVPPDGGALNACNPHNTFTVPTVMGSTVQVSWLALI 120

QY 121 QRGCGCTFADKIHLAVERWASGAVIFNFGTRNEVPMSPHAGDVAIVMIGNLKGTKIL 180
DB 121 QRGCGCTFADKIHLAVERWASGAVIFNFGTRNEVPMSPHAGDVAIVMIGNLKGTKIL 180

QY 181 QSTQGIQVTWIEVKGKGPWNHYSIFVSVSPFIITAAVTGVFIYSARLRNARQA 240
DB 181 QSTQGIQVTWIEVKGKGPWNHYSIFVSVSPFIITAAVTGVFIYSARLRNARQA 240

QY 241 SRKROLKADAKAIGRLQLRTLKQDKEIGPDGSCAVCIELYPNDLVRILTCNHIFH 300
DB 241 SRKROLKADAKAIGRLQLRTLKQDKEIGPDGSCAVCIELYPNDLVRILTCNHIFH 300

QY 301 KTCVDPLWKHKTCMPCKDILKALGIEVDVDEGSLQVPVNSISASHEEDNSE 360
DB 301 KTCVDPLWKHKTCMPCKDILKALGIEVDVDEGSLQVPVNSISASHEEDNSE 360

QY 361 TASSGYASVQGTDEPPLEEHVOSTNESLQVNHANSVAVDVIHVNDNPTFEEDTNPQE 420
DB 361 TASSGYASVQGTDEPPLEEHVOSTNESLQVNHANSVAVDVIHVNDNPTFEEDTNPQE 420

QY 421 TAVREIKS 428
DB 421 AAVREIKS 428

RESULT 6
Q9CVG1 ID Q9CVG1 PRELIMINARY; PRT; 237 AA.

AC Q9CVG1; 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DE 1300002C13Rik protein (Fragment).
GN 1300002C13Rik.

OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.

RC STRAIN=C57BL/6J; TISSUE=SMALL INTESTINE;
RX MEDLINE=21085660; PubMed=11217851;

RA Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
RA Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,
RA Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamanaka I.,
RA Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,
RA Kikuchi K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
RA Fleischnann W., Gaasterland T., Glessi C., King B., Kochiwa H.,
RA Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,
RA Schriml L.M., Staubli F., Suzuki R., Tomita M., Wagner L., Washio T.,

RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,
RA Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,
RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,
RA Gustincich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,
RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,
RA Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,
RA Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.F.,
RA Suzuki H., Toyooka K., Wang K.H., Weitz C., Whittaker C., Wilming L.,
RA Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawai H., Kohtsuki S.,
RA Hayaishizaki Y.,
RT "Functional annotation of a full-length mouse cDNA collection.";
RL Nature 409:685-690(2001).
DR EMBL; AK008312; BAB25595.1; -;
DR MGD; MGI:1914139; 1300002C13Rik.
DR InterPro; IPR003137; PA.
DR Pfam; PF02225; PA; 1.
FT NON_TER 237
SQ SEQUENCE 237 AA; 25344 MW; 319E6AA548F7379B CRC64;

Query Match 53.5%; Score 1218; DB 11; Length 237;
Best Local Similarity 96.2%; Pred. No. 3.8e-102;
Matches 228; Conservative 2; Mismatches 7; Indels 0; Gaps 0;

QY 1 MGPPPGAGVSCRGCGFSRLAWCFLLALSPQAPGSRGAETAYLVNSVRVPHGTGVR 60
DB 1 MGPPPGIGVYCRGCGAARLLAWCFLLALSPHAPGSRGAETAYLVNSVRVPHGTGVR 60

QY 61 TWELSEEGVYGQDSPLEPVAGLVPPDGGALNACNPHNTFTVPTVMGSTVQVSWLALI 120
DB 61 TWELSEEGVYGQDSPLEPVAGLVPPDGGALNACNPHNTFTVPTVMGSTVQVSWLALI 120

QY 121 QRGCGCTFADKIHLAVERWASGAVIFNFGTRNEVPMSPHAGDVAIVMIGNLKGTKIL 180
DB 121 QRGCGCTFADKIHLAVERWASGAVIFNFGTRNEVPMSPHAGDVAIVMIGNLKGTKIL 180

QY 181 QSTQGIQVTWIEVKGKGPWNHYSIFVSVSPFIITAAVTGVFIYSARLRNARQA 237
DB 181 QSTQGIQVTWIEVKGKGPWNHYSIFVSVSPFIITAAVTGVFIYSARLRNARQA 237

RESULT 7
Q95JW9 ID Q95JW9 PRELIMINARY; PRT; 376 AA.

AC Q95JW9; 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DE 01-MAR-2002 (TrEMBLrel. 20, Last annotation update)
DE Hypothetical 42.2 kDa protein.
OS Macaca fascicularis (Crab eating macaque) (Cynomolgus monkey).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Cercopitheidae;
OC Cercopitheidae; Macaca.
OX NCBI_TaxID=9541;
RN [1]
RP SEQUENCE FROM N.A.

RC TISSUE=TESTIS;
RA Hashimoto K., Osada N., Hida M., Kusuda J., Tanuma R., Hirai M.,
RA Terao K., Sugano S.;
RT "Isolation of novel full-length cDNA clones from macaque testis cDNA
RL Submitted (Aug-2001) to the EMBL/GenBank/DBJ databases.
CC -1- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.

DR EMBL; AB070058; BAB63003.1; -;
DR InterPro; IPR001309; ICE_P20.
DR InterPro; IPR003137; PA.
DR InterPro; IPR001841; Znf_ring.
DR Pfam; PF02225; PA; 1.
DR Pfam; PF00097; zf-C3HC4; 1.
DR PROSITE; PS01121; CASPASE_HIS; UNKNOWN_1.
KW Hypothetical protein; Zinc-finger.

SQ SEQUENCE 376 AA; 42248 MW; B349791C19956841 CRC64;

Query Match 40.9%; Score 930; DB 6; Length 376;

InterPro; IPRO01092; HLH_basic.
InterPro; IPRO03137; PA_
InterPro; IPRO01841; Znf_ring.
Pfam; PF02225; PA; 1.
Pfam; PF00097; zf-C3HC4; 1.
SMART; SM00184; RING; 1.
PROSITE; PS00038; HELIX_LOOP_HELIX; UNKNOWN_1.
PROSITE; PS00089; ZF_RING_2; 1.
SEQUENCE 419 AA; 46375 MW; 4E699A6D6D58CBF2 CRC64;

Query Match	26.2%; Score 595.5; DB 11; Length 419;
Best Local Similarity	42.4%; Pred.No. 2.3e-45;
Matches 134; Conservative 49; Mismatches 120; Indels 13; Gaps 7;	

QY	16	GFSRLWACFLALSPQAFSGRGAEMVAYLNVSRVPHTGVNRTVMELSEEGVGQDS	75
DBQ	8	GPALAALLATCSLWPTRADNASQEYYTALINVTVEPGRGTLTF--RIDRGYGLDS	65
QY	76	PLEPVAGVLVPP---DGPALNACNPHTNTPTVTWGSTVQVSWLAIORGCGCTPADKI	132
DBD	66	PKAEVRGOVLAPLIHGADVADHIGCDPQTFFVP----PNIK-QWIALQR-GNCTFKKI	119
QY	133	HLAYERWASGAVIFNFPGTRNEVIPMSHPGAVIDVAIMGNLKGTKILOSIORGIOVTMV	192
DBD	120	SRAAPHNAVAVIYN-NKSKEPVTMTHTPGTDIIAMITELRGKDILSVLEKNISVQMT	178
QY	193	IVGKKHGW-VNHYSIPFVSVFIIITAATVGYFIIFYSARLRNNAQRQRQAKADA	251
DBD	179	IANGTRMPKPNSRGSLVPSISFVLMISSAWLIFYIQIRYTARNDRNRRLGDAA	238
QY	252	KKAIRQLQRLTKOGDKETGGDGSCAVCIELYKPDNLVRIILTCNHI FHKTCVDPMLLKX	311
DBD	239	KKAISKLTRTVKGDKETDPDFDHCAVCIESYKQNDVVRVLPCKGFVHHKSCVDPMLEH	298
QY	312	KTCPMKCKDILKALGI 327	
DBD	299	CTCPMKLNILKALGI 314	

RESULT 14	PRELIMINARY; PRT; 419 AA.
Q9QZQ6	
ID Q9QZQ6; PRELIMINARY; PRT; 419 AA.	
AC Q9QZQ6;	
DT 01-MAY-2000 (TREMBLrel. 13, Created)	
DD 01-MAY-2000 (TREMBLrel. 13, Last sequence update)	
DE 01-MAR-2002 (TREMBLrel. 20, Last annotation update)	
GN GI-related zinc finger protein.	
OS GIRZF OR GIRP.	
OC Mus musculus (Mouse).	
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.	
NCBI_TaxID=10090;	
OR [1]__TaxID=	
RN SEQUENCE FROM N.A.	
RP MEDLINE=20267845; PubMed=10806348;	
RR Baker S.J.; Reddy E.P.;	
RA "Cloning of murine GIRP, a novel gene related to Drosophila	
RT melanogaster gl.";	
RT Gene 248:33-40(2000).	
CC -1- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.	
DR EMBL; AF171875; AAF05310.1; -.	
DR MGDB; MGI:1891717; Girzfp.	
DR InterPro; IPRO01092; HLH_basic.	
DR InterPro; IPRO03137; PA.	
DR InterPro; IPRO01841; Znf_ring.	
DR Pfam; PF02225; PA; 1.	
DR Pfam; PF00097; zf-C3HC4; 1.	
DR SMART; SM00184; RING; 1.	
DR PROSITE; PS00038; HELIX_LOOP_HELIX; UNKNOWN_1.	
DR ZINC-FINGER.	
SK SEQUENCE 419 AA; 46403 MW; F3DF4118EEB61A01 CRC64;	

Query Match	26.0%; Score 592.5; DB 11; Length 419;
-------------	--

Best Local Similarity 42.1%; Pred. No. 4.2e-45;
Matches 133; Conservative 50; Mismatches 120; Indels 13; Gaps 7;

QY 16 GFSRLIACFLALSPQAGSABAVTAVLNVSRRVPHGTGNVTRWELSEEGVYGDS 75
DB 8 GPALAALALLTCSLWPRADNASOEYITALINVTQEPGRGTPLTF--RIDRGYGLDS 65

QY 76 PLEPVAGVLVPP---DGPALNACNPHNTFTVPTVWGSTVQVSMALIQRGGCTFADKI 132
DB 66 PKAERGVQVLAFLPIHGVADHLGCDPQTRFFVP-----PNIK-QMIALIQR-GNCTFKKI 119

QY 133 HLAERWASGAVIENFPPTRENEVPMSPHGAVIDIVAIMIGNLKGTKILQSTQIRGQVTV 192
DB 120 SRAAFNVAVVIYN-NKSKERPTMTHTPGTGDIIVAMITELRGDILSYLEKINISVMT 178

QY 193 IEVKGKGPW-VNHYSIFFVSVPFIITAATVGYFIFYSARRLRNARAQSRKQRLKADA 251
DB 179 IAVGTRMPKPNFSGSLVFSISFVLMIISSAWLIFVFIQIRVYNARDNRQRLGDA 238

QY 252 KKAIGRLQRLTKQKDGKSGDSCAVCIELYKPNDLVRILTCHNHFHKTCTVDPWLLKH 311
DB 239 KKAISKLTRTVKKGKEDPDPDFDHCAVCIESYKQNDVVRVLPCKHVFHKSCVDPWLS 298

QY 312 KTCPMCKCDILKALGI 327
DB 299 CTCPMCKNLILRALGI 314

RESULT 15

Q9ULK6
ID Q9ULK6 PRELIMINARY; PRT; 462 AA.
AC Q9ULK6;
DT 01-MAY-2000 (TRENBLrel. 13, Created)
DT 01-MAY-2000 (TRENBLrel. 13, Last sequence update)
DT 01-DEC-2001 (TRENBLrel. 19, Last annotation update)
DE KIAA1214 protein (Fragment).
GN KIAA1214.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=BRAIN;
RX MEDLINE=20039619; PubMed=10574462;
RA Nagase T., Ishikawa K., Kikuno R., Hirose M., Nomura N., Ohara O.;
RT "Prediction of the coding sequences of unidentified human genes. XV.
RT The complete sequences of 100 new cDNA clones from brain which code
RT for large proteins in vitro."
RL DNA Res. 6:337-345(1999).
CC -!- SIMILARITY: CONTAINS 1 RING-TYPE ZINC FINGER.
DR EMBL: AB033040; BA86528.1; -.
DR InterPro: IPR003137; PA.
DR InterPro: IPR001841; Znf_ring.
DR Pfam: PF02225; PA; 1.
DR Pfam: PF00097; zf-C3HC4; 1.
DR SMART: SM00184; RING; 1.
KW Zinc-finger.
FT NON_TER
SQ SEQUENCE 462 AA; 49883 MW; D1279DE127C9772D CRC64;

Query Match 25.8%; Score 586; DB 4; Length 462;
Best Local Similarity 35.6%; Pred. No. 1.9e-44;
Matches 156; Conservative 46; Mismatches 124; Indels 112; Gaps 11;

QY 6 GAGVSCRCGGGFSR-----LLAWCF--LLALSFOAPGSRGAE 40
DB 47 GGGTGRGAGAGRPRRIKMAISLIQACCSLALSTLLSFCFVHLLCLDFTVAEK---E 103

QY 41 AVMTAYLNVSRRVP-----HTGVNRTWELSEEGVYGDSPLFPVAGVL 84
DB 104 EWYTFVNTYAEAPDPGAGAGGGGAEIHT-----EKTECGRYGEHSPKQDARGEV 156

Search completed: April 22, 2003, 08:26:58
Job time : 38 secs